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The  purpose  of this  thesis  is  to  investigate:  whether  cross  sectional  MRI  can  help  to 
discriminate progressive supranuclear palsy (PSP), multiple system atrophy (Parkinsonian 
subtype,  MSA-P)  and  Parkinson’s  disease  (PD);  whether  established  methods  of serial 
volumetric MRI analysis can be applied to measure in-vivo rates of brain atrophy in PSP 
and; whether cross sectional MRI and MRI-derived atrophy rates have a clinical correlate. 
Volumetric and diffusion-weighted MRI (DWI) scans were performed in 24 patients with 
PSP,  11  with  MSA-P,  12  with  PD  and  18  healthy  controls.  Detailed  clinical  and 
neuropsychological  assessments  were  undertaken,  and  results  at  the  time  of  initial 
assessment and follow-up compared.
Whole  brain  and  regional  brain  volumes  were  measured  on  positionally  matched 
(registered)  baseline  and  follow  up  MR  images.  The  boundary  shift  integral  (BSI),  an 
image analysis technique for assessing volume differences from registered MR scans was 
applied  to  whole  brain,  and  hypothesis-driven  regions  of  interest  in  order  to  allow 
quantification of atrophy rates.
•  PSP  can  be  reliably  discriminated  from  MSA-P  with  quantitative  regional  volume 
measurements  of the  superior  cerebellar  peduncle,  midbrain,  pons  and  cerebellum
(p<0.001).
•  DWI may help to identify regional pathological change in-vivo, discriminating MSA-P 
and  PSP  using  apparent  diffusion  coefficients  in  the  middle  cerebellar  peduncle
(p<0.001).
•  The mean(SD) brain atrophy rate in PSP,  1.2 (1.0) %year_ 1  was greater than in healthy 
controls 0.4(0.5)%year'1   (p=0.04)  but  similar to  MSA-P  1.0(l.l)%year'1.  In PSP, the
1mean midbrain atrophy rate was most significantly different from controls (p<0.001). 
Ponto-cerebellar atrophy rates discriminated MSA-P and PSP (p<0.05).
The  distinct  patterns  and  rates  of atrophy  in  these  diseases  have  a  meaningful  clinical 
correlate and power calculations confirm that in PSP, regional atrophy rates are quantifiable 
and feasible markers of disease progression that have utility in clinical trials as a marker for 
evaluating disease-modifying treatments in PSP.
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Progressive  supranuclear  palsy  (PSP)  is  the  commonest  of the  neurodegenerative 
extrapyramidal  syndromes after Parkinson’s disease  (PD).  Patients present with an 
insidious onset of neurological symptoms and signs including impaired balance, non­
specific visual symptoms, impaired mobility and cognitive disturbance. Even with the 
classical  presentation,  diagnosis  is  difficult  and  atypical  presentations  with 
Parkinsonism and gait freezing complicate matters further. There are no biomarkers or 
pathognomonic  neuroimaging  features  and  a  definitive  diagnosis  requires 
histopathological confirmation, usually at autopsy. The clinical diagnosis can only be 
reliably made when typical clinical signs are present, and this may not be the case, 
particularly in the early stages of the disease.
Magnetic resonance imaging (MRI) of the brain at a single time point has for some 
time been a standard investigation and an obviously small midbrain, is supportive of 
the clinical diagnosis of PSP.  Other pathologically affected regions may have been 
overlooked  and  newer  imaging  and  image  analysis  techniques,  now  more  widely 
available,  may  soon  prove  to  be  helpful  in  discriminating  the  degenerative 
bradykinetic rigid disorders.
There are no efficacious disease modifying drugs and PSP progresses relentlessly with 
a mean duration to death of between six and nine years. The cause is obscure but the 
disease is thought to result from a combination of environmental and genetic factors. 
Abnormal accumulation of hyper-phosphorylated Tau aggregates is now known to be 
an important pathological process and this understanding may pave the way for new 
therapeutic approaches. Methods for assessing disease progression in PSP are lacking. 
Outcome measures in clinical trials include clinical measures of disease progression, 
which by their nature involve subjective assessment of disease severity, are affected
19by floor and ceiling effects and may be non-linear. A subject’s ability to perform on 
these tests may fluctuate on a day-to-day basis and symptomatic effects of a drug may 
confuse the issue by improving test scores. Some of these problems can be overcome 
by adapting trial design appropriately, but clinical rating scores alone may still not 
provide truly sensitive and reliable markers of disease progression.
In PSP,  the  inevitable  downstream effect  of abnormal  protein deposition  and  cell 
death is accelerated cerebral atrophy. This needs to be distinguished from the slower 
loss  of neurones  seen  as  part  of the  normal  ageing  process.  In PSP,  whole  brain 
atrophy may be a good surrogate marker of disease progression. However because the 
most severe macroscopic atrophy at post mortem is seen in the brainstem, regional 
atrophy rates may provide a better marker of disease progression.
Imaging at a single time point can only infer that atrophy has occurred. In order to 
quantify true rates of brain atrophy, it is necessary to compare serial scans from the 
same  individual  over  time.  To  facilitate  comparison,  these  scans  can  be  digitally 
matched (registered) to one another with a high degree of precision. Rates of global 
and regional atrophy can then be calculated, by comparing brain volumes over time, 
by assessing expansion of cerebrospinal fluid (CSF) spaces or by using an automated 
method of assessing brain volume change over time such as the brain boundary shift 
integral (BBSI). Furthermore, a local boundary shift integral can be applied to limit 
automatic calculation of atrophy to a predetermined region.
The  research  undertaken  for  this  thesis  was  designed  to  determine  rates  of brain 
atrophy,  derived  from  serial  MRI  scans,  in  PSP  compared  to  established  rates  of 
atrophy in healthy controls and other bradykinetic rigid neurodegenerative conditions. 
Specifically, the aims were: (1) to look for new MRI based diagnostic markers in PSP; 
(2) to use novel image analysis techniques to determine the patterns of progressive
20global brain atrophy occurring in PSP, multiple system atrophy of the Parkinsonian 
subtype  (MSA-P)  and  Parkinson’s  disease;  (3)  to  compare  rates  of whole  brain 
atrophy in PSP, MSA-P, PD and healthy controls;  (4) to compare regional rates of 
brain atrophy in  PSP,  MSA-P,  PD  and  healthy  controls  and  to  determine  if these 
provided  better  markers  of disease  progression;  and  (5)  to  look  for  correlations 
between clinical features, clinical rating scales, neuropsychological scores and MRI 
findings.
As a consequence of these aims, I hoped to determine whether MRI could be applied 
as a method of measuring brain atrophy and disease progression in PSP, as well as 
exploring  its  potential  as  an  ancillary  aid  in  the  differential  diagnosis  of  the 
bradykinetic rigid disorders.
211.  Introduction
1.1  Degenerative bradykinetic rigid syndromes
In  progressive  supranuclear  palsy  (PSP),  multiple  system  atrophy  (MSA)  and 
Parkinson’s disease (PD), bradykinesia and rigidity occur as a result of degeneration 
of basal  ganglia  structures  including  the  globus  pallidus,  the  substantia  nigra,  the 
corpus striatum and the subthalamic nucleus. Many other brain regions are damaged 
in PSP and MSA resulting  in the additional clinical  features characteristic of these 
nosological entities.
1.2  Progressive supranuclear palsy
1.2.1.  Historical perspective
Progressive supranuclear palsy (PSP) was first described in the medical literature in 
1963  (Richardson et al.,  1963) and in more detail a year later in (Steele et al  1964). 
Nine cases with a distinct clinical syndrome consisting of  initially vague visual or 
speech difficulties,  changes  in personality  and an unsteady gait were  described.  A 
supranuclear ophthalmoplegia was a constant and distinctive finding, occurring early 
in  the  disease  course.  Barbeau  called  the  disorder  “Steele-Richardson-Olszewski 
syndrome”, after the three authors of these initial reports (Barbeau,  1965), and this 
rubric is still used in some parts of the world.
The  Canadian  authors  believed  this  clinical  picture  represented  a  distinct  disease 
entity and they conceded that it was unlikely the disease they described was a new 
one, but felt it had probably been mislabelled as “arteriosclerotic” Parkinsonism. They 
expressed a degree of surprise that for a syndrome with such a characteristic clinical
22appearance,  there  was  no  detailed  clinico-pathological  description  in  the  medical 
literature.
Fragmentory descriptions, however can be found in the early medical literature and 
Charles Dickens in “The Lazy Tour of Two Idle Apprentices” writes of  “A chilled, 
slow,  earthy, fixed old man. A cadaverous old man of measured speech. An old man 
who seemed as unable to wink,  as if his eyelids had been nailed to his forehead. An 
old man whose eyes - two spots of  fire - had no more motion than if they had been 
connected with the  back of his skull by screws driven  through  it,  and riveted and
bolted outside, among his grey hair  He had come in and shut the door, and he
now sat down. He did not bend himself to sit,  as other people do,  but seemed to sink 
bolt upright, as if in water, until the chair stopped him ” (Dickens C, 1990).
Dickens  seems  to  describe  quite  clearly:  the  paucity  of  movement  or  “body 
bradykinesia”; the  slow,  growling dysarthria; the  frontalis over-activity and  staring 
appearance; the gaze palsy; and the tendency to sit “en-bloc” (Lamer, 2002).
Although it is not possible with certainty to know whether the individuals described in 
the novel or the early medical patient descriptions had PSP, it is unlikely that PSP is a 
new disease.
1.2.2.  Epidemiology
The geographical distribution of PSP is not well described and it is presumed that in 
the  western  world,  the  population  prevalence  is  similar  from  country  to  country. 
Certain  geographic  isolates  have  reported  unexpectedly  high  rates  of  atypical 
Parkinsonism, with a clinical presentation similar to PSP, contrasting with that seen in 
Europe and North America. The island of Guadeloupe in the French West Indies is
23one  such  area.  The  characteristic  clinical  picture  of  Guadeloupean  atypical 
parkinsonism is of symmetrical bradykinesia, axial rigidity, early postural instability, 
cognitive decline with prominent frontal lobe dysfunction and a negligible response to 
levodopa (Caparros-Lefebvre et al., 2002). It was thought that the disease was related 
to the  ethnicity of the  population or to the  consumption of herbal teas  containing 
alkaloid toxins.  The  most recent  findings suggest that  it  is a tauopathy with some 
unusual pathological features.
A high incidence  of PSP  has  been described  in New  Caledonia (Angibaud et al., 
2004)  and  the  occurrence  of a  high  incidence  of parkinsonism-dementia  complex 
(PDC)  among  Chamorros  on  Guam  was  also  first  described  fully  in  the  1960’s 
(Hirano et al.,  1961a; Hirano et al.,  1961b) and it is recognised as a distinct disease 
entity  on the  basis  of clinico-pathological  studies.  However  it  has  many  features 
which closely resemble PSP including a supranuclear gaze palsy in some cases. More 
recently, a first pathologically confirmed case of PSP has been reported on the island 
of Guam.
Large studies of population prevalence are prone to under-ascertainment of cases and 
small community studies, while thorough, are only able to identify a small number of 
cases.  Ten years ago, the prevalence of PSP may have been quoted at around  1  in 
100,000  but  PSP  is  more  common  than  previously  considered  and  recently,  the 
prevalence has been adjusted to 5 per 100,000, with an age adjusted prevalence of 6.4 
per 100,000, based on detailed epidemiological studies (Nath et al., 2001; Schrag et 
al.,  1999). This means it is about as common as motor neuron disease, a condition 
with a much greater level of public and professional awareness. Nath et al undertook 
national, regional and community prevalence studies. The national studies relied upon
24the  British Neurological  Surveillance  unit,  the  PSP  (Europe)  Association and  the 
Office  of National  Statistics  for  case  identification.  In  addition,  neurologists  from 
across the UK were  invited to  refer cases.  In the regional  study, direct referral of 
cases, a review of 33,000 out patient letters, screening of regional databases such as 
gastrostomy  tube  registers  and  movement  disorder  registers  as  well  as  in-patient 
diagnosis coding registers were reviewed. In the community study,  general practice 
case records were screened for cases that might fit with a diagnosis of PSP and these 
were invited to clinic or examined at home. Cases were included if they conformed to 
the NINDS-SPSP diagnostic categories  for possible or probable PSP (Litvan et al., 
1996a). It was presumed that the national study would significantly underestimate the 
prevalence  of PSP,  which  it  did  with  a  crude  prevalence  of  1   per  100,000.  The 
regional  study  identified  an  age-adjusted  prevalence  of 2.4  per  100,000  and  the 
community study identified a prevalence of 5  per  100,000.  Clearly the methods of 
case finding and the size of the surveyed population affect the estimated prevalence 
but overall, the clear message is that PSP is under recognised. A lack of awareness of 
the  condition  amongst  physicians  and  phenotypic  variability  may  explain  the 
diagnostic underascertainment.
1.2.3.  Clinical features and differential diagnosis of PSP
Gait instability,  impairment of vertical eye movements,  spastic or ataxic dysarthria, 
dysphagia,  bradykinesia,  rigidity,  frontal  behavioural  changes  and  sub-cortical 
dementia are the cardinal signs of PSP. Most cases begin after sixty years of age and 
result in death six to nine years after disease onset (Lees, 1987).
25Patients with typical PSP tend to present with gait disturbance and unsteadiness as 
well as a marked tendency to topple backwards. The gait has a characteristic reeling 
and  staggering  quality  due  to  the  stiff posture  of the  trunk  and  the  neck  and  is 
sometimes likened to that of a “dancing bear”. Whilst a supranuclear gaze palsy with 
downgaze abnormalities is  highly characteristic,  it is often not present  in the early 
stages  and  early  visual  symptoms  may  be  non-specific  and  difficult  to  diagnose. 
Photophobia,  watering  of  the  eyes,  blurred  vision,  difficulty  focussing  on  and 
following written text have all been reported in the early stages of the disease, prior to 
the clinical diagnosis being made when other more definitive clinical symptoms and 
signs emerge.
Various clinical diagnostic criteria for PSP have been proposed over the years (Lees, 
1987)  (Blin et at.,  1990; Collins et at.,  1995; Duvoisin RC.,  1992; Golbe LI,  1993; 
Tolosa et at.,  1994). The NINDS-SPSP diagnostic criteria published in 1996 (Litvan 
et al,  1996a) and revised in 2003 (Litvan et al., 2003) is the most commonly used for 
research purposes and are outlined below (see also Chapter 3, table 3.6a):
For possible and probable PSP: A gradually progressive disorder with age at onset 
at 40 years or later.
Possible  PSP:  Either  a  vertical  supranuclear  palsy,  or  both  slowing  of vertical 
saccades and postural instability with falls less than 1  year after disease onset.
Probable PSP: A vertical supranuclear palsy and prominent postural instability with 
falls within first year of disease onset. Later defined as falls or the tendency to  fall 
(patients are able to stabilize themselves).
26Definite  PSP:  All  criteria  for  possible  or  probable  PSP  are  met  and  there  is 
histopathological confirmation at autopsy.
Supportive features:  Symmetrical  akinesia or rigidity,  proximal more than distal; 
abnormal  neck  posture,  especially  retrocollis;  poor  or  absent  response  of 
parkinsonism to  levodopa; early dysphagia and dysarthria; early onset of cognitive 
impairment  including  more  than  two  of:  apathy;  impairment  in  abstract  thought; 
decreased verbal fluency; utilization or imitation behaviour; or frontal release signs.
Exclusion  criteria:  A recent history of encephalitis;  alien limb  syndrome;  cortical 
sensory deficits; focal frontal or temporo-parietal atrophy; hallucinations or delusions 
unrelated to dopaminergic therapy; cortical dementia of Alzheimer type; prominent, 
early  cerebellar  symptoms  or  unexplained  dysautonomia;  or  evidence  of  other 
diseases that could explain the clinical features.
Once the classical syndrome is established, PSP should not be a difficult diagnosis to 
make.  However  in  the  early  stages,  the  clinical  picture  may  be  incomplete  and 
atypical phenotypes are now recognised complicating the diagnostic process. The true 
spectrum of the clinical phenotype  is,  however, broad (discussed in more detail  in 
Chapter 3.2.1).
In the early stages of PSP, Parkinson’s disease (PD) is a frequent misdiagnosis. When 
it becomes clear as in most cases that levodopa response is minimal, the differential 
often broadens to  include multiple  system atrophy,  dementia with Lewy  bodies  or 
vascular Parkinsonism. It is in this early stage, when the more striking features of the 
disease  such as the  gaze  palsy or the  retrocollis  may not  be  present,  or when the 
disease presentation is atypical that making the correct diagnosis can be difficult. This
27is reflected in the sensitivities of the different clinical diagnostic criteria which range 
from 13% to 83% (Litvan et al, 2003).
1.2.4.  Diagnostic difficulties in PSP
In addition to the early gait disturbance, postural instability and falls backwards, other 
early features include behavioural and cognitive  changes,  slurring of speech,  visual 
symptoms and slowness. The disease onset is after the age of 40, but usually in the 
seventh and eighth decades of life  (Lees,  1987; Steele et al.,  1964). In typical cases 
there  is  vertical  supranuclear  gaze  palsy  with the  earliest  neuro-ophthalmo logical 
finding  being  slowed  vertical  saccades  (Stell  and  Bronstein,  1994).  Supranuclear 
limitation  of downgaze  leading  to  falls  when  going  downstairs  and  “the  dirty tie 
syndrome” is characteristic.
There  is  a  widening  spectrum  of  clinical  phenotypes  documented  in  PSP  and 
pathologically  confirmed  cases  without  an  eye  movement  disorder  have  been 
described  (Daniel et al, 1995; Morris et al, 2002; Revesz et al, 1996). A number of 
other neurodegenerative and vascular pathologies have been associated with a clinical 
picture  of PSP  including  diffuse  cerebrovascular  disease  (Josephs  et  al,  2002; 
Winikates  and  Jankovic,  1994),  cerebral  amyloid  angiopathy  with  motor  neuron 
disease (MND)  (Weeks et al, 2003),  Cortico basal degeneration (CBD) (Litvan et 
al,  1997),  frontotemporal  dementia  with  Parkinsonism  linked  to  chromosome  17 
(FTDP-17q) (Soliveri et al, 2003), subcortical gliosis with prion protein deposition 
(Revesz et a l, 1995; Will et al, 1988) and diffuse Lewy body disease (de Bruin et al, 
1992; Feamley et al,  1991; Nakashima et al, 2003). Midbrain tumours  (Silbert et 
al,  1993),  Whipple’s  disease  (Averbuch-Heller  et  al,  1999),  neuro-syphilis 
(Murialdo et al, 2000) and neuroleptic drugs (Campdelacreu et al, 2004) are other 
rare causes of a similar clinical picture.
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bradykinetic-rigid syndrome and frontal cognitive impairment resulted in a diagnosis 
of PSP being considered during the disease course. In two of the three cases, PSP was 
the  final clinical diagnosis. Neuropathological  examination in these  cases revealed 
typical  histological  appearances  of  fronto  temporal  lobar  degeneration  with 
ubiquitinated  inclusions  (FTLD-U)  in  one  case,  and  fronto  temporal  lobar 
degeneration  with  motor  neuron  disease  pathology  (FTLD-MND)  in  two  cases 
indicating that a clinical syndrome closely resembling PSP may be seen as part of the 
clinical presentation of these pathological disorders (Paviour et al., 2004a).
The three cases described differed slightly from the clinical presentation of typical 
PSP. One presented with frontal behavioural change, which rapidly worsened within 
the  first  twelve  months.  Although  formal  neuropsychological  examination  was 
possible  on  only  one  occasion  and  was  limited  by  dysarthria,  this  patient  did 
demonstrate  significant  frontal  executive  dysfunction.  Pathological  examination  in 
this case confirmed severe involvement of the frontal cortex. The neuropsychological 
findings in all three cases were, however, in keeping with a clinical diagnosis of PSP. 
The  combination  of  severely  slowed  information  processing  and  marked  early 
executive dysfunction, are characteristic of PSP and have been suggested to help in 
differentiating it from some other degenerative dementias (Albert et al., 1974; Litvan, 
1994)  (Chapter  3.5).  In contrast,  cortical  dementia with dysphasia,  meeting Neary 
criteria for semantic dementia is well recognised in FTLD-U  (Rossor et al., 2000) 
relating specifically to regional cortical atrophy. The neuropsychological profile may 
assist in the differential diagnosis, particularly if there is a suggestion of asymmetry 
but a predominant frontal dysexecutive syndrome can be found in any of the fronto 
temporal lobar degenerations, as well as in PSP and CBD. Despite this evidence for a
29specific pattern of cognitive  dysfunction,  features of a “cortical  dementia” such as 
dynamic aphasia have also been reported in PSP (Esmonde et al., 1996).
The exclusion criteria for a clinical diagnosis of PSP  include clinical  features that 
clearly suggest an alternative diagnosis such as an alien limb and cortical sensory loss, 
favouring  CBD,  or  early  autonomic  failure  favouring  a diagnosis  of MSA.  Hence 
while  the  current  diagnostic  criteria  are  useful,  particularly  in  the  context  of 
recruitment  to  clinical  trials,  it  is  inevitable  that  even  the  most  rigorous  clinical 
diagnostic  criteria  will  have  limitations  especially  in  the  face  of the  increasing 
phenotypic variation of rare diseases such as FTLD-U and FTLD-MND.
1.2.5,  Tau and genetics
PSP is a tauopathy.  Tau  is a microtubule-associated protein (MAP).  It is  found  in 
neurones  and  in  small  amounts  in  glial  cells.  In the  normal  human  brain,  tau  is 
distributed  mainly  in  axons.  By  supporting  cytoskeletal  structure  and  sustaining 
axonal  transport,  tau  plays  a  fundamental  role  in  neuronal  survival.  In  normal 
neurones, tau is soluble, binds to microtubules reversibly and has a rapid turnover. In 
neurodegenerative diseases such as PSP, tau loses its affinity for microtubules and 
collects as insoluble aggregates in the form of proteolytic resistant straight filaments. 
PSP is characterised by the presence of neurofibrilliary tangles (NFT’s) and neuropil 
threads  (NT’s)  resulting  from  aggregation  of  hyperphosphorylated  tau  protein 
filaments.  NFT’s  are  basophilic  and  globose,  their  structure  resembling  a  ball  of 
string. However, flame shaped tangles (characteristic of Alzheimer’s disease-AD) can 
also exist in PSP.
The human tau gene is located over  lOOkb on the long arm of Chromosome  17 and 
contains 16 exons. In the adult human brain, different isoforms of tau exist as a result
30of alternate  splicing of the tau mRNA transcript.  Exons 2,3  and  10  are alternately 
spliced,  allowing  six different  combinations  of tau  isoforms.  The  spliced products 
give rise to either three tau isoforms with three repeats (in the absence of the amino 
acid sequence coded for by exon 10) or three tau iso forms containing the amino acid 
sequence coded for by exon 10, with four repeats. Normal brain has three repeat tau 
isoforms. In PSP, hyperphosphorylated four repeat tau is abundant.
Recent studies have identified a genetic polymorphism in the tau gene associated with 
a greater than chance  frequency with PSP.  The most common allele in the general 
population  is  designated  as  AO.  Other  alleles  are  designated  Al,  A2  and  A3.  A 
significant  over  representation of the  A0/A0  genotype  in PSP  has  been  described 
(Conrad et al., 1997).
Two  forms  of the  tau  gene  have  been  identified,  the  HI  and  H2  genes.  The  HI 
haplotype  corresponds  to  the  AO  polymorphism.  A  surprisingly  large  number  of 
patients  with PSP  are  HI /HI  homozygous,  suggesting  the  AO/AO  phenotype  may 
predispose  to  PSP.  Two  groups  of patients  with  clinically  typical  and  atypical, 
pathologically diagnosed progressive supranuclear palsy have been identified (Morris 
et al.,  2002).  Of the clinically typical cases,  100% had the Hl/Hl  haplotype.  Only 
73.3% of the  clinically atypical  PSP  group  had the  Hl/Hl  haplotype.  The  Hl/Hl 
haplotype is not essential or sufficient to cause the disease but increases the risk of 
developing PSP. Exactly how the Hl/Hl haplotype predisposes to PSP is unclear, but 
it may be related to splicing of exon 10.
The clinical genetics of PSP have been extensively studied (Rojo et al., 1999). Among 
133  first and second-degree relatives of cases of PSP  in  12  families,  22  secondary 
cases of PSP were identified. No clinical differences were found between familial and 
sporadic  PSP.  The  perceived  pattern  of inheritance  in  these  cases  was  autosomal
31dominant with variable penetrance. As described above, homozygosity for the tau AO 
polymorphism has been described as a risk factor for developing PSP.  It occurs in 
55% of the population and the age-adjusted prevalence of PSP does not come close to 
this.  In the  study  described  above,  a  genomic  search  in two  families  revealed  no 
linkage  in  the  region  of  the  tau  gene  (Chrl7q  21-22).  In  addition,  the  AO 
polymorphism had a similar distribution in affected and non-affected members of the 
families and so, the level of significance of the AO polymorphism seems unclear. One 
large Spanish family has been reported in which four members with clinically typical 
PSP  were  screened  and  linkage  to  chromosome  lq31.1  identified.  This  region 
contains at least three genes, and their relevance in PSP is uncertain (Ros et al, 2005).
1.2.6.  Histopathology and macroscopic atrophy at postmortem
PSP is characterised by abnormal accumulation of tau protein in a number of brain 
areas but particularly the midbrain and basal ganglia.
The  neuropathological  characteristics  of PSP  (Hauw  et  al.,  1994)  are  legion  and 
include macroscopic atrophy of the globus pallidus, subthalamic nuclei, brainstem and 
Brodmanns  area  4.  There  may  be  dilatation  of the  Illrd  and  IVth  ventricle  and 
aqueduct of Sylvius as well as de-pigmentation of the subthalamic nucleus (STN).
For the pathological diagnosis of PSP to be made accurately, the essential areas of the 
brain  that  must  be  studied  are  globus  pallidus,  putamen,  caudate  nucleus,  STN, 
midbrain, cerebellar dentate nucleus and the pons and medulla. In addition, to exclude 
or diagnose other diseases, which may be mistaken for PSP, other areas such as the 
hippocampus and parahippocampal gyrus and motor, frontal and parietal cortices need 
to be examined.
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(NFT’s) and neuropil threads (NT’s)  in selected structures of the basal ganglia and 
brainstem together with variable neuronal  loss and  astrogliosis.  These  can best  be 
identified by tau immunohistochemistry and silver staining.
In a typical case of PSP, NFT’s are  identified  in the pallidum,  subthalamic  nuclei, 
corpus  striatum  and  nucleus  of  Meynert  as  well  as  the  brainstem  (tegmentum, 
colliculi,  peri-aqueductal  grey,  red  nucleus,  basis  pontis,  dorsal  and  median raphe 
nuclei and inferior olives) and dentate nucleus of the cerebellum. The prefrontal and 
precentral cerebral cortex may also be involved.
For a definitive final diagnosis of PSP, typical pathological appearances as well as a 
clinical history compatible with the diagnosis are required.
1.2.7.  Correlation of pathology and clinical features
As already stated, NFT degeneration is greatest in the subcortical structures but PSP is 
also associated with varying degrees of cortical pathology. It has been suggested that 
the degree of cortical pathology has a bearing on the clinical phenotype and in a study 
of ten patients in whom the pre-central gyrus was the most severely affected cortical 
area, the density and location of NFT’s appeared to correlate with the severity of the 
clinical symptoms possibly related to frontal cortical pathology (Vemy et al, 1996a). 
The presence of a supranuclear ophthalmoplegia may be correlated with brainstem 
pathology. However, the frontal eye fields and the parietal cortex are also known to be 
involved in the guidance of ocular movement and were found to be severely lesioned 
in these cases.  The pathological involvement of the parietal cortex and frontal eye 
fields (FEF) was least severe in the only case without a supranuclear gaze palsy.
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palsy  in  PSP,  greater  cell  loss  and NFT  density  in the  nucleus  raphe  interpositus 
(NRI) was observed in patients with the typical clinical picture than in those without a 
gaze palsy suggesting this region of the pons is important in the generation of normal 
saccadic eye movements (Revesz et al.,  1996).
Braak et al (Braak et al.,  1992) found that in six patients with PSP, the three with 
significant  cognitive  impairment  had  greater  severity  of lesions  in  the  entorhinal 
region of the cerebral cortex.
Kluin et al (Kluin et al., 2001) concluded from a study of 14 patients with PSP that 
the hypokinetic aspects of dysarthria correlated well with the degree of pathology in 
the SN pars compacta and reticulata but not the striatum, STN or GP. The spastic and 
ataxic components of the dysarthria were not well correlated with pathological load in 
the cortex or cerebellum.
Hence the clinical features of PSP appear to be associated to some extent with the 
pathological  involvement  of definitive  brain  regions.  If these  clinical  features  are 
specific for PSP, then the neuronal loss in these areas ought to result in greater rates 
of atrophy in PSP than in other degenerative diseases and this may be apparent on 
MRI.
Consideration of clinicopathological  studies  is  of great importance therefore  when 
planning an imaging project involving a priori assumptions regarding which regions 
of the brain to study.
1.2.8.  Clinical assessment of disease severity in PSP
A definitive  clinical  diagnosis  of PSP  is usually  made,  by  a neurologist  based  on 
traditional  clinical  methods.  Application  of clinical  diagnostic  criteria  are  largely
34restricted to  clinical trials  and research.  Prognosis  depends on relating the  clinical 
stage of the disease and the presumed rate of disease progression.
Over  time,  experience  of a particular  disease  enhances  a  physician’s  expertise  in 
offering an informed opinion. This judgement is difficult to quantify and in clinical 
research,  it  is  useful  to  incorporate  clinical  rating  scales  and  bedside  tests  as 
quantifiable markers of disease severity.  This aids comparison between individuals 
with the  same disease,  group comparison with other diseases and quantification of 
change over time.
1.2.8.  l.Standardised clinical rating scales
There are a number of problems with the clinical scales currently in use. The Unified 
Parkinson’s  disease  rating  scale  (UPDRS,  see  Appendix)  is  one  of  the  most 
commonly used rating scales in Parkinson's disease (Fahn S, 1987). It consists of four 
subsets: Part I consists of 4 questions related to cognitive and psychiatric symptoms; 
Part II (often called the ADL component) comprises 13 questions related to common 
motor  symptoms  and  their  affect  on  disability;  Part  III  is  an  objective  motor 
examination; and Part IV asks questions related to complications of medications, such 
as  motor fluctuations  and  dyskinesia.  Responses  to  most  questions  are  made  on a 
scale from 0 to 4, with specific criteria for each value. It was designed to provide a 
measure of the signs and symptoms of PD in clinical practice and in research. As with 
all rating scales,  its reliability and repeatability are paramount.  As Parkinsonism is 
one of the clinical features of PSP and MSA, using the UPDRS motor subscale (Part 
III) to evaluate motor severity would seem reasonable. However rest tremor is not a 
common clinical feature of PSP, nor is limb rigidity and these are major components 
of the UPDRS motor subscale (UPDRS III). Axial rigidity and postural stability also
35feature in the UPDRS III and a recent study suggests that it is a reliable and applicable 
scale for assessing most aspects of PSP function (Cubo et al., 2000). Axial rigidity 
and gait abnormalities as well as limb bradykinesia were significantly related to the 
Hoehn and Yahr score (H+Y),  see Appendix (Hoehn and Yahr,  1967) suggesting a 
good correlation between these factors. The H+Y score is possibly the most widely 
used and the simplest clinical rating score in Parkinsonism.
Other clinical features such as the supranuclear gaze palsy and cognitive dysfunction 
are not accounted for in the UPDRS III or the H+Y, although part I of the UPDRS 
allows for some subjective self-reporting of cognitive function. For these aspects of 
the disease, it is useful to have a bedside assessment as well as more formal approach 
to quantification of severity. Rating scales specifically designed for PSP are available 
but require further validation (Schrag et al., 2005).
The mini mental state examination (MMSE) (Folstein et al.,  1975) is useful in any 
disease with a component of cognitive dysfunction, not least because it is so widely 
used and easy to administer, and most clinicians are very familiar with it. It is often 
used as a quick screening test for dementia and the score ranges from 0-30 with broad 
cut-offs of: >26 -  no impairment; >20-26- mild dementia; <20- moderate dementia; 
and  <12-  severe  dementia.  The  normal  range  is  influenced  by  age  and  level  of 
education and published normal scores are available but not often used. The MMSE 
score  is  heavily  influenced  by  verbal  and  literacy  skills.  For  neurodegenerative 
diseases with a frontal or sub-cortical pattern of cognitive dysfunction, the MMSE 
may be within the normal range despite significant impairment. With this in mind, the 
frontal assessment battery (FAB) has been developed and evaluated as a bedside test 
of frontal cognitive function (Dubois et al., 2000) (see chapters 3.5 and 5.2.3). The 
FAB comprises 6 parts, testing various aspects of frontal cognitive function. It has a
36maximum  score  of  18,  with  lower  scores  indicating  progressive  frontal  cognitive 
decline.
The severity of gaze palsy can be quantified using electro-oculography,  but this is 
time consuming,  slightly  invasive  and  not  always routinely  available.  Alternatives 
utilising computer software and infra-red cameras are expensive. Bedside assessments 
of the severity of gaze palsy can be made using a simple rating scale that focuses on 
the saccadic eye movements. Judgements are made as to the speed (normal / mildly / 
moderately  or  severely  slowed)  and  amplitude  (normal  /  mildly  /  moderately  or 
severely  hypo  metric)  of upward,  downward  and  left-right  saccades  (see  Methods 
chapter 4.2.1.5 where the scale is discussed in more detail). The scale was developed 
for  use  in  the  Neuroprotection  and  natural  history  in  Parkinson  plus  syndromes 
(NNIPPS) study. There are no validated scales of gaze palsy published, and so this 
scale was applied to asses the severity of gaze palsy in the PSP patients.  In this way, 
some standardisation of the severity and progression of the gaze palsy can be made, 
without recourse to expensive or invasive tests.
The cognitive impairment in PSP is an important component of the disease and while 
tests such as the FAB and MMSE provide some information regarding the level of 
dysfunction,  more  formal  quantification  may  be  more  useful  for  detecting  early 
abnormalities.  The  cognitive  dysfunction arises  as  a  consequence  of basal  ganglia 
pathology  and  damage  to  frontal-sub-cortical  circuits.  Many  different 
neuropsychological  tests  have  been  developed  to  quantify the  extent  of cognitive 
dysfunction in PSP, MSA and PD. These are discussed in more detail in chapter 3.4. 
For all of these tests, serial assessment may be used to determine change over time, 
but,  more than in tests of motor function,  “practice  effects” need to  be taken into 
account if there is a short interval between the tests.
37All of these clinical scales for evaluation of disease severity are influenced by: floor 
and ceiling effects; variability in the test presentation and in some cases, the clinicians 
subjective  assessment;  and the patients performance  on the  day of the  assessment 
which, may fluctuate according to a number of factors. This is regardless of the fact 
that on an individual level, the pathological disease process is relentlessly progressive. 
Hence these scales have limitations, particularly when used in isolation, when applied 
to quantify disease progression.
1.2.9.  Conclusions
In  summary,  PSP  is  a  neurodegenerative  disease  that  at  presentation  can  have 
phenotypic  similarities  with  MSA-P  and  PD.  This  may  lead  to  difficulties  in 
discriminating the  conditions.  The  established  clinical diagnostic  criteria  (NINDS) 
have limitations and when applied  late in the  clinical course of the disease have  a 
sensitivity  of 85%  (NINDS  possible)  and  34%  (NINDS  probable)  compared  to  a 
sensitivity of 100% for an experienced clinicians diagnosis (Osaki et a l, 2004). Other 
studies of pathologically confirmed cases of PSP quote the sensitivity and specificity 
of an experienced clinicians final clinical diagnosis of PSP as 84% and 97% (Hughes 
et al., 2002).  However,  earlier  in the  disease  course  identification of true positive 
cases of PSP either by an experienced clinician or by application of the diagnostic 
criteria is less accurate.  The pathological disease process in PSP affects particular 
brain regions more than others. This regional distribution of pathology has a clinical 
correlate but current quantitative clinical rating scales may not be ideal for monitoring 
disease progression. In this regard, biomarkers are needed: neuroimaging, and MRI in 
particular  may  be  useful  as  an  adjunct  to  clinical  assessment  for  increasing 
progression as well as supporting a clinical diagnosis.
382.  Imaging the brain in PSP and bradykinetic-rigid syndromes
2.1  Introduction
Neurodegenerative  diseases  are  characterised  by  progressive  neuronal  dysfunction 
and cell death.  As  neurons  contribute to the  volume  of brain tissue,  this  neuronal 
attrition and subsequent cell loss, results in tissue atrophy. Macroscopic atrophy can 
be  seen  by  the  naked  eye  in  the  brainstem  at  post  mortem  in  PSP  and  MSA, 
particularly  in  the  midbrain  in  PSP.  Modem  neuroimaging  techniques  allow  this 
macroscopic atrophy to be studied in detail and in-vivo.
2.2  Computed tomography in PSP.
The  first  study  to  demonstrate  in-vivo  midbrain  atrophy  in  PSP,  used 
pneumoencephalography  (Bentson  and  Keesey,  1974).  This  investigation  became 
obsolete with the advent of computed tomography (CT). Subsequently, numerous CT 
studies in small groups of patients with a clinical diagnosis of PSP were undertaken 
(Haldeman et a l,  1981; Masucci et a l,  1985; Masucci et a l,  1995).  Characteristic 
changes identified in these cases included pontine atrophy, a dilated third ventricle, an 
enlarged quadrigeminal cistern and  in some,  a dilated aqueduct with a low-density 
area  in  the  midbrain  between  the  interpeduncular  cistern  and  the  aqueduct.  Thin 
section CT studies of the brainstem discriminated some cases of PSP from PD on the 
basis of midbrain atrophy.
2.3  Magnetic resonance imaging.
Magnetic resonance imaging (MRI) is established as a safe, non-invasive and high- 
resolution means of imaging the brain. MRI utilises the physical principle that protons 
in a magnetic field emit a radio signal following excitation by a radio frequency (RF) 
pulse.
39In simple terms, the subject  is placed within the magnetic  field and protons in the 
water molecules of all body tissues,  line up according to the magnetic  moment  of 
force. A RF pulse is then generated to excite the protons and when this is removed, 
the protons return to their previous alignment releasing energy, which is received as a 
signal and used to reconstruct an image of the body part being scanned. Routine MRI 
scanners generate magnetic fields (Bo) which vary from 0.3-3.0 Tesla (T) in terms of 
field strength.  Unpaired protons become aligned with this field depending upon its 
strength and their thermal energy. Protons within a magnetic field “precess” (spin) in 
the direction of the field with a frequency (f>) determined by the Larmor equation:
fo=gB0
Where g is the constant defined by the magnetic property of the nuclei. When a RF 
pulse is transmitted at the resonance frequency of the proton, they absorb energy and 
move out of their original alignment to a higher energy level (decreasing longitudinal 
magnetisation)  and  such  that  they  precess  in  phase  with  each  other  (establishing 
transverse magnetisation). When the RF pulse is turned off, the protons realign with 
the magnetic field and the energy they lose is emitted in the form of radio waves. The 
subsequent increase in longitudinal magnetisation gives rise to the T1 relaxation time; 
the loss of transverse magnetisation gives rise to the T2 relaxation time and is shorter 
than the T1 time constant (figure 2.1). The radio waves thus emitted can be converted 
into spatial information, as the magnetic field within the scanner is not uniform but is 
generated  as  a  gradient,  ensuring  that  emission  of  radio  waves  is  additionally 
dependent upon the position of protons within the magnetic field.
40Figure 2.1 Principles of MRI. 
MAIN MAGNETIC FIELD, B0
The nucleus of an atom (a single proton) spins or precesses within the 
magnetic field.
Increasing transverse 
magnetisation, 
decreasing longitudinal 
magnetisation
90° RF pulse 90° RF pulse
After the RF pulse is turned 
off,  transverse magnetisation 
decreases (T1  relaxation) and 
longitudinal magnetisation 
increases (T2 relaxation)
Tissues may have different MR properties dependent on a number of factors including 
the number of free protons and how tightly bound they are.  By altering acquisition
41parameters, different T1  and T2 properties of tissues can be utilized to generate an 
image  highlighting particular tissue types.  The time to  repetition (TR)  is the time 
period between RF pulses and the longer this is, the more likely it is that protons will 
have a full recovery to their baseline state. A shorter TR allows the differential T1 
properties of different tissues to be utilized in generating an image, as tissues may be 
in different  states  of excitation.  It  follows  that  short  TR times  improve  T1  tissue 
contrast. Time to  echo  (TE)  is the time  between transmission of the RF pulse and 
collection  of the  signal.  A  short  TE thus  gives  more  T1  and  less  T2  contrast.  In 
summary, a short repetition time  leads to T1  weighting (dark CSF) and a long  TE 
leads to T2 weighting (CSF appears white).
Alterations of TR and TE will have other effects on the scan and scan quality. Signal 
to noise ratio (SNR) will be increased with longer TRs, shorter TEs, increased voxel 
sizes and increased field strength. Scan time will be increased with longer TR, smaller 
voxel  sizes  and  a  larger field of view.  Resolution  is  increased with smaller voxel 
sizes, with the consequence that this decreases SNR and increases scan time. Unlike 
CT, MRI data acquisition can be in different imaging planes and in three dimensions 
simultaneously  (volumetric  MRI).  Volumetric  MRI  scans  commonly  consist  of 
around one  million  l-2mm3  voxels  (units of volume),  each with a different tissue 
dependent contrast. T1  weighted volumetric scans have proven useful in quantifying 
atrophy.
422.4  MRI in degenerative bradykinetic rigid syndromes.
2.4.1.  Introduction
None of the current diagnostic criteria for Parkinsonian syndromes (PD, MSA, PSP, 
CBD) include the results of any investigation as inclusion criteria, although certain 
investigation  results  may  contribute  to  the  exclusion  of a  diagnosis,  for  example 
evidence of early cardiovascular autonomic failure would exclude PSP as a clinical 
diagnosis.
In PD, which remains a clinical diagnosis based upon the presence of bradykinesia 
accompanied by  at  least one  other characteristic  clinical  finding,  (a resting tremor 
with  a  frequency  of around  6Hz,  the  presence  of rigidity  and  impaired  postural 
reflexes) (Gibb and Lees, 1988), the signs and symptoms are usually asymmetrical at 
onset and when these typical findings together with a good response to dopaminergic 
treatment are present, it may not be necessary to image the brain. However, when the 
presentation is atypical,  cross  sectional  T1  weighted MR  imaging may be used  in 
order to look for regional atrophy, more suggestive of one disease over another. T2 
weighted  MR  imaging  may  also  be  used  to  exclude  significant  cerebrovascular 
disease or inflammation. MR imaging is also useful in excluding a secondary cause of 
Parkinsonism such as communicating hydrocephalus or a cerebral tumour.
An interest in the use of MRI in bradykinetic rigid disorders arose in the mid 1980’s 
when it was recognized that MRI demonstrated brain iron deposition (Drayer et a l, 
1986).  While  this  is  perhaps  most  striking  in  pantothenate  kinase  associated 
neurodegeneration (PKAN) due to  PANK-2  mutations (Hayflick et a l,  2003),  it  is 
also  a feature  in degenerative  diseases  of the  basal  ganglia (Duguid  et al,  1986). 
Since  the  early  1980’s  other  subjective  and  qualitative  MRI  findings  have  been 
proposed as helpful in discriminating Parkinsonian syndromes.
432.4.2.  Qualitative MRI measurements as an aid to diagnosis
Brainstem atrophy and putaminal hypointensity, were found to discriminate atypical 
Parkinsonism (including PSP and MSA) from PD in early MRI studies (Stem et al, 
1989).  However these  MRI  findings  were  unable  to  discriminate  MSA  from PSP 
reliably. A further study in the late  1980’s supported this conclusion and added that 
MRI  might  have  greater  utility  in  discriminating  MSA  from  PD  as  the  MRI 
appearances in MSA were more uniform than in PSP (Savoiardo et al.,  1989).  An 
extension of one of these studies reiterated that high field MRI is able to demonstrate 
iron in the brain and that Parkinsonian disorders can present an abnormal distribution 
of iron or other paramagnetic substances in the basal ganglia. In 20 patients with PSP, 
three experienced neuroradiologists evaluated the MRI findings noting atrophy of the 
midbrain in  11  cases,  and that this atrophy was best  seen on axial or mid-sagittal 
images.  In  9 other patients,  the  midbrain  size  was  considered to  be  borderline  or 
normal.  They  also  suggested  that  the  third  ventricle  was  disproportionately  large 
compared  to  the  lateral  ventricles  in  PSP  and  that  midbrain  atrophy  resulted  in 
concavity of the posterior part of the  floor of the third ventricle  (Savoiardo et al., 
1994).
The ability of imaging criteria to discriminate PSP from CBD has also been studied. 
Midbrain  atrophy  and  ventricular  dilatation  were  confirmed  as  supportive  of the 
diagnosis of PSP and asymmetric cortical atrophy supported the clinical diagnosis of 
CBD (Gimenez-Roldan et al., 1994).
Other regions said to help discriminate PSP on the basis of qualitative assessments 
include regional atrophy of the corpus callosum on mid-sagittal MRI, which has been 
described as helping to  distinguish PSP,  AD and  FTD  with the pattern of callosal
44atrophy (more anterior atrophy in PSP) consistent with areas of documented cortical 
hypometabolism (Yamauchi et al., 1997).
In MSA, and particularly MSA of the cerebellar subtype (MSA-C), abnormalities on 
T1 weighted MRI were confined to the posterior fossa with predominant pontine and 
cerebellar atrophy.
In these studies, signal change in particular areas judged subjectively to be present or 
absent on T2 or proton density weighted imaging, was suggested as being supportive 
of the diagnosis of PSP or MSA. Reduced signal intensity in the substantia nigra with 
smudging of its margins towards the red nucleus was considered as supportive of a 
clinical diagnosis of PSP. A slight increase in signal intensity was noted in PSP on 
proton density images in the peri-aqueductal region.
In  MSA,  signal  change  in the  basal ganglia was  considered  a  more  characteristic 
finding  with  low  signal  evident  in  the  putamen  and  an  occasional  thin  rim  of 
hyperintensity noted at the lateral posterior putaminal rim, particularly in MSA-P. The 
so-called “hot cross bun” sign on T2 weighted MRI (figure 2.2) has been proposed as 
a useful clinical marker of MSA-C,  (see p.49).
45Figure 2.2 72 weighted MRI in MSA
The “hot cross bun” appearance in the pons is clearly demonstrated on this 
T2 weighted MRI (arrowhead). A posterior to anterior line is clearly visible in 
the midline of the rostral pons and is bisected by a similar but less marked 
horizontal line. These signal changes are thought to reflect cell loss and 
gliosis.  ______________________________
This signal change in the pons is thought to be secondary to gliosis, which results in 
an anterior to posterior, and a left to right hyper-intense line. These specific changes 
were  felt  at the time to be pathognmonic  of MSA-C,  a  statement which prompted 
other groups to publish examples of the MRI sign in other disease processes including 
CNS vasculitis, paraneoplastic syndromes, the spinocerebellar ataxias and myasthenia 
gravis (Burk et a l, 2001; Lo et al, 2003; Muqit et al, 2001; Murata et al, 1998b). 
Signal change  on T2  or proton density  weighted  imaging  may  be  expected  in any 
region where the pathological disease process results  in cell damage and cell death 
with reactive gliosis.  The superior cerebellar peduncle is the main efferent from the 
cerebellum and is pathologically involved in PSP, with damage to the dentate nucleus
46resulting  in  anterograde  degeneration  of the  white  matter  tract  as  well  as  direct 
involvement of oligodendroglia  in this region.  The  fibres of the  SCP pass into the 
brainstem and decussate at the level of the inferior colliculi before synapsing in the 
red nucleus and the ventrolateral nucleus of the thalamus. A retrospective review of 
MRI  scans  in 9 patients with PSP  (8 probable,  1   possible)  compared with patients 
with PD and age matched controls subjectively identified signal change in 4 of 9 PSP 
patients and none in PD or healthy controls (Oka et al, 2001).
Other studies of MRI in MSA compared to PD without incorporation of PSP patients 
have revealed various differentiating features, but largely support the findings detailed 
above (Bhattacharya et al., 2002).
The main criticism of these studies is that most used crude and subjective methods for 
assessing the  MRI  abnormalities.  Few employed  any methods to  control for  inter­
individual variation in brain size and images were often acquired on different MRI 
scanners,  an  important  fact  when  interpreting  intensity  differences.  From  these 
studies, it seems that definitive and diagnostically supportive abnormalities were only 
seen  in  about  50%  of patients  with  a  clinical  diagnosis  of PSP.  Some  of these 
problems  have  since  been  addressed  in  imaging  studies  employing  quantitative 
measures of atrophy.
2.4.3.  Quantitative MRI measurements as an aid to diagnosis
Quantitative MRI measurements may have greater utility than qualitative assessments 
of MRI, in discriminating the degenerative bradykinetic rigid syndromes, particularly 
if statistical analysis demonstrates that a particular measurement discriminates PSP 
from the other diseases with a high degree of sensitivity and specificity and that the 
measurement is reliable and repeatable (see chapter 6.3.5 and 6.5.2).
47Several studies have investigated the potential of MRI as an aid to diagnosis, setting 
out specific measurements of brainstem structures as diagnostic criteria (Asato et a l, 
2000; Schrag et al., 2000; Schulz et al., 1999; Warmuth-Metz et al, 2001).
One study demonstrated that patients with MSA-P and MSA-C as well as PSP could 
be discriminated from patients with PD and healthy controls on the basis of smaller 
brainstem volumes (Schulz et al,  1999). The authors did not attempt to discriminate 
PSP on the basis of midbrain volume, or MSA on the basis of pontine volume and as 
such the conclusions have only limited clinical applications.  A later study included 
qualitative as well as quantitative assessments (Schrag et al,  2000) and concluded 
that the qualitative MRI features suggestive of a diagnosis of PSP over MSA-P were:
I.  Signal increase and atrophy of the midbrain.
II.  Thinning and smudging of the substantia nigra.
III.  Atrophy and signal increase of the globus pallidus
IV.  Atrophy of the red nucleus
In addition,  supratentorial atrophy was seen in the temporal lobes and frontal lobes 
with  infratentorial  atrophy  seen  in  the  cerebellum,  pons,  and  middle  cerebellar 
peduncle. The conclusions stated that PSP could be differentiated from MSA-P using 
the following criteria:
I.  Midbrain diameter <17mm (A-P diameter on axial scan).
II.  Dilatation of Illrd ventricle.
III.  Signal increase in the midbrain.
IV.  Frontal and temporal lobe atrophy.
V.  Signal increase in the globus pallidus.
And also that MSA-P could be differentiated from PSP by the following:
48I.  Increased  signal  in  the  cerebellum  and  middle  cerebellar 
peduncles.
II.  Increased signal in the pons.
III.  Dilatation of the IVth ventricle.
IV.  Atrophy of the dentate nucleus.
V.  Signal decrease in the globus pallidus.
VI.  Hyper intense putamen or putaminal rim.
The  only  finding  seen  more  frequently  in  CBD  compared  to  MSA-P  was  global 
atrophy (however only a small number of CBD patients were included in the study). 
The majority of these measures were qualitative and subjective, but the assessment of 
midbrain size in PSP was based on a linear measurement.  A midbrain diameter of 
<17mm  (on  axial  images)  was  very  specific  for  PSP  (96%)  and  had  a  positive 
predictive value of 80%. However its sensitivity was only 23%. A presumed correct 
diagnosis could still be made in the majority of cases of PSP and MSA-C.
Despite this, a significant number were not classified because either no characteristic 
changes were seen or because changes occurring in both PSP and MSA were seen, 
and only half the patients with MSA-P could be classified correctly.
The paper commented that 0.5T scans tended to misclassify patients with MSA as 
having PSP (19%) and that hence 0.5T scanners are unsuitable for this purpose.  In 
total, 47% of patients could not be classified unequivocally.
Another  group  suggested  similar  quantitative  MRI  criteria  for  the  differential 
diagnosis of PSP from MSA (Asato et al, 2000). Again the quantitative measurement 
focussed on linear measurements of midbrain diameter, but this time on mid-sagittal 
images at the level of the posterior commisure. The authors concluded that in PSP the
49rostral midbrain tegmentum (RMT) A-P diameter is smaller than 5.5mm (the lower 
95% C.I for the normal range).
The pontine A-P diameter is often smaller than the lower limit of the normal range in 
MSA. This finding is supported by the results of another study, which concluded that 
a midbrain diameter of less than 14mm was found only in PSP (Warmuth-Metz et al., 
2001), however there was considerable overlap between midbrain measurements in 
the PSP and MSA patients.
Linear measurements may not be the best method of looking at regional atrophy, as 
they are so dependent upon the position of the scan slice and the orientation of the 
linear measurement. Asato et al ensured their imaging plane remained perpendicular 
to the axis of the brainstem in axial scans in order to partially overcome this problem. 
They  also  commented  that  compared  to  the  methods  employed  in  their  study, 
volumetric or planimetric analyses would be less sensitive to atrophic changes in the 
midbrain as these  measuring techniques include  structures not affected  in diseases 
such as PSP.
A limitation of the studies discussed so far is that they have made little attempt to 
account for the inter-individual variation in brain volume or head size that inevitably 
influences the interpretation of such quantitative analyses.
Intracranial  volumes  vary widely between  individuals  (95%  C.I: 1.2-1.7  litres)  and 
systematically with height and gender (mean male TIV  is -12% greater than mean 
female TIV)
A ratio of linear measurements accounts in part for this variability and this has been 
employed  in  a  recent  quantitative  study  in  which,  PSP  and  MSA  were  reliably 
distinguished, suggesting future clinical usefulness (Oba et al., 2005).
50Volumetric MRI scans allow the true volume of a structure to be assessed, rather than 
an estimate based on a linear measurement. The study by Schulz et al is one of only a 
few volumetric studies to be published on PSP. Another relates to frontal atrophy and 
its  correlation  with  behavioural  change  (Cordato  et  al.,  2002).  PSP  could  be 
distinguished from PD and controls by whole brain atrophy, ventricular dilatation and 
frontal  grey  matter atrophy;  however atrophy of the  caudate  nucleus  seen  in  PSP 
patients  in the  study by  Schulz et al was  not replicated.  There was no  significant 
difference between PD and controls in any of the volume measurements.
This study concluded that  frontal grey matter volume  loss was the  most useful for 
predicting diagnostic phenotype between PD and PSP.  The authors concluded that, 
because no significant variability in frontal volume loss was seen despite significant 
variability in PSP disease duration, frontal atrophy occurs early in the disease. There 
were  also  associations  between  frontal  volume  on  MRI  and  post  mortem  frontal 
volume as well as with the severity of the frontal behavioural changes during life.
This suggests that degeneration in other areas occurs or at least accelerates in the later 
stages of the disease.  Serial studies at different stages of the disease would help to 
confirm or refute this.
2.4.4.  Diffusion weighted imaging in bradykinetic rigid syndromes
Diffusion  weighted  imaging  (DWI)  is  a  rapid  and  practical  imaging  modality 
available  on  most  clinical  1.5T  MR  scanners.  The  principles  behind this  imaging 
technique are discussed in more detail in chapter 8.  DWI has been studied in MSA 
and  PD  (Schocke  et  al.,  2002)  and  this  study  found  that  that  MSA  can  be 
differentiated from PD on the basis of higher regional apparent diffusion coefficients 
measured in the putamen, with a sensitivity and specificity of 100%. DWI has been
51studied in a small group of patients with PSP (Ohshita et a l, 2000). As yet DWI has 
not been shown to be capable of differentiating PSP from MSA.
2.S  Correlation of imaging changes with pathology.
There  have  been  few  reports  on  the  relationship  between  imaging  in-vivo  and 
pathological findings in the same patients at post mortem. If we presume that regional 
volume loss occurs as a result of pathological involvement of the brain tissue within 
that  region,  then  in-vivo  MRI  findings  should  be  associated  with  post  mortem 
pathological  involvement.  Similarly,  macroscopic  atrophy  at  post  mortem  should 
correlate with the severity of pathological involvement microscopically.
Cordato (Cordato et a l, 2000) studied patients with PSP and PD as well as dementia 
with Lewy bodies (DLB) in order to quantify regional brain atrophy at post mortem 
and to correlate this with neuropathology. Frontal cortical volume and parietal cortical 
volume were specifically reduced in PSP. All three groups demonstrated significant 
medial temporal lobe  involvement (amygdala) compared with controls.  In contrast, 
only patients with DLB had hippocampal atrophy. In PSP the severity of atrophy was 
most  marked  in  the  globus  pallidus  intemus,  however  structures  such  as  the 
subthalamic nuclei and substantia nigra were not specifically studied.
The study largely represented late stage disease processes in pathologically confirmed 
cases. It would be important to determine the temporal progression of degenerative 
changes  and  their  relationship  to  clinical  signs  in  order to  understand  better their 
clinical significance. This cannot be done with pathological studies alone. However, 
an impression of the progression of atrophy or at least an idea of correlation between 
pathology and imaging could be obtained by undertaking MRI scans at two different 
time points during life.
52Regional atrophy has been evaluated using T1  MRI of the brainstem on mid sagittal 
and  axial  images  and  compared  to  pathology  in  8  cases  of  PSP  subsequently 
confirmed  at  autopsy  (Aiba  et  a l,  1997).  The  relationship  between  tau  positive 
structures  and  atrophy was  investigated,  as was the  histological  nature of regions, 
which showed abnormal intensity on T2-weighted imaging.  Midbrain atrophy with 
aqueduct dilatation on MRI was present in seven of the eight patients. Neuronal loss, 
a decrease in density of myelinated nerve fibres,  gliosis and tau positive  structures 
such as NFT’s, glial fibrilliary tangles (GFT) and NT’s were seen in these cases.
In patients who did not have atrophy on MRI scanning, histological cell loss was not 
significant.  In areas of high  signal  intensity  on T2  weighted  imaging,  histological 
analysis revealed  severe neuronal  loss with decreased density of myelinated nerve 
fibres, marked gliosis and abundant tau positive structures.  Severity of atrophy was 
closely related to the density of the tau positive structures suggesting that atrophy on 
MRI reflects the degree of neuronal loss.
In a separate study, the most severely affected structures in the region of the midbrain 
were found to be the substantia nigra and the subthalamic nucleus (Yagishita and Oda, 
1996).
In four PSP brains, the superior cerebellar peduncle was also noted to be small at post 
mortem and  atrophy  of this  structure  as  it  decussates  may  contribute to  midbrain 
atrophy.
To  conclude,  there  seems  on  the  basis  of these  studies  to  be  some  degree  of 
correlation between imaging findings in life and the distribution of pathology at post 
mortem  in  the  brady-kinetic  rigid  syndromes.  Large  well  controlled  studies  are 
lacking, however there is some support for the idea that regional signal change and
53atrophy seen in  life using  MRI  scanning represents relevant  on-going pathological 
change in these conditions.
2.6.  Serial imaging in bradykinetic rigid neurodegenerative diseases
Cross  sectional  imaging  studies  have  limitations.  There  is  large  inter-individual 
variation  in  brain  size  and  structure,  the  progression  of atrophy  can only  ever  be 
inferred from a single scan and it must be presumed that progression of atrophy is 
similar between individuals.  Longitudinal studies use  subjects as their own control 
and  permit  progression  of atrophy  to  be  quantified  at  an  individual  level.  Hence 
longitudinal  atrophy  rates  may  distinguish  early,  mildly  symptomatic 
neurodegenerative  disease  from  “worried  but  well”  individuals.  Perhaps  more 
importantly,  rates  of  atrophy  can  be  used  as  an  outcome  measure  for  disease 
modifying drug therapies which might reduce the rate of atrophy to that of normal 
healthy ageing.  Finally, regions of atrophy may differentiate one neurodegenerative 
disease from another. This may be important if the diseases appear clinically similar 
but the underlying pathological mechanism is different, as future disease modifying 
therapies may work by combating protein dysfunction in one pathway but not another. 
For MRI to be applied as a means of supporting the diagnosis and monitoring disease 
progression: (1) it must be possible to compare serially acquired MRI scans from the 
same individual accurately and to apply robust techniques to measure volume change; 
(2) there must be an accurate understanding of the changes associated with normal 
ageing; (3) in addition to whole brain atrophy, some a priori assumptions about which 
regions to study need to be made.
In a cross sectional voxel based morphometric study of 465 healthy individuals (aged 
18-79), age related grey matter loss was seen bilaterally in the insula, superior parietal
54gyri  and  central  and  cingulate  sulci,  whereas  the  amygdala,  hippocampi  and 
entorhinal cortex exhibited little or no age effect (Good et al, 2001). In a study using 
within  subject  registration  of two  MRI  scans  a  year  apart,  of older  disease  free 
individuals (aged 59-85) age related grey matter loss in the hippocampus and in the 
orbitofrontal cortex was detected (Resnick et al., 2000). These inconsistent results are 
likely to be due to differing image analysis methods.
Rates of global atrophy in healthy people increase gradually with age from an annual 
rate of 0.2% a year between the ages of 30-50 to  0.3-0.5% per year at ages 70-80 
(Mueller et al,  1998; Resnick et al,  2003).  This normal atrophy rate needs to  be 
taken  into  account when comparing  rates  of atrophy  in  neurodegenerative  disease 
states.
Very  little  longitudinal  scanning  has  been undertaken  in  any  of the  Parkinsonian 
disorders.  It  has  usually  been  limited to  a few incidental  scans  in  cross  sectional 
studies and has not been carefully analysed or correlated with clinical or pathological 
information. Changes in MRI appearances over time in MSA have however recently 
been reported (Horimoto et al, 2000; Horimoto et al, 2002).
These studies looked at progressive atrophy in the different types of MSA compared 
to controls. The timing of the appearance of various qualitative features such as the 
“hot-cross bun” sign and putaminal slit sign in MSA-C and MSA-P respectively was 
noted. In the first study, atrophy was found to be greater in all MSA subtypes than 
controls and correlated more with duration of disease than age at onset. Atrophy rates 
were determined by two-dimensional area calculations on a single scan slice without 
registering the scans to standard space. The limitations of this method are discussed in 
more detail in chapter 6 and 9.
55The  second  study  concentrated  on the  appearances  of certain  imaging  features  at 
different stages of the disease. The hot cross bun sign in MS A-C was felt to represent 
atrophy and gliosis in the transverse pontine fibres and was present earlier in MSA-C 
than MSA-P. The putaminal hypointensity, representing iron deposition in that region 
was present earlier in MSA-P than MSA-C. No attempt was made in either study to 
correlate imaging features with the clinical phenotype. One useful clinical conclusion 
of the studies was that if putaminal hypointensity or a pontine “hot cross bun” sign 
are not present several years (~6) into the disease process, then a diagnosis of MSA 
can be considered unlikely.
In  another  longitudinal  study  of clinical  features  in  230  patients  with MSA,  139 
subjects had MRI scans reviewed qualitatively. Whilst predominantly cross sectional, 
this study demonstrated MRI findings in a large number of patients at different stages 
of the disease process, giving insight into the evolution of imaging features over time 
(Watanabe et al., 2002).
2.7  Image registration
Cell loss that accompanies histological neuro-degeneration can be examined in vivo 
as  atrophy  on  MRI.  Because  of the  wide  normal  variation  in  cerebral  structures, 
distinction  of atrophy  associated  with  neurodegenerative  conditions  from  changes 
associated  with  normal  ageing  is  difficult  using  imaging  at  a  single  time  point, 
especially in the early stages of a disease process.
Measurement of atrophy on a single  scan does not make  full use  of the  structural 
detail  available  as  small  changes  can  be  masked  by  the  biological  variability  in 
normal individuals. In serial imaging of individuals, the first scan may be used as a
56reference point for future change, hence allowing intra-individual change over time to 
be assessed.
2.7.1.  Technical considerations of serial imaging
The accurate assessment of inter-individual differences or within-subject change over 
time  is aided by matching  scans positionally so  that they are in a common spatial 
framework.  This  needs  to  be  performed  post  acquisition,  as  with  serial  scanning, 
subjects  cannot  be  placed  in  as  similar  a  position  within  the  scanner  to  allow 
meaningful comparison without post-acquisition registration.  Even with very  good 
post  acquisition  registration,  it  is  still  desirable  to  try  and  position  patients  as 
consistently as possible. The reason for this is that there are both spatial and intensity 
inhomogeneities within the  scanners field of view.  Modem short bore scanners are 
particularly  prone  to  non-linear  geometric  distortions.  As  a  result,  scanner 
manufacturers  have  put  considerable  effort  into  correcting  these  distortions. 
Positioning may be a particular problem in elderly patients with limited mobility or in 
diseases which affect posture such as Parkinson’s disease, PSP and MSA.
There are also problems due to inevitable changes in the magnetic field that occur 
over time due to scanner gradient changes. These changes can result in fluctuation in 
voxel size,  complicating comparison of baseline  and repeat scans (WhitweO  et al., 
2001).
Every effort must still be made to position reproducibly the subject in the scanner, and 
to  minimise  hardware  and  software  changes  during  longitudinal  studies.  With 
consistent  image  acquisition,  post  acquisition  registration  can  permit  precise 
assessments of change.
57The goal of post acquisition registration is to align regions of interest on a baseline 
scan to the same region in follow up studies, so that the voxels representing the same 
underlying  anatomical  structures  are  superimposed.  This  allows  for  direct 
comparisons  of  either  global  or  regional  brain  structures.  For  the  purposes  of 
comparing structural scans and calculating rates of atrophy, rigid body registration (in 
which the baseline and repeat scans are considered to be rigid structures that must be 
matched  onto  one  another without  structural change)  is the  most  commonly  used 
technique.
2.7.2.  Rigid body registration 
A number of techniques have been designed to perform rigid body registration  (for a 
review see (Ashbumer et a l, 2003). The most basic method is to identify a number of 
corresponding  anatomical  points  on  two  consecutive  scans  and  to  determine  the 
transformations that align these points accurately on top of one another. A minimum 
of three  linearly  independent  points  are  required  to  determine  the  unique  three 
dimensional co-ordinate system allowing superimposition.  The more points that are 
determined  on  the  scan,  the  greater  the  registration  accuracy.  However,  manual 
definition of such points is time consuming and accuracy is limited by the ability of 
the  user  to  define  reliably  the  anatomical  structures.  Furthermore,  the  technique 
demands the existence of several invariate points and such lack of variation cannot be 
assumed in brains undergoing neurodegeneration. Several automated techniques have 
been designed to allow accurate scan matching (Freeborough et al.,  1996; Woods et 
al.,  1998).  These  algorithms  compare  signal  intensities  from all  voxels within the 
brain.  By  matching  signal intensities  from the  voxels  of the repeat to the baseline 
scan, it is possible to improve significantly registration of intra-subject MR scans. The 
aim  is  to  superimpose  voxels  of  similar  signal  intensity,  thereby  using  all  the
58information within a scan to perform the matching process. This voxel intensity based 
method of registration (Freeborough et al.,  1996) involves: (1) segmenting the scan to 
remove  non  brain tissues;  (2)  determining  and  applying  a  series  of rotations  and 
translations to  match  a repeat  scan to the  baseline.  Translations  and  rotations  are 
applied in each direction within and around the x, y and z axes producing a so-called 
6 degrees of freedom (6dof) registration. This process can be extended to allow linear 
scaling  to  a  small  extent  in  each  of the  three  planes  (nine  degrees  of freedom 
registration -9dof). This theoretically allows for correction of inconsistencies in voxel 
size that may occur between the two scans. Once registered, a difference image can be 
created, so change between scans can be visualised (figure 2.3).
This technique  or  its  variants  has  been extensively  validated  (Freeborough et al., 
1996; Gunter et al., 2003; Paling et al., 2004) and is now widely used to compare 
serially acquired scans.
59Figure 2.3 Registered coronal T1-weighted MRI
A-Baseline image;  B-Repeat scan of the same subject approx 1  year later, registered to baseline. 
Note  the  good  anatomical  correspondence  despite  the  atrophy  that  has  occurred  over  the 
interval.; C-Difference image (scan A subtracted from scan B),  revealing tissue loss (dark areas) 
around the ventricles.
2.7.2.1.Atrophy calculations
Once two  serial scans have been registered to one another, outlining of the brain or 
brain  structures  can  then  be  performed  on  both  baseline  and  repeat  scans.  When 
performed  on  sequential  slices  of a  volumetric  image,  volumes  of certain  brain 
structures  can be  accurately  assessed  and atrophy rates  calculated.  Outlining  small 
structures by hand is inevitably associated with measurement error however (Chapter 
6).
60The  brain  boundary  shift  integral  (BBSI)  has  been  validated  as  a  robust  tool  for 
quantifying  global  brain  atrophy  in  degenerative  dementia  (Fox and  Freeborough, 
1997; Freeborough and Fox,  1997).  The BBSI calculates the  shift at the brain/CSF 
boundary at every point across the three dimensional registered scan pair, the sum of 
which approximates closely to the brain volume lost; being a direct measure this leads 
to  a reduction in the error associated with indirectly comparing two  scans.  This  is 
discussed in more detail in chapter 9.
2.7.3.  Non-linear registration
Non-linear registration  allows  for  a more  accurate  matching  of gyral  anatomy  by 
allowing  scans  not  merely  to  match  through  movement  as  a  rigid  body,  but 
additionally through a warping proceedure.  One  such approach is  fluid registration 
(Freeborough and Fox,  1998) discussed in more detail in chapter 10, which models 
the transformation from one  scan to  another based on the physical properties of a 
viscous compressible fluid. Following a 9dof rigid body registration, the model aims 
to  find  an  exact  match between the  baseline  and the  second  scan;  in doing  so,  a 
displacement vector is generated for each voxel within the image, with the degree of 
stretch or contraction demonstrating expansion or atrophy over the period; this can be 
demonstrated as an overlay  image (voxel compression map) providing a means of 
demonstrating the pattern of regional atrophy throughout the brain, occurring between 
two  scans without the need  for a priori decisions about which structures should be 
assessed.
This  allows  an  individual’s  pattern  of progressive  atrophy  to  be  visualised.  An 
extension of this is to critically compare at a group level, fluid-registered scans from 
individuals  within  a  statistical  framework  (statistical  parametric  mapping-SPM,
61(Friston, 1995), allowing consistent patterns of atrophy within groups of patients to be 
demonstrated (see Chapter 11). SPM analysis of fluid registered images incorporates 
the  neuroanatomical  sensitivity  of within-individual  registration  and  the  power of 
group comparisons done with between-individual registrations. Fluid registration has 
been shown to be useful in propagating outlined hippocampal volumes forward from a 
baseline  scan  to  a  repeat  scan,  thus  potentially  increasing  accuracy  and  saving 
operator  time  in  making  hippocampal  measurements  (Crum  et  al.,  2001).  Other 
computational methods for determining atrophy patterns in an unbiased fashion have 
also  been  developed  and  a comprehensive  overview of these  techniques  has  been 
published (Ashbumer et al, 2003).
Whatever  method  is  used  it  needs  to  have  high  spatial  resolution  and  clear 
differentiation between tissue types. Normally, three dimensional, high resolution, T1 
weighted MRI acquired with conventional 1.5T MR scanners and 1mm  voxels across 
the cranium provide sufficient detail and contrast.
As MR scanners regularly undergo substantial hardware and software modifications 
and  as these  can  substantially alter  image  quality  and  intensity  contrast,  the  same 
scanner and MR acquisition parameters should be used for baseline and repeat scans. 
As with any other method of measuring changes  in brain volume over time, these 
methods are also sensitive to subtle brain changes that are not directly disease related, 
such as hydration and confounded by movement artefact.
2.8. Brain atrophy as a marker of disease progression
The  last  five  years  have  seen the  introduction  of new  drugs  aimed  at  modifying 
disease  progression or  alleviating  the  symptoms  of neurodegenerative  disease,  for
62example  riluzole  in  motor  neurone  disease  (MND)  and  donepezil,  rivastigmine 
galantamine and memantine in AD.
Drug  trials  require  accurate  clinical  diagnosis  to  ensure  purity  or  at  least  some 
homogeneity  of the  study  cohort.  In  the  NNIPPS  (Neuroprotection  and  Natural 
History in Parkinson-Plus  syndromes),  a randomised controlled trial  looking at the 
effect of Riluzole in PSP and MSA, diagnosis depends on consensus clinical criteria 
and there is a lack of well validated methods, which are not potentially influenced by 
symptomatic drug effects, with which to monitor disease progression. Modelling of 
the  trial  can  in  part  overcome  this  problem  but  generally,  clinical  evaluation  of 
progression  suffers  from  being  difficult  to  distinguish  from  symptomatic  effects 
without complicated trial design, or else is not easily quantifiable (e.g. the severity of 
gaze palsy). In cases with cognitive decline, psychometric data are potentially useful 
diagnostically and can be used to measure treatment effects, but require large numbers 
of cases which is not always practicable for these conditions.
There are at present no biomarkers to diagnose PSP and importantly for clinical trials, 
no reliable quantitative measure of disease progression.
An  objective,  quantitative  measure  of  disease  progression  is  badly  needed  for 
evaluation of novel drug therapies.  This prospective  study will  identify volumetric 
changes over time, which may prove useful as a quantifiable pragmatic measure of 
disease progression for future clinical trials.
2.8.1.  Potential problems with current outcome measures 
The utility of many neuropsychological tests and rating scales of clinical symptoms, 
has been demonstrated in clinical studies in PSP and in the other bradykinetic rigid 
syndromes (Cubo et al., 2000). The Unified Parkinson’s disease rating scale (UPDRS) 
has  been  shown  to  correlate  with  the  degree  of  123I-beta-CIT  binding  to  striatal
63dopamine uptake sites in PD  (Brucke et al.,  1997)  suggesting that the score might 
correlate  with  nigral  degeneration.  However  in  disease  modifying  drug  trials,  the 
power  of  these  tests  to  quantify  disease  progression  rather  than  simply  the 
symptomatic effect of drug intervention is unclear and striking disparities between the 
rating scale and functional imaging changes have occurred.
In a randomised withdrawal design,  patients are initially randomised to either active 
drug  or  placebo.  The  trial  continues  for  a  significant  duration  for  the  drug  to 
demonstrate efficacy over placebo in terms of the marker of disease severity (such as 
a clinical rating scale).  Subsequently, those randomised to active drug in the initial 
phase  are  further  randomised  to  either  continue  on the  active  drug  or  to  receive 
placebo.  If at the end of this second phase, those receiving placebo  (second phase 
only) maintain their difference from those receiving placebo through both segments, a 
disease modifying effect is inferred if the second phase has been long enough. If in 
the second segment, those receiving placebo deteriorate in their clinical scores to the 
level  of those  who  have  received placebo  throughout,  then a purely  symptomatic 
effect is suggested.
In a randomised start design, patients are initially randomised to either active drug or 
placebo.  At  the  end  of  the  first  period,  those  initially  receiving  placebo  are 
randomised to receive active drug or placebo. If at the end of this second segment, the 
group initially receiving placebo but then switched to the active drug, catch up those 
who have recieved the active drug from the start, a symptomatic effect is inferred. If 
the difference between the groups is maintained, then a disease modifying effect is 
postulated.
These studies, by their nature, need to include large numbers of patients and continue 
for at least a year.
64In an effort to reduce the completion time and patient numbers, surrogate markers of 
disease progression are needed urgently.
2.8.2.  Surrogate markers 
“A surrogate endpoint for a clinical trial is a laboratory measurement or a physical 
sign used as a substitute for a clinically meaningful endpoint that measures directly 
how a patient feels, functions or survives. Changes induced by therapy on a surrogate 
endpoint  are  expected  to  reflect  changes  in  a  clinically  meaningful  endpoint.” 
(Temple, 1999). The properties of an ideal surrogate endpoint should be:
1. It must not merely be a correlate of the true clinical outcome
2. The effect of an intervention on a valid surrogate endpoint must reliably predict the 
effect of the clinical outcome of interest
3. The treatment effect on the clinical outcome should be explained by its effect on 
the surrogate marker (Fleming and DeMets, 1996).
2.8.2.1. Successful surrogate markers
An example of a surrogate marker in a clinical disease  setting is the CD4 count in 
HIV infection. The HIV pathogen attacks CD4 cells. Reduction in CD4 cells leads to 
immuno-suppression,  which  leads to  morbidity  and  mortality.  Drugs  to  treat  HIV 
should increase the CD4 count, which should reduce the morbidity and mortality rate. 
Hence the CD4 count is used as a surrogate marker for mortality (the true outcome 
measure) in HIV treatment trials.
2.8.2.2. Failed surrogate markers
There  are  a  number  of reasons  why  surrogates  may  fail.  Again  these  have  been 
highlighted by Fleming and DeMets (Fleming and DeMets, 1996):
651.  While a surrogate may be a marker of the disease process,  its progression may 
involve a different pathological process. Hence intervention that affects a surrogate, 
may not affect the true clinical outcome.
2.  A  disease  may  progress  through  several  causal pathways,  not  all  of which  are 
mediated through the surrogate. Thus an intervention affecting the surrogate may not 
fully predict the effect on the true clinical outcome.
3. An intervention might affect a pathway leading to the true clinical outcome without 
impacting on the surrogate.
4.  The  intervention might, through unintended  mechanisms,  affect the true clinical 
outcome independent of the disease process.
2.8.3.  Serial imaging as a marker of disease progression 
Using  brain  imaging  as  a  surrogate  marker  of  disease  progression  in 
neurodegenerative  diseases  is  a  concept  first  proposed  in  1996  (Smith  and  Jobst, 
1996).
No disease modifying therapy is available in PSP. A claim for dopamine agonists as a 
neuroprotective  agent  in  PD  has  been  mooted  on  the  basis  of positron  emission 
tomography (PET) and clinical outcome measures (Whone et al, 2003).  This data, 
however cannot exclude the possibility that symptomatic benefit entirely explains the 
results.  In the  absence  of any proven disease-modifying  drug,  it  is  not possible to 
determine the effect of a drug on disease progression using MRI. However, there is 
increasing interest in Alzheimer’s disease (AD), to support the use of MRI measures 
of progression, as a viable surrogate marker.
2.8.3.1.  Biological plausibility 
In PSP  and MSA,  cross  sectional  imaging  studies  imply atrophy  in  specific  brain 
regions compared to normal controls. As very few serial imaging studies have been
66undertaken  in  these  disorders,  it  remains  uncertain  whether  clinical  disease 
progression is reliably associated with an increased rate of brain tissue loss.
However in AD, numerous studies have confirmed that excess cerebral atrophy occurs 
prior to the onset of symptoms in sporadic AD (Rusinek et al., 2003) and appears an 
inevitable consequence of disease progression (Fox and Schott, 2004). Studies in AD 
have also demonstrated correlations between the rate of cerebral atrophy in life using 
MRI and underlying pathological change at post mortem (Silbert et al.9  2003). Cases 
of serial imaging correlations with pathological findings at post mortem in PSP and 
MSA are described in chapter 3.5.2.
It is reasonable to hypothesise that in PSP, as in AD, excess rates of atrophy are: (1) a 
consequence  of  neurodegenerative  disease;  (2)  that  the  rate  of  clinical  disease 
progression depends at least partly on the rate of brain tissue loss (atrophy); (3) that 
the  clinical  phenotype  depends  on  the  distribution  and  tempo  of that  tissue  loss 
(regional atrophy) and; (4) the rates and regions of atrophy can be reliably quantified 
using serial MRI.
2.8.3.2.  Feasibility
In AD, the rates of atrophy measured using serial MRI have been calculated, and the 
number of patients required to power a drug trial can predicted from this. The sample 
sizes required to power a similar study in PSP are unknown as serial imaging studies 
have not been undertaken. It would be reasonable to assume, however, that the rate of 
total tissue  loss  is  likely to  be  lower  in  PSP than  in  AD  and  for this reason,  the 
number  of  patients  required  to  power  a  drug  trial  would  be  greater.  Whether 
measuring regional rather than whole brain atrophy in PSP would provide a method of 
monitoring disease progression with a smaller sample size is unknown. In AD, it has
67been  demonstrated that  similar  numbers  are  required  regardless  of whether whole 
brain or regional atrophy rates are used (Jack, Jr. et al., 2004).
2.9  Conclusions
All  neurodegenerative  diseases  require  brain  histopathological  examination  for 
definitive  diagnosis.  Whilst  the  classical  clinical  features  may  differentiate 
neurodegenerative  diseases,  heterogeneity  and  overlap  syndromes  present 
considerable difficulties. Furthermore, the severity of clinical features may not always 
accurately predict the stage of the disease or its rate of progression. A good example 
would be the supranuclear gaze palsy which may occur early and be severe or may be 
completely absent in PSP.
The  cell  loss  that  accompanies  histological  change  in  these  neurodegenerative 
diseases can be visualised using MR imaging. Regional atrophy results in features on 
cross sectional MRI that have been proposed as helping to discriminate  PSP from 
MSA, PD and healthy controls as well as from other degenerative diseases. However, 
many of these regions have not been quantitatively examined. Based on knowledge of 
the distribution of pathological changes at post mortem, there are also other regions 
which may prove to be better candidates for discriminating PSP. Imaging studies that 
make no a priori assumptions about where differences between diseases occur may 
help to identify new regions to study in more detail.
Measures of atrophy over relatively short periods of time (a year for example)  are 
more  likely  to  be  linear.  As  progressive  excess  atrophy  rates  appear  to  be  an 
inevitable  feature  of the  neurodegenerative  disease  process  closely  allied  to  the 
underlying  pathology  of  the  disease,  that  progressive  atrophy  is  a  biologically 
plausible  marker  for  disease  progression.  Hence  any  trial  suggesting  that  an
68intervention, compared to placebo produced a significant reduction in brain atrophy 
rates would imply a disease modifying effect in addition to any cognitive, behavioural 
or motor effects demonstrated using clinical rating scales of disease severity.
693.  Designing a prospective serial imaging study in bradykinetic-rigid 
syndromes: Preliminary studies and methods overview.
3.1. Hypothesis and aims of the study
Whole  brain  atrophy  rates  in  PSP  and  MSA  might  be  similar  given  that  these 
neurodegenerative diseases have a similar age at onset; disease duration and both have 
a relentless progression over 6-9 years to death. Therefore in addition to comparing 
rates of whole brain atrophy in PSP, MSA-P, PD and healthy controls, the aims of this 
study include comparing regional rates of atrophy in PSP, MSA-P, PD and healthy 
controls.
The differential  diagnosis of PSP,  MSA-P  and  PD  can  be  difficult  as the  clinical 
picture may in some cases be similar, particularly in the early stages of disease. MRI 
may help improve the accuracy of diagnosis during life and provide correlations with 
clinical features, clinical rating scales and neuropsychological scores. This study will 
clarify the association of clinical disease progression with atrophy and look for new 
MRI  based  diagnostic  markers  in  PSP.  It  will  also  use  novel  image  analysis 
techniques to determine the patterns of progressive global brain atrophy occurring in 
PSP, MSA-P and PD without making a priori assumptions about where that atrophy 
might occur.
In this way, this study aimed to  determine how MRI,  as a method of determining 
brain atrophy and disease progression, and as a diagnostic aid can best be applied to 
PSP.
3.2. Planning the clinical assessments
In the original paper describing progressive supranuclear palsy, the authors predicted 
that  “further observations may (in the  future) broaden the  clinical  spectrum of the
70disease”  (Steele  et  al.,  1964).  Subsequently  cases  presenting  with pure  akinesia 
without rigidity (Matsuo et al,  1991; Vemy et al.,  1996a), gait freezing (Matsuo et 
al.,  1991), rest tremor (Birdi et al.,  2002; Vemy  et al.,  1996a),  isolated dementia 
(Davis et al., 1985; Masliah et al., 1991), parkinsonism without dementia (Birdi et al., 
2002;  Davis  et  al,  1985;  Vemy  et  al,  1996b),  limb  apraxia  and  asymmetric 
parkinsonism  (Motoi  et  al,  2004)  as  well  as  a  number  of cases  dying  without 
recorded  evidence  of the  distinctive  supranuclear  ophthalmoplegia  (Daniel  et  al, 
1995;  Davis  et al,  1985;  Dubas et al,  1983)  have  been reported.  Despite  these 
observations  the  current  operational  criteria  for  the  diagnosis  of  progressive 
supranuclear palsy (PSP) includes very few clinical features that were not recognised 
in the original description (Litvan et al, 2003).
Attempts have been made to embrace the broader clinical features that are now well 
documented  in pathologically  confirmed  PSP,  but  are  not  part  of the  operational 
clinical diagnostic criteria.  An imprecise classification has evolved which includes 
typical and atypical clinical subgroups. The definitions of these subgroups have varied 
and have usually been applied retrospectively. They include: the presence or absence 
of supranuclear gaze palsy (Birdi et al,  2002; Daniel et al,  1995); the presence or 
absence  of a diagnosis of PSP  in life  (Gibb et al, 2004; Morris et al,  2002); the 
application of retrospective diagnostic criteria (Morris et al, 2002); and the presence 
or absence of early  bulbar signs or falls  (Nath et al,  2003).  Several authors have 
found genetic, prognostic or pathological differences between these putative clinical 
groups (Daniel et al,  1995; Morris et al, 2002; Nath et al, 2003).
That significant prognostic factors in a progressively debilitating neurodegenerative 
condition have been found is not surprising.  However, the clinical features that have 
been  reported  to  purport  the  greatest  prognostic  significance  are  also  the  classic
71clinical hallmarks described in Richardson’s original reports (Richardson et at,  1963; 
Steele et at,  1964) and are embraced by the accepted operational diagnostic criteria 
(Litvan et at, 2003).  Accordingly the absence of supranuclear gaze palsy, early falls 
and early bulbar dysfunction, with a positive response to levodopa conveys a good 
prognosis, but patients presenting in this way are much less likely to be diagnosed 
with PSP (Daniel et at,  1995).
There are no non-invasive  biological markers for the antemortem diagnosis of PSP 
(Litvan et at,  2003), and the  “definite”  diagnostic  category  has traditionally  been 
reserved for cases that are pathologically confirmed (Litvan et at,  1996a; Litvan et 
at,  1996b). The cases that remain undiagnosed in life make up at least 20% of the 
pathologically diagnosed cases of PSP (Hughes et at, 2002) and most have unusual or 
atypical clinical pictures (Daniel et at,  1995; Litvan et at, 1999; Morris et at, 2002). 
Hence  in order to  study the  correlation  of clinical  and  imaging  features  properly 
during life, it is important to have a clear understanding of the heterogeneity of PSP. 
With this in mind, all cases with a pathological diagnosis of PSP in the Queen Square 
Brain  Bank  for  Neurological  Disorders,  were  reviewed  and  the  clinical  features 
documented in a standardised manner.
3.2.1.  Clinical features of PSP cases in a regional brain bank
3.2.1.1.  Patients
One hundred and three consecutive cases of pathologically diagnosed PSP, donated 
from all over the UK between 1988 and 2002 and stored in the Queen Square Brain 
Bank (QSBB) at the Institute of Neurology, UCL were reviewed.  The diagnosis was 
made  according  to  the  NINDS-SPSP  criteria  (Litvan  et  at,  1996b),  and  was 
retrospectively applied to those cases acquired prior to the publication of the criteria. 
All  patients  had  been  assessed  during  life  by  a  hospital  specialist  (neurologist  or
72geriatrician).  Some  of these  cases  have  been  included  in  previous  clinical  and 
pathological reviews from the QSBB (Daniel et al.,  1995; Gibb et al.,  2004; Hughes 
et al., 2002; Morris et al., 2002; Osaki et al., 2004).
3.2.I.2.  Clinical data collection 
A  systematic  chart  review was  performed on all  the  case  notes.  Specifically the 
comprehensive case notes of the family doctor and all of the correspondence between 
the family doctor and the medical specialist were reviewed.  When available, medical 
inpatient  notes,  inpatient consultations  and  emergency  room admission notes  were 
also scrutinised.  A clinical data sheet was designed to record the presence or absence 
of clinical  features  either  early  in  the  disease  course  (within  two  years  of  first 
symptom onset) or at anytime during the disease.  Symptoms were recorded as being 
absent if not reported, and clinical signs were recorded separately as unknown if they 
were not specifically mentioned in the notes.  Where conflicting clinical features were 
recorded the findings of the neurologist were used.
Definitions  were:  Age  at  onset:  Age,  in  years,  at  the  time  of the  first  reported 
symptom  considered  to  be  attributable  to  PSP  or  Parkinsonism.  Duration:  Time 
between the age at onset and the age at death.  Falls:  The presence of any report of 
falls.  Bradvkinesia: The presence of any mention of bradykinesia or motor slowing. 
Cognitive  decline:  The presence  of any perceived cognitive  decline,  either by the 
patient, patient’s relative or the treating doctor.  This included annotation of difficulty 
in concentration, reports of intellectual functional decline and comments by the family 
of mental  slowing but did  not  include  affective  disorders.  No  patients underwent 
formal neuropsychological testing in the first twelve months of their disease.  Speech 
disturbance:  The recording of any alteration in speech quality compared to speech 
prior  to  disease  onset.  Dysphagia:  A  record  of  any  swallowing  abnormality.
73Asymmetric Onset: If there was a clear difference between the signs on the left and 
the  right  asymmetry was recorded as  being present.  This  included asymmetry of 
tremor, rigidity, bradykinesia or functional decline.  It did not include specific tasks 
such as writing and using tools.  Tremor:  The recording of any tremor.  Rigidity:  The 
recording  of  axial  or  peripheral  muscle  rigidity,  extra-pyramidal  and  pyramidal 
rigidity was not differentiated.  Impaired Postural Reflexes: The presence of this sign 
was only recorded if specifically mentioned in the clinical notes.  Supranuclear Gaze 
Palsy:  The  specific  recording  of restricted range  of eye  movement  in the  vertical 
plane.  Impaired Saccadic or Pursuit Movements: The specific recording of abnormal 
saccadic or smooth pursuit eye movements.  Other visual symptoms: The recording of 
other  visual  symptoms  not  explained  by  the  presence  of gaze  palsy  or  impaired 
saccadic or pursuit movements, which evolved during the disease course.  Symptoms 
include painful eyes, dry eyes, visual blurring, diplopia, blepharospasm and apraxia of 
eyelid opening.  Extra axial-dvstonia: The presence of dystonia in any body part apart 
from trunk and neck.  Pyramidal signs: Pathologically brisk reflexes and/or extensor 
plantar  response(s).  Autonomic  dysfunction:  Either  abnormal  autonomic  function 
testing  or  documentation  of any  two  of:  urinary  urgency,  frequency  and  nocturia 
without  hesitancy;  chronic  constipation;  postural  hypotension;  sweating 
abnormalities; erectile dysfunction.  Dyskinesia:  The presence of chorea associated 
with  levodopa  therapy.  Response  to  levodopa:  The  patient  and  clinician’s 
interpretation of improvement was assessed from the case notes and in some cases 
from  the  completed  Parkinson’s  Disease  Society  Brain  Bank  Annual  Assessment 
(PDSBB) Forms.  A self reported improvement of more than 30% coincident with the 
introduction of levodopa was recorded as being a positive response.  This degree of 
response was graded by a 4 point scale modified from the PDSBB annual assessment
74forms:  1   - nil, or slight response (<30% improvement), 2 - moderate response (30- 
50%  improvement),  3  -  good  response  (51-70%  improvement)  and  4  -  excellent 
response (71-100% improvement).
3.2.1.3.  Statistical methods
A complete data set of clinical variables each coded as present or absent was available 
from 29 cases only and these were entered into a principal components analysis in 
order to  summarise the information.  Other cases had missing data on one or more 
variables and could not be included in this analysis. Statistical analysis was performed 
using SPSS  for Windows (version 12.0.1).  The principal components analysis was 
performed  using  clinical  data  from the  first  two  years  of disease.  The  first  two 
principal components were selected and “Varimax” rotation performed (this rotation 
maximises  the  number  of variables  that  have  high  loadings  on  each  factor).  The 
loadings  of each variable  on both  of these  components were  plotted  against  each 
other.  The plot was examined and two groups of variables in different areas of the 
plot were  selected.  A between groups,  hierarchical  cluster  analysis using  squared 
Euclidean  distance  measures  was  performed  to  check  that  these  sets  of clinical 
features  grouped  together.  Those  cases  that  exhibited  a  greater  number  of the 
characteristics from set 1  than from set 2 were deemed to fall within group 1, and vice 
versa for group 2.  A cross tabulation was used to examine how many cases had a 
similar number of characteristics from the two variable sets. This was then applied to 
the  cases that were excluded  from the principal  components analysis.  Where there 
were  missing  data,  the  number  of  positive  results  found  were  scaled  up  (e.g. 
multiplied  by  5/3  where  status on 3  out of 5  characteristics  was known).  Clinical 
characteristics of the patients were compared between the two groups, and
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First 2 years Throughout disease
C lin ical Feature
Present
early
Absent
early
Not
recorded
Present 
in total 
cohort 
%
Present
ever
Absent
ever
Never
recorded
Present 
in total 
cohort 
%
Fals 61 40 2 60 93 8 2 94
Bradvionesia 74 26 4 75 99 0 4 98
Trem or 20 79 4 20 23 76 4 23
rC ogn#ive Decline 28 68 7 29 72 25 6 74
Nonspecific visual symptoms 20 77 6 21 48 49 6 50
R«i*y 43 53 7 42 95 2 6 98
Dysphagia 6 89 8 6 64 29 10 69
S peech disturbance 38 60 5 39 83 12 8 87
Soared postural reflexes 49 30 24 62 84 2 17 98
Supranuclear gaze palsy 19 31 53 38 75 7 21 91
A bnorm al pursuit or saccades 21 27 55 44 70 6 27 92
Extra-axial dystonia 7 89 7 7 25 70 8 26
Pyram idal signs 8 88 7 8 18 79 6 19
Cerebellar signs 0 10 3 0 1 98 3 1
A utonom ic dysfunction 0 100 3 0 2 97 3 2
C o rtica l sensory loss 0 97 4 0 1 97 4 1
Asym m etric Onset 26 67 10 28
Levodopa response 29 62 12 32
Levodopa induced dyskinesia 4 92 7 4
PSPs progressive supranuclear pa sy  .............................................  .   ..
significance was calculated using  Student’s t-test for normally distributed data, and 
chi-square or Fisher’s exact test for binary data.
3.2.1.4.  Results
3.2.I.4.I.  Clinical features
Clinical data was available for  103 pathologically confirmed cases of PSP, of which 
65 were male (63%).  The clinical diagnosis of PSP was made during life in 71  cases 
(69%),  24 (23%) were diagnosed with idiopathic  Parkinson’s disease  (PD), 2 (2%) 
with  atypical  PD,  2  (2%)  with  multiple  system  atrophy,  1   (1%)  with  corticobasal 
degeneration  and  in  3  a  final  clinical  diagnosis  was  not  established.  Neurologists 
made the final clinical diagnosis in 87% of cases and correctly diagnosed PSP in 72%.
The mean (SD) age of onset was 66.4 (12) years, age at death 73.5 (7.5) years, and
76disease  duration  was  7.0  (3.7)  years.  The  clinical  features  of these  patients  are 
summarised in Table 3.1.
An  asymmetric  onset  was  noted  in  28%  of cases.  Slowness  of  movement  or 
bradykinesia was the most commonly reported feature early in the disease, occurring 
in  75%  of cases.  Falls  (60%),  tremor  (20%),  cognitive  decline  (29%),  speech 
disturbance  (39%),  and  non  specific  visual  symptoms  (21%)  were  early  features. 
Rigidity and impaired postural reflexes were found in nearly half of the patients early 
on in the disease course.  Later in the disease, bradykinesia was present in 98% of 
cases, rigidity in 98% and falls in 94%.  Postural reflexes were impaired in 98% of 
cases, after the first two years of illness, and other signs included speech disturbance 
(87%),  dysphagia  (69%),  cognitive  decline  (74%),  tremor  (23%),  pyramidal  signs 
(19%) and extra-axial dystonia (26%).  Cerebellar signs (1%), autonomic dysfunction 
(2%), and cortical sensory loss (1%) were rare. The alien limb phenomenon was not 
reported in any patients.
In more than half the patients, early in the disease course, examination of the  eye 
signs was not recorded in detail, beyond a statement of “cranial nerve examination 
normal”. However, clear documentation of supranuclear gaze palsy was present early 
in the disease in 38%, and pursuit or saccadic eye movements were abnormal in 44% 
of cases.  By  contrast  later  in the  disease,  91%  of cases  were  recorded  as  having 
supranuclear gaze palsy though the clinical examination findings were incompletely 
recorded in 21%.
A qualitative trial of levodopa or dopamine agonist medications was undertaken in 91 
of  103  cases  (88%).  The  trial  was  not  recorded  or  was  not  performed  in  the 
remainder.  In 32% of cases there was a better than 30% improvement in symptoms 
coincident  with  the  initiation  of the  medication.  The  duration  of treatment,  and
77continued efficacy were not measured.  In four cases dyskinesias developed (4% of 
those treated).
3.2.1.4.2.  Statistical analysis
The first two components from the principal component analysis performed on data 
from the first two years of disease explained 42% of the variance seen in all cases. 
The loading of each variable on one component was plotted against its loading on the 
other  component  (Fig.  3.1).  This  suggested  that  the  variables  fell  into  two 
approximate groups (characteristic set 1   with high positive loadings on component  1  
and characteristic set 2 with positive loadings on component 2 and negative loadings 
on component 1).  The variables grouped together in each characteristic set were: set 
1   -   falls,  cognitive  decline,  supranuclear  gaze  palsy,  abnormal  saccadic/pursuit 
movements,  postural  instability;  set  2  -  tremor,  bradykinesia,  asymmetrical  onset, 
extra axial dystonia, response to levodopa.
78Figure 3.1.  Plot of factors for components 1  and 2, derived from factor analysis
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or pursuit movements; SPEECH, speech disturbance._________________________________
A  cluster  analysis  of  clinical  variables  confirmed  this  grouping  of  variables  as 
reasonable (Fig. 3.2).  This suggests that sufficient information was incorporated into 
the first two components of variance in order to determine groupings of characteristics 
between patients.
79Figure 3.2 Hierarchical cluster analysis of clinical variables: dendrogram using average 
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The frequency of the two sets of characteristics in the 29 cases with a complete data 
set  is  summarised  in  Table  3.2a  Fourteen  cases  (48%)  had  more  features  in 
characteristic set  1   than set 2, and were deemed to belong to  group  1.  Nine cases 
(31%) had more features in characteristic set 2, and were deemed to belong to group
2.  Six cases (21%) had an equal number of features in each characteristic set.
The frequency of the two sets of characteristics in the 71 cases with incomplete data is 
shown in Table  3.2b.  Five  cases  (7.4%)  had  an equal number  of features  in each 
characteristic  set.  Three  cases  were  excluded  from  the  analysis  because  of 
insufficient clinical information.  The low percentage of cases that were unclassified 
according to this division suggests that the identified characteristics are reasonable at 
distinguishing  two  groups.  The  two  groups  share  few  variables  from  each 
characteristic set, suggesting that they are clinically distinct.
80Table 3.2a Cross tabulation of the number of 
characteristics in each of two sets exhibited by 
each case for initial data set.
Set 2
0  1 2   3  4
Total
0
1
2
3
T  4  ■
co  5
1 1 1 2 2 7
0 2 0 0 0 2
1 0 3 2 0 6
0 0 0 0 1 1
2 2 1 1 0 6
0 6 1 0 0 7
Total 4 11 6 5 3 29
Set 1: falls, cognitive decline, 
supranuclear gaze palsy, abnormal 
saccades/pursuit movements, 
postural instability.  Set 2: tremor, 
bradykinesia, asymmetric onset, non- 
axial dystonia, response to levodopa
The 66 cases that were not included in the principal components analysis, and were 
able  to  be  separated  into  two  groups  with  the  cross  tabulation,  were  compared 
according to the presence or absence of early clinical features (Table 3.3).
The  co-occurrence  of clinical  features  appeared  to  be  similar  to  the  cases  with  a 
complete data set, included in the principal components analysis.  Early bradykinesia 
occurred in around three quarters of cases  in  both groups and did  not differentiate 
them.
Table 3.2b Cross tabulation for the second data
set where at least one variable was missing.
Set 2 Total
0 1 2 3 4
0 2 7 8 6 2 25
1 1 0 0 0 0 1
2 0 1 1 1 0 3
3 2 10 4 2 0 18
T  4 a> 1 3 3 0 0 7
“   5 3 8 2 4 0 17
Total 9 29 18 13 2 71
81Table 3.3 Early clinical features in cases with an incomplete data set
Group 1 Group 2
% reported as % reported as p value
present present
Symptoms
‘Falls 85.7 0% <0.001°
(36/42) (0/24)
‘Cognitive decline 50.0 0 <0.001°
(19/38) (0/22)
*Tremor 9.8 39.1 0.007°
(4/41) (9/23)
Speech disturbance 32.5 26.1 0.406°
(13/40) (6/23)
Dysphagia 2.7 4.3 0.624°
(1/37) (1/23)
Other visual symptoms 23.1 4.3 0.051°
(9/39) (1/23)
Clinical signs
‘Asymmetric onset 17.9 45.0 0.030°
(7/39) (9/20)
‘ Bradykinesia 75.6 73.9 0.880a
(31/42) (17/23)
Rigidity 39.5 52.5 0.333a
(15/38) (12/23)
‘ Postural Instability 84.4 7.7 <0.001°
(27/32) (1/13)
‘ Extra-axial dystonia 0 8.7 0.138°
(0/38) (2/21)
‘Supranuclear gaze palsy 70.0 0 0.002°
(7/10) (0/9)
‘Abnormal saccades/pursuits 63.6 0 0.017*
(7/11) (0/6)
Pyramidal tract signs 7.9 4.3 0.513°
(3/38) (1/23)
‘ Response to Levodopa ever 14.3 50.0 0.005°
(5/35) (11/22)
‘ variables used in initial analysis; chi-square analysis;D  Fisher’s exact test
Group 1: Richardson’s Syndrome, Group 2:  PSP-P
All 89 cases that could be separated into groups were compared according to profile 
(Table 3.4) and the late clinical features that they displayed (Table 3.5).  There was a 
difference in sex distribution between the two groups.  Men were over represented in 
group  1   (64.3%,  95%  confidence  interval  (Cl):  52-77%),  but  sex distribution was 
equal in group 2 (51.5%, 95% Cl 33-67%).  The age of disease onset was not different 
between the two groups.
82Table 3.4 Patient profiles
Group 1 Group 2 *p value
Sex (male,  %) 64.3 61.5
Age at disease onset (years) 66.1 66.4 0.872
Age at death (years) 72.1 75.5 0.041
Disease duration (years) 6.94 9.12 <0.001
* student’s t test
Table 3.5 Late clinical features in 89 cases separated into distinct groups
Group 1  Group 2
% reported  % reported as  p value
________________________________ as present  present______________
Symptoms
Falls 100 80.6 0.001a
(56/56) (25/31)
Cognitive decline 90.7 51.6 <0.00f
(49/54) (16/31)
Tremor 13.0 43.8 0.002b
(7/54) (14/32)
Speech disturbance 90.2 81.3 0.242a
(46/51) (26/32)
Dysphagia 75.5 56.3 0.070s
(37/49) (18/32)
Other visual symptoms 56.6 34.4 0.047s
(30/53) (11/32)
Clinical signs
Bradykinesia 98.2 96.9 0.685a
(55/56) (31/32)
Rigidity 98.1 96.8 0.687a
(53/54) (30/31)
Postural Instability 100 96 0.142a
(51/51) (23/24)
Extra-axial dystonia 21.2 42.4 0.054b
(11/51) (13/32)
Supranuclear gaze palsy 100 71.4 <0.001'
(50/50) (15/21)
Pyramidal tract signs 17.0 15.6 0.561b
(9/53) (5/32)
Levodopa induced dyskinesia 1.9 6.3 0.323b
(1/52) (2/32)
a chi-square analysis;D  Fisher’s exact test 
Group 1:  Richardson’s syndrome, Group 2: PSP-P
The ages at death and disease duration were significantly different: those in group 1  
died at a younger age, and after shorter disease duration.
Falls,  cognitive  decline  and  supranuclear  gaze  palsy  continued to  be  significantly 
associated with group  1   later in the disease (p<0.001).  Tremor was the only clinical 
feature significantly associated with group 2  later in the disease though extra-axial 
dystonia was also more frequent in that group.  There was no significant difference in
83the frequency of bradykinesia, speech disturbance, postural instability, pyramidal tract 
signs or levodopa induced dyskinesias.
3.2.I.5.  Conclusions 
These data seem to confirm that two distinct clinical phenotypes exist in patients with 
pathologically  proven  PSP.  One  is  characterised  by  early  falls,  early  cognitive 
dysfunction,  abnormalities  of  gaze  and  postural  instability,  and  the  other  by 
asymmetric onset, tremor, early bradykinesia, non-axial dystonia and a response to 
levodopa  medications.  The  clinical  characteristics  present  in  this  first  group  are 
similar to those first described in PSP by Richardson (Richardson et al,  1963; Steele 
et al.,  1964), whereas the clinical features in the second group more closely resemble 
PD. Phenotype one has a shorter duration of disease and the female to male ratio is 
1:1.8, whereas the sex distribution is equal in phenotype two (see Table 3.4).
Because  of  ascertainment  bias  the  proportions  of patients  presenting  with  these 
phenotypes  in this  study may not  reflect the  proportions  of these  subtypes  in the 
community  (Maraganore  et  al,  1999).  However  the  frequency  of  falls  (94%), 
bradykinesia (98%),  speech disturbance  (87%)  and  dysphagia  (69%)  in the  whole 
group  was  consistent  with  data  reported  in  other  clinical  and  clinicopathological 
studies  (Maher and Lees, 1986; Nath et al, 2003; Vemy et al,  1996b).  In contrast to 
some studies there was a higher incidence of levodopa responsiveness (32%), extra- 
axial dystonia (26%) and a longer duration of disease  (Maher and Lees, 1986; Nath et 
al,  2003).  The  inclusion  of only  pathologically  proven  cases  of PSP  partially 
accounts for this, and is a strength of this study, allowing us to more clearly identify 
atypical clinical features in cases that would have been automatically excluded from 
clinical reports relying on PSP clinical diagnostic criteria.
84Previously, attempts have been made to define clinical subgroups in cohorts of PSP 
(Birdi et al., 2002; Gibb et al., 2004; Maher and Lees, 1986; Morris et al., 2002; Nath 
et al.,  2003)  and to  apply this  classification in  small pathologically proven  series 
(Bergeron et al.,  1997; Braak et al.,  1992; Daniel et al.,  1995; Vemy et al.,  1996b). 
Daniel  and  co-workers  found that  in  a  subgroup  without  supranuclear  gaze  palsy 
women were over represented,  age at onset was  later and duration of disease  was 
longer when compared to the group with supranuclear gaze palsy, where men were 
over represented (Daniel et al.,  1995).  No  quantitative or qualitative pathological 
differences  were  distinguished,  although a  subsequent  study  on the  same  material 
showed greater neuronal loss in the nucleus interpositus in those with a supranuclear 
gaze palsy (Revesz et al.,  1996). Birdi and collaborators reported that patients with 
gait or balance difficulties at onset were less likely to improve on levodopa therapy, 
more likely to develop supranuclear gaze palsy and had a shorter duration of disease 
(Birdi et al., 2002).  Morris and colleagues classified pathologically confirmed cases 
of PSP according to the diagnosis of PSP in life and the retrospective application of 
diagnostic  criteria for PSP  (Morris et al.,  2002).  All cases  in their “typical PSP” 
subgroup had a diagnosis of PSP  in life, all retrospectively satisfied the diagnostic 
criteria, and such cases were more likely to have the PSP susceptibility tau haplotype 
(HI,HI).  In a series where only 60% of cases had pathological confirmation, Nath 
and co-workers found that the subgroup with early falls and bulbar dysfunction had a 
shorter survival, and those with a diagnosis of probable PSP according to the National 
Institute  for Neurological  Diseases  and  Stroke -   Society  for  PSP  (NINDS-SPSP) 
criteria had a worse prognosis (Nath et al., 2003). The variations in definition between 
these studies make it difficult to compare clinical groups and even more difficult to 
apply  clinical  characteristics  objectively to  pathological  cohorts.  By  applying the
85clinical distinctions identified in this study, comparisons can be made between more 
homogenous  clinical  groups  potentially  enabling  a  better  understanding  of  the 
spectrum of pathological changes in PSP.
A number of authors have found pathologic differences in cases of clinically “typical” 
and “atypical” PSP, without applying a standardised system for clinical classification. 
In one report two  subgroups were  identified that  could be  divided on clinical  and 
pathological grounds (Vemy et al,  1996b).  A group with mild involvement of the 
pedunculopontine nucleus invariably had mild cortical involvement and a number of 
“unusual”  clinical  signs  including  absence  of oculomotor palsy  and  axial  rigidity, 
severe  early dementia and rest tremor.  The  subcortical  structures  involved had  a 
preferentially  ‘pallido-luyso-nigrar  distribution.  The  second group  all  had typical 
clinical  signs  with more  severe  involvement  of the  pedunculopontine  nucleus  and 
cortex, and more widespread involvement of subcortical structures.  The sample size, 
however, was too small to come to definitive conclusions relating to differences.  In 
other reports patients with early severe dementia were found to have more cortical 
pathology (Bigio et al,  1999; Braak et al,  1992)  , and pathological changes in the 
nucleus raphe interpositus which correlate with supranuclear gaze palsy in PSP  have 
been reported (Revesz et al,  1996). The variation of pathological involvement in PSP, 
and the  identification of some clinical  correlation with  it,  supports the notion that 
different clinical groups exist and differences in early pathological involvement of the 
striatum,  pallidum  or  subthalamus  may  account  for  the  observed  marked  clinical 
differences between these different presentations of PSP.
No  cases  exhibiting  any  of the  NINDS-SPSP  mandatory  exclusion  criteria  were 
identified  (Litvan et al,  1996a).  However,  according  to  the  data  some  features
86included in the NINDS-SPSP “supportive criteria” may be misleading.  Early speech 
disturbance was found in 39% of cases, and 32% had a modest or good response to 
levodopa (PDSBB grade 2 or 3), though an excellent response to levodopa (PDSBB 
grade 4) was never recorded.  While an asymmetrical onset was a feature in 28%, 
persistent markedly asymmetrical Parkinsonism was not seen.
With the results of this preliminary data analysis in mind, the collection of clinical 
data in this imaging study was prospectively planned. The principal aim was to look 
at rates of brain atrophy, but in order to relate brain atrophy to the clinical features 
and determine whether the phenotypic variability has a clinical correlate, an accurate 
and standard method of clinical data collection needed to be used. The datasheet used 
to  retrospectively collect data in the post mortem study was altered for use in this 
prospective  study.  Clinical  rating  scales  including  the  UPDRS  were  used  so  that 
parameters  such  as  bradykinesia,  rigidity,  cognitive  decline,  mobility  and postural 
stability could be quantified.
Full details of clinical data collection,  is provided in the following  sections  and in 
chapter 4. The clinical exclusion criteria for PSP were adhered to strictly as the results 
of this preliminary study indicate that they are helpful in preventing a false positive 
clinical diagnosis of PSP.
3.3.  The clinical diagnostic criteria
The current accepted clinical diagnostic criteria for PSP (Litvan et al., 2003), MSA 
(Gilman et a l, 1999) and PD (Gibb and Lees, 1988) are outlined below (Tables 3.6a- 
c).
87Table 3.6a Diagnostic criteria for PSP
PSP
Inclusion criteria:
For clinically probable and 
definite:
Gradually progressive 
disorder with age at onset at 
40 or later;
Clinically possible PSP:
Gradually progressive 
disorder >12 months 
duration, onset over 40 yrs, 
tendency to fall within 1 year 
of onset.
Supportive criteria:
Symmetric akinesia or 
rigidity, proximal more than 
distal; abnormal neck 
posture, especially retrocollis; 
poor or absent response of 
parkinsonism to levodopa; 
early dysphagia & dysarthria; 
early onset of cognitive 
impairment including > 2 of: 
apathy, impairment in 
abstract thought, decreased 
verbal fluency, utilization or 
imitation behaviour, or frontal 
release signs
Clinically probable PSP:
Either vertical supranuclear 
palsy or both slowing of 
vertical saccades & postural 
instability with falls < 1 yr 
disease onset 
Clinically definite PSP: 
Vertical supranuclear palsy 
and prominent postural 
instability with falls/tendency 
to falls, within first year of 
disease onset 
Definite PSP:
All criteria for possible or 
probable PSP are met and 
histopathologic confirmation 
at autopsy
Exclusion criteria:
Recent history of 
encephalitis; alien limb 
syndrome; cortical sensory 
deficits; focal frontal or 
temporoparietal atrophy; 
hallucinations or delusions 
unrelated to dopaminergic 
therapy; cortical dementia of 
Alzheimer type;  prominent, 
early cerebellar symptoms or 
unexplained dysautonomia; 
or evidence of other diseases 
that could explain the clinical 
features
88Table 3.6b Diagnostic cntena for MSA
MSA
Autonomic and urinary 
dysfunction
Orthostatic hypotension (by 
20 mm Hg systolic or 10 mm 
Hg diastolic); urinary 
incontinence or incomplete 
bladder emptying
Parkinsonism 
Cerebellar dysfunction
Corticospinal tract 
dysfunction
B, R, I, and T
Gait ataxia; ataxic dysarthria; 
limb ataxia; sustained gaze- 
evoked nystagmus 
Extensor plantar responses 
with hyperreflexia
Orthostatic fall in blood 
pressure (by 30 mm Hg 
systolic or 15 mm Hg 
diastolic) and/or urinary 
incontinence (persistent, 
involuntary partial or total 
bladder emptying, 
accompanied by erectile 
dysfunction in men)
1  of 3 (R, I, and T) and B 
Gait ataxia plus at least one 
other feature
No corticospinal tract 
features are used in defining 
the diagnosis of MSA
B, bradykinesia; R, ngidity; I, postural instability; T, tremor
for PD Table 3.6c Diagnostic criteria 
PD
Inclusion criteria
Bradykinesia (slowness of 
initiation of voluntary 
movement with progressive 
reduction in speed and 
amplitude of repetitive 
actions)
And at least one of the 
following:
Muscular rigidity.
4-6 Hz rest tremor.
Postural instability not 
caused by primary visual, 
vestibular, cerebellar, or 
proprioceptive dysfunction.
Supportive criteria
(Three or more required  for 
diagnosis of  definite PD) 
Unilateral onset.
Rest tremor present. 
Progressive disorder. 
Persistent asymmetry 
affecting side of onset most. 
Excellent response (70- 
100%) to levodopa.
Severe levodopa-induced 
chorea.
Levodopa response for 5 yr 
or more.
Clinical course of 10 yr or 
more.
Exclusion criteria
History of repeated strokes 
with stepwise progression of 
parkinsonian features 
History of repeated head 
injury
History of definite 
encephalitis 
Oculogyric crises 
Neuroleptic treatment at 
onset of symptoms 
More than one affected 
relative
Sustained remission 
Strictly unilateral features 
after 3 yr
Supranuclear gaze palsy 
Cerebellar signs 
Early severe autonomic 
involvement
Early severe dementia with 
disturbances of memory, 
language, and praxis 
Babinski sign
Presence of cerebral tumour 
or communicating 
hydrocephalus on CT scan 
Negative response to large 
doses of levodopa (if 
malabsorption excluded) 
MPTP exposure
89From the most recent update on research clinical diagnostic criteria (Litvan et al., 
2003), patients are considered to have clinically possible PSP if they suffer from a 
gradually progressive disorder of more than 12 months duration, with onset over 40 
years of age, and with a tendency to fall within the first year of disease onset, in the 
absence of defined exclusion criteria (Table 3.6a). There should be no clinical features 
suggestive  of Creutzfeldt-Jakob  disease  or  any  other  identifiable  cause  for  their 
postural instability.
3.4.  Planning the neuropsychological assessments
A  number  of neuro-cognitive  models  have  been proposed  for  “frontal”  cognition. 
These  are  inevitably  incomplete.  These  are  associated  with  structure  function 
correlations which are also  inadequate. Despite these caveats, the following section 
may be useful as background to the results described in later sections.
3.4.1.  Frontal sub-cortical circuit syndromes 
A series of parallel frontal-subcortical circuits that link specific regions of the frontal 
cortex,  important  in  human  behaviour,  to  the  striatum,  globus  pallidus  and  the 
thalamus have been defined (figure 3.3) (Alexander et al, 1986).
Frontal cortex
Striatum
Globus 
Pallidus / 
Substantia 
Nigra
Thalamus
Fig. 3.3 Schematic diagram of the 
frontal cortical sub-cortical loop
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1.  The motor circuit (originating in the supplementary motor area).
2.  The oculomotor circuit (originating in the frontal eye fields).
3.  The dorsolateral prefrontal circuit (originating in Brodmann area 9+10).
4.  The orbital-frontal circuit (originating in Brodmann area 10+11).
5.  The anterior cingulate circuit (originating in Brodmann area 24).
More recently, it has been suggested that the original five-circuit scheme should be 
broadened to include seven general categories of circuits: skeletomotor; oculomotor; 
dorsolateral  prefrontal;  lateral  orbitofrontal;  medial  orbitofrontal;  cingulate  and 
inferotemporal-posterior parietal (Middleton and Strick, 2000).
Within each circuit, there is a direct and an indirect pathway. These modulate input to 
the thalamus in response to different stimuli.
Fibres  in each circuit originating from the  frontal lobe  are mediated by excitatory 
glutaminergic neuro-transmission. These projections are mainly to the striatum. The 
dorsal  striatum  has  two  separate  cytochemical  structures,  the  striosomes  and  the 
matrix.  The striosomes mature earlier; have a lower dopamine concentration and a 
higher concentration of limbic associated membrane protein. The striosomes receive 
input  mainly  from  the  orbitofrontal,  temporal  and  insular  cortex  and  the  ventral 
substantia nigra (pars compacta). Output is mainly to the medial substantia nigra. The 
matrix receives input from the sensorimotor cortex and the parietal cortex as well as 
the cingulate  gyrus  and output is mainly to the  globus pallidus  and the  substantia 
nigra.
913.4.1.1. Dorsolateral prefrontal syndrome
Patients  with  damage  to  the  dorsolateral  prefrontal  circuit,  are  concrete  and 
perseverative  with  slow and  impaired  reasoning  and poor mental  flexibility.  They 
have an inability to maintain and to redirect attention. Typically they perform poorly 
on tests of attention and set shifting such as the Wisconsin Card Sorting Test. They 
have difficulties with verbal fluency and alternating motor sequences.
3.4.1.2. Orbitofrontal syndrome
The orbitofrontal circuit connects frontal monitoring systems to the limbic  system. 
Dysfunction here is characterised by behavioural disinhibition and emotional lability. 
Patients  are  irritable  and  may  have  explosive  aggressive  outbursts.  Inappropriate 
responses to  social cues,  lack of interpersonal sensitivity,  improper sexual remarks 
and inappropriate jocularity are other clinical features.
3.4.1.3. Anterior cingulate syndrome
The anterior cingulate circuit mediates motivated behaviour and dysfunction in this 
area is reflected by apathy.  A bilateral anterior cingulate  lesion results  in akinetic 
mutism, which has the features of prominent apathy, an indifference to pain, thirst and 
hunger, inertia, a lack of motor initiative, and a lack of verbalization and response to 
commands. Abulia is a less severe form of this psychomotor retardation.
The  major  deficit  of patients  with damaged  anterior  cingulate  circuit  structures  is 
response inhibition on go/no-go tests.
The cognitive deficit seen in PSP has features consistent with damage to all of these 
frontal sub-cortical circuits.
923.4.2.  Review of the Neuropsychological profile in PSP
In the seminal description of PSP, emphasis was placed upon the distinctive clinical 
features  of  early  postural  instability,  a  supranuclear  gaze  palsy  predominantly 
affecting  vertical  eye  movements,  axial  rigidity,  retrocollis  and  symmetrical 
Parkinsonism (Richardson et al.,  1963; Steele et al,  1964). Cognitive dysfunction was 
also noted in seven of the nine patients described in 1964. In one case this was limited 
to  mild bradyphrenia but in the others, emotional lability,  increased irritability and 
personality change were present. While these changes were often reported early, they 
tended to remain mild and in only two cases became severe.  Only one of the nine 
cases had early severe dementia.
Since  the  original  description,  the  neuropsychological  features  of PSP  have  been 
extensively reviewed (Albert et al.,  1974; Grafman et al.,  1995; Litvan et al.,  1989; 
Litvan, 1994; Litvan et al., 1996d; Maher et al., 1985; Robbins et al., 1994). Albert et 
al  further  expanded  the  cognitive  profile  of PSP  with  a  study  documenting  the 
neuropsychological findings in five of their own cases of PSP and 42 other cases from 
the medical literature where sufficient information was available (Albert et al.,  1974). 
They  described  a  constellation  of symptoms  including  slowed  thought  processes, 
emotional lability, personality change and an impaired ability to manipulate acquired 
knowledge, which they referred to as “subcortical dementia”.
This syndrome of subcortical dementia has been claimed to be distinct from cortical 
dementia in its clinical manifestation and in its anatomico-pathological correlations. 
Sub-cortical  dementia  describes  a  combination  of profound  slowing  of cognition, 
memory disturbance and executive dysfunction as well as changes in personality and 
affect  (Albert  et  al.,  1974).  It  has  been  argued  however  that  neuropsychological 
profiles of cortical and sub-cortical dementia are not sufficiently distinct (Brown and
93Marsden, 1988) and that cortical cognitive deficits may occur with subcortical lesions 
(Hughes et al., 1993).
In Alzheimer disease (AD), typical clinical findings  include dyscalculia, dysphasia, 
dyspraxia and agnosia.  Accelerated forgetting is also said to be  striking.  These are 
said to result from cortical dysfunction. Apathy and irritability along with depression 
are less common in AD than they are in Parkinson’s disease (PD) (Aarsland et al., 
1999)
Executive  dysfunction  is  one  of the  main  features  of sub-cortical  dementia  and 
consists of difficulty with verbal fluency,  set  shifting, categorisation and planning. 
There is some evidence that this is may also be impaired  in early AD (Kopelman, 
1991).  In sub-cortical dementia,  learning  impairment can be partially  corrected by 
providing  richer  or  more  salient  cues  to  encourage  learning  and  to  promote 
recognition.
None  of the  PSP  patients Albert  et al reviewed  in  1974  had evidence  of aphasia, 
agnosia or apraxia (Albert et al.,  1974),  although mild  apraxia  may  occur  in PSP 
(Leiguarda et al.,  1997; Pharr et al.,  1999; Pharr et al., 2001) and aphasia has been 
rarely reported (Esmonde et al.,  1996). A quantitative study of the cognitive profile in 
PSP  found  that  bradyphrenia  was  evident  but  short-term  memory  was  unaffected 
(Litvan,  1994).  In  PSP,  difficulties  with  concept  formation  and  with  shifting 
established conceptual sets were common, as were  slowed psychomotor responses. 
Attention was impaired and this was related to disease duration.
Subcortical  lesions  have  been  well  documented  to  cause  a  specific  pattern  of 
dementia.  Symptoms  of  mental  impairment  such  as  inattention,  disorientation, 
confusion  and  emotional  disturbances  dominated  the  clinical  picture  in  an  early 
clinico-pathological  study  of tumours  of the  thalamus  (Smyth  and  Stem,  1938).
94Various other reports of dementia in the absence of cortical pathology appear in the 
literature. These variously describe, some form of memory defect, a general slowing 
of  intellectual  activity,  alterations  of  personality  (typically,  inertia  or  apathy, 
occasionally with episodic irritability) and an impaired ability to manipulate acquired 
knowledge.
Visual  attention  is  affected  in  PSP,  and  patients  have  difficulty  orientating  their 
attention when compared to controls. The severity of this impairment correlates well 
with the course of the disease. Hence, all tasks requiring visual scanning may result in 
impaired performance in PSP (Kimura et al., 1981). This may mean that some aspects 
of the  pattern  or  severity  of cognitive  impairment  described  in  PSP  arise  as  a 
consequence  of the  psychological test  scores being  influenced by  defective  visual 
scanning  and  are  not  an integral  feature  of the  disease.  More recent  testing  using 
techniques not dependent on visual scanning support the presence of a clear pattern of 
dementia but as stated this is not typically early or severe. Defective visual scanning 
needs to be taken into account in any test battery for PSP.
Patients with PSP have a slowed speed of information processing. This is in part due 
to slowed motor response times, but sensory and cognitive information processing are 
also slowed and subject to degradation. Working memory (short term memory stores), 
from  which  information  is  transferred  to  more  permanent  knowledge  stores,  is 
unaffected in PSP. However, several aspects of episodic (long-term) memory appear 
to be impaired. Verbal learning with the Rey Auditory Verbal learning test has shown 
that  patients  with  PSP  recalled  fewer  words  than  controls.  Cueing  improves 
performance  (Pillon  et  al.,  1994)  suggesting  a  difficulty  in  accessing  stored 
information. This contrasts with the recognition and recall deficits with hippocampal 
and cortical impairments.  Strategic encoding and retrieval procedures subserved by
95the  fronto-striatal  system  seem  particularly  compromised  in  the  “sub-cortical” 
dementia of PSP.
Executive  functions  are  impaired  in  PSP  and  this  is  thought  to  be  due  to 
deafferentation between the  basal  ganglia and the prefrontal cortex.  The prefrontal 
cortex  has  been  described  as  supporting  “executive  function”  including  working 
memory,  reasoning,  problem  solving,  conceptualisation,  planning  and  social 
cognition.  PSP patients have problems forming  concepts and interpreting proverbs. 
They make more errors on the Wisconsin Card Sorting test and the majority of these 
are of the perseverative type. They also have difficulty ordering events in the correct 
sequence as shown by poor performance on the picture arrangement  subtest of the 
Wechsler Adult Intelligence Scale (WAIS). Word and figural fluency tests both result 
in perseverative responses in PSP.
There is little information available regarding the mood state and personality change 
of PSP patients following the onset of their disorder.
In summary, changes in executive function and information processing appear early in 
the course of PSP and are relatively severe. Both of these are characteristic of PSP 
and help to differentiate it from other dementias.  Orientation and episodic memory 
although impaired, are less severely affected. The majority of these cognitive defects 
are attributed to frontal deafferentation secondary to sub-cortical lesions.
The executive dysfunction in PSP is also to a lesser extent, a feature in other akinetic- 
rigid syndromes such as MSA and PD.
Cognition and emotion have been compared in different akinetic rigid disorders. The 
risk of developing  dementia in PD  is at  least 3 times greater than in age-matched 
subjects.  A recent  study,  including 224 patients with PD, with a mean age of 73.4
96years and a mean disease duration of 9.2 years suggested that, based on a clinicians 
assessment and scores on three cognitive rating scales, the eight year prevalence of 
dementia in PD is around 78% (Aarsland et al, 2003). In PD, visuospatial, executive 
function and memory are impaired in the absence of genuine amnesia or impairment 
of instrumental  activities  resulting  in  aphasia,  apraxia  or  agnosia.  Mild  executive 
dysfunction is observed  even at the early  stages of PD when  lesions  are probably 
restricted to the brainstem structures supporting the hypothesis that they derive from 
sub-cortical pathology of the disease. Dementia in PD is associated with depression, 
institutionalization, older age at onset, and atypical neurologic features, such as early 
occurrence of autonomic failure, symmetrical disease presentation, and only moderate 
response to a dopaminergic drug (Aarsland et al, 1996).
Compared with PD,  executive  functions  in PSP  are much more  severely  affected. 
Although the  cortex  is  involved  in  PSP,  the  severe  frontal  syndrome  observed  in 
patients with PSP seems to be as a consequence of the loss of specific afferents to the 
pre-frontal cortex from sub-cortical regions.
MSA is classically thought of as having normal cognitive and affective status with a 
mild  impairment  of  memory  and  executive  function,  selective  for  frontal  lobe 
involvement.  This  is  qualitatively  different  from  PD  and  PSP.  As  well  as  being 
severely  affected  in  PSP,  there  is  involvement  to  a  lesser  extent  of the  frontal 
functions in the cognitive changes associated with PD, however, patients with PSP 
tend to have significantly lower scores in frontal behavioural tests than PD or MSA at 
all  levels  of  cognitive  impairment.  In  PD  there  is  slow  verbal  production  and 
formulation of answers. There is a decline in attention, an incapacity for abstraction 
and criticism and impaired judgement. In addition, visuo-spatial function, executive 
function  and  memory  are  all  affected  in  the  absence  of  genuine  amnesia  or
97impairment  of instrumental  activities  such  as  aphasia,  apraxia  or  agnosia.  These 
features are related to the  sub-cortical pathology of the disease.  In PD, the biggest 
problems arise from difficulties with executive function involving problem solving 
and planning. Generally speaking, the PD patients with deteriorating cognition tend to 
be  older,  have  greater  motor  impairment  and  more  psychotic  symptoms  and 
hallucinations (Aarsland et al,  1996).
Soliveri et al (Soliveri et al., 2000) followed up 23 patients with MSA-P, 21 patients 
with PSP and  18 patients with PD.  The patients were matched for disease severity, 
according to the Hoehn and Yahr scale and the activities of daily living (ADL) on the 
UPDRS.  The  rates  of deterioration  in  most  cognitive  tests  did  not  differ  greatly 
between the groups, but the relatively short follow up period (21 months) and a high 
dropout rate (40%) limits definitive conclusions.
3.4.3.  Choice of neuropsychological test battery
The neuropsychological test battery for this thesis was chosen in order to attempt to 
optimise the distinction between PSP, MSA-P and PD. Ability of the tests to detect 
change in cognition over time was also given consideration, but given that a relatively 
short  interval between  assessments  was  planned,  this was  felt  to  be  of secondary 
importance. An experienced neuropsychologist was involved from the outset. Tests of 
more general cognitive function were also included in order to enable assessment of 
how for example memory impairment might affect other cognitive test scores.
Each patient’s  level of education was noted.  This was  scored  in terms of years of 
education with each year of schooling after the age of 5 counted. As an example, an 
individual  leaving school at age  16, would have  11  years of education, whereas,  a
98person continuing to a university degree would have  11  plus 2 (schooling from age 
16-18), plus 3 (university degree) years, totalling 16 years of education.
The  pre-morbid  level  of intellectual  functioning  was  estimated  using  the National 
Adult  Reading  Test  (NART)  (Nelson,  1982).  The  neuropsychological  test  battery 
included: the Mattis dementia rating scale-2 (which consists of the following subtests: 
attention,  verbal  and  non-verbal  memory,  motor  initiation,  construction  and 
conceptual ability) with a maximum score of 144 and a cut off suggesting cognitive 
dysfunction of 130 (Mattis S.,  1973); current Verbal IQ based on completion of the 
Vocabulary, Similarities and Digit Span subtests of the Wechsler Adult Intelligence 
Scale-revised (WAIS-R) (Weschler,  1981); the Rey Auditory Verbal Learning Test 
(RAVLT)  (Rey  A,  1958)  ;  the  Short  Recognition  Memory  for  Faces  (RMF) 
(Warrington,  1984); the Reitan Trail Making Test (TMT) which included Trail A, a 
simple measure of behavioural regulation, sequencing and motor speed and Trail B, in 
which the subject alternates between sequences of numbers and letters necessitating 
shifting of mental set. For each version, the time to complete the test is recorded. The 
difference  score  of the  two  versions  has  been  used  as  an  index  of behavioural 
regulation  and  “cognitive  speed”  independent  of motor  speed  (Reitan,  1958).  In 
addition, patients were asked to carry out the Wisconsin Card Sorting Test (WCST) 
(Nelson,  1976);  the  semantic,  phonemic  and  alternating  semantic  versions  of the 
verbal  fluency  test  (Benton,  1968)  and  the  paced  auditory  serial  addition  test 
(PASAT)  (Gronwall  and  Wrightson,  1981).  At the  end of the  session; the  Apathy 
Scale (Marin, 1990), the Beck Anxiety and Depression Inventories (Beck et al., 1961; 
Beck and Steer, 1990), were completed by all patients (Table 3.7).
While  PSP  and  MSA  subjects  typically  may  only  have  minimal  levodopa 
responsiveness,  some patients do report subjective improvement with levodopa. All
99patients in this study were assessed in the “on”  state with regard to their levodopa
response.
Table 3.7 Neuropsychological test battery completed by each subject
Mattis Dementia Rating Scale (Mattis DRS)
Rey Auditory Verbal Learning Test (Rey AVLT) 
WAIS-R 
NART
Wisconsin Card Sorting Test 
Reitan Trail Making Test A and B 
Recognition Memory Test 
Paced Auditory Serial Addition Test 
Verbal Fluency Test 
Beck Anxiety Inventory 
Beck Depression Inventory 
Apathy Questionnaire
3.5.  Planning the imaging
A  preliminary,  retrospective  review  of serial  volumetric  MRI  scans  acquired  on 
patients  referred  to  the  cognitive  disorders  clinic  and  a  specialised  movement 
disorders  clinic  at  the  National  Hospital  for  Neurology  and Neurosurgery,  Queen 
Square, was undertaken. The purpose of this was to identify individuals with PSP and 
MSA in whom serial imaging had been undertaken, and in whom the diagnosis had 
been pathologically confirmed.
3.5.1.  Methods
A retrospective review of the database from the specialist cognitive disorders clinic 
and  a  specialist  movement  disorders  clinic  was  undertaken.  Three  cases  with 
pathologically  confirmed  PSP  and  one  with  pathologically  confirmed  MSA  were 
identified, in whom serial MRI had been undertaken on the same scanner, during life. 
In  two  of the  PSP  cases,  movement  artefact  on  the  second  scan  rendered  them 
unsuitable for image registration. Hence the clinical histories and MRI appearances in
100one  PSP  patient  and  one  MSA  patient  were  reviewed.  The  post  mortem 
histopathological features in the two cases were compared to the imaging findings.
3.5.2.  Case reports
3.5.2.I.  PSP Case
A 59 year-old male presented with a three-month history of non-specific symptoms 
including  fear  that  he  may  be  developing  dementia.  His  son  commented  that  his 
driving  skills  had  deteriorated.  Past  history  included  hypertension controlled  with 
bendrofluazide and enalapril, and he drank 60 units of alcohol a week. Examination 
by a neurologist revealed no focal neurological signs. Over the next six months his 
balance deteriorated and there was a change in his speech.
He was seen at the cognitive disorders clinic at The National Hospital for Neurology 
and Neurosurgery. By this time he had had several falls and he felt “clumsier”. His 
speech was  slurred  and  he  had  difficulty  in  adjusting  focus  from near  to  distant 
objects. He was admitted to hospital where he was noted to have absent convergence, 
supranuclear  vertical  gaze  palsy  and  slow  vertical  saccades.  Smooth  pursuit  was 
impaired and optokinetic nystagmus was sluggish with eye deviation in the direction 
of  the  slow  phase.  He  had  a  cautious  hesitant  gait,  postural  instability  and 
bradykinesia  but  minimal  limb  rigidity.  There  was  no  improvement  an  hour  post 
Madopar-250mg. Autonomic function testing was normal. Neuropsychological testing 
showed that he had significant cognitive impairment particularly in frontal domains.
A diagnosis of PSP was made. His condition progressed relentlessly and he developed 
axial rigidity, frequent falls, cervical dystonia, a worsening dysarthria and dysphagia. 
He died 5 years after disease onset, 19 months after his second scan.
Cross sectional imaging during life was reported simply as showing global atrophy.
1013.5.2.2. MSA Case
A 60 year-old right-handed man was referred with a three year history of increasing 
unsteadiness. At the time of initial assessment, he had limited mobility and difficulty 
getting in and out of his car. He also reported increasingly slurred speech, problems 
swallowing and difficulty with dextrous movements. He was also  impotent and had 
nocturia and alteration in bowel habit. His sleep was disturbed by laboured breathing 
and  he  occasionally  shouted  and  struck out  during the  night.  The  patient  and  his 
family reported that his memory had been deteriorating for approximately 1  year, and 
that  he  had  become  increasingly  irritable  and  aggressive.  Past  medical  history 
included lumbar discectomy and tonsillectomy. He was a nonsmoker who drank very 
little; he only took Gaviscon, and there was no relevant family history.
On examination he  scored 21/30 on the Mini-Mental State Examination.  He had a 
mask-like facies and bradykinesia with slurred monotonous speech. Examination of 
eye  movements  revealed jerky pursuit  and  nystagmus  on  lateral  gaze.  There  was 
cogwheel rigidity and bradykinesia in the limbs. The leg reflexes were brisk, and the 
plantar responses extensor. There was finger-nose dysmetria, dysdiadochokinesis and 
heel-shin ataxia, and diminution of vibration sense at the ankles. The gait was slow 
and broad-based. There was no postural hypotension.
The  following  investigations  were  normal  or  negative:  full  blood  count,  urea  and 
electrolytes, liver function, thyroid function, B12, folate, ESR, VDRL, chest X-ray, 
antineuronal antibodies and genetic testing for SCAs 1, 2, and 3. A CSF examination 
was  unremarkable  apart  from  a  slightly  elevated  protein  (0.7  g/1).  Autoantibody 
testing revealed a positive anti-nuclear antibody (ANA) titre at  1/320, and strongly 
positive anti-axonal antibodies of uncertain significance. Formal autonomic function
102testing confirmed no  orthostatic hypotension and a normal heart rate response,  but 
absent  pressor  responses  and  a  partially  blocked  valsalva  manoeuvre,  thought  to 
indicate possible early autonomic  failure.  A sphincter electromyogram (EMG) was 
abnormal,  and  suggestive  of a diagnosis of MSA.  A  first MRI  was  carried  out  in 
December 1996, and the patient underwent neuropsychological testing. A diagnosis of 
probable MSA was made.
Over the following year, the patient continued to decline. He fell more frequently and 
experienced  increasing  slurring  of speech,  with  worsening  dysphagia,  urinary  and 
sexual  dysfunction,  and  memory  impairment.  Around  this  time,  he  required 
permanent urethral catheterisation, having gone into urinary retention.  By  1998, he 
was unable  to  walk unaided,  and was  dependent  for  all  activities  of daily  living. 
Examination at  this  time  revealed  square-wave jerks,  gaze-evoked nystagmus  and 
impaired tongue movements. There was marked generalised axial and limb rigidity 
with bradykinesia, but no tremor. The reflexes were now all brisk and he had bilateral 
Babinski signs. An ear, nose, and throat examination revealed normal vocal cords, and 
there  was  no  response  to  a  formal  challenge  with  Co-beneldopa  (Madopar  250; 
Roche, SA). A second MRI and repeat neuropsychological testing were carried out. 
The clinical features were again thought to be consistent with a diagnosis of MSA. 
There was continued decline over the following months, and the patient died 1   year 
later (February 1999). A postmortem examination was carried out.
Neuropsychological  testing  was  obtained  on two  occasions,  approximately  1   year 
apart. A comprehensive battery was used, including estimates of intelligence using the 
National  Adult  Reading  Test  (NART)  and  Wechsler  Abbreviated  Scale  of 
Intelligence-Revised (WAIS-R) scores. Memory was assessed using the Recognition
103Memory  Tests  (RMT),  nominal  skills  using  the  Graded  Difficulty  Naming  Test 
(GNT),  and perceptual functioning was assessed using the  Fragmented Letters and 
Cube Analysis of the Visual Object and  Space Perception Battery (VOSP). Frontal 
lobe  function  was  assessed  using  the  Weigl  colour-form  sorting  test  and  tests  of 
verbal  fluency.  At  the  second  assessment,  additional tests  sensitive  to  speed  and 
attention (months of the year backwards and counting back from 30 to 1) were carried 
out.
The first MR scan revealed marked atrophy of the cerebellum and moderate atrophy 
of the pons and middle cerebellar peduncles.  By the second scan,  14 months later, 
there had been progression in the infratentorial atrophy, particularly of the pons and 
middle  cerebellar  peduncles,  the  former  demonstrating  the  “hot-cross  bun” 
configuration seen in MSA.
3.5.2.3.  MRI protocol
T1-weighted volumetric MR scans were acquired at two points, (14 months apart in 
the MSA case and 18 months apart in the PSP case) on the same 1.5-T GE Signa Unit 
(General Electric,  Milwaukee,  WI) using a spoiled gradient-echo technique  (256  x 
192 matrix, FOV 20 x 20 cm, TR/TE/NEX/FLIP = 15.8/4.2/1/20°). This yielded 124 
contiguous  1.5-mm  thick  slices,  which  were  transferred  to  a  Sun  Enterprise  250 
workstation (Sun Microsystems, Mountain View, CA) for analysis. T2-weighted and 
proton-density  scans  were  acquired  at  each  time  point.  An  experienced 
neuroradiologist reported all MRI scans. Image processing was carried out using the 
MIDAS software tool (Freeborough et al,  1997). A semiautomated technique, using 
intensity thresholding and a series of erosions and dilations, was applied to delineate 
brain tissue.
104Using the rigidly aligned repeat scan as a starting point, the model generates a voxel- 
level deformation field to match the scans accurately. The determinant of the Jacobian 
matrix from the fluid model gives a voxel-by-voxel measure of volume change, and 
voxel compression maps are created using a colour overlay to  signify this volume 
change (details are given in chapter 2.7.3 and chapter 10) (Crum et al., 2001).
3.5.3.  Results
3.5.3.  l.Neuropathology
3.5.3.I.I.  PSP
The  brain  (l,529g)  was  bisected  and  the  right  half,  flash  frozen.  Histological 
examination of the fixed tissue used routine stains and immunohistochemistry for tau 
(AT8  1:600, Autogen Bioclear, UK), ubiquitin (1:300, Dako, UK) and a-synuclein 
(1:2000, Autogen Bioclear, UK). Frozen sections (7pm) from the right anterior and 
posterior frontal lobe were cut and stained using tau immunohistochemistry.
Coronal slices from the formalin fixed left half brain, showed moderate dilatation of 
the lateral ventricle with atrophy of the globus pallidus (GP) and subthalamus (STN), 
which was discoloured. The substantia nigra (SN) and locus ceruleus (LC) were pale. 
There was severe neuronal loss with free pigment and gliosis in the SN. Moderate cell 
loss and gliosis was evident in the STN and LC.
105are illustrated by immuno-histochemical staining Pathological features of progressive supranuclear 
for tau. (A) Neurofibrilliary tangles and neuropil threads are present in the pontine base. (B) Tufted 
astrocytes are demonstrated in the anterior frontal cortex and (C) oligodendroglial inclusions in the 
cerebellar white matter. Comparison of the anterior frontal (D, F) and motor cortices (E, G) in each 
hemisphere shows more numerous tau positive structures including glial inclusions and neuropil threads in 
the motor cortex than in the corresponding anterior frontal cortex (arrows on D pointing to the apical 
dendrite of a tau positive neurone). D, E show frozen sections from the right half brain, while F, G illustrate 
paraffin embedded tissue from the left hemisphere (magnification x40).
Fig 3.4 Histopathological findings in PSP patient
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106Immunohistochemical staining for tau demonstrated NFTs and NTs in the neocortex, 
striatum, GP, STN, SN, LC, pontine base and dentate nucleus. In addition there were 
tau immunoreactive oligodendroglial inclusions particularly evident in the striatum, 
GP  and  cerebellar  white  matter.  Tufted  astrocytes  were  most  easily  found  in  the 
frontal cortex and putamen (Fig 3.4 A-C).
In both hemispheres, the motor cortex was more severely affected than the anterior 
frontal cortex (Fig 3.4 D-G). It was not possible to determine any difference in the 
amount of tau pathology between the right and the left frontal lobes due to processing 
differences and no absolute neuronal counts were obtained.
3.5.3.I.2.  MSA
At postmortem examination the brain was of normal weight (1276 g), although the 
brainstem  and  cerebellum  were  light  by  comparison  (122  g).  On  macroscopic 
examination, the most notable abnormalities were the small size of the basis pontis, 
pallor of the substantia nigra, and atrophy of the cerebellum.  There was very mild 
sulcal widening over the frontal poles and slight dilatation of the lateral ventricles. On 
microscopy, the temporal neocortex showed some slight superficial spongiosis.  The 
hippocampus was well preserved; amyloid plaques were absent and only occasional 
tangle-like  structures were  seen.  The  frontal and parietal  lobes  had  no  plaques  or 
tangles,  and the  frontal cortex exhibited  some  mild  spongiform change.  The  basal 
ganglia and thalamus revealed inclusions within the oligodendroglial cells that stained 
positively to  Galiyas silver stain and a-synuclein,  and  surrounded the nucleus  in a 
cup-like shape.
107The  cerebellum  showed  similar  inclusions  that  also  were  revealed  on  ubiquitin 
staining.  In addition,  occasional  granule  cells  exhibited ubiquitin  and  a-synuclein 
positive  inclusions.  There  was  loss  of Purkinje  cells  with  replacement  Bergmann 
astrocytosis  and  white  matter  gliosis.  The  substantia  nigra  also  showed  some 
vacuolation,  loss of pigmented neurones,  and some free pigment. No Lewy bodies 
were  seen.  Again,  there  were  large  numbers  of Galiyas  and  a-synuclein  staining 
inclusions,  with  occasional  whorled-like  intraneuronal  inclusions  visible  on  a- 
synuclein staining. The pons was small, especially in the region on the basis pontis, 
with  many  oligodendroglial  inclusions  and  some  neuronal  a-synuclein  positive 
globular  inclusions.  Sections  from  the  medulla  revealed  almost  complete  loss  of 
neurons in the inferior olivary nucleus, with oligodendroglial inclusions again seen on 
Galiyas,  a-synuclein  and ubiquitin  staining.  Occasional neurons  also  contained  a- 
synuclein positive inclusions.  The spinal cord exhibited oligodendroglial inclusions 
on the Galiyas silver stain.
In  summary,  the  presence  of  widespread  a-synuclein  positive  oligodendroglial 
inclusions was diagnostic for multiple system atrophy with no evidence of coexisting 
Alzheimer's disease or other cerebral pathology.
3.5.3.2.  MRI results
In the PSP patient, the fluid registered images demonstrated regional volume loss and 
picked out particularly high rates of atrophy in the midbrain and cerebral peduncles as 
well as the precentral gyrus compared to the anterior frontal cortex (figure 3.5).
The motor cortex was pathologically more severely affected than the anterior frontal 
cortex  and this  is  reflected  in the  volume  changes  seen on  serial  imaging,  which
108demonstrate a greater atrophy rate  in the posterior frontal cortex than the  anterior 
frontal cortex (figure3.5).
In the MSA case,  fluid registration of the serial scans revealed striking differences 
between areas of very rapidly progressing atrophy (e.g., pons and cerebellum) and 
other  areas  ostensibly  unaffected  by  atrophy  (e.g.,  parietal  and  occipital  cortices; 
Fig.3.5).  The most prominent atrophy involved the pons and the middle  cerebellar 
peduncles. Increased rates of atrophy were  seen also  in the midbrain and medulla, 
vermis  and  cerebellar  white  matter,  superior  and  inferior  cerebellar  peduncles, 
tegmentum, and olives. There was mild progressive atrophy of the pallidum, but not 
of the amygdalae, hippocampi, or caudate. The thalami were relatively spared. There 
was moderate progressive frontal and anterior temporal lobe atrophy, with a notable 
antero-posterior and infero-superior  gradient,  extending to  involve the  genu of the 
corpus callosum.
109Fig 3.5 Fluid registered imaging in PSP and MSA (pathological correlation in PSP)
contracting expanding
PSP - Axial magnetic resonance imaging scan with voxel-compression mapping overlay mapping changes in the 18 
months between scans, demonstrates greatest rates of volume loss in the midbrain. Sagittal magnetic resonance 
imaging scan with voxel-compression mapping overlay of the right hemisphere, showing volume loss affecting the 
frontal lobes, particularly the precentral gyrus. Concomitant expansion is seen in the cerebrospinal fluid spaces.
MSA - Coronal MRI scan with voxel-compression-mapping overlay to demonstrate areas undergoing atrophy in the 14 
months between scans. Greatest rates of atrophy are demonstrated in the pons and middle cerebellar peduncles and 
the immediately adjacent midbrain and medulla.  Increased atrophy, but at a slower rate, is seen in the upper midbrain 
and lower medulla. Even slower, but definitely pathological atrophy rates are seen in both temporal lobes. Ventricular 
enlargement is also shown.
1103.5.3.3. Conclusions
Significant and focal progressive atrophy of the same regions most heavily affected at 
post mortem, were demonstrated using fluid registration of serial MRI scans acquired 
during  life.  In  the  PSP  patient,  fluid  registered  serial  MRI  identified  regions 
undergoing rapid atrophy that closely reflected the anatomical location of cell loss and 
tau positive NFT load.
These preliminary findings support the tenet of this thesis that the topography of brain 
tissue  loss determines the clinical phenotype,  and that both the rate and region of 
atrophy may be reliably identified using MRI.
Severe  cognitive  impairment  is  not  a  prominent  feature  of MSA,  and  dementia 
excludes  a  diagnosis  of MSA  according  to  the  consensus  criteria  (Gilman  et al, 
1999).  Although the  generalised  intellectual deterioration and  memory  impairment 
seen in the patient described in this chapter are not typical of MSA, they have been 
described  previously  (Robbins  et  al,  1994).  Fluid  registration  revealed  subtle 
progressive  frontal  and  some  temporal  atrophy  that  may  have  contributed  to  this 
dysfunction.  Subtle atrophy in these cortical areas was seen on gross inspection at 
postmortem, and pathological involvement of both the anterior frontal and temporal 
lobes was confirmed by the histological findings of slight superficial spongiosis  in 
these regions.
The distribution of cortical pathology in the PSP case corresponds with findings in 
previous  studies  (Daniel  et  al,  1995;  Vemy  et  al,  1996a)  which  suggested  that 
atrophy is greatest in the posterior frontal lobes. This supports the notion that cortical
111atrophy  observed  on  in-vivo  imaging  is  due  to  primary  pathology  rather  than 
deafferentation secondary to loss of projecting neurons.
Despite a 19-month interval between the final MRI scan and death in the PSP case, a 
close correlation was  seen between volume loss  in-vivo  and pathology at  autopsy. 
This suggests that either frontal lobe atrophy occurs relatively early (2-3 years from 
symptom onset) in the course of the disease (Cordato et al, 2002) and that the pattern 
of volume loss remains consistent into the latter stages.  Serial imaging in the early 
stages may show accelerated rates of atrophy in areas specific to PSP and MSA, and 
could prove useful in differential diagnosis of the bradykinetic-rigid syndromes.
We have demonstrated that the focal atrophy pattern revealed using fluid registration 
seemed to predict that found at postmortem. Additional prospective imaging studies 
were  next  carried out to  assess the  diagnostic  value  of MR regional  volumes and 
atrophy patterns in the diagnosis of PSP and MSA-P, and to confirm whether atrophy 
rates are feasible markers of disease progression.
3.5.4.  Imaging protocol
One major consideration was the ability of patients to tolerate MRI acquisition. This 
is dependent upon the time spent in the scanner during which minimal movement is 
paramount.  Scans  from patients  with  a  neurodegenerative  movement  disorder  are 
likely to be subject to movement artefact, limiting their validity. A compromise needs 
to be reached between better anatomical detail and grey/white matter differentiation 
being achieved with a longer scan time and the capacity of a patient to tolerate the 
scan.
Criteria for the scanning protocol included:  minimum acquisition time to maximize 
patient compliance; high signal to  noise ratio  (SNR);  minimum distortion,  shading
112and susceptibility artifact; high contrast between grey matter and cerebrospinal fluid 
(CSF)  and between grey matter and white matter and;  anatomical  accuracy (hence 
resolution). The scan interval also had to be taken into consideration; if too short, it 
would lead to difficulties detecting the desired signal (atrophy) and if too long would 
lead to increased attrition due to  disease progression and death. A  scan interval of 
around one year was decided upon.
In addition to T1  volumetric imaging,  T2 and proton density weighted  MRI  scans 
were  acquired.  These  help  to  identify  alternative  pathologies  such  as  vascular  or 
inflammatory  CNS  disease  that  would  exclude  a  clinical  diagnosis  of PSP,  and 
exclude healthy controls from the study.
Diffusion weighted MRI scans (chapter 2.4.4 and chapter 8) can be acquired over a 
very short period of time (less than one minute) and provide information regarding the 
integrity  of  normal  tissue  architecture.  Such  a  short  scan  acquisition  time  has 
considerable advantages in movement disorders.
All MRI  scans were  acquired on the  same  1.5  Tesla (T)  GE  Signa Unit  (General 
Electric, Milwaukee, WI).
3.5.4.1.T1 weighted imaging
T1-weighted  volumetric  MR  scans  were  acquired  using  a  spoiled  gradient-echo 
technique with: a 24 x 18cm field of view (FOV); 256mm x 256mm matrix; inversion 
time (TI)- 650ms; repetition time (TR)-15ms; echo time (TE)-5.4 ms; and flip angle- 
150. This yielded 124 contiguous 1.5mm thick slices.
3.5.4.2.T2 and PD weighted imaging
Dual  echo  proton  density  and  T2  images  were  acquired  using  the  following 
parameters.  Axial  5mm  slices  to  cover  the  brain:  FOV-250xl80mm,  256mm  x 
256mm matrix, TR-2500ms, TE-30/90ms and, number of excitations (NEX)-l).
1133.5.4.3.Diffusion weighted imaging
Axial  DWIs  were  obtained  using  spin-echo  planar  sequences  (TR-  1000ms,  echo 
time, TE- 99ms, matrix size-128 x 128 pixels, field of view, FOV: 240mm x 240mm, 
slice thickness 7mm and slice gap 2mm). Diffusion-sensitising gradients were applied 
perpendicular to the axial slice plane with a b-value of 1000 s/mm .
3.6.  Recruiting subjects
Recruitment of subjects for the studies incorporated within this thesis was undertaken 
at the National Hospital for Neurology and Neurosurgery,  Queen Square,  London. 
Recruitment was largely from specialist movement disorder clinics (Prof. A.J Lees) 
but subjects were also recruited from a cognitive disorders clinic (Prof. M.N. Rossor). 
Prior  to  inclusion,  patients  had  undergone  full  clinical  assessments.  Appropriate 
investigations  such  as  neuropsychological  evaluation,  routine  haematological  and 
biochemical blood tests and neuroimaging had been performed in order to support the 
clinical diagnosis. All patients included (and their next of kin where appropriate) were 
aware of their clinical diagnosis.
Initially the aim was to recruit 25 PSP subjects with 12 MSA-P subjects and 12 PD 
subjects. As differences in regional volumes and rates of atrophy between the PSP, 
MSA-P and PD subjects and correlations with the clinical phenotype in these cases 
was the main interest of this study. MRI scans from healthy control subjects using the 
same  T1  acquisition parameters,  acquired  for a  separate  study ongoing  within the 
Dementia  Research  Centre  (UCL)  at  the  National  Hospital  for  Neurology  and 
Neurosurgery, were also used for comparison of disease and healthy control rates of 
brain atrophy.
1143.6.1.  Matching of cohorts for age, sex, disease duration or severity
Patients were recruited from outpatient clinics at the National Hospital for Neurology 
and Neurosurgery. All were required to meet the diagnostic criteria for PSP, MSA and 
PD. Potential subjects were then informed about the nature of the study and given a 
patient  information  sheet  outlining  its  nature  as  well  as  the  answers  to  common 
questions (appendix).
Recruitment  was  undertaken  over  a  period  of several  months.  Consideration  was 
given to the ability of patients to tolerate the MRI which required that the subject lie 
flat and still for approximately 20 minutes. Those whose disease had already resulted 
in severe disability were not included if it was felt that they would be unlikely to 
tolerate the initial or the follow up scan.
As far as possible, recruitment was directed towards age and  sex  matching of the 
groups, and for the PSP and MSA-P subjects, towards matching of disease severity. 
Parkinson’s disease  subjects with severe peak dose  dyskinesias were not recruited 
because of concerns about movement artefact.
No financial incentive to take part was offered, but reimbursement of travel expenses 
was built into the costing of the study.
3.7.  Brain donation: addressing the issue early
The accuracy of the clinical diagnostic criteria for these diseases has been reported. 
Hughes et al have reported the accuracy of diagnosis of PSP and other parkinsonian 
syndromes in the specialist movement disorder service from which the subjects in this 
study were recruited (Hughes et al.,  2002).  In their series of 143  cases  seen at the 
National  Hospital  for  Neurology  and  Neurosurgery,  at  Queen  Square,  with 
Parkinsonism,  19 had a diagnosis of PSP. The positive predictive value, sensitivity, 
and specificity for this diagnosis were 80.0%, 84.2%, and 96.8%, respectively. They
115did  not  apply  specific  diagnostic  criteria  but  relied  on  pattern  recognition  by 
movement  disorder  specialists.  The  sensitivity  and  specificity  of the  diagnostic 
criteria  for  PSP  in  table  3.6a  above  have  been  reported  at  between  50-60% 
(sensitivity) and  100% (specificity) for probable PSP, and 70-80%  (sensitivity) and 
90-100% (specificity)  for possible PSP.  The  accuracy of the  diagnostic  criteria for 
MSA may not be so high and none have been validated in the context of post mortem 
verification of the disease (Litvan et al.,  2003). An experienced clinicians judgement 
has been reported as being a better diagnostic marker of the disease, perhaps because 
it takes into account the results of ancillary investigations. In a large study of post 
mortem confirmed cases of PD (Hughes et al, 2002), the positive predictive value of 
the final clinical diagnosis of PD was extremely high, at 98.6%.
Confirmation of the diagnosis, in the absence of a biomarker, relies on post mortem 
histopathological  analysis.  The  issue  of  brain  donation  was  broached  with  all 
participating subjects.
It was  felt that discussion with the  subject and their next  of kin,  at the time  of a 
second consultation, rather than late in the course of the illness was more appropriate 
for this sensitive topic. All subjects who expressed an interest were given information 
on the procedure for brain donation and allowed time to formulate and ask questions 
before consenting. An example of the current information sheet and consent form can 
be seen in the appendix.
At the time of writing, 11 subjects in total (7 with PSP, 3 with MSA-P and 1  with PD) 
have consented to brain donation.
3.8.  Conclusions
A summary of the proposed study design and methods is outlined in Table 3.8. This 
design is based upon conclusions drawn from the preliminary study of an extensive
116series of brain bank cases of pathologically proven PSP and from the case studies of
serial imaging reported in this chapter.
Table 3.8 Summary of study design and methods overview.
Recruitment according to clinical diagnostic criteria y
Visit 1 Visit 2
History Y -
Full clinical examination Y y
Review of inclusion and exclusion criteria - y
Proposed interval (weeks] - 52
MRI scan: T1 Y Y
T2/Proton density Y Y
DWI y y
Neuropsychological testing y y
Bedside cognitive tests MMSE y y
FAB y y
Clinical rating scales UPDRS y Y
HY y Y
Schwab and England y Y
Gaze Palsy y Y
Discussion regarding brain donation y Y
t
Whilst the proposed scan interval was set at 52 weeks, the MRI scanner designated 
for use in this study was upgraded during the course of the project, meaning that some 
subjects had to have their proposed second scan date brought forward. This meant a 
greater variability in  scan interval than had been envisaged.  In addition,  follow up 
appointments in patients had to be adjusted to ensure that the mean interval was not 
significantly different between the groups.
Other problems encountered during the project regarding the methods and design of 
the  study,  included  co-ordinating  the  neuropsychology  appointments  and  scan 
appointments. These could not always be undertaken on the same day and so some 
patients  had  to  return  after  their  scan  in  order  to  complete  the  psychology 
assessments.
1174.  The clinical assessment
4.1. Introduction
For inclusion, patients had to have a clinical diagnosis of PSP (possible or probable), 
MSA-P or PD made after appropriate exclusion of alternatives and based upon the 
diagnostic criteria described in chapter 3. The patients were also required to be able to 
tolerate an MRI scan, with no contraindications. Healthy control subject MRI scans 
were acquired from partners of patients where consent was obtained.  The inclusion 
criteria for controls were that there was no history of neurological disease, cognitive 
decline,  head  injury,  stroke  or psychiatric  illness.  The number of healthy  controls 
included  for  comparison  of  MRI  features,  was  increased  by  including  serial 
volumetric MRI  scans that had been acquired for a separate research study on the 
same scanner using the same T1 weighted MRI protocol.
4.2. Methods
At  the  initial  visit,  consent  for  participation  in  the  study  was  obtained.  A  semi­
structured  medical  history  was  taken,  from  the  patient  and  a  close  informant, 
focussing on important clinical features of PSP, (determined in part from the study 
outlined in chapter 3.2.1.) MSA-P and PD.
The semi-structured medical history included details on occupation, current age and 
handedness, age at symptom onset, estimated disease duration and the presence of: 
falls (and whether these were backwards); rigidity; tremor (and whether asymmetric 
or  not);  bradykinesia;  visual  symptoms  (blurred  vision,  watery  vision,  reading 
difficulties,  photophobia,  visual  hallucinations,  eyelid  dysfunction);  speech  and 
swallowing  difficulties;  the  presence  of perceived  cognitive  dysfunction;  postural
118dizziness  and  syncope;  bladder  dysfunction;  drug  therapy  and  levodopa 
responsiveness.
On  clinical  examination,  the  presence  of  features  such  as  myoclonus,  apraxia, 
dystonia,  dyskinesia,  cortical  sensory  loss,  alien  limb  phenomena,  pyramidal  tract 
signs and cerebellar signs were recorded.
This information was collected in order to support the suspected clinical diagnosis at 
the  initial  visit  and to  ensure that  at the  follow up  visit,  no  features  excluding  a 
diagnosis of PSP, MSA-P or PD were present. Any revision of the clinical diagnosis 
was recorded if appropriate the patient was excluded from further data analysis.
A single rater (myself) undertook all clinical assessments.
4.2.1.  Clinical rating scales
All subjects had the MMSE, see Appendix (Folstein et al,  1975) recorded in addition 
to scores on other clinical rating scales detailed below.
4.2.I.I.  UPDRS
The Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn S, 1987) as described 
in section  1.2.8.1  was designed to provide a semi-quantitative measure of the signs 
and symptoms of Parkinson’s disease (PD) in clinical practice and research. Because 
clinicians are familiar with the scale and because the motor examination (part III) of 
the UPDRS has been validated as a method of assessing function in PSP (Cubo et al., 
2000) and in MSA (Tison et al, 2002), this scale was chosen as a method of assessing 
various aspects of disease severity. To recap, part one of the scale assesses mentation 
behaviour  and  mood,  part  two,  activities  of  daily  living  (ADL)  and  part  four, 
complications of therapy.  A more detailed assessment  of mentation behaviour and 
mood was obtained from the more formal neuropsychological testing (chapter 5). The
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as  there  is  little  if any  response  to  levo-dopa  in  most  MSA  and  PSP  cases  and 
dyskinesias are much less common. For these reasons, comparison between the three 
disease groups was limited to scores on the UPDRS II and III.
4.2.1.2.  Hoehn and Yahr
The Hoehn and Yahr staging of disease has five levels of severity (Hoehn and Yahr, 
1967):  stage  1-  unilateral  disease;  stage-2  bilateral disease  without  impairment  of 
balance;  stage  3-  mild  to  moderate  bilateral  disease,  some  postural  instability, 
physically  independent;  stage  4-  severe  disability,  still  able  to  walk  or  stand 
unassisted;  and  stage  5-  wheelchair  bound  or  bedridden  unless  aided  (appendix, 
chapter 14.5). This has the advantage of being a simple and easily applicable method 
of grading disease severity.
4.2.1.3.  Schwab and England ADL score
The Schwab and England ADL score, measures disease severity in terms of activities 
of daily living (ADL). A score of 100% means complete independence and 0% is a 
bedridden state with dependency for all activities including swallowing, bladder and 
bowel functions (appendix). Allocation to a particular percentage level is dependent 
on subjective interpretation of an individuals level of disability and very few will fit 
perfectly with the description at each percentage level. Nevertheless, an assessment of 
functioning based on this  score  is widely  accepted as  a measure  of disability  and 
many physicians are familiar with its use.
4.2.1.4.  Frontal assessment battery
The  frontal  assessment  battery  (FAB)  is  a  bedside  test,  focussing  on  frontal/sub- 
cortical cognitive impairment (Dubois et al, 2000). It can be administered in less than 
ten minutes and consists of six sections, each with a maximum score of 3 points. It
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correlate with more formal neuropsychological tests. A detailed analysis of the FAB 
and its relation to formal neuropsychological test scores in the patients recruited to 
this thesis can be found in chapter 5.
4.2.1.5.  Gaze palsy score 
A supranuclear vertical gaze palsy is one of the cardinal features of PSP, and yet as 
described in section 1.2.8.1, there is no validated bedside scale. The severity of the 
gaze palsy varies from individual to individual and its onset during the course of the 
disease  is  variable.  The  neurological  control of eye-movements  is  complex.  Many 
brainstem, basal ganglia and cortical areas have roles in the generation of normal eye- 
movements. Abnormalities of saccadic eye movements occur early in PSP (Leigh and 
Riley, 2000) and this is reflected in the diagnostic criteria. In contrast, abnormalities 
of saccadic eye movements in MSA-P and PD are less common, less severe and occur 
later in the course of the illness. Many different anatomical structures or pathways are 
involved  in the  generation  of normal  saccadic  eye  movements  (for  a  review  see 
(Leigh and Kennard, 2004).
In PSP, pathological involvement of brainstem nuclei including those in the rostral 
interstitial  medial  longitudinal  fasciculus  (riMLF)  contributes  to  slow  vertical 
saccades  and pathology  in  the  para-pontine  reticular  formation to  slow  horizontal 
saccades.  A  schematic  diagram  of the  brainstem  saccadic  generators  is  shown  in 
figure  4.1.  Accurate  measurement  of saccadic  eye-movements  is  best  undertaken 
using electro-oculography or by using  infrared video recording of eye movements. 
These  recording  methods  are  either  moderately  invasive  or  rely  on  expensive 
equipment and neither was undertaken in this thesis.
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important in the PSP patients.  For this reason, and with a view to relating the gaze 
palsy  severity  to  the  imaging  features  of  the  disease,  a  novel  scale  (devised 
specifically for a large multi-centre clinical trial of Riluzole  in PSP and MSA, the 
NNIPPS trial) based on the clinical assessment of gaze palsy was used (appendix). 
Grades of normal, mild, moderate or severely hypometric (score 0,  1, 2, 3) or slow 
(score 0,  1, 2, 3) saccades in the vertical (up), vertical (down) or horizontal planes 
were added to scores of no, mild, moderate or severe eyelid dysfunction (0, 1,2 or 3) 
to give a maximum severity score of 21. This is a pragmatic and quickly administered 
scoring  system.  As  yet,  it  has  not  been  validated  by  comparison  with  accepted 
methods of assessment such as electro-oculography, nor has inter-rater reliability been 
assessed. The scale was incorporated specifically to detect the more severe vertical 
gaze palsy typical of PSP. Abnormalities associated with MSA such as square wave 
jerks and nystagmus, do not feature and would not have affected the gaze palsy score 
in this group of patients.
CNIII  riMLF
MIDBRAIN
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Neural integrator 
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Figure 4.1  Schematic summary of brainstem saccadic generators.
Horizontally acting  extra-ocular muscles,  such  as the  lateral  rectus,  are  innervated  by motor neurons in the abducens 
nucleus (CN VI);  these motor neurons  receive their saccadic commands from the PPRF.  Vertically acting  extra-ocular 
muscles, such as the superior rectus, are innervated by motor neurons in the occulomotor nucleus (CN III) and trochlear 
nucleus (not shown); these motor neurons receive saccadic commands from burst neurons in the riMLF in the midbrain. 
B urst neurons in both the PPRF and riMLF receive inhibitory inputs from omnipause neurons, which lie in nucleus raphe 
interpositus  (RIP)  in  the  pons.  When  omnipause  neurons  cease  discharge,  burst  neurons  in  the  PPRF  and  riMLF 
generate a saccadic pulse,  which  is passed to the motor neurons and causes a phasic contraction  of the extra-ocular 
muscles to move the eye rapidly in a saccade.  Horizontal saccadic pulse signals are integrated  by a network consisting 
of neurons in the medullary  nucleus prepositus hypoglossi  and adjacent medial vestibular nucleus (NPH/MVN); vertical 
saccadic pulses are integrated in the midbrain interstitial nucleus of Cajal (INC) for vertical  saccades.  The output of this 
neural integrator is a step signal that makes it possible for extra-ocular muscles to sustain a tonic contraction and  hold 
the eye in its new position (Leigh and Kennard, 2004).4.2.2.  General clinical examination
In  addition  to  the  structured  assessments  of disease  severity,  a  full  neurological 
examination was carried out at the initial assessment.
4.2.3.  Statistical analysis
Tests of skewness and kurtosis were performed to assess the normality of the data. 
For normally  distributed data,  a one-way analysis  of variance  was performed  and 
where  significant  differences  were  detected  (p<0.05),  post  hoc  analysis  was 
undertaken  to  determine  between  which  groups  (PSP,  MSA-P,  PD  or  healthy 
controls)  the  differences  occurred.  For  non-normally  distributed  data,  a  Mann- 
Whitney U test was performed to assess differences between group mean values. A 
Chi-squared test was used to assess sex distribution between groups. The relationship 
between these measures of disease severity and disease duration, at the time of the 
first assessment, in PSP, MSA-P and PD was assessed using a bootstrapped linear 
regression analysis with age as a co-variable.
4.3.  Results
Twenty-four patients with PSP,  eleven with MSA-P, twelve with PD  and eighteen 
healthy controls were included. Three of the PSP subjects were then excluded from 
further follow up as the first scan was of poor quality because of excessive movement 
artefact. These patients were not included in any of the data analyses. One PSP and 
one MSA-P patient failed to attend for a second scan a year later because of disease 
progression. Two PD patients withdrew from the study after the initial scan but gave 
consent for their data up to the point of withdrawal to be included. One patient with 
MSA-P  and  one  with  PSP  died  before  the  follow  up  appointment.  One  patient 
classified as PSP at the initial visit on the basis of the diagnostic criteria developed
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diagnosis  of dementia  with  Lewy  bodies  (DLB)  and  was  excluded  from  all  data 
analysis.  Follow up  scans in one patient with PSP  and one with PD were  of poor 
quality and were not included in the data analysis.  Of the 65  subjects recruited,  21 
patients with PSP,  11 with MSA,  12 with PD and 18 healthy controls were included 
for analysis of clinical data from the first visit (total 62).  18 PSP, 9 MSA, 10 PD and 
18 healthy controls (total 55) were included for analysis of follow up clinical data, 
and  17 with PSP, 9 with MSA, 9 with PD and  18 healthy controls, for analysis of 
follow up imaging data. These data are reported in table 4.1. The numbers of subjects 
included in imaging analysis and neuropsychological test score analysis are reported 
later.
There  were  no  age  or  sex  differences  between  the  groups,  disease  duration  was 
significantly longer in the PD group (p<0.001) and motor deficit was less severe in 
the PD group according to UPDRS II, III and H+Y scores. There was no difference 
between the PSP and MSA-P groups. At the time of the initial visit, the MMSE was 
lower in the PSP, MSA-P and PD groups than in healthy controls, with no significant 
differences between the diseased patients.  The  FAB  score  discriminated PSP  from 
MSA-P and from PD (this is expanded on in chapter 5).
The  gaze  palsy  score  was  markedly  increased  in  the  PSP  patients.  The  group 
differences at the initial visit were consistent with those found at the time of follow 
up.
Bootstrapped regression analysis did not reveal any significant relationship between 
disease duration and any markers of disease severity.
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PSP MSA PD Control P value
n 21 11 12 18 ----------------
Sex (M:F) 14:7 6:5 8:4 10:8 0.8
Age (yrs) 65.4 (6.2) 62.0 (7.6) 65.5 (9.2) 66.8 (5.4) 0.3
Disease duration 
(yrs)
4.5 (1.5) 5.4(1.6) 13.3(6.7) - PD vs. PSP/MSA, p<0.001
First visit
UPDRS2 20.2 (6.9) 24.9 (7.0) 13.4 (4.6) * - <0.001
UPDRS3 21.0(7.9) 26.8 (9.7) 16.7(5.1)* - 0.01
HY 3.5 (0.6) 3.9 (0.8) 2.7 (0.5)^ - 0.001
MMSE 26.0(3.1) 26.4 (3.2) 27.7 (2.5) 29.5 (0.6)
C vs. PSP/MSA, p<0.001, 
C vs. PD, p=0.009
FAB 11.7(3.6) 14.7 (2.5) 16.5(1.4) -
PD vs.  PSP, p<0.001 
PSP vs. MSA, p=0.02
Schwab and Eng. 59.5 (23.9) 53.4 (21.6) 78.3(12.7) -
PSP vs. PD, p=0.02 
MSA vs. PD, p=0.005
Gaze palsy score 12.2 (5.9) 2.4 (2.3) 0(0) -
PSP vs. MSA/PD, p<0.001 
MSA vs.  PD, p<0.001
Interval (days) 292 (59) 262 (66) 268 (52) 252 (40) PSP vs. C, p=0.02
Second visit
n 18 9 10 18
UPDRS2 28.2 (7.8) 30.4 (7.6) 17.9 (5.7)* - <0.001
UPDRS3 29.0 (7.9) 32.0(10.3) 20.6 (7.2)r - 0.01
HY 4.1  (0.7) 4.2 (0.8) 3.1  (0.6)4 - 0.001
MMSE 26.2 (3.1) 26.4 (3.4) 27.7 (2.2) - 0.4
FAB 10.3(4.2) 13.2 (3.3) 15.8 (2.4)t - 0.002
Schwab and Eng. 47.2 (21.1) 41.1  (21.5) 77.0 (8.2) -
PSP vs. PD, p<0.001 
MSA vs. PD. p=0.001
Gaze palsy score 13.9(5.8) 4.1  (4.1) 0.1  (0.3) -
PSP vs. MSA/PD, p<0.001 
MSA vs. PD, p<0.001
Reported p values are from ANOVA or from Mann-W 
MSA, p=0.001, PD vs. PSP, p=0.03; *PDvs. MSA P= 
$PD vs. MSA,  p=0.002, PDvs.  PSP, p=0.003;  *PDv! 
p=0.002, PD vs. MSA, p=0.004; tPD vs. PSP, p=0.00
litney U test. Post hoc (bonferroni) tests- "PD vs. 
=0.01;  ♦PDvs. PSP,  p=0.01, PDvs. MSA, p=0.001; 
s. MSA, p=0.02, PDvs. PSP, p=0.05; 4PDvs. PSP, 
2.
UPDRS-unified Parkinson’s disease rating scale; HY- Hoehn and Yahr;  MMSE-mini mental state 
examination; FAB- frontal assessment battery.
4.4.  Conclusions
The groups are not significantly different in terms of age and sex distribution. There 
are however significant differences in scores on the clinical rating scales, and bedside 
tests of cognitive function between the patients with PSP and MSA-P and those with 
PD.
Disease duration is significantly longer in the PD patients. This is because an attempt 
was  made to  recruit  subjects with more  severe  disease,  in order to  achieve  closer 
matching with the PSP and MSA-P subjects. There is no significant difference in the
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assessments  is  longer  in the  PSP  group than the  healthy  control  group.  However 
progression in clinical  scores  and  imaging findings was  standardised to  an annual 
interval or the interval used as a covariate in all analysis.
That the mean UPDRS II and III scores were significantly different between PSP and 
PD, and MSA-P and PD patients is not surprising. The UPDRS II assesses activities 
of daily living (ADL). Speech, swallowing, hygiene and falling scores are likely to be 
higher in PSP and MSA-P than in PD. On the UPDRS III, speech, finger taps, arising 
from a chair,  gait and postural stability scores are likely to  be greater in PSP and 
MSA-P than in PD. These factors account for the greater disease severity scores in 
PSP and MSA-P.  The Hoehn and Yahr is an assessment of motor disability and if 
there is postural instability, a score of at least 3 must be recorded. This means that all 
PSP and most of the MSA-P patients will have a score of at least 3. PD patients on the 
other hand are less likely to have impaired balance and so may score lower.
The  gaze  palsy  score  differentiates  the  groups  well,  as  would  be  expected.  No 
saccadic eye movement abnormalities were detected in the PD patients.
The  FAB  also  differentiates  the  groups  suggesting  it  can  help  to  detect the  more 
severe sub-cortical cognitive impairment in PSP. This is discussed further in chapter 
5.
There were no clear associations detected between disease duration and measures of 
disease  severity.  This  is  surprising  as  it  is clear that  on an  individual  level,  these 
diseases result in greater disability as they progress. This lack of association could be 
explained,  firstly  by  the  heterogeneity  of  the  diseases  studied,  resulting  in 
considerable  variation  in  individual  disease  duration  from  onset  to  increasing 
disability and death in PSP and MSA-P. Secondly, the start of the disease process was
126recorded at the time of the first symptom, taken from the history. This is subjective 
and, in some cases likely to be an inaccurate measure of onset, which will affect any 
association between disease duration and severity. The clinical rating scales used have 
inevitable ceiling effects. Hence once a patient with PSP is falling more than once per 
day,  or  is  unable  to  arise  from  a  seated  position  without  help,  then they  cannot 
increase their score for that particular aspect of the UPDRS assessment regardless of 
true disease progression.
Despite  efforts  to  match  the  patient  groups,  disease  severity  measured  using 
established and new disease rating scales in PSP and MSA-P patients was greater than 
in PD patients.
In summary, all patient groups and healthy controls were relatively well matched in 
terms of age and sex.  PSP and MSA-P patients were matched for disease  severity; 
however  aspects  of cognitive  function assessed  according  to  the  FAB  were  more 
severe in the PSP patients.
1275.  Neuropsychological assessments
5.1. Introduction
The neuropsychological test battery was selected specifically in order to detect the 
presence of subcortical cognitive impairment, but also other aspects of more general 
cognitive function (Chapter 3.5.2).
The objectives behind analysis of the neuropsychological scores were:  (1) to assess 
the subjects with PSP, MSA-P and PD, at entry and at a follow up assessment; (2) to 
assess the change in neuropsychological test scores over time, in the different disease 
groups;  (3)  to  assess the  ability  of the  FAB  to  quantify  executive  dysfunction  in 
bradykinetic-rigid disorders as well as; (4) determining the correlation between the 
FAB and more extensive tests of executive function and cognitive function in order to 
evaluate the  practical  value  of the  FAB  in  differentiating  these  bradykinetic-rigid 
syndromes.
A total of 40 individuals completed or partially completed the neuropsychological test 
battery at the time of initial assessment. These included 17 with PSP, 11 with MSA-P 
and  12  with PD.  A total  of 38  subjects  attended  for a second neuropsychological 
assessment, including 18 with PSP (3 with no initial assessment), 9 with MSA-P and 
10 with PD. In total, 33 subjects completed neuropsychological assessments at entry 
and at follow up, 15 with PSP, 9 with MSA-P, and 9 with PD.
5.2. Neuropsychology profiles at initial assessment.
5.2.1.  Methods
Neuropsychological testing was completed at the time of the clinical assessment and 
undertaken by a trained neuropsychologist. The clinical tests were completed with no 
knowledge of the results of the formal neuropsychological evaluation.
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parametric data and for non-parametric data, Chi-squared or Mann Whitney U tests 
were used.
Neuropsychology test scores at the first visit were standardised: 
z-score = (x-mean)/SD
Where, x is the raw neuropsychology score,  mean is the mean overall score for the 
entire cohort and SD is the standard deviation of the group.
Group  differences were determined using  one-way analysis  of variance  (ANOVA) 
with  post-hoc  analysis  for  parametric  data  and  a  Mann-Whitney  U  test  for  non- 
parametric data.
5.2.2.  Results
The groups did not differ significantly in terms of age or gender distribution (p>0.05). 
Duration  of illness,  severity  of motor  symptoms  (UPDRS  III)  and  disability  in 
activities of daily living  (UPDRS  II) were significantly different across the groups 
(table 5.1). Post-hoc analyses showed that the significant group differences were due 
to the patients with PSP and MSA-P having more severe motor symptoms and greater 
disability than the PD group; whereas the UPDRS II and III ratings for the MSA-P 
and  PSP patients  did  not  differ  significantly.  The  PD  patients  had  a  significantly 
longer duration of illness than those with PSP or MSA-P. There was no significant 
difference in disease duration between PSP and MSA-P.
Table 5.1 Mean (SD) subject details for those attending first psychology assessment
n (M:F) age (yrs)
disease 
duration (yrs)
UPDRS2 UPDRS3 H+Y
PSP 17(12:5) 64.8 (5.9) 4.4 (1.6) 20.1  (6.4) 20.6 (7.2) 3.5 (0.7)
MSA-P 11  (6:5) 61.9(7.6) 5.4 (1.6) 24.9 (7.0) 26.8 (9.7) 3.9 (0.8)
PD 12(8:4) 65.4 (9.2) 13.3 (6.7)♦ 13.9(5.1)* 16.7(5.1)** 2.8 (0.6)4
P Value 0.7 0.5 <0.001 <0.001 0.009 0.002
♦-p<0.001  vs PSP and MSA; *-p=0.04vs PSP, p<0.001 vs. MSA; **-p=0.008 vs MSA;  *-p=0.02vs 
PSP,p=0.001 vs MSA
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standardised neuropsychology  scores  (z-scores), between the  PSP,  MSA-P  and PD 
subjects detected significant differences in the  following:  scores on the vocabulary 
subtest  of the  WAIS-R were  significantly  lower  in PSP  compared to  PD  subjects 
(p=0.03); the PSP group made more errors than PD subjects on the WCST (p=0.03); 
and scores on the verbal fluency tests in PSP were also lower than in PD (p=0.001). 
For non-parametric data, the Mann-Whitney U test detected group differences in: the 
Mattis  DRS  total  score,  which  was  significantly  lower  in  PSP  than  in  MSA-P 
(p=0.01) and in PSP compared to PD (p=0.03); the DRS initiation and perseveration 
sub-test  scores  which  were  lower  in  PSP  compared  to  PD  (p=0.04);  the  DRS 
construction sub-test which was lower in PSP compared to PD (p=0.007); the number 
of categories  sorted on the  WCST  which was  lower  in PSP compared to  MSA-P 
(p=0.003);  and  in  the  apathy  scores  which were  greater  in  PSP  compared  to  PD 
(p=0.03)  and  in  MSA-P  compared  to  PD  (p=0.006).  Differences  in  other 
neuropsychological test scores between groups did not reach significance at the 5% 
level.
5.2.3.  Conclusions
Significant  differences  in  the  neuropsychological  test  scores  between  the  patient 
groups suggest more severe cognitive impairment in PSP. The Mattis DRS subscores 
which are  influenced most by executive  function (DRS-initiation/perseveration and 
DRS construction) were lower in PSP than in PD.
While executive dysfunction is described in some cases of PD (Levin and Katzen, 
1995),  it  is  much  more  severe  in  PSP  (Maher  et  al.,  1985).  The  results  of the
130psychological profiles of the patients studied for this thesis are in keeping with these 
previous observations.
PSP, MSA-P and PD all have pathological dopaminergic depletion in the substantia 
nigra  and  other  basal  ganglia  neurons  but  there  are  important  and  widespread 
neuroanatomical and neurochemical differences between these conditions. Alexander 
et  al  proposed  that  three  of five  cortico-subcortical  circuits  are  affected  in  PSP 
(Chapter  3.4.1).  They  suggested  that  the  preferentially  affected  circuits  were,  the 
dorsolateral preffontal circuit which is involved in cognition, the lateral orbitofrontal 
circuit which is involved in social affect, and the anterior cingulate circuit which is 
involved in attention (Alexander et al,  1986; Alexander and Crutcher, 1990). In PSP, 
as  well  as  damage  to  the  striato-ffontal  pathways  due  to  pathology  in  the  basal 
ganglia, the preffontal cortex is directly involved (Vemy et al,  1996a). This may help 
to explain some of the differences in the results of formal neuropsychological testing, 
observed in these degenerative basal ganglia disorders (Testa et al, 1993; Lange et al, 
1993; Robbins et al,  1994; Pillon et al,  1995; Meco et al,  1996; Soliveri et al, 2000; 
Dujardin  et  al,  2004).  In  general,  these  previous  studies  using  a  variety  of 
standardized  batteries  of  cognitive  tests  or  the  Cambridge  automated 
neuropsychological test battery (CANTAB) have established that the differences in 
the  cognitive  profile  of patients  with  idiopathic  PD,  PSP  or  MSA  are  mainly 
quantitative rather than qualitative (i.e. the test scores differ at a group level but this is 
difficult to appreciate at the bedside). Across studies, patients with PSP show the most 
severe and extensive cognitive deficits particularly on tests of executive function and 
patients with PD the least severe deficits. Nevertheless, some qualitative differences 
in the profile of cognitive dysfunction in the three Parkinsonian groups have also been 
reported. For example, simple and alternating semantic and phonemic verbal fluency
131tests have been shown to correctly differentiate PSP, PD and MSA and are considered 
sensitive measures to aid in the differential diagnosis (Lange et al., 2003).
The differences between patient groups observed  in this thesis are similar to those 
reported  in  previously,  demonstrating  that  PSP  patients  performed  poorly  on  the 
Mattis DRS and the WCST compared to MSA and PD patients (Pillon et al., 1995). In 
contrast, other studies comparing the cognitive profile of PSP with that seen in MSA- 
P and PD  identified clear differences in verbal fluency not replicated in this thesis 
(Lange et al., 2003).
The number of patients in each disease group in this study compares favourably with 
those  recruited  to  previous  studies  and  the  test  battery  also  bears  similarities. 
However,  the  cohort was  relatively  small  and the  larger  number  of patients  with 
MSA-P in particular, may have allowed identification of further differences between 
the disease groups.
5.3.  Change in Neuropsychology Profiles
5.3.1.  Introduction
PSP, MSA-P and PD are all progressive neurodegenerative diseases.  It is expected 
that the cognitive dysfunction observed progresses more rapidly in PSP than in MSA- 
P or PD. Few studies report the results of neuropsychological follow up in patients 
with PSP,  compared with MSA-P  and  PD.  The  results  of those  that  do  are  often 
confounded by the fact that the patients most affected, who progress rapidly, drop out 
from the study (Soliveri et al., 2000).
The results of neuropsychological testing at follow up were compared with those at 
baseline in patients with both sets of data.
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The change in psychology test scores at first and second assessments were corrected 
for differences in interval: corrected difference= difference x (365 - 5- Interval in days). 
A one-way analysis of variance was used to look for significant group differences in 
normally distributed data, and for non-parametric data, Mann-Whitney U analysis was 
used.
5.3.3.  Results
In total,  37  subjects  completed  neuropsychology  tests  at  the  time  of their  second 
appointment.  Two subjects with PD dropped out of the study,  and a further patient 
with PD did not complete the neuropsychology testing.  One patient with MSA died 
and another  was too  ill to  attend.  Three  subjects  with  PSP  who  did  not  complete 
neuropsychology testing at the first appointment attended at the time of their second 
appointment.  Of  the  17  who  attended  the  first  appointment,  one  PSP  patient
subsequently died and another was too ill to attend.
Table 5.2 Mean (SD) subject details for those attending second psychology assessment.
n (M:F) Age (yrs)
Disease
duration
(yrs)
UPDRSII UPDRSIII H+Y
PSP 18(11:7) 65.4 ± 6.3 4.6 ± 1.6 28.2 ± 7.8 29.0 ±7.9 4.1  ±0.7
MSA-P 9 (5:4) 62.3 ± 8.0 5.4 ± 1.7 30.4 ± 7.6 32.0 ±10.3 4.2 ±0.8
PD 10(7:3) 64.4 ± 7.8 12.0 ±5.0# 17.9 ±5.7* 20.6 ± 7.2** 3.1  ± 0 .6 *
P value 0.8 0.6 <0.001 0.003 0.01 0.001
♦-1*0.001 vs. PSP and MSA; *-p=0.003 vs. PSP, p=0.002 vs.  MSA; **-p=0.02 vs. MSA  p=0.05 vs.  PSP; *- 
F0.002 vs. PSP, p=0.004 vs. MSA
TjNiW Mean (SD) subject details and annualised severity score differences for those attending both psychology 
®mments.
n (M:F) Age (yrs)
Disease 
duration (yrs)
UPDRSII
change
UPDRSIII
change
HY
change
MMSE
change
FAB
change
P S P 15(10:5) 63.6 (5.0) 6.9 (4.5) 12.0 (7.7) 13.4(11.3) 0.9 (1.0) 0.8 (3.0) 3.1  (4.6)
9(5:4) 62.3 (8.0) 5.4 (1.7) 8.9 (6.5) 10.3 (7.7) 0.7 (0.9) -0.9 (3.1) 1.8 (3.2)
T O 9(6:3) 64.3(8.3) 12.9 (4.3)* 7.3 (4.5) 7.6 (9.8) 0.5 (0.7) 0.7 (2.9) 1.2(2.1)
p   value 0.8 0.8
p<0.001  vs 
PSP and MSA
0.3 0.3 0.7 0.4 0.6
±P<0.001 vs PSP and MSA
133Data for patients attending both neuropsychology assessments is shown in table 5.3. 
The only significant difference in the groups was in the delayed recall subtest of the 
Rey AVLT (Mann-Whitney U, p=0.006). In this test, the difference in scores between 
the first and second assessments was greatest in the MSA-P group with a significant 
deterioration  compared  to  the  PD  group  and  a  trend  towards  a  difference  in 
comparison to the PSP group (p=0.07). No other significant differences between the 
rates  of change  in  neuropsychological tests,  in  the  different  disease  groups  were 
found.
5.3.4.  Conclusions
The PSP group showed greater change on all tests, however, no significant differences 
in  the  mean  change  in  neuropsychology  test  scores  between  groups  were  noted. 
Soliveri et al detected more rapid decline in tasks related to attention, set shifting and 
categorisation in PSP, in a similarly sized sample of patients with PSP, MSA-P and 
PD (Soliveri et al.,  2000), although the  interval between testing was  longer (18-21 
months compared to 6-12 months in this study). Another factor is differential drop 
out. If the subjects who progress fastest drop out differently between groups then a 
real  effect  may  be  lost.  Hence,  the  smaller  number  of  subjects  with  complete 
neuropsychological test scores, and the effects of differential drop out, particularly in 
MSA may have contributed to the lack of a significant difference.
Neuropsychology tests are prone to problems with floor and ceiling effects. If a test 
score is already at its limit, then no change can be observed. This may be reflected in 
the  PSP  group  results.  Reviewing  the  individuals  recruited  to  this  study  on  a 
subjective basis certainly gives the impression that there was a progressive decline in 
the  cognitive  deficit as well as the  motor disability,  and  it  was  surprising that  no 
statistically significant group differences are observed. The change in the psychology
134scores  is  unlikely  to  be  linear,  whereas  applying  a  correction  for  an  annualised 
interval presumes that  it  is.  Whilst this  is not  an ideal  method  of normalising the 
groups, it standardises the change.
The diseases studied are  heterogeneous and, progress at varying rates  (Chapter 3). 
They also differ in the degree of cognitive impairment and its evolution. In PSP, this 
was recognised in the first description of the disease (Steele et al.,  1964). This could 
help to  explain why  more profound  differences  on  initial  assessment  or  on  serial 
testing were not detected between the disease groups.
Formal neuropsychological tests are useful and have a place in both diagnosis and the 
clinical management of these conditions.  However for the  clinician, a reliable and 
repeatable bedside test of executive function would have utility as an adjunct to the 
other clinical examination findings, if it were able to help discriminate PSP from other 
degenerative bradykinetic rigid syndromes.  One  such test with this potential  is the 
frontal assessment battery (FAB, appendix).
5.4.  The Frontal Assessment Battery
5.4.1.  Introduction
The  frontal  assessment  battery  (FAB,  appendix,  (Dubois  et  al.,  2000)  has  been 
described briefly in chapters 2 and 3. It consists of a sequence of six subtests and has 
been  designed  specifically  as  a  quantitative  bedside  test  of sub-cortical/executive 
dysfunction.
The  six  subtests  (scoring  between  0-3  on  each)  explore:  conceptualisation  (the 
similarities  subtest);  mental flexibility  (verbal  fluency  for  the  letter  ‘S’);  motor 
programming (a Luria motor sequence, “fist-edge-palm”); sensitivity to interference
135(the conflicting  instructions  subtest);  inhibitory control (the  go-no-go  subtest);  and 
environmental autonomy (a test of prehension behaviour).
The  testing  of these  features  at the  bedside  allows  for  simple  quantification  of a 
patients ability to conduct appropriate goal directed behaviour and for adapting their 
response to new or challenging situations. These functions are mediated by the pre- 
frontal cortex,  and  it  would be  expected  for patients with PSP to  perform poorly 
compared to those with PD or MSA-P, in whom there is pathological involvement of 
the basal ganglia, but not extensive involvement of the pre-ffontal cortex. The scores 
on  the  six  subtests  add  up  to  give  a  maximum  of  18  (indicating  no  executive 
dysfunction). The scale has been well validated in PSP, MSA-P and PD (Dubois et 
al, 2000), as well as FTD and AD (Slachevsky et al., 2004).
5.4.2.  Methods
A  single  examiner  (myself) recorded the  FAB  scores,  prior to the  patients  formal 
neuropsychological testing. Mean FAB scores in the different diseases were compared 
using a one-way analysis of variance with post-hoc t-tests. In order to assess whether 
difference in the FAB scores between the disease groups was influenced by disease 
severity or duration, group differences were assessed with disease duration and the 
UPDRS III  score as covariates.  Additionally, patients were divided into those with 
PSP and those with MSA-P or PD and these two groups subdivided into those with a 
Hoehn and Yahr score >3 or < 3. Mean FAB scores at both levels of disease severity 
were compared.
In the whole cohort, the cut off score on the FAB that best discriminated PSP from 
MSA-P or PD was determined by applying a receiver operator characteristic (ROC) 
curve analysis.
1365.4.3.  Results
The FAB took approximately  10 minutes to complete  in each patient.  FAB  scores 
were significantly different across the three groups (pO.OOl, table 5.4).  The mean 
FAB scores of the PSP patients were significantly lower than those of the MSA or PD 
patients (p=0.02 and p<0.001 respectively). FAB scores of the MSA group were only 
just significantly lower than those of the PD group (p=0.047).
Table 5.4 Number of subjects with FAB scores in the ‘normal’ and ‘abnormal’ range and 
mean (SD) FAB scores in the PSP, MSA-P and PD groups.
PSP MSA-P PD
Mean (SD) FAB 11.7 (3.0)*## 14.7 (2.5) # 16.5 (1.4)
50th Centile 15
FAB £15 3 7 11
FAB <15 14 4 1
*p=0.02 vs. MSA; ##p<0.001 vs. PD; #p=0.047 vs. PD
The group differences in FAB scores remained significant even after controlling for 
duration of illness and disease severity (p<0.001).
Applying a non-parametric test (Mann-Whitney U) of group differences in the FAB 
for two  different levels of physical disease severity based on the Hoehn and Yahr 
scores, confirmed that FAB scores in PSP patients with Hoehn and Yahr of less than 
or equal to 3 (n=10) compared to those with PD/MSA-P with Hoehn and Yahr at the 
same level (n=l 1) were significantly different (p=0.003). FAB scores for Hoehn and 
Yahr of 4 or more were also compared between PSP and PD/MSA (n=7 and n=8) and 
remained significantly different (p=0.009).
A receiver-operating characteristic (ROC) curve analysis showed that a cut-off of less 
than 15 discriminated PSP from MSA-P and PD with a sensitivity and specificity of 
78%.  The  area under the ROC  curve was 0.84  indicating that the  FAB  had  good 
discriminant ability.
Subsequently,  scores  of less  than  15  were  considered  to  reflect  greater  executive 
dysfunction.  The proportion of patients with FAB  scores  below  15  or scores  >15
137were compared across the three groups (table 5.4). While in the PSP group 14 patients 
(82%)  had FAB  scores in the  “low” range, only 4  MSA-P  (36%)  and  1   PD  (8%) 
patients had scores below  15.  The differences across the groups were  significantly 
different (Chi-Squared =16.12, df=2, pO.OOl).
Of the six FAB sub-scores, differences between the PSP, MSA-P and PD groups were 
significant  for  the  lexical  fluency  (p=0.001),  motor  series  (p=0.001),  conflicting 
instructions (p=0.03), and prehension behaviour (p=0.02), but not the similarities or 
go no go subtests (p=0.08 and p=0.4 respectively). Post-hoc analyses showed that the 
PSP and MSA-P groups differed significantly on the lexical fluency and motor series 
(p=0.002 for both), whereas the PSP and PD groups differed on similarities (p=0.04), 
lexical  fluency (p=0.002),  motor series (p=0.001),  conflicting  instructions (p=0.01) 
and prehension behaviour (p=0.009) but not the go-no-go subtest (p=0.2).
A stepwise discriminant function analysis using the six FAB subtests showed that the 
lexical fluency and motor series sub-scores correctly classified 70% of the PSP, MSA 
and PD patients (motor series: Wilk’s lambda =0.611, F[2,37]=11.7, pO.OOl; lexical 
fluency:  Wilk’s lambda =0.50, F[2,37]=7.5, pO.OOl). Predicted group membership 
on the basis of these two FAB sub-scores was accurate for 76.5% of the PSP, 75% of 
the PD and 54.5% of the MSA patients.
5.4.4.  Conclusions
The FAB scores differentiate PSP, MSA-P and PD, with the PSP group having the 
lowest scores and the PD patients the highest. Discriminant function analysis confirms 
that 70% of the patients were correctly assigned their clinical diagnosis of PSP, MSA- 
P or PD on the basis of their FAB scores alone. Furthermore, while 82% of the PSP 
patients had FAB scores of less than 15, such scores were only found in 36% of the 
MSA and 8% of the PD group. In a stepwise multiple regression analysis, alternating
138semantic fluency was found to be the variable that accounted for 80% of the variance 
of the FAB scores.
In the original description of the FAB, no difference between the score in MSA and 
PD was detected (Dubois et al,  2000).  This may have been because of the limited 
number of MSA patients recruited (n=6). The PSP patients (n=47) in the Dubois study 
had a mean (SD) FAB  score of 8.5  (3.5), considerably lower than that  seen in the 
patients described in this thesis and their mean age was also greater (66.9 years). The 
mean FAB  score  in the 42  healthy controls  studied was  17.3  (0.8)  and  in the PD 
subjects 15.9 (3.8). This compares favourably with the mean FAB score reported in an 
Italian study of 364 healthy controls subjects (Appollonio et al, 2005).
The MSA-P patients in this thesis had a mean FAB score of 14.7 (2.5). PD patients 
had a FAB score of 16.5 (1.4). The value for the PD subjects is similar to that seen in 
the original report of the FAB (mean in PD=15.9, SD=3.8). Both of these values are 
close  to  the  mean  values  seen  in  healthy  control  subjects  but  this  should  not  be 
interpreted as showing intact cognitive functioning in PD as the sensitivity of the FAB 
to  detect the mild executive  deficits known to  occur  in PD  (Emre,  2003)  may be 
limited.
It is important to ascertain whether the FAB  score, thought to be fairly specific for 
subcortical and executive dysfunction (Dubois et al, 2000) is appropriately associated 
with more formal neuropsychological test scores and not excessively influenced by 
tests of general cognitive function. Dubois et al stated that the FAB  score was not 
associated with the MMSE and hence concluded that the FAB score was not overly 
influenced by more general cognitive decline. In order to be certain of this, and to be 
certain that the FAB score is reflective of executive dysfunction, associations between 
the FAB and formal neuropsychological scores were studied.
1395.5.  Associations between the FAB and formal neuropsychology scores
5.5.1.  Methods
Linear regression models were fitted to investigate the relationship between the FAB 
score and the test results from more formal tests of cognitive function.
Not all subjects were able to complete the full set of neuropsychological tests,  (the 
maximum number of patients who had missing data on a particular cognitive test was 
five) and subjects with missing data were excluded from the  statistical analysis for 
those tests.
To  increase  statistical  power  by  ensuring  that  there  were  sufficient  numbers  of 
patients in each subgroup, we divided the whole sample of 40 patients into high or 
low FAB scores. The FAB cut-off score of 15 was used to separate the 40 cases into 
two groups: 21 with high (>15) versus 19 with low (<15) FAB scores. A series of t- 
tests were used to identify significant differences between the groups with high and 
low  FAB  scores.  As  we  used  a  series  of 38  t-tests,  a  Bonferroni  correction was 
performed to adjust the level of significance for multiple comparisons. Only p values 
of p=0.001 or less were considered significant.
5.5.2.  Results
Significant positive associations were found between the FAB total score and more 
formal tests of cognitive function across the entire patient cohort. These are shown in 
table 5.4. The associations between FAB scores and the Reitan Trail A, Recognition 
Memory for Faces, the Beck depression inventory, the Beck Anxiety Inventory, or the 
number of repetitions or intrusions on the verbal fluency test and the Rey AVLT were 
not significant.
140Table 5.5 Associations between the FAB and detailed neuropsychological assessment
Positive Correlations
Tests influenced by frontal executive function Tests of general cognitive function
Test
Correlation
coefficient
P value Test Correlation
coefficient
P value
WAIS-R Similarities 0.68 < 0.001 NART 0.61 < 0.001
WCST correct categories 0.48 0.002 WAIS-R VIQ 0.71 < 0.001
Verbal Fluency phonemic 0.7 < 0.001 WAIS-R vocabulary 0.78 < 0.001
Verbal Fluency semantic 0.59 < 0.001 WAIS-R digit span 0.67 < 0.001
Verbal Fluency alternating 
semantic
0.75 < 0.001 MMSE 0.62 < 0.001
PASAT 0.65 < 0.001 Mattis DRS total 0.67 < 0.001
Mattis DRS
Initiation/perseveration
0.6 < 0.001 Mattis DRS construction 0.44 < 0.001
Mattis DRS 
conceptualisation 0.39 0.01 Mattis DRS memory 0.36 0.03
Mattis DRS attention 0.33 0.04
Rey AVLT (various components) 0.39 - 0.65
0.01  - 
< 0.001
Negative Correlations
Tests influenced by frontal executive function Tests of general cognitive function
Test
Correlation
coefficient
P value Test Correlation
coefficient
P value
WCST perseverative 
errors
-0.5 0.003
Cognitive decline NART-WAIS-R 
IQ
-0.41 0.017
WCST non-perseverative 
errors
-0.37 0.03
Reitan TMT B -0.65 < 0.001
Reitan TMT B-A -0.67 < 0.001
Apathy Questionnaire -0.42 0.009
When studied separately with multiple regression analysis and co-varying for MMSE, 
Mattis  DRS,  age  and  disease  duration,  the  FAB  score  in  the  PSP  group  alone, 
correlated with the following neuropsychological tests: PASAT (R2 = 0.78, t = 4.7, p 
= 0.001), RTMT B (R2 = 0.93, t = -4.5, p = 0.02), WCST perseverative errors (R2 = 
0.7, t = -3.1, p = 0.02) and the vocabulary sub-test of the WAIS-R (R2 = 0.7, t = 3.0, p 
= 0.01). No correlations with other neuropsychological tests in the PSP group were 
detected.
141There were no  significant differences in UPDRS II, III or age between the patients 
with high versus low FAB scores (p>0.05). The patients with FAB scores >15 had a 
longer  disease  duration  (p=0.005)  but  this  did  not  reach  significance  after  a 
Bonferroni correction (table 5.6). The group with low scores on the FAB (i.e. more 
severe executive dysfunction) had significantly lower scores on the Mattis DRS (total 
score and initiation subtest), the WAIS-R (Verbal IQ, vocabulary and similarities), 
Verbal  fluency (phonemic,  semantic and alternating  semantic), the Paced Auditory 
Serial Addition Test and the 4th and 5th trials of the RAVLT.
No  significant  differences  were  detected  between  the  groups  on  the  Mattis  DRS 
construction or memory subtests, measure of cognitive decline (difference between 
NART premorbid IQ estimate and WAIS-R current Verbal IQ), information retention 
across a 30 minute delay on the RAVLT (difference between delayed trial and trial 5), 
the number of errors or the percentage  of perserverative  errors on the  WCST,  the 
Reitan TMT-A, the recognition trial of the RAVLT, the recognition memory (RMT) 
for faces, scores on the Beck depression inventory or the Beck anxiety inventory.
The group with low scores on the FAB had a trend towards higher Reitan TMT-B, 
Reitan TMT B-A difference scores, number of perseverative errors on the WCST and 
scores on the Apathy Scale.
There was a trend towards lower scores on the NART VIQ, the Mattis DRS (attention 
and conceptualisation sub-tests), the MMSE, the second, third and delayed trial of the 
RAVLT, the number of categories correctly sorted, and the number of perseverative 
errors on the WCST. None of these reached significance after a Bonferroni correction.
Since  the  FAB  includes  one  item on  conceptualization/similarities  and  one  verbal 
fluency  item,  we  also  examined  the  correlation  between  adjusted  FAB  scores
142(omitting  these  items)  and  the  Similarities  subtest  of  the  WAIS-R,  the 
conceptualisation subtest of the Mattis DRS and the phonemic verbal fluency scores. 
The Similarities subtest of the WAIS-R (r=0.49, p=0.003) and the phonemic verbal 
fluency  test  (r=0.69,  pO.OOl)  had  positive  and  significant  correlations  with  the 
adjusted FAB score, whereas the conceptualisation subtest of the Mattis DRS did not.
With the exception of the phonemic verbal fluency, WAIS-R Similarities and DRS 
conceptualisation subtests, which have overlapping items in the FAB, the variables 
that showed sizeable and significant correlations with the FAB score were entered in a 
stepwise regression analysis to  determine which of them accounted for the greatest 
proportion  of its  variance.  These  were  duration  of illness,  the NART  estimate  of 
premorbid IQ, WAIS-R, Verbal IQ, MMSE, Mattis DRS total score, RAVLT trials 1- 
5 and delayed recall, WCST categories correct, perseverative and non-perseverative 
errors, semantic verbal fluency, alternating semantic fluency, PASAT, Reitan TMT B, 
the TMT B-A difference  score, the Apathy scale, the measure of cognitive decline 
(difference between NART and WAIS-R Verbal IQ). Only the alternating semantic 
fluency entered the stepwise regression and accounted for 80% of the variance of the 
FAB  scores.  (Standardized coefficient =  0.906, Adjusted R square 0.904,  F(l,ll)=
50.2,  pO.OOl).
143Table 5.6 Mean (SD) scores for age, disease duration,  UPDRS and neuropsychological tests for patients with FAB 
scores equal to or higher than 15 or those with FAB scores lower than 15.  Significant differences after a Bonferroni 
correction are in bold.
FAB score £ 15 FAB score < 15 T-test
n Mean SD n mean SD P value
Patient details
Age(years) 21 62.7 6.6 19 65.8 8 =0.2
'Disease Duration (years) 21 9.5 6.7 19 4.8 2 =0.005
U PD R S B 21 18.9 7.5 19 20.3 7.5 =0.5
U PD R S B l 21 21.2 8 19 21.1 8.9 =0.9
Tests of general cognitive function or mood
M M S E 21 27.9 2.2 19 25.1 3 =0.002
N A R T V IQ 20 117.8 12.1 15 107.9 12.7 =0.03
W A IS-R  VIQ 20 113.2 16.7 18 93.6 15.3 =0.001
Vocabulary (scaled) 19 13.5 3.6 17 8.8 3.0 <0.001
Cognitive decline (NART- WAIS- 
RIQ)
19 3.4 12.8 14 11.9 11.7 =0.06
M atfs DRS total 21 137.6 6.7 18 121.8 18.2 =0.001
M a M is DRS memory 21 23.0 3.9 18 21.8 3.7 =0.3
M ads DRS Construction 21 5.5 1.3 18 4.8 2.1 =0.2
R E Y 1 21 5.5 2.7 19 4.4 2.2 =0.2
R E Y 2 21 8 2.8 19 5.9 2.8 =0.02
R E Y 3 21 9.9 2.7 19 7.3 3.5 =0.01
R E Y 4 21 11.2 2.2 19 8.0 3.3 =0.001
R E Y 5 21 11.7 2.7 19 8.5 3.1 =0.001
R E Y  Delay 21 10.4 4.7 19 6.3 4.4 =0.007
M em ory Loss with delay 
(R E Y 5-REY Delayed recall)
21 1.3 3.2 19 2.2 2.2 =0.3
Recognition Memory for Faces 21 22.1 2.8 15 21.1 3.9 =0.4
B eck Depression Inventory 21 11.1 8 18 13.6 6.3 =0.3
B eck Anxiety Inventory 21 16.0 12.9 18 11.7 8.2 =0.3
Tests of executive function
M ads DRS Initiation 21 34.3 3.2 19 25.9 7.9 <0.001
M ads DRS Concenptualization 21 37.6 1.7 19 32.2 9.4 =0.02
W A IS  Similarities (scaled) 18 12.1 3.7 17 7.8 3.3 =0.001
M ade DRS attention 21 37.8 0.5 19 33.5 6 =0.03
W isconsin CST categories 
sorted
21 4.3 2.5 18 2.7 2.2 =0.04
W isconsin CST number of errors 19 6.7 7 14 11.6 8.4 =0.07
W isconsin CST perseverative 
errors
19 3.6 5.1 14 6.8 5 =0.03
W isconsin CST %  perseverative 
errors
19 28.3 27.4 14 38.1 18.7 =0.3
R oN anA 20 76.5 50.9 13 104.6 82.1 =0.2
R eitan  B 19 136.4 65.1 10 227.3 106.3 =0.03
R eN an  Trail B-A difference 19 69.4 48.5 10 156.8 88.1 =0.01
V erb al fluency phonemic (total
m
21 41.5 16.2 18 16.4 9.1 <0.001
V erb al fluency semantic animals 21 14.3 5 18 8.7 4.5 =0.001
V erb al fluency alternating 
categories
21 15.8 4.4 18 7.7 4.7 <0.001
P A S A T 20 20.2 6.7 16 13.6 5.8 =0.001
A P A T H Y  scale score 20 11.8 6.5 18 21.8 12 =0.004
R E Y  Repetition errors 21 13.7 1.6 19 12.5 2.9 =0.1
R E Y  Intrusion errors 21 0.6 0.9 19 1.0 1.4 =0.3
1445.5.3.  Conclusions
The FAB showed sizeable and significant correlations in the expected direction with 
tests  of  executive  function  (verbal  fluency,  Reitan  TMT,  Similarities,  WCST, 
PASAT,  the  initiation  and  conceptualisation  subtests  of the  Mattis  DRS,  and  the 
apathy  questionnaire).  FAB  scores  also  showed  significant  correlations  with more 
general tests of cognitive function such as the MMSE, Mattis DRS total score, Verbal 
IQ, NART estimated IQ and measures of cognitive decline.
Patients with high FAB  scores significantly differed in terms of scores on tests of 
executive  ‘frontal’  function  namely  the  Mattis  DRS  initiation  and  perseveration 
subtest, verbal fluency, the PASAT and WAIS Similarities as well as a trend towards 
higher scores on the apathy questionnaire than those with low FAB scores.
The associations between the FAB and the age of the patient and severity of illness 
assessed  on  the  UPDRS  II  and  III  subsets  were  neither  large  nor  significant.  A 
significant association with duration of illness (r=0.41, p=0.009) arose because the PD 
subjects  had  significantly  higher  FAB  scores  and  longer  disease  duration.  This 
occurred  simply  because  all  subjects  considered  together  and  should  not  be 
interpreted  as  suggesting  that  FAB  scores  increase  as  bradykinesia  and  rigidity 
increase.
The  association  between the  FAB  score  and  the  NART  estimated  pre-morbid  IQ 
suggests that pre-morbid intellectual functioning might influence the FAB score. This 
has also been suggested in a large study of the FAB score in healthy control subjects 
(Appollonio  et al,  2005).  Hence  education or pre-morbid IQ  should be taken into 
account when interpreting the results of the FAB score.
Together with disinhibition and impulsivity, apathy is considered to be one of the key 
behavioural  manifestations  arising  from  frontal  dysfunction  (Marin,  1996).  It  is
145interesting to note that while FAB scores were significantly correlated with scores on 
the Apathy scale, the correlations between FAB scores and measures of depression or 
anxiety were not significant.
One advantage of the FAB for assessing cognitive function in PSP is that it does not 
contain any subtests dependent on intact oculomotor function. The gaze palsy in PSP 
should  not therefore  contribute  to  the  difference  between FAB  scores  in the  PSP, 
MSA-P and PD patients. This is not the case for the more formal cognitive tests and 
particularly scores on the WCST, the Reitan TMT and the recognition memory test 
for faces which can all be influenced by the oculomotor dysfunction in PSP. However 
this  should not  affect the  results  in this  study as  all patients who  were unable  to 
complete these tests due to  severe gaze palsy were excluded from the analysis for 
these specific tests.
These results are partly in agreement with the findings of Dubois et al in that the FAB 
score reflects scores on more formal tests of executive function (Dubois et al., 2000). 
However, in addition, the results outlined in this chapter demonstrate that the FAB 
may help differentiate MSA-P and PD and Dubois et al may have failed to show this 
because of their small MSA sample size (n=6).
These results exteild those of Dubois et al by showing clear correlations between the 
FAB  and not only the  WCST but also  other formal tests of executive  function.  In 
contrast  to  the  results  of Dubois  et  al,  in  this  study,  FAB  scores  also  showed 
significant correlations with more global measures of cognitive function such as the 
MMSE, as well as the Mattis DRS total score (although this test has components that 
test executive function), the  WAIS-R Verbal IQ, and the estimate of premorbid IQ 
from the NART. Furthermore, there were significant differences in the mean scores of
146several tests of general cognitive function between the subgroups with high and low 
FAB scores.
This is not surprising given that degenerative disorders often have multiple cognitive 
domains affected  simultaneously.  This means there  is an inevitable element  of co­
linearity with frontal and global cognitive decline and suggests that global cognitive 
decline, as well as sub-cortical dementia is likely to affect the FAB score.
The correlation between the NART and the FAB score could suggest that a lower pre- 
morbid IQ is associated with poorer performance on the FAB. However there was no 
significant difference between the NART scores in the high and the low FAB groups.
A criticism of other bedside tests of frontal function such as the EXIT 25 test, has 
been that they showed significant correlations with more global measures of cognitive 
function such as the MMSE, which meant they measured aspects of cognition other 
than executive function  (Royall et al.,  1992). The results above suggest that this is 
also true of the FAB. Nevertheless, given its discriminant validity and its ability to 
correctly differentiate patients with PSP, MSA-P or PD, administering the FAB at the 
bedside  may  be  useful  in  the  routine  clinical  assessment  of  bradykinetic  rigid 
syndromes.
That  simple and alternating  semantic  and phonemic verbal  fluency tests have been 
shown to  correctly  differentiate  PSP,  PD  and  MSA  and  are  considered  sensitive 
measures  in  the  differential  diagnosis  of these  disorders  (Lange  et  al.,  2003)  is 
reflected in the results of this thesis in which lexical fluency seems to be one of the 
more important sub-scores of the FAB with regard to its ability to differentiate PSP, 
PD and MSA-P.
147Studies measuring reaction times and event-related potentials have shown that speed 
of processing is significantly slower in PSP than in PD and in PSP than in MSA or PD 
(Dubois  et al.,  1988;  Pirtosek et al.,  2001).  Hence  a potential  confounding  factor 
when applying the  FAB  to  these parkinsonian syndromes  is that processing  speed 
might have been slower in PSP than in MSA-P or PD and this could have influenced 
the  group  differences  in  FAB  scores.  However,  with the  exception  of the  lexical 
fluency subtest, none of the FAB subtests have a time limit. For this reason, one might 
suggest that the significant differences between the PSP, MSA and PD patients are not 
simply reflective of differences in processing speed. However lexical fluency is one 
of the  most  important  FAB  subscores with regard to  correct classification of PSP, 
MSA and PD, and a measure of motor speed (Reitan TMT A) did not correlate with 
FAB scores, while the more cognitively demanding Reitan TMT B, and the TMT B-A 
difference  score  did.  These  psychological tests  are  not  restricted to  testing  motor, 
cognitive or processing speed independently of each other, but could be interpreted as 
suggesting that speed of cognitive processing may be relevant to performance on the 
FAB in bradykinetic rigid syndromes after all.
5.6. Overall conclusions
These results confirm that PSP has more severe subcortical and executive dysfunction 
than  MSA-P  and  PD.  The  lack  of any  significant  difference  between the  patient 
groups  in the  rate  of cognitive  decline  is  likely to  be  a  consequence  of the  short 
interval between testing, as well as patient drop out.
FAB scores at the initial assessment discriminated PSP from MSA-P and PD and also 
MSA-P  from  PD  and  appear  to  have  clinical  validity  as  a  test  supportive  of the 
diagnosis of PSP. While a normal or abnormal FAB score cannot be defined because 
the FAB has not been administered to a healthy control group here, a score of <15
148indicates significant impairment, well below the mean (-1  SD) seen in control groups 
in two studies (Appollonio et al, 2005; Dubois et al, 2000).
The FAB  scores in all patients were associated predominantly with performance on 
tests of executive function, further supporting the use of the FAB as a quick bedside 
test in differentiating the more severe executive dysfunction of PSP from that seen in 
MSA  and  PD.  However  the  fact  that  in  contrast  to  previous  studies,  significant 
correlations with tests of general cognitive were detected, suggests that the FAB score 
is influenced by more global cognitive impairment and the results of the test should be 
interpreted cautiously and in the correct clinical context.
Imaging correlates of these findings in PSP, have been examined and are discussed in 
later chapters.
1496.  Cross Sectional Volumetric Imaging
6.1.  Introduction
The phenotypic differences that characterise different neurodegenerative diseases are 
underpinned  by  the  topography  of cerebral  dysfunction.  Certain  diseases  have  a 
predilection for affecting particular regions of the brain, and the resulting atrophy may 
be visible during life when the brain is imaged. In PSP, a reduction in midbrain size is 
the imaging finding most frequently quoted. Qualitative assessments regarding its size 
and shape in PSP mention concavity of the superior midbrain in the mid-sagittal view 
on  MRI  (Righini  et  al.,  2004),  and  have  drawn  comparisons  to  the  profile  of a 
hummingbird (Kato et a l, 2003) and on axial views to the “morning glory” flower 
(Adachi  et  al.,  2004).  Volume  differences  in  numerous  other  regions  have  been 
commented upon including the third ventricle (Savoiardo et al,  1994; Schrag et al.,
2000), the corpus callosum (Yamauchi et al., 2000) and the frontal and temporal lobes 
(Schrag et al,  2000). Many of these studies have relied on qualitative judgements as 
to  the  presence  or  absence  of atrophy,  although  more  recently,  studies  based  on 
quantitative volumetric and area measurements have been published. Further studies, 
however,  are  needed  to  validate  published  findings.  It  is  also  important  to  study 
regions quantitatively, such as the third ventricle, in which only qualitative data is so 
far available (Schrag et al.,  2000). Quantitatively studying brainstem regions such as 
the midbrain, pons and cerebellum and analysing clinico-radiological correlations in 
PSP  and  MSA-P  may  further  understanding  of the  clinical  phenotype  in  these 
diseases.
Region of interest (ROI)  segmentation requires assumptions regarding the areas we 
expect to be affected in PSP. These assumptions are largely based on: (1) information
150from  previous  imaging  studies  in  PSP;  (2)  Information  from  post-mortem 
histopathological  studies;  (3)  assumptions  regarding  which  anatomical  regions  are 
expected to be involved given the clinical phenotype of a disease. In this way, ROI 
studies are at least partly hypothesis driven.
Manual region of interest studies remain the gold standard for detection of differences 
in brain and regional brain volume between diseases and healthy controls. However, 
novel image analysis techniques such as voxel based morphometry (VBM, Chapter 7) 
can be used to  identify regional differences and  support the  findings of hypothesis 
driven ROI studies, without making any a priori assumptions regarding which regions 
to study.
Segmentation is the process of outlining a particular region of interest (ROI) on an 
MRI scan. Outlining of large CSF spaces is straightforward as their borders are often 
easily identified. Likewise, outlining the borders of a structure surrounded by a CSF 
space, such as the anterior border of the pons, is aided by that high contrast boundary. 
However CSF may not surround all parts of a ROI, and this makes segmentation more 
difficult  and  requires  subjective  and  often  arbitrary  assessment  of the  boundaries 
concerned. For small structures, that are difficult to outline, variability secondary to 
measurement error can mask true group differences in regional volume. Because of 
this, clear protocols for segmentation need to be adhered to in order to minimise error 
and to standardise the anatomical cut-offs in regional volume measurement. This can 
mean that some of the relevant structure volume is excluded. For regions that have not 
been studied previously,  preliminary region of interest  studies can be analysed and 
segmentation protocols adapted and refined in order to minimise measurement error.
151For  all  image  segmentation  performed  in  this  study,  the  digitised  structural  MR 
images  were  transferred  to  a  SUN  workstation  (Sun  Microsystems  Inc, 
Mountainview,  CA)  and  image  analysis  undertaken  using  the  MIDAS  software 
package  (Freeborough et al,  1997)  with  images  registered to  standard  space.  The 
MIDAS package, allows manual segmentation of regions of interest using a 
mouse-driven cursor. The simultaneous display of orthogonal views allows the 
operator to  outline  the  structure  in  the  coronal,  axial  or  sagittal  view  whilst  the 
segmentation is updated in real time in another plane, viewed in a second window. 
This aids  in decisions about  where  regional  boundaries  are  defined.  Segmentation 
protocols are described in more detail in Chapter 6.5.
6.2. Aims
The  aims  of cross  sectional  volumetric  image  analysis  were  directed  principally 
towards:  1)  identifying  any  novel  regions  of volume  difference  that  may  help to 
discriminate PSP during life; 2) identifying group differences in whole brain volumes 
between PSP, MSA-P, PD and healthy controls; and 3) undertaking region of interest 
segmentation in  order to  quantify regional,  particularly  brainstem atrophy patterns 
using manual,  semi-automated and template-based ROI analysis techniques in these 
diseases;  and  4)  determining  the  combination  of  regional  atrophy  that  best 
differentiates PSP and MSA-P.
In order to achieve these aims, new region of interest measurement protocols had to 
be devised and assessed for repeatability and reliability.
6.3. The superior cerebellar peduncle as a potential discriminator of PSP
6.3.1.  Introduction
In their original description of PSP in 1964 (Steele et al.,  1964), the authors described 
cell  loss  and  gliosis  in  the  cerebellar  dentate  nucleus  as  well  as  atrophy  and
152demyelination in the superior cerebellar peduncle (SCP) or brachium conjunctivum. 
This structure contains fibres projecting from the dentate nucleus to the ventral lateral 
nucleus  of the  thalamus.  Recently,  macroscopic  atrophy  of  the  SCP  has  been 
systematically studied pathologically in PSP and neurodegenerative  disease control 
subjects, concluding that SCP atrophy at post mortem reliably differentiates between 
PSP and other clinically related neurodegenerative diseases  (Tsuboi et al, 2003).
The SCP consists mainly of efferent fibres from the cerebellar dentate nucleus, which 
run in the lateral wall of the fourth ventricle. The fibres enter the posterior aspect of 
the pontine tegmentum, postero-medial to the upper fibres of the middle cerebellar 
peduncle, inferior to the inferior colliculus. Just anterior to the SCP fibres in this part 
of the brainstem are the fibres of the mesencephalic tract of the trigeminal nerve and 
the motor nucleus of the Trigeminal nerve. The SCP fibres continue in the upper pons, 
move medially and begin to decussate as the pons merges with the midbrain. Within 
the midbrain the fibres are situated between the interpeduncular fossa anteriorly and 
the  IVth ventricle  posteriorly  and  are  bounded  by  the  pontine  reticular  formation 
laterally. Within the midbrain, the SCP fibres sit anterior to the cerebral aqueduct and 
the peri-aqueductal grey  (PAG),  the  medial  longitudinal  fasciculus  and tectospinal 
tract.  The  interpeduncular  nucleus  and  fossa  are  anterior  to  the  SCP  with  the 
substantia  nigra  and  corticopontine  fibres  anterolateral.  The  fibres  enter  the 
cerebellorubrothalamic tract, which is sited between the red nucleus posteromedially 
and  the  substantia  nigra  anterolaterally.  The  in-vivo  anatomical  mapping  of these 
brainstem axonal connections has been demonstrated recently, using diffusion tensor 
MRI (Mamata et al., 2002; Stieltjes et al., 2001). A schematic representation of the 
pathway is shown in figure 6.1.
153Figure 6.1  Schematic diagram of the cerebello-rubrothalamic pathway
The schematic diagram displays the origin of the pathway in the cerebellar dentate nucleus 
from which the fibres run in the superior cerebellar peduncle, decussating in the midbrain 
above the level of the superior colliculi. Some of the fibres synapse in the red nucleus, others 
continue rostrally to synapse in the ventral anterior and ventrolateral thalamic nuclei.
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Atrophy of the  SCP on MRI  has been  noted, in SCA-3  and  SCA-6  (Murata et al., 
1998b;  Murata  et al.9   1998a),  and  in one  case  of SCA-3  coming  to  post  mortem,
154atrophy of the SCP seen on MRI in life was confirmed by grumose degeneration of 
the dentate nucleus and moderate atrophy of the  SCP at autopsy (Tokumaru et al., 
2003).
The  only previous  MRI  study  looking  at  the  SCP  in  PSP  concentrated  on  signal 
change detected using proton density weighted MRI, within the decussating fibres in 
the midbrain (Oka et al., 2001). This was felt to reflect demyelination and gliosis but 
was only present in 4 of the 9 cases studied. However it is worth noting that partial 
volume effects are inevitably more important in thick slice imaging (e.g. 3-5mm axial 
slices  in proton density imaging).  These  partial volume  effects may make  atrophy 
appear as signal change with increased CSF signal on proton density or T2 “shining 
through”.
Pathological studies suggest that at the macroscopic level, a reduced SCP  size may 
identify cases of PSP with a high sensitivity and specificity. Previous imaging studies 
suggest  that  MRI  can  be  used  to  detect  features  consistent  with  pathological 
involvement of the SCP during life in PSP and anatomically, the structure is partially 
bounded  by CSF  and  so  it  may  be possible to  outline  it  accurately on volumetric 
scans.
6.3.2.  Projections and function of the SCP fibres
The cerebellum and basal  ganglia  are  critically  involved  in motor  control  and the 
programming, initiation and execution of limb and eye movements. The outputs of the 
cerebellum  and  basal  ganglia  are  mediated  in part  through projections  to  various 
thalamic nuclei. Dysfunction of these pathways results in a number of profound motor 
disturbances.
The projection of the  dentate  nucleus to  different cortical  areas has  been disputed 
(Asanuma et al,  1983; Holsapple et al,  1991). More recently, it has generally been
155accepted that the dentate nucleus contains a topographical motor map of the body, 
with face, arm and leg areas projecting via the thalamus to the motor cortex (Hoover 
and Strick, 1999). Cells projecting to the motor cortex make up only about 30% of the 
dentate nuclear volume, so 70% of its cells must project elsewhere.
The  nucleus  probably  contains  multiple  topographically  organised  body  maps 
projecting to different cortical areas and more recently, it has been shown that cells 
project to the pre-ffontal and posterior parietal cortex as well as to the primary motor 
cortex (Dum and Strick, 2003).  The non-motor domain in the ventral portion of the 
dentate  contains  output  channels  concerned  with  aspects  of cognition  and  visuo- 
spatial  function.  These  ventral  portions  are  activated  during  a  variety  of tasks 
involving  short  term  working  memory,  rule  based  learning  and  higher  executive 
functions such as planning (Kim et al., 1994).
The functions of the neurons travelling within the SCP are complex and varied. While 
the majority of the fibres originate from the dentate nucleus, a small number come 
from the nucleus interpositus and the fastigial nucleus. Lesional studies often provide 
good information regarding the function of specific structures and this has certainly 
been true of a large retrospective study of basal ganglia lesions (Bhatia and Marsden, 
1994).  Lesions  isolated  to  the  superior  cerebellar  peduncle  have  been reported  as 
causing  impaired  smooth  pursuit  while  saccadic  eye  movements  were  preserved 
(Ohtsuka et al, 1992). Other authors have reported that a lesion of the dentate and its 
projections results in severe postural tremor. This is not a typical clinical finding in 
PSP, but can certainly occur. A lesion in the superior cerebellar peduncle, at the level 
where  it  is  closest to  the  oculomotor nerve  fascicles  at the  caudal  end of the  red 
nucleus has been cited as the most likely site causing Claude’s syndrome (Seo et al.,
1562001).  This  syndrome  is  characterized  by  ipsilateral  occulomotor  nerve  palsy  and 
contralateral cerebellar ataxia. Again these are not typical clinical features of PSP. 
Lesional studies in animals have shown that damage to the SCP results in abolition of 
eyelid and limb conditioned responses (McCormick et al., 1982; Voneida, 2000). It is 
not immediately apparent that we can use this information to postulate how pathology 
in the dentate nucleus and subsequent atrophy in the SCP may be correlated with loss 
of specific functions and clinical signs in PSP, particularly as the pathology in PSP is 
not confined to this one region.
6.3.3.  Aims
The purpose of regional segmentation of the SCP on volumetric T1  weighted MRI, 
was  to  determine  whether  the  MRI  appearances  of  this  structure  can  help  to 
distinguish PSP from other Parkinsonian syndromes in life, and whether this can be 
specifically related to particular clinical features of the disease. Prior to undertaking 
this analysis however, a method of segmenting the SCP and calculating its volume 
needed to be devised.
The aims of this preliminary study of the SCP were:
1.  To devise a protocol for segmentation of the SCP.
2.  To assess the repeatability and reliability of the protocol in a preliminary series  of
segmentations.
3.  To assess the methodology looking for error between paired segmentations and to 
alter the segmentation protocol as required.
4.  To repeat the segmentations and reassess repeatability and reliability.
5.  With the final protocol, assess the ability of SCP volume to differentiate PSP from 
other degenerative diseases.
6.  To review the clinical value of SCP atrophy as a marker for PSP.
1576.3.4.  Preliminary methods of SCP segmentation
A preliminary study of the SCP was undertaken once a suitable number of initial MRI 
scans had been acquired. T1  volumetric MRI scans in 12 patients with PSP,  12 with 
PD, 8 patients with MSA-P and 11  non-diseased controls were included. MRI scans 
were  acquired  on the  same  1.5GE  Signa Unit  (General  Electric,  Milwaukee,  WI) 
using  the  T1  acquisition  parameters  described  previously.  The  images  were 
transferred to a SUN Microsystems workstation for analysis.
The  images were  acquired  coronally  and the  SCP  was  initially  segmented  in this 
plane,  from anterior to posterior.  The superior margin was taken at the level of the 
inferior  colhculus  and  the  inferior  margin  the  parabrachial  sulcus.  The  SCP  is 
bounded medially and laterally by CSF in coronal section.  Sagittal and axial views 
were available for comparison throughout and subsequently the axial sections were 
checked and the segmentations modified. On Sagittal section, the anterior border was 
taken as where the SCP entered the brainstem and the posterior border, where it joins 
the cerebellum (figure 6.2A). This measurement protocol only takes into account the 
fibres  of the  SCP  after  they  have  left  the  cerebellum  and  prior  to  entry  into  the 
brainstem.
The  images were  segmented  in standard  space,  in random order by  a  single  rater 
(myself) blinded to the identity and clinical diagnosis in each case. A second blinded 
measurement  was  then  made  once  the  complete  data  set  had  been  analysed  and 
compared to the first set of measurements to allow assessment of the repeatability and 
reliability of the method.
158Figure 6.2 Examples of superior cerebellar peduncle segmentation.
B
T 1 weighted volumetric MRI of the superior cerebellar peduncle in a healthy control  subject demonstrating outlining of 
he structure (A- sagittal,  B- coronal,  C- axial views of MIDAS window,  showing the superior cerebellar peduncle-SCP, 
outlined in green).  The  superior  cerebellar  peduncle  contains  efferent fibres from  the  deep  nuclei  of the  cerebellum 
mainly  the  dentate  nucleus)  which  pass  superiorly  to  the  red  nucleus  and  thalamus,  decussating  in  the  caudal 
midbrain.
6.3.S.  Repeatability and reliability measures
When an instrument is used to measure a clinical quantity it is desirable that pairs of 
measurements made on the same individual using the same instrument give “similar” 
results  in  the  absence  of any  other  variation  in  circumstances.  Repeatability  and 
reliability are both concerned with quantifying the degree of similarity between such 
pairs of measurements.
Repeatability relates to the standard deviation of within person differences and hence 
is measured in the same units as the clinical quantity of interest. Reliability relates the 
variation seen within individuals, to that seen between individuals and hence is unit 
free.
If a  second  instrument  is  used  to  measure  the  same  clinical  quantity,  then  interest 
centres on the agreement between the two instruments.
In deciding whether two  instruments agree,  consideration needs to  be given to  bias 
(does one  instrument  give  higher measurements than  another)  and  variability  (how
159variable are the differences between measurements made on the same individual using 
different instruments).
If a variable is measured twice in n individuals using a single measurement technique, 
then  the  within  subject  standard  deviation  (Gw )  can  be  used  as  a  measure  of
repeatability.  The  smaller  the  within  subject  standard  deviation,  the  greater  the 
repeatability.  Alternate measures of repeatability,  such as the  standard deviation of 
differences and the  95% reference range  for differences (i.e for a variable,  95% of 
observations are expected to lie within ±1.96 standard deviations from the mean) can 
also be used.
For  a  measurement  technique  with  the  best  possible  repeatability,  observed 
differences  should  have  zero  mean and  constant  variance.  The  mean difference  in 
measurements should be seen to lie at around zero.
In order to estimate reliability, the simple model for repeatability can be extended to 
give the between subject variability. This can be estimated using analysis of variance. 
The estimated between person variance is given by:
ab2 = (BMS-RMS)/m
where m  is the  number of measurements per subject,  BMS  is the  between subject 
mean squared difference and RMS the residual or within individuals mean squared 
difference.
The reliability coefficient can be calculated from:
2  .  2 
<5b  + C W
The reliability coefficient is the proportion of the total variance that is due to between 
person variability and as  such takes values in the range (0-1) and is unit free.  The
160closer it  is to  1, the  more reliable  is the method.  Another name  for the reliability 
coefficient is the intraclass correlation coefficient (ICC).
6.3.6.  Results
The  results  of the  mean  difference  in  blinded  segmentation  of the  SCP  and  the 
calculated within person SD and ICC in the preliminary measurements are detailed 
below.
Table 6.1 Superior cerebellar peduncle repeatability and reliability measures
Pairs of 
observations
Mean (SD) 
SCP 
volume 
(ml)
Range (ml) 95% C.l
Mean absolute 
difference in 
segmentations
Within person 
sd (ml)
Initial
protocol
43
0.312
(0.039)
0.176-0.462 0.295-0.329 0.02 0.031
Iniraclass corre ation coefficient -  0.850 (95% C.l- 0.77-0.93)
SCP- superior cerebellar peduncle; sd-standard deviation; C.l-confidence interval
From these  data,  the  method  seems  repeatable  (within person  standard  deviation- 
0.03 lml) and reliable (ICC -  0.850). However whether this can be improved upon by 
revising the methodology depends upon determining where the differences between 
an individuals first and second assessment occurred, and if altering the technique can 
minimise these errors without creating new ones.
6.3.6.1.  Where do measurement inconsistencies arise?
For  segmentations  in the  axial,  coronal and  sagittal planes,  the  area segmented  on 
each scan slice,  in standard space, was recorded. The difference in the first and the 
second blinded measurements at each level was noted together with the total number 
of paired scans recorded at that scan slice. From this it is possible to assess where the 
greatest disparity between the first and second measurements occurred. The first and 
the  second  blinded  segmentations  were  reviewed  manually  for  each  individual 
regardless of diagnosis and the location of the most obvious disparities between the 
first and the second segmentations was noted.
161Figure 6.3 Mean difference in SCP measurement 1 and 2 at different axial slices Axial scan data
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162Figure 6.4 Mean difference in SCP measurement 1  and 2 at different coronal slices Coronal scan data
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163Figure 6.5 Mean difference in SCP measurement 1 and 2 at different sagittal slices Sagittal scan data
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164Reviewing the results of analysis of the  initial and repeated blinded measurements 
(figures 6.3-6.5), it is apparent from the tabulated and the graphical data, where the 
most  important  discrepancies  between  paired  measurements  lie.  On  the  axial 
measurements, the  most significant errors were made superiorly,  between slices 42 
and  46  and  inferiorly  between  slices  60-65  (figure  6.3).  Coronally,  the  biggest 
discrepancies  arose  anteriorly,  between slices  90  to  95  with a  few  less  significant 
errors posteriorly (figure 6.4). On the sagittal measurements, the greatest errors were 
made  laterally (figure  6.5).  However  in  all planes,  in  scan  slices where the  mean 
difference in measurement one and two was large, the actual number of subjects with 
scans  that  included  tissue  in  that  slice  was  small  and  unlikely  to  be  of much 
significance at a group level.
A qualitative review  of the  segmentations  in the  cases  with the  largest  intra-rater 
variability confirmed that these regions were the most likely to result in within subject 
measurement error due to the protocol utilised. These results confirm that the tissue 
boundaries are best detected at brain/CSF interfaces and poorly delineated where clear 
brain tissue/CSF boundaries were not present. These parts of the structure rely most 
heavily on manual measurements. Despite this, an interclass correlation coefficient of 
0.85 suggests good intra-rater reliability.
6.3.6.2.  Improving repeatability and reliability of SCP 
measurements
On the basis of this preliminary analysis, modifications to the measurement protocol 
were  made.  Care was  taken  in the  axial plane  at the  superior border of the  SCP. 
Rather than starting  in the coronal plane, the  initial measurement was made in the 
axial plane  with the  superior border  of the  SCP  taken at the  level of the  inferior 
margin  of the  inferior  colliculus  in the  sagittal plane.  A  straight  line  between the
165inferior border of the inferior colliculus and the posterior border of the pons marked 
the anterior border of the SCP. The posterior border of the SCP was marked at a point 
where  it  entered the  cerebellum and  became  indistinguishable  from the  cerebellar 
hemisphere.  The axial sections were carefully checked with the  sagittal and coronal 
sections and  any deviation from the protocol rectified appropriately.  Particular care 
was taken in the slices prone to measurement inconsistencies. As before, the inferior 
border of the SCP was taken as the level of the parabrachial sulcus. Repeatability and 
reliability measures were undertaken as before and are shown in table 6.2.
Table 6.2 Superior cerebellar peduncle repeatability and reliability measures for modified protocol
Pairs of 
observations
Mean (SD) 
SCP 
volume 
(ml)
Range (ml) 95% C.l
Mean difference 
in
segmentations
Within person 
sd (ml)
Initial
protocol
43
0.273
(0.063)
0.164-0.395 0.257-0.289 -0.054 0.058
Interclass corre ation coefficient -  0.215 (95% C.l- 0 - 0.50)
SCP- superior cerebellar peduncle; sd-standard deviation; C.l-confidence interval
Clearly using the revised method did not result in improved reliability (ICC) or 
repeatability of the SCP segmentation.
6.3.7.  Conclusions
In conclusion,  the  ICC  and within person  standard  deviation confirm that the  first 
method for segmentation of the SCP is both reliable and repeatable. Using the revised 
method  did not improve on the original  method.  The  mean SCP  volume using the 
revised  method  is  slightly  lower  which  would  be  expected  given that  the  revised 
technique used a more rigid cut off for the anterior border of the SCP. Therefore for 
the  purposes of SCP  segmentation on the  entire  data  set, the  original  method was 
used. The results of SCP volume analysis on the entire data set are reported in Chapter
6.5.4.  The clinical utility of these measurements is commented upon in Chapter 6.7 
and 6.8.
1666.4. Differential Bias Correction
Intensity bias or intensity inhomogeneity is the slowly changing and smooth spatial 
variation that can occur within any MRI scan. Grey and white matter in one part of 
the brain can have systematically lower signal intensity than at another part of the 
scan.  This  inhomogeneity  causes  significant  problems  with  image  analysis  and 
consistency in automated segmentation and image registration.
The artefact  is caused by (1)  inhomogeneity of the magnetic  field (Bo)  of the  MR 
system.  (2)  inhomogeneity  of the  radio-frequency  (RF)  pulse  generated  by  the 
oscillating secondary magnetic field (Bi). (3) non-uniform sensitivity of the receiver 
coils used to detect the MR signal.
Automated segmentation techniques require a model for signal intensity for different 
tissue  types.  These  models  become  invalid  for  images  with  a  large  bias.  Manual 
segmentation, using thresholding may also be affected.
Pre and post processing may be used to correct bias. Pre processing techniques require 
increased acquisition time and cannot be used to correct retrospective data.
Linear registration which relies on the brain boundary shift integral (BBSI) will be 
affected by intensity changes and deformation based atrophy techniques will also be 
affected as the artificial intensity change will produce unrealistic warps.  The BBSI 
will  not  give  a  valid  measure  of  atrophy  when  there  is  significant  tissue 
inhomogeneity between the  scans.  Hence,  for all data analysis  in this thesis,  MRI 
scans  were  corrected  for  inhomogeneity  artefact  using  differential  bias  correction 
(DBC) (Lewis and Fox, 2004).
In order to determine whether differential bias correction improved the repeatability 
and  reliability  of regional  segmentation,  segmentation  of the  third  ventricle  was 
undertaken  on  non-DBC  scans  and  on  DBC  scans,  using  the  same  segmentation
167protocol. The third ventricle was chosen as it is a CSF space and therefore rapidly 
segmented  using  semi-automated  threshold  based  measurement  techniques,  with 
minimal operator input. This should minimise measurement error and allow a more 
accurate assessment of whether DBC influences the accuracy of the segmentation.
In describing the extent to which the instruments agree with each other, three issues 
are of importance:
1)  Bias: On average, are measurements made with the second method, higher or 
lower than those made with the first? If so, what is the extent of the bias?
2)  Differences in variance: Are measurements made with the second instrument
more  variable  than  those  made  with  the  first?  This  method  concerns  the
2  2 similarity between within subject standard deviation (<JW ;  and Ow2 ).
3)  Variability  of  differences:  How  variable  are  the  differences  between
measurements made on the same individual using different instruments? This
2  2 question concerns the size of Owj  and Ow2 .
6.4.1.  Methods
For third ventricle measurements, all of the above points were addressed with respect 
to volume measurements using MRI scans registered to standard space: (1) with; and 
(2)  without  differential  bias  correction  (DBC)  to  determine  whether  this  post­
processing  tool  improved  repeatability  and  reliability  of  the  regional  volume 
measurements.
The third ventricle volume was measured by a single rater blinded to the identity of 
the individual, the clinical diagnosis and the time sequence of the scan, in 50 subjects 
randomly selected from the data set. To minimise practice effect, the third ventricle 
was segmented on DBC and non-DBC MRI scans with a six-week interval.
168T1 weighted MRI in MIDAS window showing seed (pink cross in A) planted within the CSF space. A- 
Axial third ventricle ROI. B- Sagittal third ventricle ROI. The anterior cut off at the anterior commissure is 
clearly demonstrated as is the posterior and superior border defined by the splenium of the corpus 
callosum.
Each subject  had  the  third  ventricle  volume  segmented twice,  for the  scan at time 
point  one  and  time  point  two  and  for  non-DBC  and  DBC  scans  (hence  8 
segmentations).
For  ventricular  segmentation,  the  objective  is  to  exclude  brain  voxels.  Using  a 
threshold based automated segmentation proceedure (Freeborough et al.,  1997), the 
upper threshold was set at 60% of mean brain intensity and the lower threshold at zero 
in order to exclude voxels that were predominantly brain tissue. The anterior border 
was set at the anterior commisure and the posterior border at the anterior border of the 
splenium of the corpus callosum in the mid sagittal slice. The inferior border was set 
at  the  level  of the  mamillary  bodies.  Voxels  within the  aqueduct  of sylvius  were 
excluded. A horizontal line at the level of the inferior border of the splenium of the 
corpus callosum,  in the mid sagittal slice was set as the superior border of the third 
ventricle. These definitive cut-offs were set in order to increase the repeatability and 
reliability of the volume measurements. Examples of third ventricle segmentations are 
shown in figure 6.6A and B.
Figure 6.6. Third ventricle region of interest segmentation
169For all subjects with a complete data set, the within subject standard deviation (aw ) 
was calculated as a measure of repeatability for the non-DBC and the DBC scans at 
time point one and two. A Pitman’s test was performed to test the hypothesis that the 
non-DBC and the DBC measurements have the same variance (null hypothesis Owj  =
<*»■/)•
The reliability of the methods used was evaluated by calculating the between person 
variance  in each measurement  method and from this, the reliability coefficient (or 
ICC) was calculated.
Bias in the measurement techniques was assessed by using a one-sample t-test applied 
to differences in the mean measurements at each time point, comparing the non-DBC 
segmentations with the DBC segmentations, with a null hypothesis that the true mean 
difference was zero.
6.4.2.  Results
Of the  50  subjects  studied,  eight  sets  of  segmentation  data  were  included  for 
evaluation of third ventricle measurements.
(1)Third ventricle, time 1, segmentation l.(5)DBC third ventricle, time 1 segmentation 1.
(2)Third ventricle, time 1, segmentation 2.(6)DBC third ventricle, time 1 segmentation 2.
(3)Third ventricle, time 2, segmentation l.(7)DBC third ventricle, time 2 segmentation 1.
(4)Third ventricle, time 2, segmentation 2.(8)DBC third ventricle, time 2 segmentation 2.
170Table 6.3 Third ventricle segmentation data
n Mean (ml) SD Min Max
3v11 50 1.95 .81 .63 3.95
3v12 50 1.99 .83 .63 4.07
3v21 50 2.03 .85 .64 4.10
3v22 50 2.07 .86 .70 4.20
DBC3v11 50 2.00 .83 .63 4.04
DBC3v12 50 2.00 .82 .64 3.94
DBC3v21 50 2.08 .87 .69 4.16
DBC3v22 50 2.07 .86 .69 4.17
3v11-Third ventricle, time 1, segmentation 1  ; DBC3v11-DBC third ventricle, time 1  segmentation 1.
3v12-Third ventricle, time 1, segmentation 2 ; DBC3v12-DBC third ventricle, time 1  segmentation 2.
3v21-Third ventricle, time 2, segmentation 1  ; DBC3v21 -DBC third ventricle, time 2 segmentation 1.
3v22-Third ventricle, time 2, segmentation 2 ; DBC3v22-DBC third ventricle, time 2 segmentation 2.
A simple model of repeatability implies that for two measurements per subject, the 
observed group differences should have zero mean and constant small variance.
The within subject standard deviations, and the results of the variance ratio test are
shown in table 6.4.
Table 6.4 Repeatability data for third ventricle measurements
Within subject Variance ratio test
SD Mean difference 
(ml) (95%C.I)
Null Hypotheses
3v1 * DBC 3v1 3v1 < DBC 3v1 3v1 > DBC 3v1
3v1 0.061 0.06 (0.04-0.08)
P=0.0014 P=0.99 P=0.0007 DBC3v1 0.038 0.04 (0.03-0.05)
3v2 * DBC 3v2 3v2 < DBC 3v2 3v2 > DBC 3v2
3v2 0.065 0.07 (0.05-0.09)
P=0.0054 P=0.99 P=0.0027 DBC3v2 0.038 0.04 (0.03-0.05)
3v1- non DBC thirc 
point 1; DBC3v1- C 
measurements at ti 
1   and 2.
ventricle measurements at time point 1; 3v2- non DBC third ventricle measurements at time 
>BC third ventricle measurements at time point 1;  DBC3v2- DBC third ventricle 
me point 2; sd-standard deviation; Mean difference- mean difference between segmentation
The  reliability  of the  method  for  measuring  the  volume  of the  structures  can  be 
calculated  from  a  one-way  analysis  of  variance  between  the  first  and  second 
measurements of the third ventricle volume at each time point for the non-DBC and
171the DBC scans. This allows calculation of the between subject variance and the within 
subject variance, and enables the ICC to be derived.
Table 6.5 Reliability coefficients for third 
ventricle measurements
Reliability coefficient 
(ICC)
3v1 0.994
3v2 0.994
DBC 3v1 0.998
DBC 3v2 0.998
From this data it is apparent that both methods are reliable (ICC close to 1). The DBC 
scan segmentation has a slightly greater ICC.
Analysis of the mean of the 3vl, DBC3vl, 3v2 and the DBC3v2 measurements and 
the differences between measurements of the non-DBC and DBC scans at the same 
time point suggests that the non-DBC measurement method has a tendency (a bias) to 
give a lower volume for the third ventricle using the same measurement protocol in 
every other respect. The results of a one-sample t-test are shown in the table below, 
confirming this suspicion.
Table 6.6 Statistical comparison of methods of third ventricle measurement
Volume (ml) Difference 
in means 
(ml)
95% C.l
Null hypothesis
(SD) Differences Difference>0
Mean 3v1 1.97 (0.82)
0.027 0.006-0.05 P=0.01 P=0.005
Mean DBC3v1 2.00 (0.83)
Mean 3v2 2.05 (0.86)
0.024 0.008-0.04 P=0.004 P=0.002
Mean DBC3v2 2.07 (0.87)
6.4.3.  Conclusions
These data confirm that the methods of third ventricle segmentation have excellent 
intra-rater repeatability and reliability. The results of a Pitman’s test on third ventricle 
measurements suggest that the repeatability and reliability are improved when using 
scans that have been corrected for differential bias.  Segmenting the non-DBC scans
172has  a  bias  to  returning  a  lower  volume  for  the  third  ventricle  compared  to 
segmentation of the DBC scans.
The improved repeatability and reliability for segmenting this region with DBC  is 
difficult to explain on the basis of this post acquisition processing technique alone. 
The difference in the ICC is minimal suggesting the reliability of the measurement is 
only minimally influenced by DBC.
DBC should reduce artefactual intensity differences and as such, thresholding may be 
affected, particularly around brain and CSF boundaries. This could help to explain the 
improvement in repeatability and lead to the bias towards a larger volume recorded 
for the DBC scan segmentations.
The main difficulty is in discounting the intrarater practice effect as a causal factor in 
these improvements. A six-week gap was left between segmenting the regions in the 
non-DBC and the DBC scans, although despite this, some practice effect is likely to 
remain.  As  the  DBC  measurements  were  conducted  after  the  non-DBC  scan 
measurements, it could explain the reduced within subject standard deviation but this 
would not contribute to the bias which is also seen.
Fully automated regional segmentation is possible but whilst this results in excellent 
repeatability and reliability, the accuracy of regional measurement is not as good as 
manual,  semi-automated  techniques.  For  this  reason  manual,  semi-automated 
segmentation was used for ROI studies in this thesis.
DBC scan pairs registered to standard space were used for all further whole brain and 
regional volume segmentations, to ensure the best repeatability and reliability.
1736.5. Whole brain and region of interest (ROI) segmentation 
6.5.1.  Methods
All scans were registered to standard space and were segmented as scan pairs with 
baseline and repeat scans viewed together with the operator blinded to the identity and 
diagnosis  of the  individual as  well  as the  temporal  sequence  of the  images  being 
viewed.  The  results  section  in  this  chapter  (6.5.4)  only  describes  cross  sectional 
volume analysis.
ROI segmentation relies partly on manual application of boundaries. For all scans a 
semi-automated  intensity-threshold  based  processing  routine  was  used  to  delineate 
regions that were “brain” and “non-brain”. This involves using the MIDAS  software 
tool (Freeborough et al,  1997) to “plant” a seed within the ROI on each scan slice. In 
this way, the brain/CSF boundary can be delineated without manual outlining.  Each 
scan slice is reviewed and manually adjusted to include only the desired region on the 
basis of anatomical knowledge of the regional boundaries.
Individual MR images were segmented with the operator blinded to the identity and 
diagnosis.  Specific  methodology  for  whole  brain  and  regional  segmentation  is 
detailed in the following sections.
6.5.1.1.Brain volume 
The aim of whole brain segmentation is to label the 3D brain while excluding non­
brain (i.e. scalp, CSF, dura and the superior sagittal sinus). The following four steps 
describe the segmentation process in detail (Freeborough et al.,  1997).
Step 1 - Setting the threshold values
1.  An  upper  threshold  value  was  set  and  any  voxels  brighter  than  this  upper 
threshold excluded. The lower threshold is set at zero (figure 6.7a). Susceptibility
174artefact occasionally appears around the fusiform and inferior temporal gyri in the 
temporal lobe as abnormally bright tissue. Any susceptibility artefact is excluded 
but normal white matter remains.
2.  The lower threshold is then set to just over half the value of the upper threshold. 
Anything darker than the lower threshold will be excluded.
The  aim  is  to  outline  the  brain  as  accurately  as  possible.  The  green  intensity 
region should now include most of the brain. The brain is checked to ensure that 
the cerebellum and the temporal lobes are included.  Ideally the number of bridges 
(connections between brain and dura which lie within the intensity range defined 
for brain) should be zero. Inevitably a compromise must be struck but, ideally, the 
lower threshold should be taken to a high enough value so that  in the  next step 
only one erosion is needed to remove non-brain and leave only brain (figure 6.7b).
3.  The final part of this step is to set the axial cut off slice. This removes any non­
brain below the cerebellum and aims to give a reproducible lower/inferior limit to 
what is included in the brain stem.
Figure 6.7 Step one in brain segmentation, removin\ non-brain tissue
A- exclusions of voxels above the upper threshold
B- outlining of brain voxels with minimal bndges between 
brain and non-brain tissue
175Step 2 -  Erosions
This step eats away at the external surfaces of the brain region that has been outlined 
above until only brain remains (figure 6.8a). The upper threshold value set in step 1   is 
used to limit the erosion to tissue with a signal intensity below the threshold.
Figure 6.8a Removal of non-bra  in tissue Figure 6.8b Recovery of brain tissue
Step 3 - Dilations
The purpose of this step is to recover the brain removed by the erosion process. Each 
dilation reclaims pixels that fall within the permitted threshold range and are adjacent 
to  the  brain  region  (figure  6.8b).  The  thresholds  that  appear  at  this  point  are 
automatically set by calculating the mean signal intensity over the whole brain region 
after step 2, taking 60% and  160% of this value.  These thresholds are re-calculated 
after each dilation as more voxels are recovered.
Step 4 -  Re-thresholding box
This step completes the segmentation process. The re-thresholding box is an invisible 
box of voxels that  moves across the outlined brain region filling  in any area within 
that  region that  has  been omitted  by  step  3.  However,  there  are  three  rules  which 
govern this procedure. The first is that the omitted area must be smaller than the box.
176Secondly, only those voxels within this area that have a signal intensity of between 60 
and  160% of the mean will be included.  Finally, the missing area must already be 
included within the region.  Therefore, any voxels outside the brain region will not be 
recovered.  Generally, a rethresholding box size of 6 voxels is large enough to recover 
any areas previously excluded.
Finally, axial and sagittal views are checked one final time to ensure accuracy of the 
regional segmentation.
6.5.1.2.Midbrain
For midbrain segmentation, two orthogonal views were available. A consistent lower 
threshold of 70% of mean brain intensity was applied to exclude voxels with a lower 
intensity that were predominantly cerebrospinal fluid (CSF). The superior border of 
the midbrain was taken as the upper border of the midbrain tegmentum in the mid- 
sagittal slice and the inferior cut-off taken at the level of the superior border of the 
pons in the mid-sagittal slice. The posterior and anterior borders were defined by the 
brain tissue/CSF boundary.  Higher up  in the  midbrain,  where no  CSF border was 
present, a manual outline of the grey white tissue boundary was made. Returning to 
sagittal slices, care was taken to ensure that voxels within the quadrigeminal plate 
were  included. Examples of midbrain volume segmentation are displayed  in figure 
6.9A and B.
6.5.1.3.Pons
As  for other regions, the  segmented brain was registered into  standard  space.  The 
lower threshold was set at 70% of the mean brain intensity, and the upper threshold 
set at maximum intensity.  The mid sagittal slice was selected in the main MIDAS 
window.  A seed was  inserted in the pons and the  anterior  convex  border  and the 
posterior border delineated by thresholding. The upper border was set at the level of a
177horizontal line extending from the posterior upper-most tip of the pons convexity. The 
lower border was set at the level of a horizontal line extending from the posterior and 
lower most tip of the pons convexity. The uppermost axial slice was then selected and 
a horizontal line drawn through the median suclus on the posterior aspect of the brain 
stem. This was taken as the posterior border of the pons in the axial view.
When the middle cerebellar peduncles become apparent, the lateral border is taken as 
a  vertical  line  medial  to  the  emergence  of the  trigeminal  nerve.  Examples  of 
segmentation of the pons are shown in figures 6.9E and F.
6.5.1.4.Cerebellum
For the cerebellum, a lower threshold at 60 % of the mean brain intensity was set with 
the upper threshold set at maximum. The cerebellum was segmented from anterior to 
posterior. Voxels within the cerebellar peduncles (superior, middle and inferior) were 
only  included  if,  on  the  axial  slice,  cerebellar  tissue  was  visible  in  the  midline, 
connecting  the  cerebellar  hemispheres.  Examples  of cerebellar  segmentation  are 
shown in figure 6.9C and D.
6.5.1.5.Superior cerebellar peduncle 
The SCP was segmented using the protocol outlined earlier in this chapter (section 6.3 
and figure 6.2)
6.5.1.6.Lateral ventricle 
The  protocol  for  lateral  ventricle  segmentation  is  well  established  (Dalton  et  al., 
2002). The aim of the segmentation is to label all voxels of ventricular cerebrospinal 
fluid, but not extraneous CSF spaces or brain tissue. The coronal view was selected in 
the main MIDAS window.  The upper threshold was set at 60% of the mean brain 
voxel intensity and the lower threshold at zero.
178All the ventricle regions are included and the temporal horn specifically checked to 
ensure its inclusion.
Each coronal slice was viewed, adding the lateral ventricle regions moving anteriorly 
through the brain. Where the region spills out into surrounding CSF spaces, the border 
of the ventricle was manually corrected. The third ventricle was manually excluded. 
Finally all slices were checked to ensure only voxels within the lateral ventricles are 
included. Examples of lateral ventricle segmentation can be seen in figure 6.10. 
6.5.1.73rd Ventricle
Segmentation of the third ventricle was undertaken using the protocol described in 
section 6.4 (figure 6.6).
179Figure 6.9. Examples of region of interest segmentation
A- Sagittal midbrain ROI. B- Axial midbrain ROI
C-Sagittal cerebellar ROI. D- Coronal cerebellar ROI.
|  E-Sagittal Pons ROI. F- Axial Pons ROI.
180Figure 6.10.  Ventricular Region of Interest Segmentation
A- Axial lateral ventricle ROI.  B- Coronal lateral ventricle ROI
6.5.2.  Repeatability and reliability of regional segmentation
Repeatability  and reliability of whole  brain and  lateral  ventricle  measurements  are 
well established (Freeborough et al.,  1997; Whitwell et al, 2001). For midbrain, pons 
and cerebellar volume measurements, after initially segmenting the volumes on the 
entire cohort of subjects, 10 MRI scans were reassessed using the same methods, with 
the  rater  blinded  to  the  diagnosis.  Repeatability  and  reliability  measures  were 
calculated from these data using the methods outlined previously.
Repeatability  and  reliability  analysis  of midbrain measurements,  with  both  sets  of 
blinded measurements conducted using DBC scan pairs are reported in table 6.7.
For assessment of repeatability and reliability scores relating to midbrain, pons and 
cerebellar volume measurements, four sets of data were evaluated.
(1)Region timel, segmentation 1.
(2)Region timel, segmentation 2.
(3)Region time2, segmentation 1.
(4)Region time2, segmentation 2.
181Hence,  for  all  structures,  if the  individuals  TIV  was  larger  than  the  mean TIV  in 
controls, correction results in a reduced volume of that structure.
Normalizing the brain volumes in this way reduces the scatter of data and reduces sex- 
related differences in brain volumes (Whitwell et al., 2001).
6.5.3.3.ResuIts
Figure  6.11  demonstrates  that  the  disease  groups  have  a  greater  degree  of brain 
atrophy  compared  to  healthy  controls  when  the  healthy  control  brain  volume-TIV 
regression line is used as a rough guide.
Figure 6.11 Relationship between brain volume and TIV in PSP, MSA and PD compared to healthy controls.
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Y axis-Brain volume (ml), X axis-TIV-total intracranial volume (ml). Green (diamond) - PSP subjects, Orange (square) 
-  MSA-P, Grey (triangle) -PD. Line and 95% confidence interval represents the relationship between Brain volume 
and TIV in healthy controls.
185In the  group as a whole, the  mean TIV  in men was  11%  greater than in women
(p<0.0001), in keeping with previous studies (table 6.9).
Table 6.9 Age and TIV in all subjects and in controls
n (male:female)
Mean age (SD) 
(years) meanTIV ± sd (ml) 95% C.l
Whole group 55 65.1  (6.4) 1504(149) 1464-1544
& 32 65.3 (6.0) 1577 (125)* 1532-1622
9 23 64.9(7.1) 1403(117) 1352-1454
Healthy Controls
18 66.7 (5.4) 1514(125) 1452-1577
s 10 67.6 (3.9) 1586(111)** 1507-1666
9 8 65.7 (6.9) 1424 (74) 1363-1486
* p<0.0001c?>9; ** p=0.003 <$>$
Table 6.10 Age and TIV in healthy controls and disease subsets
n (male:female) Mean age (SD)(years) meanTIV (SD) (ml) 95% C.l
Healthy controls 18(10:8) 66.7 (5.4) 1514(125) 1452-1577
PSP 18(11:7) 65.1  (5.7) 1489(158) 1410-1566
MSA-P 9 (6:3) 62.3 (8.0) 1484(183) 1345-1625
PD 9 (5:4) 64.3 (8.3) 1545  (159) 1423-1667
There  were  no  significant  differences  in the  TIVs  between healthy  controls,  PSP, 
MSA or PD subjects (One way analysis of variance, F=0.36, p=0.7, table 6.10). 
Plotting the logs of the baseline brain and regional volumes against the log of the TIV 
in controls established the slope of the relationship between TIV and the volume of 
each structure. The resulting coefficient (table 6.11) was used to correct the volume of 
each structure.
Table 6.11 List of coefficients from regressing In(volume) and 
InfTIV) in control subjects.
Structure Grad
Midbrain
1 -0.05
2 -0.05
Pons
1 0.42
2 0.43
Superior cerebellar peduncle 1 0.17
2 0.18
In-natural logarithm,  1-first scan, 2 follow up scan.
Grad- regression coefficient (slope) of In(structure) and In(TIV)
1866.5.3.4.Conclusions
Total  intracranial  volume  measurements  in  controls  were  consistent  with  those 
published in previous studies (Whitwell et al.,  2001). These data confirm the well- 
recognized  wide  range  in  intracranial  volumes between  individuals.  The  smallest 
volume was less than 70% of the largest TIV.  On average, the men had TIVs that 
were  11%  larger  than  those  of the  women.  In  conclusion,  these adjustments  are 
important in studies assessing group differences in total and regional cerebral volume, 
which otherwise may be confounded by differences in head (and TIV) size between 
groups.  The  coefficients  from  regressing  ln(volume)  and  ln(TIV)  in  the  control 
subjects are the same or very close to the same value for baseline and follow up scans. 
However, while the value for the midbrain and the SCP is close to zero, suggesting 
little  relationship  with  a  changing  TIV,  that  for  the  pons  is  larger  suggesting  it 
increases with an increasing TIV.
6.5.4.  Results of Region of interest segmentations 
For normally distributed data, a one-way analysis of variance, and for non-parametric 
data a Mann-Whitney U test, were used to determine group differences in brain, third 
ventricle and lateral ventricle volume as well as, midbrain, pons, cerebellar and SCP 
volume, all corrected for TIV as described above. There were significant differences 
in frontal, midbrain, SCP and third ventricle volumes between PSP and MSA, PD and 
healthy controls.  Significant differences were  seen in pons and cerebellar  volumes 
between MSA and PSP, PD and controls (tables 6.12 and 6.13 and figure 6.12).
For all regions where the mean volume differentiated one disease group from another 
or  from controls,  forward  stepwise  logistic  regression using  a  likelihood ratio  test 
(with  p<0.05  as  criteria  for  addition  to  the  model),  was  performed  to  determine
187whether  these  volumes  were  useful  predictors  of  the  clinical  diagnosis  when 
considered together. The results of this analysis are reported in section 6.7.
Table 6.12. ROI segmentation mean (SD) volumes (TIV uncorrected)
Subject Group ROI volumes (ml) (mean 1 sd)
PSP MSA-P PD Control
Whole brain volume 1052.4 (124) 1074.2 (130) 1138.2(141) 1128.9(82.4)
Cerebellar volume 109.6(17.3)* 89.9 (27.3)* 126.1  (14.3) 119.8(13.5)
Midbrain volume 5.79 (1.0)*7 ** 7.08 (1.2)a 7.87(1.1) 8.33 (0.8)
Pons volume 12.8 (1.7)Y 9.60 (4.3)# 15.4 (2.6) 13.9(1.5)
SCP volume 0.41 (0.08)* 0.54 (0.05) 0.55 (0.05) 0.55 (0.06)
LV volume 38.5(16.1) 33.7(17.0) 36.2 (18.1) 26.8(13.1)
Third ventricle volume 2.5 (0.8)° 1.82(0.6) 1.96 (0.9) 1.59 (0.7)
Values with significant differences are shown in bold. *-p=0.02 vs.  PD;  ^-p=0.05 vs. PSP, p=0.003 vs.  PD, p=  0.005 
vs. controls; *-p=  0.007 vs. MSA, ** p<0.001 vs. PD and controls; A-p= 0.004 vs. controls;  Y-p=0.01 vs.PD; # -p=0.02 
vs.  PD/controls;  *-p<0.001 vs. M  SA-  P/P D/control s; °-p=0.002 vs. control._______________________________________
Table 6.13. ROI segmentation mean (SD) volumes (TIV corrected)
Subject Group ROI volumes (ml) (mean 1 sd)
PSP MSA-P PD Control
Whole brain volume 1085.9(57.2) 1109.8(59.9) 1130.4 (78.7) 1132.5(74.3)
Cerebellar volume 110.2(15.9)* 90.2 (26.9)** 125.9(13.1) 119.9 (13.4)
Midbrain volume 5.69 (1.1)*7 ** 7.08 (1.2)a 7.87(1.1) 8.33 (0.8)
Pons volume 12.8(1.6) 9.60 (4.3)** 15.4 (2.5) 13.9(1.5)
SCP volume 0.40 (0.08)** 0.54 (0.05) 0.55 (0.05) 0.55 (0.06)
LV volume 39.3 (14.9) 34.4(15.3) 36.0(18.0) 26.7 (12.3)
Third ventricle volume 2.52 (0.8)° 1.93 (0.6) 1.92 (0.8) 1.59 (0.6)
Values with significant differences are shown in bold. *-p=0.04 vs.  PD *-p=0.009 vs.  MSA, **-p<0.001  vs.  PD/Control 
(and MSA-P for SCP volume), (and p=0.01 vs.  PSP for cerebellar volume),  A-p=0.03vs. controls; °-p=0.001 vs. 
controls.
188Figure 6.12 Segmented brainstem and cerebellar volumes in PSP and MSA-P demonstrating relative 
differences in midbrain, pontine and cerebellar volume, within and between the diseases.
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Figure 6.13 Segmentation of lateral ventholes and third ventricle superimposed on brain volume.
1906.5.5.  Conclusions
In this prospective MRI based study comparing volumetric ROI in PSP, MSA-P, PD 
and  healthy  controls,  reliable  and  reproducible  manual  and  semi-automated  ROI 
volume  analysis  confirm that  PSP  and  MSA-P  have  differences  in  regional  brain 
volume which distinguish them from PD and healthy controls and more importantly 
from each other.  Correcting the volumes  for  TIV  has  little  effect  in terms  of the 
difference  in  the  mean  values  between  the  groups.  Midbrain  volume  in  PSP  is 
approximately 80% of the midbrain volume in MSA-P and ponto-cerebellar volume in 
MSA-P is approximately 80% of the ponto-cerebellar volume in PSP. It is only the 
larger  SD  in pontine  volume  in MSA-P  (possibly due to  measurement  error) that 
results in a less significant difference between MSA and PSP.
The  results  from this  study  support  previous  retrospective  and  qualitative  studies 
suggesting that midbrain size is significantly reduced in PSP. Interestingly it is also 
reduced  in MSA-P,  perhaps reflecting the  known pathological  involvement  of the 
subtantia nigra and subthalamic nucleus in this disease.
Comparing  the  shape  of the  midbrain  on  MRI  in the  PSP  subjects  with  healthy 
controls, suggests that it is the height of the midbrain tegmentum that is lost in PSP 
resulting in a reduction in volume (figure 6.12 and 6.14). This macroscopic atrophy is 
also  frequently commented on in post mortem reports of PSP  cases at  the  Queen 
Square  Brain Bank.  The reduction  in  height possibly  occurs  as  a  consequence  of 
pathological  involvement  and  subsequent  tissue  loss  in  the  subthalamic  nucleus, 
substantia nigra and red nucleus.
191Fig 6.14 Reduction in Midbrain tegmentum height in PSP.  The vertical white line demonstrates height.
Reduced  pontine  and  cerebellar  volumes  distinguish  MSA-P  from  PSP,  PD  and 
healthy controls.  That a reduced cerebellar  volume  is observed  in MSA-P  is not a 
surprise  as  this  is  a  finding  often-cited  in  previous  qualitative  imaging  studies. 
However,  our  cohort  of  MSA  patients  includes  only  those  with  a  predominant 
parkinsonian phenotype at entry into the study and despite this, a significantly lower 
mean cerebellar  volume,  compared to  healthy controls,  PD  and  PSP  was detected. 
This suggests that significant cerebellar and pontine pathology resulting in atrophy is 
present in MSA even when a Parkinson’s syndrome is the presenting phenotype. This 
is  supported by  the  results of a recent pathological  study  in which the  severity  of 
pontine pathology did not differentiate predominantly cerebellar (MSA-C)  from the 
predominantly Parkinsonian forms (MSA-P) (Ozawa et al., 2004).
Cerebellar volumes in PSP were lower than in PD.  Cerebellar cortical pathology is 
minimal in PSP although the dentate nucleus of the cerebellum is lesioned. However 
atrophy of this structure would not be expected to result in a large volume of tissue 
loss as relative to the rest of the cerebellum its volume is small. There is an absence of
PSP Healthy control
192cerebellar signs in PSP,  and in fact their presence would exclude the diagnosis on 
clinical grounds. However as the cerebellar outflow tracts are consistently damaged, 
this  lack of clinical signs is  surprising. It may be that as in MSA, the presence of 
significant pathology  in other brain regions  such as the basal  ganglia,  resulting  in 
extrapyramidal motor deficit, masks any cerebellar signs.
Despite the fact that brain volumes in the diseased subjects seemed to fall below the 
expected confidence  interval  for healthy  control brain volume-TIV  regression  line 
(figure 6.9), there was not a significant difference between the whole brain volume in 
PSP, MSA-P, PD or healthy controls, consistent with relatively localised subcortical 
loss rather than very generalised atrophy (see also Chapter 6.6).
In  contrast  to  an  earlier  study  from  the  National  Hospital  for  Neurology  and 
Neurosurgery (Schrag et al., 2000), the third ventricle volume only differentiated PSP 
from healthy controls and not  from MSA-P  or PD.  This suggests that an enlarged 
third ventricle should not be considered as supporting a diagnosis of PSP.
Dilatation of the  lateral ventricles is unlikely to result simply as a consequence of 
tissue  loss  from  peri-ventriclar  regions.  More  probable  is  that  it  occurs  as  a 
consequence  of tissue  loss  from the  frontal cortex  and  white  matter  with  smaller 
contributions from the temporal lobes. There is no statistically significant difference 
between lateral ventricle volumes  in PSP,  MSA-P,  PD or healthy controls.  This  is 
despite a 40%  larger lateral ventricle volume in PSP than in healthy controls.  The 
wide natural variability  in ventricular volume probably accounts  for this  lack of a 
significant difference.
1936.6.  Segmentation of frontal quadrants and posterior-inferior regions
6.6.1.  Introduction
Accurate volumetric segmentation of the frontal lobes is a labour intensive process. It 
requires  that  many  manual  judgements  based  on  established  anatomy  are  made 
regarding lobar boundaries.  This increases the potential for measurement error and 
subsequent variability. One potential solution to this problem is to transform regional 
templates  onto  the  MRI  scans  of each  subject  in  order  to  calculate  the  regional 
volumes.
Post mortem studies confirm that the frontal cortex is commonly involved in PSP, 
contributing to the neuropsychological deficits that are seen in this disease (Cordato et 
al,  2000). The results of MRI studies suggest that the reduced frontal lobe volume 
can be detected during life and that there are associations with the typical behavioural 
changes  characteristic  of PSP  (Cordato  et al,  2002;  Cordato  et al.,  2005).  These 
studies  suggest  that  frontal  lobe  volumes  measured  using  MRI  during  life  can 
differentiate  PSP  from PD  and healthy  controls.  VBM  studies  suggest that  while 
frontal lobe volume is reduced in MSA and PSP (Brenneis et al., 2003; Brenneis et 
al.,  2004), there  is no  clear  indication as to  whether regional  cortical  atrophy  can 
differentiate them.
The aim of this section of the thesis was to investigate whether application of a similar 
quadrant  based  protocol  had  utility  in  measuring  frontal  and  posterior-inferior 
regional  volumes  in  PSP,  MSA-P  and  PD.  A  quadrant-based  method  of regional 
segmentation has  been proposed  as a guide to  assessment  of frontal  lobe  volume. 
These  methods  are  far  less  labour  intensive  than  other  manual  segmentation 
techniques  and  have  been  applied  successfully  in  Alzheimer’s  disease  (AD)  and 
frontotemporal dementia (FTD) (Chan et al., 2001a).
1946.6.2.  Methods
A standard anatomic space defined by the MNI 305 average brain (Mazziotta et al, 
2001)  was  split  into  four  sub-volumes.  An  initial left to  right  split  was  made  by 
dividing the whole brain volume along the interhemispheric fissure. These two sub­
volumes were each then divided mid-way along the anterior posterior axis to define 
left frontal and right frontal quadrants. The left and right posterior quadrants were 
then divided at the midpoint of the superior to inferior axis to define the left and right 
posterior-inferior volumes.  These regions  were then transformed onto the  baseline 
scan of each subject (registered to standard space) and thresholding applied.
For all scans the MIDAS software tool (Freeborough et al.,  1997) was used to delineate 
the brain/CSF boundary applying a consistent lower threshold of 70% of mean brain 
intensity  to  exclude  voxels  with  a  lower  intensity  that  were  predominantly 
cerebrospinal fluid (CSF).
In this  way,  left  and  right  frontal  quadrants  and  left  and  right  posterior  inferior 
regional volumes were determined. Examples of these can be seen in figure 6.15. 3D 
reconstructions of these volumes are shown in figure 6.16.
Left and right anterior quadrant volumes and left and right PI volumes were added to 
give a total frontal volume and total PI volume. This technique does not rely on any 
manual editing of the ROI.
TIV corrections were applied using the same methods described previously.
195Figure 6.15.  Regional template segmentation of anterior quadrant and posterior-inferior regions.
Sagittal view showing (A) Left anterior quadrant PSP; and (B) Right postero-inferior region MSA-P
Coronal view showing (C) Left anterior quadrant PSP; and (D) Right postero-inferior region MSA-P
Axial view showing (E) Left anterior quadrant PSP; and (F) Right posterior-inferior region MSA-P
196UADRANT
Figure 6.16 3D reconstructions of anterior quadrant and posterior inferior (PI) region.
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Lateral (above) and medial (below) views of anterior quadrant and posterior inferior (PI) 
regions.
ANTERIOR
6.6.3.  Results
The frontal quadrant and posterior-inferior regional volumes are shown in table 6.14 
(uncorrected) and 6.15  (TIV corrected). One-way analysis of variance with post hoc
197Bonferroni tests revealed that significant differences occurred between mean frontal 
volumes in PSP, PD and healthy controls. For the posterior-inferior region, significant 
differences  between  group  mean  volumes  in  MSA-P  and  healthy  controls  were
detected.
Table 6.14. Quadrant basedROI segmentation volumes (uncorrected)
Subject Group ROI volumes (ml) (mean ± sd)
PSP MSA-P PD Control
Total frontal volume 457.6 ±65.1 458.4 ± 44.3 482.1  ±65.7 475.3 ± 49.8
Total PI volume 326.0 ± 37.7 311.1 ±23.0* 333.7 ± 39.7 332.3 ± 30.3
Values with significant differences are shown in bold.  ^-p=0.04 vs controls.
Table 6.15. Quadrant basedROI segmentation volumes (TIV corrected)
Subject Group ROI volumes (ml) (mean ± sd)
PSP MSA-P PD Control
Total frontal volume 449.2 ± 26.8°* 474.8 ± 22.3 480.4 ± 35.0 484.2 ±21.1
Total PI volume 323.0 ±21.6 314.9 ± 22.6^ 333.9 ± 20.8 337.2 ± 15.7
Values with significant dil 
control, *-p=0.03 vs PD.
ferences are shown in bold. v-p=0.001 vs control,  ^ = 0 .0 5  vs
6.6.4.  Conclusions
These results suggest that frontal lobe volumes in PSP are significantly lower than in 
PD  and  healthy  controls  and that posterior  inferior regional  volumes are  lower  in 
MSA-P than in healthy controls. These findings support those detailed in a previous 
but more labour intensive study (Cordato et al., 2002).
The post hoc Bonferroni test is a strict correction for multiple comparisons and as 
such,  some  true  differences  may  be  missed.  With this  in  mind,  a t-test  was  also 
applied to test for differences in mean volumes between groups. This suggested that 
frontal volume in PSP is significantly lower than in MSA-P (p=0.01) as well as PD 
and  healthy  controls.  The  same  test  was  applied  to  the  posterior-inferior 
measurements, suggesting that this volume was lower in PSP than healthy controls 
(p=0.01), and lower in MSA-P than in PD (p=0.04).
198This  is  a  new  and  significant  finding,  as until  now,  volumetric  studies  have  not 
demonstrated any difference in frontal volumes between PSP and MSA-P. These easy 
to apply measures of lobar volume can detect group differences between PSP, MSA- 
P, PD and healthy controls.
The frontal quadrant includes parts of the anterior temporal lobes as well as the frontal 
lobes and in addition the method of segmentation means that parts of the posterior 
frontal lobe are not included and these are affected by the pathological process at post 
mortem in PSP. The temporal lobes may also be damaged in PSP and may contribute 
to  the  reduced  frontal volume.  For this  reason  any  conclusions  regarding  clinical 
associations with frontal lobe volume loss need to be made cautiously.
The posterior inferior volume is made up of the cerebellum and the brainstem as well 
as the inferior part of the occipital lobe. It is therefore not surprising that the MSA-P 
group have the lowest mean volume,  as the mean cerebellar volume was  lower in 
MSA-P than the other groups.  This raises the possibility that this rapid method of 
regional measurement could provide an approximation of the cerebellar volume. This 
is supported by the results of a linear regression of cerebellar volume on posterior- 
inferior volume showing a significant association (R =0.55, p<0.001).
While the group means may be significantly different, there is considerable variation 
in the individual volumes measured in all these structures and because of this there is 
group overlap,  hence the clinical utility of these regional volumes may be  limited. 
This is discussed further in Chapter 6.7.
Finally,  it  is  possible  that  in  making  assumptions  about  which  regions  to  study, 
regions where significant group differences do occur are being missed. Voxel based 
morphometry offers  a  method  of looking  for  group  differences  without  making  a 
priori assumptions regarding where they might occur.
1996.7. Clinical utility of cross sectional regional assessments
Entering all of the ROI showing significant group differences into a forward stepwise 
regression analysis revealed the following: midbrain volume alone differentiated PSP 
from  all  the  other  groups  (pO.OOOl,  sensitivity  72.2%,  specificity  91.9%).  The 
discriminating ability of the MRI findings was improved by adding SCP volume into 
the analysis (pO.OOOl, sensitivity 83.3%, specificity 91.9%). The best discrimination 
of PSP  from the  other groups was achieved by  adding  frontal,  third ventricle  and 
whole brain volumes, as additional separate variables (p<0.0001, sensitivity 88.9%, 
specificity 97.3%).
Discriminating  PSP  and just  MSA-P  on the  basis  of midbrain volume  alone  was 
unreliable  (p=0.004,  sensitivity  83%  but  specificity  33%)  with  six  false  positives 
(66%).  Considering  SCP  volume,  midbrain  volume,  pons  and  cerebellar  volume 
together  however  correctly  classified  93%  of cases  (p<0.0001,  sensitivity  94.4%, 
specificity 88.9%). Reduced cerebellar and pontine volume alone were very specific 
for MSA-P (100%) but not sensitive (44%).
These results suggest that midbrain, superior cerebellar peduncle, pons and cerebellar 
atrophy considered together rather than in isolation are the best discriminators of PSP 
from MSA-P. Taken together with the high false positive rate in the MSA group when 
considering  midbrain  size  alone  as  a  marker  of PSP,  this  suggests  that  a  visual 
assessment of midbrain to pons ratio might help to better identify cases of PSP.  A 
paper confirming this assumption on the basis of area measurements has recently been 
published (Oba et al., 2005). The authors demonstrated no overlap between the ratios 
of midbrain to pons area measurements in PSP and MSA or PD and MSA suggesting 
that the ratio of midbrain to pontine area measurements might have genuine clinical
200utility. Another advantage of this kind of measurement is that it requires no correction 
for individual variation in baseline brain volume (such as correcting for TIV).
The kind of accumulated tissue  loss demonstrated in most cross sectional  studies  is 
unlikely  to  be  present  early  in the  course  of the  disease.  This  means  that  there  is 
overlap  in  regional  volume  measurements  between  disease  and  healthy  control 
groups.  So  while  apparent  volume  reduction  in  a  region  may  help  to  support  a 
particular diagnosis, sensitivities and specificities of 100% will never be achieved. 
Based on the volume measurements in this study,  similar midbrain to  pontine ratios 
were calculated but as can be  seen in the boxplot below (figure  6.17),  there  is  still 
some  group  overlap,  even though  statistically  significant  differences  were  detected 
between the groups using a Mann-Whitney U test.
Fig.6.17 Boxplot showing ratio of midbrain to pons volume
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PSP vs.  MSA, p=0.03;  PSP vs. PD,  p=0.01; MSA vs.  PD,  p=0.002;  MSA vs.  healthy controls, 
p=0.005.
1-PSP, 2-MSA, 3-PD, 4-healthy controls
201The overlap detected in this study could be as a result of using volume rather than 
area measurements. The area measurements undertaken by Oba et al were made on 
the  mid-sagittal  T1  weighted  image.  This  image  is  particularly  appropriate  for 
viewing  the  reduction  in  midbrain  height  and  it  may  be  that  using  a  volume 
measurement incorporates tissue that is not so badly affected and hence the ratio is not 
so robust in terms of discriminating the groups.
6.8.  Differential diagnosis using subjective assessment of the SCP
Quantitatively measuring and comparing these regions is one way of studying their 
ability  to  differentiate  the  diseases  concerned.  Quantitative  measurements  are 
important and have definitive clinical utility if they can be shown to discriminate a 
disease with 100% sensitivity and specificity.
The stepwise logistic regression model was applied as a method of analysis in this 
study  because  it  is  considered  to  be  similar  in  nature  to  the  methods  used  by  a 
radiologist in image interpretation. Neuroradiological diagnosis usually depends on 
looking at particular regions first if asked a specific question (perhaps the midbrain in 
PSP) and then, if no clear conclusion is made regarding the presence of atrophy to 
support the clinical diagnosis,  other areas (such as the third ventricle  or the  basal 
ganglia and cerebellum) are assessed.
Qualitative MRI assessments are most frequently undertaken in clinical practice and 
as such it is important to assess this approach for any novel region of interest that on 
the basis of volumetric studies are shown to discriminate PSP from MSA-P and PD.
As the SCP volumes of the subjects included in this study had the most statistically 
significant differences in their mean values, a neuroradiologist was asked to classify 
subjects as PSP or non-PSP  (MSA-P,  PD or healthy controls)  on the basis  of the 
presence  or  absence  of atrophy.  The  neuroradiologist  was  blinded  to  the  clinical
202diagnosis  and the  results  of volume  measurements.  19  patients with PSP,  10  with 
MSA-P,  12 with PD and 12 healthy controls were available for review. More subjects 
with PSP,  MSA and PD  were available than  for volumetric  segmentation as those 
without a follow up scan were included in this qualitative assessment. Examples  of 
images are shown in figure 6.18.
Fig 6.18 Examples of SCP in PSP and PD
A- SCP T1 weighted axial view in PSP B- SCP T1 weighted coronal view in PSP 
C- SCP T1  weighted axial view in PD D- SCP T1  weighted coronal view in PD
SCP atrophy on visual rating alone differentiated PSP from other neurodegenerative 
conditions and controls with a sensitivity of 74% and specificity of 94%. Fourteen of 
19 PSP cases were graded as having SCP atrophy while the SCP was rated as atrophic
203in only 2 of 34 non-PSP cases. Both non-PSP cases identified as having SCP atrophy 
had a clinical diagnosis of MSA-P (positive and negative predictive values 88% and 
86%).  Hence,  an  easily  clinically  applicable  visual  assessment  differentiated  PSP 
from the other bradykinetic rigid  syndromes with positive  and negative predictive 
values  approaching  90%.  This  is  in  fact  better than  the  values  achieved  for  this 
structure alone using logistic regression.
Of the 53  scans visually assessed, there were only two false positives, both with a 
clinical diagnosis of MSA-P. Three of the five false negative cases had a diagnosis of 
clinically probable rather than clinically definite PSP, suggesting that SCP atrophy is 
most likely to be seen in PSP with typical clinical features. The false negative cases 
did not have the largest SCP volumes of the PSP group on formal measurement nor 
did the two false positive cases (both MSA-P) have the smallest SCP volumes. These 
results suggest that on the basis of cross sectional imaging, a number of features in 
addition to  midbrain  atrophy can  be  used to  support  a clinical  diagnosis  of PSP. 
Additionally, visual assessment by an experienced rater of some of these structures 
appears to be clinically useful. This method was in fact able to discriminate PSP from 
other  diseases  better  than  a  volume  measurement  of the  structure.  This  may  be 
because  other  regional  information  is  taken  into  account  at  the  time  of a  visual 
assessment, and it is difficult to control for this possibility.
6.9.  Overall conclusions
Comparing volumetric ROI in PSP, MSA-P, PD and healthy controls has identified 
that PSP and MSA-P have differences in regional brain volume which distinguished 
them  from  PD  and  healthy  controls  and  more  importantly  from  each  other.  The 
clinico-radiological correlations for these regions are discussed in chapter 12.
204There is however considerable overlap in these ROI measurements and this, together 
with  the  time  taken,  the  software  required,  and  the  corrections  necessary  for 
inhomogeneity  and  TIV,  limits  their  usefulness  in  clinical  practice.  Combining 
measurements in a ratio (such as midbrain to pons) may be more helpful.
A  priori  assumptions  regarding  which  regions  to  study  are  based  principally  on 
established knowledge from previous imaging studies, theoretical assumptions about 
which areas are affected pathological studies. Quantitative and qualitative analysis of 
the  SCP  in this study demonstrate that it has clinical utility in discriminating PSP 
from MSA-P, PD and healthy controls.
Further imaging analysis  studies using techniques that  do  not require  assumptions 
about  which  regions  to  study  would  help  to  confirm  the  results  outlined  in  this 
Chapter and may identify other regions of interest. Voxel based morphometry is one 
such technique.
2057.  Cross Sectional Voxel Based Morphometry
7.1.  Introduction
Global  and  regional  brain  volumes  in  PSP,  MSA-P  and  PD  have  so  far  been 
considered. Some predictions as to the likely topography of the regional volume loss 
that can be detected during life on MRI scans can be made on the basis of knowledge 
from  previous  imaging  studies  and  from  pathological  studies.  These  a  priori 
assumptions have limitations however.
It is reasonable to assume that the earliest pathological changes in PSP might occur in 
regions  functionally responsible  for balance  and  intact  gaze.  However,  volumetric 
studies carried out so far have required a priori decisions as to which substructures 
should be assessed.
The size of unambiguous structures with sharp contrast boundaries such as the lateral 
ventricles are relatively easy to assess. Other morphometric features of disease may be 
more difficult to quantify by inspection, meaning that many structural lesions of a 
degenerative disease may be overlooked.
An alternative approach is to use automated techniques that can accurately localize 
regional  volume  differences  in  an unbiased  manner.  One  such  approach  involves 
assessment  of  volume  difference  between  groups  of  individuals,  which  can  be 
compared  using  statistical parametric  mapping  (SPM),  a well  validated  automated 
technique for performing such group comparisons.
SPM can be used to  identify structural disease related change in brain tissue when 
applied to volumetric scans.  The voxel based morphometry (VBM) approach is not 
biased and provides an assessment of anatomical differences, between subject groups, 
throughout the brain (Ashburner and Friston,  2000).  VBM removes positional  and
206global volume differences through spatial normalisation and then detects differences 
in tissue density by comparing local intensities of tissue after smoothing. VBM avoids 
some of the shortcomings of other methods by being operator-independent and semi­
automated.
Image processing can be divided into:
1)  Processes that deal with differences in brain shape
2)  Processes that deal with differences in the  local composition of brain tissue 
after macroscopic differences in shape have been discounted. This compares images 
on a voxel basis after deformation fields have been used to  spatially normalise the 
scans.
Hence residual anatomical differences in the normalised data can be partitioned.
VBM involves spatially normalising all the  images to the  same  stereotactic space, 
extracting grey matter from the normalised images, smoothing and then performing a 
statistical  analysis  to  localise  and  make  inferences  about  group  differences.  The 
output shows where tissue concentration differs significantly between groups. Several 
steps are involved.
1.  Spatial  Normalisation:  Transforms  all  subjects’  imaging  data  to  the  same
stereotactic space, registering each image to the same template image by minimising 
the  sum of the  squared  differences  in  voxel  image  intensity  between  them.  This 
method  of spatial  normalisation  does  not  attempt to  match  every  cortical  feature 
exactly but corrects for global brain shape differences. If the spatial normalisation was 
exact, then all segmented images would appear identical and no differences would be 
identified.  A  mean  image  of the  series  (or  another  registered  image)  is  used  to 
estimate the warping parameters that map it onto a template already conforming to
207some  anatomical  space.  Put  simply,  this  finds the  deformation that  is  most  likely 
given the data.
Spatially normalised images should have a relatively high resolution so that tissue- 
extraction methods are not excessively confounded by partial volume effects. These 
occur when voxels contain a mixture of different tissue types (e.g. white matter voxels 
close to CSF voxels).
2.  Image partitioning: Spatially normalised images are next partitioned into grey 
matter,  white  matter  and  CSF.  The  tissue  classification  method  also  includes  a 
correction for image intensity non-uniformity.
3.  Pre-processing of tissue segments: Grey matter images are smoothed, meaning 
that each voxel in the  smoothed  image  contains the average  concentration of grey 
matter from around that voxel. The original segmented images contain values between 
0 and 1. Most of these values are close to either one or other extreme. Smoothing (e.g. 
with an 8mm gaussian kernel) results in the data becoming more normally distributed, 
increasing  the  validity  of  the  parametric  test.  Where  possible,  the  size  of  the 
smoothing kernel should be comparable to the size of the expected regional difference 
between the groups of brains.
4.  Statistical  analyses:  Statistical  tests  are  applied  to  compare  and  identify 
differences  in  tissue  concentration  between  groups  as  well  as  to  identify  tissue 
concentrations that are related to specific covariates such as disease severity or age. 
The  significance  of any  difference  noted  is  then  ascertained  using  the  theory  of 
Gaussian random fields (Friston et al., 1996). A voxel wise statistical parametric map 
comprises the results of many statistical tests, and it is necessary to correct for these 
multiple dependent comparisons.
The technique also makes some important assumptions.
208a) Segmentation must correctly identify grey matter and white matter.
b)  Confounding  effects  must be  eliminated.  For  example,  the  same 
MRI scanner and the same MR sequence should be used.
5.  Evaluation  of segmentation:  Segmentation  methods  require  good  contrast 
between different tissue types.  However many  central  grey  matter  structures  have 
image  intensities  that  are  almost  indistinguishable  from  white  matter,  so  tissue 
classification is difficult in these regions.
The model assumes that all voxels contain only one tissue type. Voxels that contain a 
mixture of tissue types (e.g. white matter and CSF) may not be modelled correctly. In 
particular,  voxels  at  the  interface  between  white  matter  and  CSF  in  the  lateral 
ventricles often appear as grey matter, suggesting tissue differences where there are 
none.
7.2.  Methods
20 patients with PSP,  11  with MSA-P,  12  with PD  and  12  healthy controls  were 
included in the cross sectional VBM study.
7.2.1.  VBM analysis
The  digitised  structural  MR  images  were  processed  on  Sun  workstations  (Sun 
Microsystems  Inc,  Mountainview,  CA)  using  Matlab  (Mathworks,  Natick, 
Massachusetts, USA) and  SPM99 (Wellcome Department of Cognitive Neurology, 
ION, London). VBM was carried out using an optimised method (Good et al., 2001). 
First, scans were spatially normalized to a customized template to remove any bias 
potentially  caused by  gross  structural differences  between the  groups,  which  may 
have resulted in spurious areas of difference being identified. All scans were spatially 
normalized to the SPM T1  template, then smoothed with an 8-mm, full-width half­
209maximum (FWHM) smoothing kernel, followed by averaging to create a customized 
template. The images were then segmented into grey matter (GM) and white matter 
(WM),  using  customized  prior  probability  maps.  These  segments  were  then 
modulated to correct for volume changes occurring during spatial normalization. The 
images were then smoothed, using an isotropic 8-mm FWHM Gaussian kernel.
Regionally specific differences in grey and white matter were assessed statistically 
using a one-tailed test to highlight decreases in grey (or white) matter in PSP subjects, 
compared with MSA-P,  PD  and controls.  Age  and sex were  included as  nuisance 
variables.
Significance  levels were  set at p<0.001  uncorrected over the  whole  brain volume. 
Comparisons  of  voxels  over  the  whole  brain  involve  a  great  many  tests,  and 
correction for multiple comparisons is desirable. This imposes stricter criteria on each 
voxel, reducing the number of false-positives. The analysis was repeated at p<0.05 
corrected for multiple comparisons.
Inverse one-tailed tests were also performed for each segment to ensure that changes 
seen were due to real disease effects and not movement of artefact.
The analysis was run including GM/WM/ globals, as appropriate, as a covariate, to 
only highlight differences over and above the general tissue change.
7.3.  Results  ,
The clinical characteristics of the patient and healthy control groups are detailed in 
table 7.1.
210Table 7.1  Mean (SD) Characteristics of patient groups in cross sectional VBM analysis.
PSP MSA-P PD HC P
n 20 11 12 12 -------- ----------------------
Age 66(6.1) 62 (7.7) 65.5 (9.2) 67.4 (4.7) 0.3
Disease
duration
4.5(1.5) 5.4(1.6) 13.3 (6.7) - PD vs. PSP/MSA-P, p<0.001
MMSE 26.3 (3.0) 26.4 (3.2) 27.7 (2.5) 29.5 (0.7)
HC vs. PSP,  p<0.001; vs. MSA- 
P, p=0.002; vs. PD,  p=0.03
FAB 12.2 (3.0) 14.7 (2.5) 16.5(1.4) - <0.001
UPDRSII 19.6 (6.4) 25 (7.0) 13.9 (5.1) - <0.001
UPDRSIII 20.5 (7.6) 26.8 (9.7) 16.7 (5.1) - 0.01
HY 3.5 (0.7) 3.9 (0.8) 2.8 (0.6) - 0.001
All results are for analysis carried out using GM/WM globals as covariates and age 
and sex as nuisance covariates.
Comparing PSP with healthy controls (figure 7.1), revealed reduced grey matter in the 
region of the midbrain and thalamus, the insular cortex, the caudate nucleus and the 
medial frontal gyrus.  White matter differences were identified predominantly  in the 
region  of the  cerebral  peduncles.  After  correcting  for  multiple  comparisons,  grey 
matter  tissue  differences  remained  in  the  insular  cortex  and  white  matter  tissue 
differences remained in the region of the upper midbrain and cerebral peduncles.
Comparing PSP with PD (figure 7.2), revealed grey matter tissue differences in the 
region of the superior cerebellar peduncle and white matter tissue differences confined 
to the midbrain and cerebral peduncles. Only the white matter tissue differences in the 
region of the upper midbrain survived correction for multiple comparisons.
Figure 7.3 shows tissue differences between PSP and MSA-P demonstrating reduced 
grey matter volume in the region of the dentate nucleus of the cerebellum. There were 
no differences in white matter and the grey matter tissue differences did not survive 
correction for multiple comparisons.
Comparing  MSA-P  and  healthy  controls  demonstrated  reduced  grey  matter  in  the 
putamen bilaterally and in the cerebellar grey matter as well as in the region of the
211posterior thalamus.  Reduced  grey matter in the  insular  cortex bilaterally  was  also 
detected.  White matter tissue differences were detected in the pons and the middle 
cerebellar  peduncle  and  these  remained  after  correction  for  multiple  comparisons 
(figure 7.4).
Figure 7.5 shows grey matter tissue differences in MSA-P compared to PD, present in 
the  putamen and the  cerebellar  grey  matter.  White  matter tissue  differences  were 
present  in  the  pons  and  middle  cerebellar  peduncle  (figure  7.6)  but  only  the 
differences in the pons survived correction for multiple comparisons.
Comparing MSA-P and PSP (figure 7.7) revealed tissue differences to be present only 
in the grey matter of the putamen and the white matter of the pons. None of these 
regions survived correction for multiple comparisons.
Finally,  when  comparing  PD  and  healthy  controls  grey  matter  differences  were 
detected  in  the  region  of  the  hypothalamus  and  occipital  gyri.  White  matter 
differences were minimal and neither survived correction for multiple comparisons 
(figure 7.8).
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A p<0.001  uncorrected,  1-grey matter;  2-white matter
o H   2
B p<0.05 FWE corrected,  1-grey matter; 2-white matter
Figure 7.1  Patterns of reduced grey and white matter in PSP compared with healthy controls.
Statistical parametric maps (SPM) are shown indicating regions of reduced grey (1) and white (2) matter voxel intensity in PSP compared with 
healthy control subjects. In PSP, significantly (p<0.001) reduced grey matter intensity is present in the midbrain, cerebral peduncles and the insular 
cortex as well as the frontal cortex. White matter intensity is reduced in the cerebral peduncles. A strict correction for multiple comparisons (B) 
reveals significant differences between PSP and healthy controls in the insular cortex and midbrain.om m  2
B p<0.05 FWE corrected,  1-grey matter;  2-white matter
Figure 7.2 Patterns of reduced grey and white matter in PSP compared with PD.
Statistical parametric maps (SPM) are shown indicating regions of reduced grey and white matter voxel intensity in PSP compared with PD.
A p<0.001  uncorrected,  1-grey matter; 2-white matterA p<0.001  uncorrected B p<0.05 FWE corrected
Figure 7.3 Patterns of reduced grey matter in PSP compared with MSA-P.
Statistical parametric maps (SPM) are shown indicating regions of reduced grey matter voxel intensity in PSP compared with MSA-P.
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216Figure 7.5 Patterns of reduced grey matter in MSA-P compared with PD.
Statistical parametric maps (SPM) are shown indicating regions of reduced grey matter voxel intensity in MSA-P compared with PD. Regions of 
reduced voxel intensity are demonstrated in the putamen (A) and the cerebellar grey matter (B).
B p<0.001  uncorrected
217Figure 7.6 Patterns of reduced white matter in MSA-P compared with PD.
Statistical parametric maps (SPM) are shown indicating regions of reduced white matter voxel intensity in MSA-P compared with PD.
A p<0.001  uncorrected B p<0.05 FWE corrected
218Figure 7.7 Patterns of reduced grey and white matter in MSA-P compared with PSP.
Statistical parametric maps (SPM) are shown indicating regions of reduced (A) grey and (B) white matter voxel intensity in MSA-P compared with 
PSP.
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219Figure 7.8 Patterns of reduced grey and white matter in PD compared with healthy controls.
Statistical parametric maps (SPM) are shown indicating regions of reduced (A) grey and (B) white matter voxel intensity in PD compared with healthy 
controls.
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2207.4. Conclusions
VBM revealed differences in regional volumes between PSP, MSA-P and PD as well 
as healthy controls and supports the findings of cross sectional ROI analysis that these 
regional volume differences are relatively specific to PSP and MSA-P.
In PSP these significant group differences were located in the upper brainstem and 
cerebral peduncles and in MSA-P, in the putamen, pons and cerebellum. In addition, 
this method of analysis involving no a priori assumptions regarding regional volume 
differences, detected significant group differences between PSP and healthy controls 
with reduction in grey matter in the insular cortex, the caudate nucleus and the medial 
frontal gyrus,  confirming that  frontal cortical  volume  loss  is present  in PSP.  This 
supports the  findings of the quadrant based region of interest analysis described in 
chapter 6.
The statistically significant differences on VBM reflect regional atrophy patterns that 
are consistently different between subject groups and which cannot be explained by 
global differences.
Using VBM to identify regional atrophy differences may prove to be of more use in 
clinical  practice  than  making  assumptions  regarding  regional  atrophy  based  on 
postmortem studies as changes seen at post mortem largely reflect the disease in its 
latest stages.
No significant differences in the grey matter or white matter structure of the upper 
brainstem was seen between PSP and MSA-P, but did show significant reduction in 
pontine and putamen volume in MSA-P. It is surprising that no difference in midbrain
221volume between PSP and MSA-P was detected but the region of interest segmentation 
described in the previous chapter identified midbrain volume loss in MSA-P as well 
as  in PSP.  It was reassuring that this unbiased  method of analysis  produced  very 
similar results.
In PSP compared with MSA-P, grey matter volume differences were identified in the 
region  of the  dentate  nucleus  of the  cerebellum.  This  deep  cerebellar  nucleus  is 
severely damaged in PSP, but not in MSA-P. Efferent fibres from this nucleus travel 
in the, the dentato-rubro-thalamic tract, which forms the superior cerebellar peduncle 
(Tsuboi et ah, 2003). Atrophy of this region in PSP compared to healthy controls and 
PD is also demonstrated using the VBM methods described in this chapter, supporting 
the findings of the ROI studies already outlined.
In MSA-P,  significant grey matter differences were  detected in the putamen.  This 
region  was  not  assessed  in  the  ROI  analysis  described  in  Chapter  6.  It  is  well 
established that putaminal damage is usually severe in MSA-P, and that a more severe 
lesion in this region as opposed to the cerebellum results in the more parkinsonian 
phenotype  of MSA-P  (Ozawa et ah,  2004).  Qualitative  evaluation of MRI  can be 
applied  to  help  discriminate  MSA-P  from  PD  on  the  basis  of  putaminal 
hypointensity/hyperintensity (Schrag et ah,  2000). VBM analysis confirmed regional 
differences  between  MSA-P  and  PSP,  PD  and  healthy  controls  in this  deep  grey 
matter structure. Cerebellar grey matter differences were also identified in the MSA-P 
subjects  confirming  that  as  suggested  by  the  results  detailed  in  Chapter  6,  the 
cerebellum is atrophied in MSA even when parkinsonism predominantes.
VBM has already been used to study degenerative basal ganglia disorders including 
PD, dementia with Lewy bodies (DLB) (Burton et ah, 2002), and MSA (Brenneis et
222al,  2003;  Specht  et al,  2003).  Recently 2  studies  in PSP  (Brenneis et al,  2004; 
Cordato  et al,  2005)  have  also  been published.  In PD  patients without  dementia, 
reduced grey matter volume in the frontal lobe has been demonstrated (Burton et al, 
2004). In the same study, grey matter atrophy was noted in the occipital lobe when 
comparing PD with dementia to PD without dementia. The mean MMSE in the PD 
group in the present  study did not  suggest marked cognitive  impairment but  some 
occipital grey matter tissue differences compared with healthy controls were detected, 
while no frontal volume differences were found.
In  MSA-P,  VBM  has  previously  detected  differences  in  cortical  and  subcortical 
regions  compared  to  controls  (Brenneis  et al,  2003),  suggesting that  a degree  of 
cortical atrophy occurs relatively early in the disease. This may help to explain why 
no differences in cortical volume were seen between PSP and MSA-P, even though 
more  extensive cortical  atrophy probably  does  not occur until  later  in the  disease 
process in MSA (Konagaya et al, 1999b; Wakabayashi et al, 1998).
Cerebral and subcortical metabolic differences have been demonstrated in PSP with 
reduced glucose metabolism in frontal cortical areas as well as midbrain and basal 
ganglia regions (Hosaka et al, 2002). This corresponds well with the known areas of 
pathological  involvement  (Litvan  et  al,  1996b).  Whether  this  regional 
hypometabolism predates histopathological change is unclear.
Pathological volumetric studies comparing regional brain atrophy in PSP and Lewy 
body disease are  limited.  One  study suggested that PSP could be differentiated by 
marked atrophy of the  internal globus pallidus and that a trend for greater  frontal 
atrophy correlated with dementia in PSP (Cordato et al, 2002).
223Given the  abnormalities  seen  in the  frontal cortex in metabolic  imaging and more 
recently in other VBM studies, it is perhaps surprising that the results in this chapter 
do not show a more dramatic difference between the patient groups in frontal cortical 
regions, particularly between PSP,  PD  and MSA-P was not found here.  There  is a 
significant difference between the FAB scores in the two groups, and frontal cortical 
atrophy is common in PSP  at autopsy.  However,  frontal cortical tissue differences 
between PSP and healthy controls were clear and of a similar distribution to those 
demonstrated in a previous study where frontal atrophy was the most striking finding, 
even though the mean disease duration is slightly longer here than in another recently 
published study of VBM in PSP in which frontal lobe atrophy was the most dramatic 
finding  (Brenneis  et al.,  2004).  Another  MRI  study has  suggested  frontal volume 
losses occur early in PSP  (Cordato  et al.,  2002) and one of the most recent VBM 
studies detected an association between frontal cortical volume and the severity of the 
neuropsychological deficits associated with frontal cognitive impairment (Cordato et 
al., 2005). Another possibility is that some of the early frontal behaviour seen in PSP 
occurs as a result of extensive basal ganglia and brainstem pathology.
Since VBM is generating maps of statistical differences in brain tissue, it is important 
that  each  of the  regions  (grey,  white,  and  CSF)  is  examined  in  combination  to 
highlight  areas  where  change  is  due  to  tissue  atrophy  rather  than  movement  of 
structures caused by tissue loss in other areas. By assessing the grey, white, and CSF 
maps together, a clearer picture can be obtained of where genuine tissue losses have 
occurred.
As with most cross-sectional studies, the present study is somewhat limited by the 
inherent differences in regional volumes between individuals. Calculation of atrophy
224rates,  from serial MRI  scans  would  overcome  some  of these  problems.  However, 
using reasonably sized subject groups should overcome some of these interindividual 
differences. This study demonstrates that MRI and VBM can be used to detect regions 
of interest for further imaging studies and volume analysis in PSP. One such region 
not evaluated in the volumetric studies detailed in chapter 6 is the middle cerebellar 
peduncle in MSA-P. This would be a candidate region to study with novel imaging 
techniques such as diffusion weighted MRI (see chapter 8).
In conjunction with postmortem studies, MRI information may help us to determine 
the sequence of cortical and subcortical structures affected in the early and later stages 
of PSP,  potentially  aiding  earlier  diagnosis  and  identification  of MRI  markers  of 
disease progression. However cross sectional studies can only imply atrophy and no 
firm conclusions as to the ongoing rate of atrophy can be drawn.
2258.  Cross Sectional Diffusion weighted imaging
8.1.  Introduction
Diffusion refers to the  general transport of matter whereby molecules or ions  mix 
through  normal  thermal  agitation  in  a  random  way.  Each  molecule  in  a  sample 
behaves  independently  from  the  others.  Collision  between  molecules  provokes  a 
random  displacement  of each  one  without  a  preferred  direction,  tracing  the  path 
known as the random walk.
Given a time  interval,  it  is possible  to  calculate a  statistical measure  of diffusion 
distance averaged over an equilibrium ensemble of molecules (the root mean square 
distance), but it is not possible to say how far an individual given molecule has moved 
during that time.
Ficks first law of diffusion states that: the diffusion process drives tracer from areas of 
high to areas of low concentration.
F= - D (5C/5X)
Where  F  =  the  rate  of transfer  of a  diffusing substance  through  unit  area,  C  = 
concentration of diffusing substance and X  = the space co-ordinate measured normal 
to the section. D is the diffusion coefficient with units (length) (time) '.
Every  fluid  has  a  characteristic  intrinsic  self  diffusion  coefficient  reflecting  the 
mobility  of  molecules  in  their  environment  (Crank,  1998).  Magnetic  resonance 
imaging can be made sensitive to dynamic displacements of water molecules over 10"8  
and  lO^m in a timescale  of a few  milliseconds to  seconds.  These magnitudes  are 
similar to the size of cellular structures.
In the adult brain, white and grey matter, have structural complexity, which affects the 
diffusion coefficient of water in tissues. In bundles of nerve fibres, diffusion of water 
is  easier  along  the  fibres  than  across  them.  This  dependence  on  direction  is
226“anisotropy”. Damage to the tissue structure, reduces this anisotropy. Even at an early 
stage of disease, measurement of the diffusion coefficient may be useful.
Quantification of diffusion behaviour is relatively straightforward, the complexity of 
brain  tissue  structure  means  that  the  results  obtained  are  dependent  on  the  pulse 
sequence  and  acquisition  parameters.  This  means  careful  planning  of imaging  is 
essential.
The diffusion tensor is a measure of diffusion behaviour in all directions.  From the 
tensor,  we  obtain  the  mean  diffusivity  (equivalent  to  the  apparent  diffusion 
coefficient, ADC, over all directions). This increases with tissue destruction.
In  MRI,  the  tissue  is  excited  using  a  radio  frequency  (RF)  pulse,  then  the 
magnetization is refocussed with for example a 180 degree RF pulse at time t = TE/2. 
This refocusing pulse reverses the phase of the proton spins leading to a cancellation 
of the phase due to magnetic field inhomogeneity and the formation of a spin echo at t 
=TE. If there has been a drift of the spins between dephasing and rephasing, then the 
refocusing of the spins is only partial and there is an extra damping (loss) term in the 
description of transverse magnetisation evolution. The resulting phase distribution is 
not coherent, resulting in decreased signal amplitude at t = TE.
The amount of diffusion attenuation depends on two factors;
1.  The sample structural characteristics, which determine the motion of the 
spins.
2.  Sequence parameters,  which determine the  magnetic  field  gradients and 
the time during which the diffusive motion takes place.
On DWI, areas of higher diffusivity (such as the ventricles) appear darker. Areas with 
similar diffusion properties in every direction are said to  be isotropic and on DWI
227have the same signal characteristics irrespective of the direction of application of the 
diffusion gradient.
Areas where tissue structure favours water movement along a particular direction are 
characterised by different diffusion coefficients in different directions. In these cases, 
the signal attenuation reflects the diffusion properties in the direction of application of 
the diffusion gradients. These areas are anisotropic.
When diffusion gradients are applied along the gradients of highest diffusivity, signal 
attenuation is most evident.
DWI is open to qualitative evaluation (for example in acute cerebrovascular disease). 
It is sensitive to the choice of acquisition parameters and positioning in the scanner. 
The MRI signal also depends upon the T2 properties of the tissue and signal increase 
due to T2 may be interpreted as a reduction in diffusivity, or may mask an increase in 
diffusivity (the T2 shine through effect).
An ADC map shows the average diffusion coefficient of the tissue contained in that 
voxel, measured along the direction of application of the diffusion gradient.
Diffusion weighted MR imaging  has the potential to  detect ultrastructural changes 
earlier than T1 or T2 weighted MRI. Increased ADC measurements in the presence of 
normal T2-weighted images have been shown in a number of diseases including MS 
and AD (Symms et al., 2004). Studies of degenerative bradykinetic-rigid syndromes 
have established that DWI can help to distinguish MSA from PD and PSP from PD 
(Ohshita et al,  2000; Schocke et al,  2002; Seppi et al, 2003).  So far however, the 
ability of DWI to  discriminate PSP from MSA-P has not been demonstrated.  It  is 
important to establish whether ADC measurements correlate with clinical measures of 
disease severity as this imaging technique may have potential as an outcome measure
228in clinical trials. It is possible that DWI may provide information about tissue damage 
which is complementary to the information obtained from volumetric MRI.
The aim of the DWI analysis was to determine: whether ADCs in regions such as the 
middle cerebellar peduncle, in which tissue differences between PSP, MSA-P, PD and 
healthy controls had been identified, could help to further discriminate between PSP 
and the other conditions; whether the ADC values are associated with clinical markers 
of the  diseases;  and  whether  any  conclusions  can be  drawn  from the  relationship 
between the ADC value and ROI volumes described in Chapter 6.
8.2.  Methods 
MRI Protocol
Axial  diffusion  weighted  MRIs  (DWI)  were  obtained  using  spin-echo  planar 
sequences (repetition time, TR- 1000ms, echo time, TE- 99ms, matrix size-128 x 128 
pixels,  field  of view,  FOV:  240mm x 240mm,  slice thickness  7mm and  slice  gap 
2mm). Diffusion-sensitising gradients were applied along 3 orthogonal directions in 
turn at two gradient strengths corresponding to diffusion-weighting (‘b’) factors of 0 
and 1000 s/mm2. Following magnitude reconstruction, images obtained with diffusion 
weighting in the 3  orthogonal directions were co-added yielding diffusion-weighted 
images, which were essentially rotationally invariant.
T1 images were obtained using a spoiled gradient-echo technique as described before 
(Chapter  7)  (256  x  256  matrix,  FOV  24  x  18cm,  TI/TR/TE/NEX/FLIP  = 
650ms/13ms/5.4ms/lms/35°). This yielded 124 contiguous 1.5mm thick slices.
Image analysis
ADC maps were calculated on a pixel by pixel basis assuming a signal dependence of 
the form S/So = exp(-b. ADC) where S and So represent the signal intensities with and 
without diffusion sensitisation. The ADC maps were then thresholded at an arbitrary
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level of 2.0 x  10'  mm s'  in order to exclude pixels predominantly containing CSF 
(Seppi et al, 2003). Anatomical regions of interest (ROIs) were manually defined on 
the (T2-weighted) images obtained with zero diffusion weighting, using Displmage 
software  (Plummer,  1992).  A  single  rater  blinded  to  the  identity  of each  subject 
analysed all the images. Elliptical ROIs (figure 8.1) were placed in the left and right 
middle cerebellar peduncles (MCP), the caudal and rostral pons, the decussating fibres 
of the superior cerebellar peduncle, the left and right thalamus, the splenium and genu 
of the corpus callosum, the left and right caudate nuclei, putamen and globus pallidus, 
and the left and right frontal and parietal white matter as well as the left and right 
centrum semi-ovale. The midbrain was manually outlined at the level of the collicular 
plate.
The  ROIs  were  then  transferred  to  the  inherently  co-registered  ADC.
230\V -
m   •  h i  ■   «   « s
’  *
) - J   -J   i - . 1' .
ar/A x  t- ' ^  IS  T ,  • ■  1   4/
S v ^ fM   '  
^   .  4 ^ ’
Thresholded ADC maps (exduding pixels >2.0 x 10‘Jm m V ) demonstrating regions of interest: A-caudal pons;  B- rostral pons; C- middle cerebellar 
peduncle (MCP); D- Midbrain; E-Thalamus; F-Putamen; G-parietal white matter;  H- frontal white matter._______________________________________
I   Figure 8.1 ADC Maps Demonstrating Regions of Interest
*  ’  A  *  •  ‘i ■f  A  ^   ;  .  -V  I  •’  JE **-  |  l "i  1 1  ■.  i i .   L
■  m
&  * f k , »  I U*  »
231For each ROI, the mean (SD) ADC, minimum ADC and maximum ADC value were 
recorded.
In 10 randomly selected subjects, rADCs were measured a second time and the intra­
rater  repeatability  (within  subject  SD)  and  reliability  (intraclass  correlation 
coefficient, ICC) calculated using methods described previously.
Statistical analysis
For non-parametric  data,  the  Kruskall  Wallis  test  was  used to  compare the  mean 
rADC measurements between PSP, MSA-P, PD and healthy controls. An adjustment 
for multiple comparisons was made when interpreting the p-values for regions that 
were not  independent  of each other.  So  for  the  left  and  right  MCP,  the  adjusted 
significance  level was set at p=0.025.  For the  SCP and the midbrain,  similarly the 
significance level was set at 0.025.  Where significant differences were found (after 
adjustment for multiple  comparisons), multiple group comparisons were performed 
using Mann-Whitney U tests. Normally distributed data was assessed using a one-way 
analysis of variance with post-hoc t-tests when  significant group differences  (after 
adjustment for multiple comparisons) were found.
To assess the ability of rADC measurements to distinguish PSP and MSA-P, forward 
stepwise logistic regression analysis was performed including the rADC values that 
were significantly different between PSP and MSA-P, as independent variables.
For  non-parametric  data,  the  Spearman  rank  test  was  used  to  study  correlations 
between disease duration and mean rADC values as well as between motor deficit 
(UPDRS II, III and Hoehn and Yahr score) and mean rADC values in the brainstem 
structures  for  PSP  and  MSA-P.  The  same  test  was  applied  to  study  correlations 
between the MMSE and mean rADC in the parietal white matter and the FAB and
232mean  rADC  in  the  brainstem  structures,  thalamus  and  frontal  white  matter.  For 
normally  distributed data,  linear regression models studying the  same  associations 
were applied. Age and disease duration were included as covariates.
Correlations between total intracranial volume (TIV) corrected cerebellar volume and 
mean  MCP  rADC,  midbrain  volume  and  mean  midbrain  rADC,  as  well  as  pons 
volume and mean pons ADC at both levels of the pons, in PSP and MSA-P were also 
studied,  using  multiple  regression  models  with  age,  disease  duration  and  TIV 
corrected whole brain volume  as  covariates.  Partial correlation coefficients  (Corr.) 
were calculated to assess the  strength of the correlation if the covariates were held 
constant.
8.3.  Results
The diffusion-weighted protocol requires that the subject  spends only a very  short 
time  in the  MRI  scanner.  This  means  that  some  individuals  who  were  unable  to 
tolerate a ten-minute volumetric sequence were able to manage the DWI sequence. 
For this reason, the number of patients included in the cross sectional DWI data is 
different from the volumetric data.
20  PSP,  11  MSA-P  and  12  PD  patients  had  DWI  scans.  Only  7  healthy  control 
subjects had DWI  scans.  Significant  differences in disease  duration,  MMSE  score, 
FAB score, UPDRS II and III as well as Hoehn and Yahr score are reported in table 
8.1.
ICC values of 0.9 for the MCP, pons, midbrain and thalamus, and values for the left 
and  right  frontal  white  matter  of  between  0.7  and  0.9  suggested  a  reliable 
measurement method in these areas. The within subject standard deviations in these 
regions were low indicating good repeatability. Measurements in the corpus callosum,
233SCP, CN, putamen and globus pallidus as well as other cerebral white matter regions 
suggested poor repeatability and reliability (ICC, 0.2-0.6).
Table 8.1 Mean (SD clinical characteristics of DWI subjects
PSP MSA-P PD HC P values
n 20 11 12 7
Age 66.1  (6.1) 62.0 (7.7) 65.5 (9.2) 63.1  (8.6) 0.5
Disease duration 4.6 (1.8) 5.4(1.6) 13.3(6.7)* - <0.001
MMSE 25.6 (3.2)" 26.4 (3.2)** 27.7 (2.5) 29.3(1.11) 0.006
FAB 11  (3.7)** 14.7 (2.5)A 16.5(1.4) - <0.001
UPDRS 2 20.0 (7.0) 24.9 (7.0) 13.9 (5.1) * - 0.001
UPDRS 3 20.8 (7.8) 26.8 (9.7) 16.7 (5.1) T - 0.01
HY 3.6 (6.7) 3.9 (0.8) 2.8 (0.6) * - 0.001
Post hoc tests: PD vs. PSP/MSA-p<0.001; "PSP vs.  PD-p=0.04, vs. HC-p=0.001; " 
p=0.02; **PSP vs.  MSA-p=0.006, vs.PD-p<0.001,  aMSAvs. PD-p=0.05; * HC vs. 
vs. MSA-p<0.001;  THCvs. MSA-p=0.005;* HC vs. PSP-p=0.003, vs. MSA-p=0.00
MSA vs. HC- 
PSP-p=0.01, 
1.
MMSE-mini mental-state examination; FAB-frontal assessment battery; UPDRS 2/3-unified 
Parkinson’s disease rating scale parts 2 and 3;  HY-Hoehn and Yahr score.
Significant  differences  in  mean  (SD)  rADC  values  between  the  different  disease
groups are reported in table 8.2.
Table 8.2 Mean (SD) rADC (x1CfJmm* s'1 ).
PSP MSA-P PD HC P values
n 20 11 12 7
L MCP 0.729 (0.059) 0.885 (0.16) 0.710(0.041) 0.701  (0.038) <0.001*
R MCP 0.718(0.044) 0.878 (0.15) 0.714 (0.037) 0.705 (0.023) <0.001**
Caudal Pons 0.789 (0.089) 0.845 (0.133) 0.771  (0.101) 0.763 (0.079) 0.11
Rostral Pons 0.754 (0.114) 0.872 (0.149) 0.708 (0.061) 0.780 (0.074) 0.005"
Midbrain 0.925 (0.087) 0.907 (0.062) 0.867 (0.053) 0.909 (0.066) 0.19
SCP 0.845 (0.092) 0.793 (0.046) 0.791  (0.034) 0.771  (0.033) 0.06
L Thalamus 0.813 (0.074) 0.766 (0.022) 0.775 (0.028) 0.767 (0.023) 0.09
R Thalamus 0.823 (0.074) 0.801  (0.028) 0.786 (0.037) 0.790 (0.031) 0.35
Splenium CC 0.853 (0.136) 0.800 (0.060) 0.908 (0.245) 0.961  (0.133) 0.16
Genu CC 1.037 (0.191) 0.960 (0.134) 0.962(0.166) 0.923 (0.087) 0.52
L putamen 0.763 (0.053) 0.756 (0.031) 0.767 (0.069) 0.752 (0.025) 1.0
R putamen 0.780 (0.070) 0.769 (0.041) 0.759 (0.042) 0.760 (0.051) 0.9
L Globus Pallidus 0.782 (0.078) 0.757 (0.029) 0.767 (0.051) 0.771  (0.061) 0.4
R Globus Pallidus 0.795 (0.083) 0.773 (0.055) 0.767 (0.045) 0.748 (0.071) 0.2
L Caudate 0.837 (0.098) 0.811  (0.104) 0.823 (0.060) 0.840 (0.089) 0.8
R Caudate 0.866 (0.098) 0.852 (0.095) 0.840 (0.072) 0.870 (0.077) 0.8
L Frontal WM 0.825 (0.072) 0.799 (0.062) 0.777 (0.036) 0.792 (0.010) 0.14
R Frontal WM 0.833 (0.069) 0.799 (0.050) 0.778 (0.051) 0.802 (0.020) 0.05
L Parietal WM 0.810(0.056) 0.782 (0.039) 0.774 (0.036) 0.783 (0.026) 0.19
R Parietal WM 0.825 (0.057) 0.801  (0.061) 0.791  (0.050) 0.806 (0.024) 0.3
L Centrum Semi Ovale 0.790 (0.082) 0.743 (0.044) 0.733 (0.035) 0.740 (0.057) 0.05
R Centrum Semi Ovale 0.772 (0.072) 0.734 (0.049) 0.723 (0.033) 0.730 (0.045) 0.04
Post hoc tests: * MSA vs. PSP/PD-p<0.001 
p=0.002; * MSA vs. PSP-p=0.017, vs. PD -
, vs.  HC-p=0.001; ** MSA vs. PSP/PD-p<0.001, vs. HC-
-p=0.002.
234Significant group differences in mean (SD) rADC values were detected in the MCP 
and rostral pons. Post hoc analysis confirmed that group differences in MCP rADC 
and pontine rADC arose because values in MSA-P were significantly greater than in 
PSP,  PD  and  healthy  controls.  After  correcting  for  multiple  comparisons,  group 
differences detected for right frontal white matter (p=0.05) and left and right centrum 
semi-ovale (p=0.05 and p=0.04) fell short of significance. No other significant group 
differences were detected.
Mean rADC values  (mean of left  and right rADC)  for regions with left  and right
values were calculated and are reported in table 8.3 below.
Table8.3 Mean(SD) combined left and right rADC (xlCFmm2 s'1 ).
PSP MSA-P PD HC P values
n 20 11 12 7
MCP 0.723 (0.05) 0.881  (0.160)* 0.712 (0.03) 0.703 (0.03) <0.001
CN 0.851  (0.09) 0.831  (0.06) 0.831  (0.06) 0.795 (0.08) 0.9
Thalamus 0.818(0.07) 0.783 (0.02) 0.780 (0.03) 0.735 (0.02) 0.2
Putamen 0.772 (0.05) 0.762 (0.03) 0.763 (0.05) 0.703 (0.04) 0.9
Globus Pallidus 0.788 (0.08) 0.765 (0.04) 0.767 (0.04) 0.855 (0.06) 0.3
Frontal 0.829 (0.07)# 0.799 (0.05) 0.778 (0.04) 0.797 (0.01) 0.01
Parietal 0.817 (0.05) 0.791  (0.04) 0.782 (0.04) 0.795 (0.01) 0.06
Centrum Semi Ovale 0.781  (0.07)® 0.738 (0.05) 0.723 (0.03) 0.735 (0.05) 0.02
Post hoc tests: * MSA vs. PSP/PD/HC-p<0.001; * PSP vs. PD-p=0.005, ®PSP vs. MSA -p=0.03, vs. PD-
p=0.02.
Significant group differences were detected in the MCP (greater in MSA-P than in 
PSP, PD and controls -p<0.001), the frontal white matter (greater in PSP than PD- 
p=0.005) and in the centrum semi ovale (greater in PSP than MSA-P and PD-p=0.02). 
Forward stepwise logistic regression analysis confirmed that rADC in the right MCP 
was the most significant region in terms of discriminating MSA-P from PSP (p=0.01). 
The sensitivity and specificity for rADC in the MCP were calculated using a receiver 
operator characteristic (ROC) curve analysis. The optimal cut-off level (with an area 
under the ROC curve of 0.89) to discriminate MSA-P from PSP was a MCP rADC > 
0.733  xl0'3mm2  s'1   (sensitivity  of 91%  and  a  specificity  of 80%).  This  correctly 
classified 84% of PSP and MSA subjects.
235There  were  no  correlations  between  any  of the  mean  rADC  values  and  disease 
duration or age in any of the disease groups. The Spearman test revealed correlations 
between the rADC in the rostral pons and motor deficit measured using the Hoehn 
and Yahr scale in MSA-P (rho=0.61, p=0.05), rADC in the rostral pons and UPDRS 3 
in PSP (rho=0.44, p=0.05). There were also associations detected between thalamic 
rADC  and  UPDRS  III  in  PSP  (left  thalamus:  rho=0.54,  p=0.014;  right  thalamus: 
rho=0.052, p=0.018) and between the right thalamus rADC and FAB in PSP (rho= - 
0.67, p=0.001). The association for the left thalamus approached but did not reach 
significance (p=0.08).
TIV corrected cerebellar volume was significantly associated with rADC values in the 
left and right  MCP  in  MSA-P  (LMCP:  Corr.= -0.81,  p=0.05;  RMCP  Corr.=  -0.9, 
p=0.02; combined left and right MCP, Corr.=-0.86, p=0.03), but not in PSP or PD. 
There was a trend towards an association between TIV corrected midbrain volume 
and  midbrain  ADC  in  PSP  (p=0.06).  In  MSA-P,  a  lower  TIV  corrected  pontine 
volume was associated with increased rADC in the caudal pons (Corr.=-0.82, p=0.05). 
No associations between pontine volume and rADC in the pons were detected in PSP.
8.4.  Conclusions
This  study demonstrates that rADC values  in the  middle  cerebellar peduncles and 
pons are significantly increased in MSA-P compared to PSP, PD and healthy controls. 
These differences were able to discriminate MSA-P from PSP and confirm that the 
consequences of cerebellar and pontine pathology known to occur in MSA-P can be 
detected with DWI during life and help to discriminate it from diseases, which may 
present with a similar phenotype. None of the rADCs measured, differentiated PSP 
from healthy controls or from PD, although there was a trend towards an increased 
rADC  in the  superior  cerebellar  peduncle,  the  frontal white  matter  and  the  white
236matter of the  centrum  semi-ovale  in  PSP,  which did  not  survive  a  correction  for 
multiple comparisons. PSP could however be differentiated from PD on the basis of 
the mean (left and right) frontal white matter rADC. The association between rADC 
values  in  the  brainstem  and  disease  severity  supports  the  hypothesis  that  tissue 
damage  in these  regions contributes to the  motor deficit characteristic of PSP  and 
MSA-P.  The  associations  between  rADC  and  brainstem  volume  supports  the 
established hypothesis that cell damage results in the regional atrophy detected in vivo 
in volumetric MRI studies.
There  was  overlap  in  the  individual  rADC  measurements  between  the  groups, 
meaning that using rADC values to distinguish PSP and MSA-P has limitations as 
there will  inevitably  be  false  negatives  (1  of 11  MSA-P  classified  as PSP  in this 
study) and false positives (4 PSP patients classified as MSA-P). The rADC cut-off 
would have to be set at 0.886x10'3mm2s'1  to exclude all PSP patients and this would 
increase the false negative classification of MSA-P patients.
There was no association between rADC and disease duration in any of the disease 
groups, however previous studies have identified associations between rADCs in the 
MCP and Pons, and disease duration in MSA-C (Kanazawa et al, 2004). In MSA-C 
(cerebellar phenotype), the association between rADC values in the MCP and pons 
and disease duration may be clearer than in MSA-P where more severe pathology may 
be expected in the basal ganglia. An alternative explanation is that there was greater 
variability in the disease duration of the MSA-P subjects we studied (mean, 5.6 years) 
compared to the MSA-C patients (median, 3 years) (Kanazawa et al, 2004). Disease 
heterogeneity and measurement  error may  also  influence the observed relationship 
between disease duration (which is notoriously inexact) and rADC measurements. 
Previous studies have demonstrated that rADC measurements in the putamen, globus
237pallidus and caudate nucleus discriminated PSP from PD (Seppi et al., 2003). We 
were not able to reproduce these results.
The patients in our study were of a similar age to those reported previously but both 
the PSP and MSA-P patient groups in our study had longer mean disease durations. 
Despite this, the mean rADC values in the putamen were lower in PSP and MSA-P in 
our study than  in those  reported previously.  The boundaries  of the putamen were 
difficult to  clearly  identify  on  our  DWI  images,  both with  a b-value  of 0  s/mm2 
(which are essentially T2-weighted)  and with  a  b-value  of 1000  s/mm2.  This  was 
especially the case in MSA-P where a decrease in T2 signal intensity of the putamen 
is often present (Bhattacharya et al.,  2002).  The repeatability and reliability of the 
rADC measurements was reduced and hence measurement error may have contributed 
to the lack of group differences in this region.
An association was detected between increased motor deficit measured on the Hoehn 
and  Yahr  scale  and  increased  rADC  in  the  upper  pons  in  MSA-P.  Motor  deficit 
measured using UPDRS III was associated with rADC in the upper pons and thalamus 
in  PSP.  In  PSP  and  MSA-P,  the  pathological  damage  to  tissue  architecture  is 
predominantly present  in  the  brainstem,  and  it  is  not  surprising  that  rADCs  here 
correlate with the motor deficit.
The motor thalamus is affected in PSP and a recent study has implicated pathological 
involvement  of this  structure  in  postural  instability  (Halliday  et  al.,  2005).  The 
thalamic rADC was also  associated with FAB  score in PSP although frontal white 
matter  rADC  values  were  not.  The  only  previous  study  to  look  for  associations 
between frontal white matter ADC values and measures of cognitive function in PSP 
was negative in five patients (Ohshita et al., 2000). The association between thalamic 
rADC values and FAB  scores,  and a lack of association with frontal white matter
238rADC,  suggests that  subcortical  structures  may  influence  the  subcortical  cognitive 
impairment characteristic of PSP more than cerebral cortical pathology. There is also 
evidence to suggest that diffusion imaging may be particularly sensitive to damaged 
thalamic  grey  matter  in  CADASIL  and  that  this  is  strongly  associated  with  sub­
cortical cognitive impairment (O'Sullivan et al., 2004).
The association of a lower TIV corrected volume in the pons and cerebellum, with 
higher rADC values in these regions in MSA-P is to be expected. The pathological 
hallmark  of  MSA  is  alpha  synuclein  positive  glial  cytoplasmic  inclusions  in 
oligodendroglia.  These  are  widely  distributed  throughout  the  brain  but  are  most 
numerous in the pontine base and cerebellar white matter, resulting in damage in these 
regions to  myelinated  structures (Matsuo  et al.,  1998; Papp and Lantos,  1994).  In 
regions where pathological processes have altered the  integrity of the tissue in this 
way, microstructural barriers to water diffusion are reduced, resulting in an increased 
ADC.
Another inevitable eventual outcome is regional atrophy due to cell loss. Pathological 
studies have demonstrated that neuronal cell loss (which is the basis of macroscopic 
atrophy)  is  correlated  with  the  severity  of glial  cytoplasmic  inclusions  in  MSA 
(Ozawa  et  al.,  2004)  supporting  the  association  between  TIV  corrected  pontine 
volume and the caudal pons ADC  in MSA-P.  The  increased rADC  in the  MCP  in 
MSA-P may arise as a consequence of direct involvement of oligodendroglia in the 
MCP but also Wallerian degeneration. This is a potential further explanation for the 
ADC changes particularly in the cerebellar peduncles, where diffusion changes and 
T2 hyperintensities have been described following infarcts in the pons (Marx et al., 
2004).  Both processes  would potentially  contribute to the  association between the 
ADC in the MCP and cerebellar volume, although the latter process would probably
239not damage tissue architecture to the same extent. That a stronger association between 
midbrain volume and midbrain rADC was not seen in PSP, may be because while the 
normal cellular architecture is disrupted by the pathological process resulting in cell 
loss and atrophy,  the  ADC  is  not  so  severely  affected because there  is  less white 
matter pathology.  Pathological  involvement  of the  red  nucleus  and  the  substantia 
nigra in the midbrain may not affect the rADC value but cell loss in these regions 
does result in atrophy.
The  results  reported  in  this  chapter  are  cross  sectional  and  we  cannot  establish 
whether rADC changes precede atrophy.  However, in AD, diffusion changes in the 
hippocampus precede volume loss and the full clinical manifestation of the disease 
(Kantarci et al., 2005), confirming that DWI is sensitive to ultrastructural changes at 
an  early  disease  stage.  Similar  longitudinal  studies  are  necessary  to  establish the 
sensitivity of ADC measurements in degenerative bradykinetic-rigid syndromes. 
Echo-planar DWI has the advantage of rapid acquisition and is therefore less prone to 
movement artefact, which can affect the clinical utility of other quantitative methods, 
such as volumetric MRI, in neurodegenerative movement disorders. This makes it an 
attractive imaging modality in degenerative movement disorders such as PSP.
The rADC values recorded in this chapter for the pons and MCP are similar to those 
reported by other groups  (Kanazawa et al.,  2004).  The rADC  values  (pons,  MCP, 
thalamus, caudate nucleus and parietal white matter) previously reported for healthy 
controls are lower than those in this thesis but this may be explained by the younger 
age of the control subjects (mean  57.6,  SD  12.0 years)  in the Japanese study.  The 
frontal rADC values, however, are similar to those reported in previous DWI studies 
in PSP,  although the parietal  white  matter rADC values  are  lower (Ohshita et al., 
2000). However the patient cohort in the Japanese study was smaller (n = 5) and the
240disease  duration  shorter  (3.2  years).  This  could  explain  the  lower  rADC  value 
recorded in the parietal white matter, as this brain region may only be pathologically 
involved later in the disease course.
2419.  Serial volumetric imaging analysis
In cross-sectional  imaging  studies,  accumulated tissue  losses  are  unlikely to  yield 
dramatic  differences  in  structural  volumes  between  disease  groups,  or  volumes 
outside  of the  normal  range  in  healthy  controls  because  of  considerable  inter­
individual variation in the normal volume of these structures. A shortcoming of cross 
sectional studies is that they can only imply that group differences reflect that atrophy 
has occurred. In order to calculate the rate of brain atrophy, using serial MRI at two or 
more time points is necessary.
Serial imaging studies in MSA using qualitative and quantitative area measurements 
have been undertaken (Horimoto et al, 2000; Horimoto et al.y  2002; Konagaya et al., 
2002; Watanabe et al,  2002) and registration of longitudinal volumetric MRI brain 
scans has been thoroughly evaluated in AD (Fox et al,  1996; Fox et al,  1999; Fox 
and Freeborough, 1997; Jack, Jr. et al, 2000) and FTD (Chan et al, 2001b; Chan et 
al,  2001a;  Schott et al,  2003).  However analysis of longitudinal imaging  has not 
been  applied  to  study  rates  and  patterns  of atrophy  based  on  volumetric  brain 
measurements in PSP.
Determination of rates of whole brain and regional brain atrophy in PSP compared to 
MSA-P, PD and healthy controls using registration of serial MRI brain scans in PSP 
was therefore carried out.
9.1.  Serial regional segmentation
9.1.1.  Introduction
Whole  brain  and  regional  brain  atrophy  can  be  assessed,  by  measuring  brain  or 
regional brain volumes at two time points and subtracting the volume at time point 
two from the  same volume measured at time point one.  Atrophy rates can then be 
expressed as a percentage change in brain volume over a specified time interval.
2429.1.2.  Methods
Patients with PSP, MSA-P and PD who had attended for baseline and follow up MRI 
scans were included. The digitised structural MR images were transferred to a SUN 
workstation  (Sun  Microsystems  Inc,  Mountainview,  CA)  and  image  analysis 
undertaken  using  the  MIDAS  package  as  outlined  in  the  previous  chapters 
(Freeborough et al,  1997).  Post-acquisition correction of heterogeneity artefact was 
applied as before (Lewis and Fox, 2004). Images were registered to standard space. 
Serial  brain  scans  were  registered  to  each  other  (spatially  matched  using  9  doj) 
applying whole brain to whole brain matching (Woods et al,  1998). Whole brain and 
regional brain volumes on the baseline and follow up scan were measured using the 
methodology described in section 6.1.  Regional  segmentations were undertaken on 
the baseline and follow up scan at the  same time, with the operator blinded to the 
identity, diagnosis and time sequence of the scans.
For  each  scan  pair,  the  change  in  brain  and  regional  volume  was  calculated  by 
subtracting  the  volume  of the  second  manually  segmented  scan  region  from  the 
volume of the first manually segmented scan region.
The percentage rate of brain or regional atrophy per annum was then calculated by 
applying the following formula:
Atrophy rate (%) = (([voh-voh] / voh) X 100) X 365 / Scan interval
Where volj is the brain or regional volume at time point 1, voh the same at time point 
2 and scan interval is the time between scan 1 and scan 2 in days.
2439.1.3.  Results
Twenty-four patients with PSP,  eleven with MSA-P,  twelve with PD  and eighteen 
healthy controls had an initial scan. Three of the PSP patients were excluded from 
further follow up  as the  first  scan was of poor quality due to  excessive  movement 
artefact.  Two  patients  (one  PSP  and  one  MSA-P)  were too  unwell to  attend  for a 
second scan a year later, 2 PD patients withdrew from the study and 1   with MSA-P 
and  1   with PSP died.  One individual classified as PSP at the initial visit developed 
visual  hallucinations  and  a  clinical  syndrome  more  in  keeping  with  a  clinical 
diagnosis of dementia with Lewy bodies (DLB) and was excluded from data analysis. 
Follow up scans in one patient with PSP and one with PD were of poor quality and 
were not included. Of the 65 individuals recruited, 53 (17 PSP, 9 MSA, 9 PD and 18 
healthy controls), or 82% had serial MRI scans analysed.
The atrophy rates calculated from simple subtraction of segmented images at two time 
points, are shown in table 9.1. For normally distributed data, a one-way analysis of 
variance with post hoc Bonferroni testing was used to look for significant differences 
between group means. For non-parametric data, a Mann-Whitney U test was applied.
Table 9.1  Mean (SD) NManually calculated annualised rates of atrophy (% per year)
PSP MSA-P PD Healthy
Controls P value
Scan interval (days) 291.6 (58.8) 262.3 (65.5) 268.2 (51.5) 251.9(39.7) 0.2
Whole brain 0.84(1.7) -0.29(1.4) -0.14(0.95) -0.28(1.1) 0.07
Midbrain 2.5 (2.2)* 2.8 (1.8)# 0.59 (2.6) -0.08(1.2) 0.003
Pons 2.4 (2.2) 6.4 (4.3) 0.82 (0.74) 0.96(1.4)
MSA vs. PSP p=0.04 
MSA vs. PD p-0.007 
MSA vs. HCp=0.001 
PSP vs. PD/HCp=0.01
SCP 3.6 (7.2) 1.4 (7.5) 1.1  (2.3) 1.6 (5.0) 0.7
Lateral Ventricle 9.9(10.7) 10.0(11.7) 5.3 (5.7) 3.0 (3.8) PSP vs. HCp=0.01
Third Ventricle 7.5 (6.4) 7.7 (9.8) 4.3 (4.3) 0.88 (3.5)
PSP vs. HCp<0.001 
MSA vs. HCp-0.04
Frontal quadrant 0.64(1.8) -0.22(1.3) -0.18(1.4) 0.06(1.5) 0.5
Posterior Inferior 0.44 (2.0) 0.07 (2.1) -1.1  (2.8) -0.7 (2.8) 0.4
* PSP vs.  PD, p=0.05 vs.  HC, p<0.001; # MSA vs. PD, p=0.05, vs.  HC,  p<0.001. P values in italics are from 
Mann-Whitney U test for equality of means.
244The  mean (SD)  values give  the  impression that  despite the  significant  differences 
between the group mean values, there is considerable overlap in individual atrophy 
rates calculated in this way. This can be seen in figure 9.1, which shows the manually 
calculated percentage atrophy rates in the different groups in the brain, the midbrain, 
and the pons, as well as rates of expansion in the third ventricle.
245Figure 9.1  Scatterplots displaying manually calculated,  annualised atrophy rates (%,
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2469.1.4.  Conclusions
Manually  calculated  whole  brain  atrophy  rates  were  not  significantly  different 
between the groups (p=0.07). While the mean whole brain atrophy rate in the PSP 
group was greater than in MSA-P, PD and healthy controls, the large inter-individual 
variation  in  atrophy  rates  calculated  in  this  way  results  in  considerable  overlap 
between the groups.
Significant differences between mean midbrain, pontine,  lateral ventricle, and third 
ventricle  rates  of  atrophy  or  expansion  were  detected  between  the  groups. 
Surprisingly, midbrain atrophy rates in MSA-P were similar to those in PSP. Pontine 
atrophy rates were greatest in MSA-P, but in PSP, atrophy rates in these regions were 
also significantly greater than in PD and healthy controls.
One subject with PD had a rate of midbrain atrophy well above the rest of the values 
(figure 9.1). A single individual with MSA-P had a rate of third ventricle expansion 
well above the values of the rest of the group. The MRI scans in these patients were 
visually checked for obvious segmentation errors, but no clear erroneous voxels were 
included  in  the  region  concerned.  Figure  9.2  shows  that  the  third  ventricular 
enlargement  in the  MSA-P  case  was  indeed  marked and that  segmentation of the 
region was accurate.
Despite this, manual measurements are likely to be more prone to measurement error 
than semi or fully automated measurements and this measurement error is likely to be 
one factor contributing to the variance in individual atrophy rates within the groups. 
True heterogeneity of atrophy rates within groups  is another important factor with 
variability in whole brain atrophy rates in healthy controls being less marked in PSP.
247Figure 9.2 Third ventricle enlargement.  Registered MRI scans in MSA demonstrating large
amount of expansion (segmented and non-segmented scans).
Initial scan  Registered follow up scan
248Although the median disease duration from onset to death in PSP is approximately 6 
years  (Litvan  et  al,  1996c),  the  disease  is  known  to  have  a  variable  rate  of 
progression (Williams et al., 2005).
Misclassification of individuals is a further factor that may lead to variation in atrophy 
rates within a disease group, however the clinical diagnostic criteria applied in this 
study  have  good  sensitivity  and  specificity,  and  all  individuals  were  followed up, 
beyond the time of the second scan and reviewed to ensure accuracy of the clinical 
diagnosis, at a centre in which there is a good record of clinical diagnostic accuracy 
(Hughes et al,  2002). To date, of the subjects included in this serial imaging section 
of the  study,  2  with  PSP  and  one  with  MSA-P  have  had  the  clinical  diagnosis 
confirmed at post mortem.
Brainstem atrophy rates calculated using manual measurements on serial MRI scans, 
were greater in PSP and MSA-P than in PD and healthy controls. Whole brain atrophy 
rates reveal no significant differences between the groups.
One  way  of assessing  whether  measurement  error  has  a  marked  influence  on the 
manually calculated atrophy rates, is to compare them with atrophy rates derived from 
semi-automated measurement methods. One such method is the brain boundary shift 
integral (BBSI).
9.2.  The brain boundary shift integral (BBSI) and rigid body registration
Several methods of measuring whole brain atrophy from serially acquired volumetric 
brain scans have been developed. The majority rely on positional matching of serially 
acquired scans (registration, see chapter 2.7), followed by a quantification process. At 
the simplest level, this can be achieved by subtraction of the follow up volume from 
the baseline volume.  This requires that whole brain and regional brain volumes are
249corrected  for  total  intracranial  volume  (TIV),  or  are  registered  using  a  9  dof 
registration to provide protection against voxel drifts. These subtraction methods are 
more dependent on individual measurements at each scan time point and as such are 
likely to result in more measurement error.
9.2.1.  Introduction and theoretical aspects 
The brain boundary shift integral (BBSI) has been proposed as a measure of cerebral 
volume change from serial MRI (Freeborough and Fox,  1997; Gunter et al.,  2003). 
This technique is based on identifying the brain tissue in two different scans from the 
same  individual,  registering  the  two  scans  spatially,  and  then  subtracting  scan 
intensities in the area between the borders of the aligned brains. Once the two scans 
have been segmented, the remainder of the process is fully automated, requiring only 
two user-defined parameters that define the  location and the width of the sampling 
(image  intensity)  window  (see  figure  9.3).  The  BBSI  increases  the  precision  of 
estimation  of  atrophy  (as  compared  to  the  differences  in  manually  segmented 
volumes)  by  eliminating  some  random  measurement  error.  However,  it  also 
introduces a systematic underestimate of volume change due to some of the changes 
in scan intensity not spanning the parameter-defined window.
The BBSI operates on the following principles. Viewed in cross section, the boundary 
between brain and CSF, on a T1 weighted MRI scan, can be seen as an intensity curve 
crossing from brain (high intensity to CSF (low intensity). This intensity curve can be 
considered  for  the  baseline  ibaseoo  and  the  registered  follow  up  scan  ireg(x).  If the 
boundary in the  second scan has shifted by a certain amount (Aw) then this can be 
plotted schematically (figure 9.3).
250Figure 9.3 The brain boundary shift integral (BBSI)
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A representation of an intensity profile through a boundary of brain on a baseline (ibese) and a registered 
repeat (img) MRI scan. During the interval, the boundary has shifted by an amount Aw, which we determine as 
the area A (divided by li-l2).
The area labelled A in figure 9.3 represents the integral with respect to the intensity of 
the difference in position of the profiles over the interval [/;, I2] ; hence
A = (I1-I2) Aw
The area A may alternatively be calculated as integral of the intensity profile of the 
registered scan from that of the baseline over the range I1-I2.
Thus Aw, the boundary shift may be calculated and extended to three dimensions, in 
order to  obtain the  brain  boundary shift integral (BBSI).  This  represents the  total 
volume  traversed  by the  boundaries  of the  brain going  from  the  first  scan to  the 
second scan, and is a direct measure of change in volume. Calculation of the BBSI 
requires that appropriate values are selected for 7/ and h\ both should be within the
251range  of the  intensity transitions  at  the  boundaries of the  brain.  Using 7/ and I2, a 
window size can be calclated Iw  as can the window centre 7c.
9.2.2.  BBSI and regional BSI Methods 
As in the case of the manually measured regions of interest, serial brain scans were 
first registered (spatially matched using 9 dof) applying whole brain to whole brain 
matching  (Woods  et  al.,  1998).  The  percentage  annual  brain  volume  loss  was 
calculated from the BBSI, taking the BBSI as the volume (ml) of brain tissue loss and 
applying the following equation:
Atrophy rate (%) = ((BBSI / voh) X 100) X 365 / Scan interval 
Local BSIs were calculated by restricting the BSI calculation to the defined region of 
interest.  Serial  brain  images were  registered  applying  whole  brain to  whole  brain 
matching as above. ROI were then further spatially matched by registering baseline 
ROI to the follow up ROI using a 6 dof registration. The region created by subtracting 
an eroded  (by  one  voxel)  intersection region  from a dilated  (by one  voxel) union 
region of the resulting two brain regions was generated and a dilated (by one voxel) 
baseline and follow up ROI used to mask this in order to allow calculation of the BSI 
in this anatomical area of interest. This is illustrated schematically in figure 9.4. For 
the cerebellum, only the baseline cerebellar volume was manually segmented and the 
regional BSI calculated using only this baseline  (dilated by one voxel) region. This 
technique has been applied to hippocampal ROI measurements in Alzheimer’s disease 
(Barnes et ah,  2004). All registrations were visually checked for accuracy and data 
excluded  if the  registration  of the  local  region  was  considered  to  be  poor  as  a 
consequence of movement artefact.
252Annualised changes were calculated by taking the BBSI and the regional BSIs in each 
group (ml) and adjusting for scan interval. Atrophy rates were calculated as an annual 
percentage change from the baseline volume.
Total intracranial volume was not used as a covariate in atrophy rate calculations as 
regression analysis reported no relationship between TIV and atrophy rates. A one­
way analysis of variance test was used to compare whole brain and regional atrophy 
rates for normally distributed data, and a Mann-Whitney U test was used to compare 
atrophy rates for non-parametric data.
Pitman’s  test  was  used  to  assess  whether  BBSI  and  regional  BSI’s  reduced  the 
variance in atrophy rates reported using the manually calculated rates of atrophy.
Logistic regression models were applied to assess the ability of BSI derived atrophy 
rates to discriminate between PSP and MS  A-P.
253;igure 9.4. Summary of steps necessary to generate regional BSI
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The steps leading to region of interest (ROI) registration are described (for the Pons in this case).  Firstly, a 
nine degrees of freedom (9dof) registration is used to match whole brains, then a 6dof registration is applied 
to match the ROI. Following this, the region that contains the ROI boundary shift is generated and the ROI 
BSI calculated in this region only.
2549.2.3.  Results
Of 65  individuals recruited, 53 (17 PSP, 9 MSA, 9 PD and  18 healthy controls), or 
82% had serial MRI scans analysed. In the PSP group, the pontine and midbrain BSI 
in one individual was very different from the rest of the group. On visually checking 
the images, artefact in the region of the brainstem secondary to movement was felt to 
have influenced the unusual outcome of the BSI  measurement.  Local BSIs  for the 
midbrain  and  pons  in  this  individual  were  excluded  from  further  data  analysis. 
Annualised rates of atrophy (% year'1 ) are reported in table 9.2.
Table 9.2. Mean (SD) percentage tissue lost per annum
PSP MSA-P PD Controls ANOVA significance levels
N 17 9 9 18 _______ ________ _— ----------------
Brain 1.2 (1.0)* 1.0(1.1) 0.6 (0.7) 0.4 (0.5) 0.04
Frontal 1.2 (1.3) 0.9 (1.2) 0.6 (0.8) 0.4 (0.5) 0.13
PI 1.0 (1.0) 1.4 (1.2) 0.8 (0.6) 0.3 (0.5) 0.008
Mann-Whitney U 
significance levels
Midbrain 2.2 (1.5) 1.8 (1.9) 0.6 (0.9) 0.3 (0.6)
PSP vs. PD p=0.004, vs. Controls 
p<0.001; MSA vs. Controls p=0.006
Pons 1.5 (1.3) 4.5 (3.2) 0.4 (0.5) 0.2 (0.3)
MSA vs. PSP p=0.03, vs.  PD 
p=0.002; MSA/PSP vs. Controls 
p<0.001; PSP vs. PD p=0.01
Cerebellum 1.4 (1.1) 3.2 (1.9) 0.8 (0.6) 0.3 (1.0)
MSA vs. PSP p=0.02, vs.  PD 
p=0.005, vs. Controls p<0.001; PSP 
vs. Controls p=  0.009
SCP 3.5 (4.0) 3.7(10.0) -1.1  (2.0) 0 (2.5)
PSP vs. PD p=0.004, vs. Controls 
p=0.008; MSA vs. PD p=0.05, vs. 
Controls p=0.03
Third Vent. 6.1  (6.0) 7.6 (10.1) 4.7 (3.9) 2.2 (3.8) PSP vs. Controls p=0.02
Lateral Vent 9.6 (9.8) 9.5(12.4) 5.3 (5.2) 3.3 (3.3) PSP vs. Controls p=0.008
ANOVA *-Controls vs. PSP, p=0.045; "-MSA vs. Controls, p=0.008.
Rates of brain atrophy calculated from the BBSI were greater in PSP than in healthy 
controls. Rates of atrophy in the midbrain in PSP were the most significantly different 
from controls (seven times the mean rate in controls). SCP atrophy rates were greatest 
in PSP, but the variability in the measured atrophy rate limited the significance of the 
group differences. Pontine atrophy rates were greatest in MSA-P (20 times the mean 
rate in controls and three times the mean rate in PSP).
255Pitman’s  test  confirmed  that  using  the  BSI  to  calculate  whole  brain  and  regional 
atrophy rates, rather than the difference in manually measured volumes, significantly 
reduced  the  variability  in  the  atrophy  rates  reported  for  whole  brain  (p<0.001), 
midbrain (p=0.001), pons (p=0.001) total frontal (p=0.002) and PI (p<0.001) regions, 
but not for the SCP, the lateral or third ventricles. This reduced variability in atrophy 
rates  can  be  appreciated  in  figure  9.5,  which  shows  individual  BSI  derived  and 
manually  derived  atrophy  rates  for  the  whole  brain,  the  pons,  the  midbrain  and 
percentage expansion rates for the third ventricle.
In addition to calculating rates of ventricular expansion as a percentage change from 
the  baseline  measurement,  rates  were  also  calculated  as  a  percentage  of baseline 
whole  brain volume.  This  second  method was  employed as  for  individuals with a 
small  baseline  ventricular  volume,  a  small  change  results  in  a  large  percentage 
expansion over one year. For those with a larger baseline volume, the same volume 
change over  one  year will be  much smaller when expressed  as  a percentage.  The 
results of ventricular rates of expansion calculated in this way are presented in table
9.3.
fable 9.3. Mean (SD) ventricular expansion per annum(% of whole brain volume\
PSP MSA-P PD Controls ANOVA significance levels
N 17 9 9 18 _______ — ■ ---------------"
Third Vent 0.02 (0.02) 0.009 (0.001) 0.007 (0.006) 0.003 (0.004) PSP vs. Controls p=0.001
Lateral Vent. 0.35 (0.38) 0.21  (0.24) 0.19(0.20) 0.08 (0.08) PSP vs. Controls p=0.001
While the ventricular expansion expressed as a percentage of brain volume results in a 
different value to that seen when expressed as a percentage of baseline ventricular 
volume, the rates of expansion are still only significantly different in PSP compared 
with healthy controls.
256Figure 9.5 Scatterplots comparing BSI derived and manually calculated, annualised atrophy rates (%)
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257From logistic regression models, rates of BSI derived pontine atrophy (p=0.02) were 
marginally  better  than  cross  sectional  TIV  corrected  pontine  volume  (p=0.04)  at 
discriminating  between MSA-P  and  PSP.  BSI  derived  rates  of cerebellar  atrophy 
(p=0.02) were marginally better than cross sectional TIV corrected cerebellar volume 
(p=0.05) at discriminating between MSA-P and PSP.
9.2.4.  Conclusions
Regional rates of brainstem atrophy are greater than whole brain rates of atrophy in 
PSP and MSA-P.  These regional atrophy rates differentiate PSP  and MSA-P  from 
each other and from PD and healthy controls, whereas whole brain atrophy rates are 
only able to distinguish PSP from healthy control subjects.  Mean rates of midbrain 
atrophy in PSP were seven times the mean rate in controls.  SCP atrophy rates were 
greatest  in  PSP,  but  the  variability  in  the  measured  atrophy  rate  limited  the 
significance of the group differences. Pontine atrophy rates were greatest in MSA-P 
(20 times the mean rate in controls and three times the mean rate in PSP). It is likely 
that these regional atrophy rates discriminate PSP from MSA-P with greater accuracy 
than corresponding regional volumes measured at a single time point.
Using the BSI, rather than manually calculated measurements, reduced the variability 
seen  in  regional  atrophy  rates.  Differences  between  the  mean  BSI  derived  and 
manually derived atrophy rates are likely to arise because the BSI measurements are 
less  prone  to  operator  error.  This  seems  to  be  confirmed  when  comparing  the 
manually and the BSI derived atrophy rates (figure 9.5). Group outliers in manually 
derived rates of midbrain and pontine  atrophy are no  longer present when atrophy 
rates calculated using the BSI are plotted side by side. For those BSI derived atrophy 
rates in which the variance was lower than manually derived atrophy rates, testing for 
equality  of matched  pairs  revealed  that  the  BSI  derived  atrophy  rates  had  a  bias
258towards a greater rate of brain, frontal quadrant and PI atrophy (p<0.001) and a lower 
rate of pontine atrophy (p<0.001).
Serial volumetric imaging studies have so far been confined to single case reports or 
individual cases within the context of cross sectional studies (Paviour et al.9  2004b; 
Schott  et al.,  2003).  A previous  study of MRI  changes  over  time  in  MSA relied 
largely  on  qualitative  interpretation  of  imaging  changes,  but  provided  useful 
information  regarding  the  development  of  certain  imaging  features  over  time 
(Horimoto et al.,  2002). Other studies have utilised area measurements to determine 
atrophy rates in MSA  (Horimoto et al, 2000; Konagaya et al., 2002; Watanabe et al., 
2002). Konagaya et al studied nine MSA patients in whom the mean scan interval was 
seven years. The ratio of cerebral hemisphere area to intracranial area decreased from 
a mean of 82% to 70% suggesting a hemisphere atrophy rate of 2% per annum. Brain 
atrophy  rates  reported  in  this  thesis  are  of  a  lower  magnitude.  However  area 
measurements  cannot  be  directly  extrapolated  to  volume  change  due  to  the  non- 
uniform distribution of brain tissue loss, as demonstrated in this study. As such, whole 
brain atrophy rates based on area measurements may give different rates depending 
upon at  which  level,  the  area  is  measured,  although the  true  rate  of whole  brain 
atrophy is the same. In fact, longitudinal imaging studies based on area measurements 
in MSA, support the presence of non-uniform atrophy, and conclude that cerebellar 
and pontine atrophy are more significant in MSA with predominant cerebellar signs 
(Watanabe et al., 2002). These regions had the greatest rates of atrophy in the MSA-P 
patients  in  our  study,  however  our  patients  had  a  Parkinsonian  phenotype.  This 
confirms that atrophy in these regions  is still significant when Parkinsonism is the 
predominant clinical feature. This finding is supported by a large pathological study
259which  concluded  that  pontine  pathology  is  present  in  both  MSA-P  and  MSA-C 
(Ozawa et al, 2004).
The BSI is semi-automated and because it calculates change directly from differences 
between MR images, is less vulnerable to errors of manual outlining. It has also been 
shown to be a repeatable and reliable measure of whole brain atrophy in AD (Fox and 
Freeborough, 1997). The results of this study suggest that in these neurodegenerative 
diseases,  in which the pathological load has a predilection for brainstem structures, 
regional  rather  than  whole  brain  atrophy  rates  are  better  markers  of  disease 
progression.  Case  reports  of MSA and PSP  with pathological  correlation of serial 
imaging studies in life suggest that the regional rates of atrophy that distinguish these 
conditions are associated with greater pathological load (Paviour et al, 2004b; Schott 
et al,  2003). The study of a larger number of patients in this thesis confirms these 
findings.
The  rates of regional  atrophy within the  subject  groups reported  in this  study  are 
heterogeneous. This can partly be explained by manual segmentation errors or scan 
artefact, but a significant component is likely to be due to true differences in rates of 
disease progression between individual patients.  Although one  study based on area 
measurements, found only weak associations between rates of atrophy and measures 
of disease severity suggesting that atrophy rates may be relatively constant throughout 
the disease (Konagaya et al, 2002).
Image analysis methods cannot completely control for differences in scan acquisition 
and errors may arise due to registration difficulty because of movement artefact or 
quality  differences  between  the  scans.  Inevitably,  with  all  of  these  regional 
measurements conducted in this thesis, there are some arbitrary decisions about which
260structures to include. Errors related to these measurements as well as acquisition may 
occur and important changes may in fact be under-estimated.
Finally,  atrophy  rates  in these  diseases  may  well  be  increased relative  to  healthy 
controls in the earliest stages of the illness. MRI  studies at this stage with a repeat 
scan (e.g 6-12 months later) may be warranted. It is also at this very early stage that a 
disease-modifying drug may be at its most useful and so early identification is likely 
to become increasingly important.
26110. Fluid registration
10.1.  Introduction
As demonstrated in chapters 7 and 9, accurate positional matching (registration) and 
subtraction  of 3D  MR  brain  scans  allows  detection  of volume  differences  in  an 
individual brain over time.
The  image  registration  described  so  far  has  been  achieved  using  a  rigid  body 
transform  allowing  detection  of  positional  shifts  at  high  contrast  boundaries. 
Positional shifts in uniform tissue regions are also likely to occur but do not result in 
differences on the subtraction image. Hence the exact location of any tissue changes 
that bring about the boundary shifts are not revealed.
Large  changes  in  brain tissue  volume  mean that  some  of the  boundary  shifts that 
occur,  reflect  changes  in the  relative  positions of structures rather than tissue  loss 
simply at the nearest brain/CSF tissue boundary.
Figure 10.1  Schematic representation of fluid vs. rigid body registration.
In rigid body registration, the results are represented as a shift at tissue boundaries (BSI) where red 
represents expansion and green a region of contraction. The brain is not a rigid body however and 
so  ventricular expansion  may  occur  because  of tissue  loss  distant  from  the  brain/CSF  boundary 
(blue  region).  A  non-linear registration  overcomes some of these  problems and  allows  regions of 
tissue volume loss within the brains structure to be identified.
262A non-linear or “fluid” registration overcomes some of these problems (Freeborough 
and Fox,  1998).  Some of the principles behind this method of image analysis have 
been discussed in chapter 2.7.3 and this technique was used to study the PSP case and 
the MSA case discussed in chapter 3.5 (Paviour et al, 2004b; Schott et al., 2003). The 
method is dependent on being able to determine the general deformation that brings 
one scan into exact structural correspondence with another.
MRI  scans  from  the  same  patient  possess  extremely  similar  topology.  “Fluid” 
registration maintains this topology through the deformation process that registers a 
follow up scan to a baseline scan. Image intensities on the baseline (Bx) and on the 
repeat (Rx) scan are denoted. For each voxel position (x), a displacement vector U(x) 
is obtained. Determining the deformation field Ux that yields point-by-point structural 
correspondence between the baseline and the repeat scan represents the registration, 
which is driven to minimise image mismatch.
10.2.  Methods
T1  weighted MRI scans were acquired using the protocol described throughout the 
study.  All patients and controls described in chapter 9 with serial MRI  scans were 
assessed.  Brain  tissue  was  segmented  from  non-brain  tissue  on  the  scans  after 
correction for inhomogeneity artefact.  The repeat scan was matched to the baseline 
scan with an automatic  image registration technique  (Freeborough et al.,  1996).  A 
non-linear or “fluid” registration algorithm was then applied in order to  determine 
local structural changes. Voxel compression maps were derived from the deformation 
field  Ux,  by  calculating  the  determinant  of the  Jacobian  matrix  at  each  point  to 
provide  an  estimate  of volumetric  change.  These  maps  are  displayed  as  a  colour 
image overlaying the volumetric MRI scan to allow association of patterns of change
263with neuro-anatomically significant regions. This also allows the pattern of regional 
atrophy occurring in an individual to be demonstrated clearly.
10.3.  Results
The fluid registration of an individuals serial scans currently requires several hours of 
SUN workstation processing time,  but  can be  set to  run automatically without the 
need  for an operator to  be  present.  This  processing  time  is rapidly reducing  with 
improving processor speeds.
Individual  examples  of the  subtraction  images  are  shown  in  figures  10.2-10.7.  In 
addition to the volume loss described in chapter 9, the brains of individuals with PSP 
and  MSA-P  clearly  undergo  deformation  and  positional  shifts  as  brain  atrophy 
progresses.
Derived voxel compression maps were different between the patients with PSP and 
those  with  MSA-P  and  PD.  Consistent  patterns  of  tissue  contraction  were 
demonstrated in PSP in the midbrain, the frontal cortical areas and frontal and parietal 
white matter in PSP (figures 10.2, 3 and 4). In MSA-P much more dramatic cerebellar 
tissue contraction was evident with consistent disproportionately high rates of tissue 
contraction  in  the  middle  cerebellar  peduncle.  Compared  to  PSP,  the  superior 
cerebellar peduncle was unaffected in MSA-P and this is demonstrated in figure 10.3 
compared  to  10.5.  Patients  with  MSA-P  also  had  evidence  of increased  rates  of 
cortical  and  white  matter  tissue  contraction  (figure  10.6),  particularly  around  the 
region  of  the  basal  ganglia  structures.  Clear  sparing  of  the  midbrain  with 
disproportionate  atrophy of the pons  was  also  evident  in the  MSA-P  cases  (figure 
10.6).
PD and healthy control subjects demonstrated little in the way of tissue contraction.
264Figure 10.2 MRI with voxel compression map and colour overlay in PSP.
Tissue contraction (green) is evident, particularly in the midbrain and the brainstem, the collicular plate and 
thalamus and in the cerebellum.
265Figure 10.3 MRI with voxel compression map and colour overlay in PSP.
Increased rates of tissue loss (green) in the superior cerebellar peduncle, with relative sparing 
of the  pons  is  evident  in  the  coronal  and  axial  image.  The  frontal  and  parietal  lobes  also
demonstrate atrophy.  In the coronal scan (top), expansion of the ventricles is evident.
266Figure 10.4 MRI with voxel compression map and colour overlay in PSP.
Increased rates of tissue loss (green) in the frontal lobe with  relative sparing of the posterior 
cortical structures is evident in the sagittal and axial images.  In the axial  scan,  expansion of 
the ventricles is evident.
267Figure 10.5 MRI with voxel compression map and colour overlay in MSA-P.
An  Increased  rate  of  tissue  loss  (green)  in  the  pons  with  relative  sparing  of  the  superior 
cerebellar peduncle is evident in the image.  In the coronal scan, disproportional  involvement 
of the middle cerebellar peduncle is clear.
268loss around the basal ganglia structures is clear.
Figure 10.6 MRI with voxel compression map and colour overlay in MSA-P.
An  increased  rate of tissue  loss  (green)  in the  pons with  relative sparing  of the  midbrain  is 
evident in the sagittal  image.  In the axial scan,  diffuse atrophy in the white matter is evident 
and
269in the healthy control subject below.
Figure 10.7 MRI with voxel compression map and colour overlay in PD and a healthy control. 
There  is  minimal  change  between  the  baseline  and  follow  up  scans,  most  notably  in  the 
temporal
10.4.  Conclusions
The results of this method of image analysis support the  findings of the rigid body 
registration ROI analysis, which demonstrated that volume change over time is most
270pronounced in sub-cortical structures in PSP and MSA-P. As suspected these changes 
do not simply occur at tissue boundaries. The regions affected correspond well with 
the distribution of the known histopathological changes seen at post mortem.
In the MSA-P cases, despite the predominant parkinsonian phenotype, marked tissue 
volume  loss  was  demonstrated  in the  cerebellum  confirming  that  the  pathological 
process  affects  the  cerebellum,  supporting  the  results  outlined  using  different 
techniques in chapters 6 and 9. The middle cerebellar peduncle was one of the most 
dramatically affected areas, supporting the findings reported in Chapter 8.
Visual assessment of the fluid registered images gives some information as to where 
regional atrophy is greatest, without any a priori assumptions regarding the regions 
concerned.  In  order  to  compare  disease  groups  and  identify  changes  that  are 
significantly different, groups of patients need to be compared using robust statistical 
techniques. SPM can be applied to fluid registered MRI scans in order to achieve this.
27111. An unbiased analysis of regional atrophy rates
11.1.  Introduction
So  far,  the  analysis  of the  longitudinal  imaging  findings  has  been  based  around 
hypothesis  driven  region  of interest  analysis.  Based  on  knowledge  from previous 
imaging and pathological studies, specific brainstem and lobar regional volumes have 
been measured and atrophy rates calculated in these regions.
An alternative approach is to use automated techniques that can accurately localise 
regional atrophy in an unbiased manner. If repeat scans are matched to baseline scans 
using  voxel  -level  deformation  fields  based  on  a  viscous  fluid  model  as  in  the 
previous  chapter,  then the  Jacobian  determinants  from the  model  can  be  used  to 
quantify change at the voxel level and colour overlays can be used to illustrate this 
qualitatively  on  an  individual  level.  To  determine  changes  that  differentiate  one 
disease  from  another  and  from  healthy  controls,  groups  of  individuals  can  be 
compared using SPM (Friston, 1995). This combination of SPM and fluid registration 
analysis  has  been  used  successfully  in  Alzheimer’s  disease  to  demonstrate 
significantly increased rates of hippocampal atrophy in pre-symptomatic and mildly 
affected patients (Scahill et al., 2002).
An understanding of the regional pattern and progression of atrophy in PSP and MS A- 
P may be useful and an un-biased fluid-SPM analysis may highlight new regions of 
increased atrophy. If applied to monitor atrophy rates in clinical trials, it may be able 
to highlight differing patterns of atrophy occurring in treated and placebo groups of 
patients.
Combined  fluid-SPM  analysis  has  therefore  been  applied  to  determine  significant 
group differences in atrophy between PSP, MSA-P, PD and healthy controls, without
272making assumptions regarding the sites of atrophy. The fluid-SPM technique has also 
been applied to investigate whether atrophy patterns are different in groups of PSP 
patients with differing clinical features.
11.2.  Methods
11.2.1. MRI acquisition
T1  weighted MRI  scans were acquired at two time points as previously described. 
Inhomogeneity artefact was corrected for using DBC (Lewis and Fox, 2004) and as 
previously  described,  the  brain  was  outlined  using  a  semi-automated  technique 
following which a 9 dof registration was performed to align the repeat scan onto the 
baseline image (Freeborough et al.,  1996). A non-linear fluid registration was then 
carried  out  (chapter  10).  The  Jacobian  value  produced  by  this  model  provides  a 
measure of the volume change occurring at each voxel within the image.
Voxel compression maps were visually inspected to  ensure adequate image quality 
before  being  entered  into  the  group  comparison  as  some  images  may  have  been 
marred by artefact.
11.2.2. Statistical MRI analysis
Analysis  was  performed  using  SPM-99  (Wellcome  department  of  cognitive 
neurology,  London)  running  in  MATLAB  (Mathworks  incorporated,  Sheraton, 
Massachusetts).  The  Jacobian  images  were  spatially  normalised  to  a  customised 
template  in  standard  stereotactic  space.  Contraction  and  expansion  images  were 
separated based on Jacobian values alone producing voxel expansion (value >1.0) and 
contraction (value <1.0) images. This was performed, as without it smoothing would 
remove any change detected (as expansion and contraction occur close to each other) 
and would  effectively  cancel each other out.  Images  were then  smoothed with an 
isotropic Gaussian kernel of 8mm full width half maximum.
273A  condition  and  covariate  model  was  used  for  analysis  with  time  interval  as  a 
covariate  and  age  and  sex  as  nuisance  variables.  The  contraction  and  expansion 
images were masked with a generous brain mask in order to remove non-brain matter 
and define the analysis volume.
Significance  levels were  set at p<0.001  uncorrected  and  in order to  determine the 
areas undergoing the greatest rates of change, a second analysis, with a significance 
level set at p<0.05, corrected for false discovery rate (FDR) multiple comparisons was 
performed.
The PSP patients were divided into approximately equal groups on the basis of the 
median (50th centile) FAB score, MMSE score, gaze palsy score and disease duration 
(years). The two groups were then compared independently with healthy controls and 
with  each  other,  in  order  to  determine  whether  atrophy  in  specific  areas  was 
associated with poorer performance on the FAB or MMSE, a more severe gaze palsy 
or longer disease duration.
11.3.  Results
Scans from 16 patients with PSP, 9 with MSA-P, 9 with PD and 12 healthy controls 
were  included  in  the  analysis  after  visual  inspection  for  artefact  on  the  fluid 
registrations was made.  The clinical characteristics of the patients are described in 
table 11.1.
274Table 11.1 Mean (SD) characteristics of patients in fluid-SPM analysis.
PSP MSA-P PD HC P
n 16 9 9 12 ------- -----------------
Age 65 (5.9) 62.4 (8.1) 64.4 (8.3) 64.8 (5.3) 0.8
Disease duration 4.3 (1.4) 5.4 (1.7) 12.9 (4.3) -
PSP/MSA-P vs. PD,
p<0.001
Scan interval 296 (58.9) 262 (65.5) 268 (51.5) 254 (39.4) PSP vs.  HC,  p=0.04
MMSE 26.4 (2.7) 25.9 (3.4) 28.2 (2.5) 29.5 (0.7)
PSP vs.  HC, p<0.001, vs. 
PD, p=0.04, MSA-P vs. 
HC, p=0.004.
FAB 12 (2.9) 14.6 (2.8) 17(1.1) -
PSP vs.  PD p<0.001, vs. 
MSA-P, p=0.05, MSA-P 
vs.  PD, p=0.03
HY 3.4 (0.7) 3.8 (0.8) 2.7 (0.5) - p=0.006
UPDRS II 18.6 (6.8) 24.1  (7.6) 13.4 (4.6) - p=0.006
UPDRS III 19.1  (7.8) 24.7 (9.5) 16.4 (3.1) - NS
Gaze Palsy 12 (5.8) 2.5 (2.8) - - p<0.001
Post hoc tests:  HY- PSP vs. PD, p=0.04, MSA-P vs.  PD, p=0.006;  UPDRS II- MSA-P vs. PD, p=0.005.
Figures 11.1 and 11.2 show statistical parametric maps in PSP and MSA-P, compared 
to healthy controls demonstrating regions of significantly increased rates of atrophy 
(tissue contraction).  In the PSP patients, atrophy rates are significantly increased in 
the  midbrain,  cerebral peduncles  and  in the  region  of the  medial thalamic  nuclei. 
These regions survive a stricter statistical test of significance (FDR corrected p<0.05). 
In the MSA-P patients, significantly increased atrophy rates are seen in the pons, the 
midbrain, the cerebellar white matter and middle cerebellar peduncles. The thalamus 
in contrast to  PSP  is  spared.  These regions  survive  the  stricter  statistical test  and 
figure 11.2 B also shows that greater rates of contraction compared to healthy controls 
are  also  seen  in  the  medial  and  superior  frontal  gyri  and  in  the  temporal  lobes. 
Increased rates of atrophy in MSA-P, compared with healthy controls are also clearly 
demonstrated in the cingulate gyrus, the orbitofrontal gyri, the gyrus rectus and the 
inferior rostral gyrus in figure 11.3.
275Figure 11.1  Patterns of regional atrophy in PSP.
Statistical parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of atrophy (tissue contraction) in PSP 
compared with healthy control subjects.
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276Figure 11.2 Patterns of regional atrophy in MSA-P.
Statistical parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of atrophy (tissue contraction) in MSA-P
compared with healthy control subjects.
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277Figure 11.3 Patterns of regional atrophy in MSA-P. Statistical 
parametric maps (SPM) are shown indicating regions undergoing 
significantly increased rates of atrophy (tissue contraction) in 
MSA-P compared with healthy control subjects. Atrophy of the 
orbitofrontal cortex is demonstrated.
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Figure 11.4 Statistical parametric maps (SPM) are shown 
indicating regions undergoing significantly increased rates of 
atrophy (tissue contraction) in MSA-P compared with PSP.
p<0.05 FDR correctedFigure 11.4 shows regions undergoing significantly increased rates of tissue 
contraction in MSA-P compared with PSP. A significantly increased rate of atrophy in 
the pons and cerebellum as well as the temporal stem and insular cortex in MSA-P is 
the only clear significant difference. SPM analysis of atrophy patterns in PSP 
compared to MSA-P did not demonstrate any clear differences after FDR correction.
Figure 11.5 Statistical parametric maps (SPM) are shown 
indicating regions undergoing significantly increased rates of 
atrophy (tissue contraction) in PD compared with healthy controls.
p<0.001  uncorrected
Figure 11.5 shows that in PD compared to healthy controls, only a minimal increase 
in atrophy rates in the region of the cingulate gyrus. This region did not survive FDR 
correction (p<0.05)..
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Figure 11.6 Patterns of regional tissue expansion in PSP and MSA-P.
Statistical  parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of expansion in PSP (A) and MSA-P (B)
compared with healthy control subjects.
p<0.05 FDR corrected B MSA-P vs.  healthy controls
280Figure 11.6 shows regions of significant expansion in PSP compared to healthy 
controls (11.6A) and in MSA-P compared to healthy controls (11.6B). The differences 
in the PSP patients are confined to the frontal horns of the lateral ventricles and in 
MSA-P to the fourth ventricle and quadrigeminal cistern as well as the CSF space 
around the cerebellar hemispheres. Figure 11.7 shows regions undergoing 
significantly increased rates of expansion in MSA-P compared to PSP. The fourth 
ventricle and quadrigeminal cistern as well as CSF spaces around the superior aspect 
of the cerebellum are the most affected regions. There were no regions of significantly 
increased rates of expansion in PSP compared to MSA-P
Figure 11.7 Statistical parametric maps (SPM) are shown 
indicating regions undergoing significantly increased rates of 
expansion in MSA-P compared with PSP.
p<0.001  uncorrected 
11.3.1.  The influence of FAB, MMSE, gaze palsy and disease duration
Table  11.2  shows the  division of PSP  subjects based on  FAB,  MMSE,  gaze palsy 
scores  and  disease  duration.  The  subgroups  of PSP  patients  were  compared  with
281healthy controls and with each other using age and sex as nuisance variables and scan 
interval as a covariate in the SPM analysis.
Table 11.2 Subgroups based on median scores in
PSP
Median PSP
score n
FAB 12
;>  12 
<12
7
9
MMSE 27
£ 28 
<28
7
9
Gaze palsy 12
£ 12 
<12
9
7
Disease duration 4.5
>4.5
<4.5
8
8
FAB: Dividing the PSP patients according to the FAB separated the group into two 
subgroups of n=7 and n=9. There was no difference in mean disease duration (p=0.14) 
or  age  (p=0.87)  between  them.  SPMs  showing  regions  undergoing  significantly 
increased rates of contraction and expansion are shown in figures 11.8 and 11.9.
Figure  11.8  (Bl)  demonstrates  that  patients  with  a  high  FAB  score  (less 
ffontal/subcortical cognitive impairment) have significantly increased rates of tissue 
contraction,  bilaterally  in  the  superior  and  middle  frontal  gyri  as  well  as  the 
orbitofrontal gyrus, the cingulate cortex, the pre-central gyrus and the superior parietal 
regions.
Those patients with a lower FAB score did not have any areas of increased atrophy 
rates compared to the group with a higher FAB score. Those with a higher FAB score 
had a greater rate of atrophy in frontal regions, particularly the superior and middle 
frontal gyri and the cingulate gyrus, when compared directly to those with a lower 
FAB score (more severe cognitive impairment). Rates of expansion were greater in 
those with a higher FAB score compared to those with a low FAB score (figure 11.9).
282patients with a low and a high FAB score compared with healthy controls (A1 and B1) and each other (A2 and B2). A higher FAB score
ass s e v e r e  frontal/sub-cortical cognitive impairment  ___ indicates It
and  B-PSP with high FAB score (£12) compared to healthy controls (1) 
and to PSP patients with a low FAB (<12) (2) -p<0.001 
uncorrected
A-PSP with low FAB score(<12) compared to healthy controls (1) 
to PSP patients with a high FAB (£12) (2) -p<0.001  uncorrectedFigure 11.9 Statistical parametric maps (SPM) are shown 
indicating regions undergoing significantly increased rates of 
expansion in PSP (FAB £12) vs. PSP (FAB<12).
p<0.05 FDR correctedFigure 11.10 Patterns of regional tissue contraction.
Statistical  parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of contraction in PSP patients with a disease
duration of >4.5 and <4.5 compared with healthy controls (A1  and B1) and each other (A2 and B2).
A-PSP with disease duration >4.5 compared to healthy controls (1) and to  B- PSP with disease duration <4.5 compared to healthy controls (1) and 
PSP patients with disease duration <4.5 (2) -p<0.001  uncorrected  to PSP patients with disease duration >4.5 (2) -p<0.001  uncorrected
286Figure 11.11 Statistical parametric maps (SPM) are shown 
indicating regions undergoing significantly increased rates of 
expansion in PSP (disease duration <4.5 years) vs. PSP (disease 
duration >4.5 years).
p<0.05 FDR correctedGaze palsy: Dividing the PSP patients into two groups according to gaze palsy score 
produced two groups (n=7 and n=9) with no difference in mean disease duration 
(p=0.78) or age (p=0.48). SPMs show greater rates of atrophy in those patients with a 
more severe gaze palsy in the superior, medial and orbitofrontal gyri as well as the 
parietal cortex and brainstem regions, when compared to healthy controls (figure 
11.12 A). In PSP patients with a less severe gaze palsy, the significantly different 
regional rates of atrophy were confined to the brainstem (figure 11.12 B). Comparing 
the two sub-groups of PSP patients, showed significantly increased rates of atrophy in 
the superior parietal lobule in those with a more severe gaze palsy (figure 11.12 C). 
Figure 11.13 A and B show that rates of expansion were significantly greatest in the 
lateral ventricles and over the frontal cortex in PSP with more severe gaze palsy 
compared to healthy controls but that only minimal differences in regional expansion 
persisted when directly comparing the two subgroups of PSP patients.
288Figure 11.12 Patterns of regional tissue contraction.
Statistical parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of contraction in PSP patients with a low and a high gaze 
palsy score compared with healthy controls and each other. A higher gaze palsy score indicates a more severe gaze palsy.
A- PSP (gaze palsy>12) compared to healthy 
controls-p<0.001  uncorrected
1
\J *
1-  /
1
IBS
B- PSP (gaze palsy<12) compared to healthy 
control s-p< 0.001  uncorrected
C- PSP (gaze palsy^12) compared to PSP (gaze 
palsy<12) p<0.001  uncorrected
289Figure 11.13 Statistical parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of 
expansion in PSP with severe gaze palsy (score >12) compared to healthy controls (A) and to PSP patients with a gaze 
palsy score <12 (B).
A PSP (gaze palsy £12) vs healthy controls p<0.05 FDR  g PSP (gaze pa,sy a12) vs  psp (gaze pa|sy <12) p<0 05 
corrected  FDR correctedMMSE: Dividing the PSP patients according to MMSE resulted in two groups (n=7 
and  n=9).  There was no  significant  difference  in age  (p=0.59)  or disease  duration 
(p=0.18) between the two groups. The SPMs reveal similar patterns of significantly 
increased atrophy in those with a high MMSE and those with a low MMSE compared 
to  healthy  control  subjects  and  only  very  small  regions  of significantly  increased 
atrophy rates when comparing the two PSP subgroups with each other (figure 11.14 
A1-B2).
A similar pattern of significant regional expansion affecting the anterior horns of the 
lateral ventricles  is also  seen in both PSP  subgroups compared to  healthy controls 
(figure 11.15 A and B).
291Figure 11.14 Patterns of regional tissue contraction.
S t a t i s t i c a l   p a r a m e t r i c   m a p s   ( S P M )   a r e   s h o w n   i n d i c a t i n g   r e g i o n s   u n d e r g o i n g   s i g n i f i c a n t l y   i n c r e a s e d   ra te s of contraction in  P S P  patien ts with  M M S t  of <28 a m i .  
2   28 com pared with  healthy controls  (A 1   a n d   B 1 )   a n d   e a c h   o t h e r   ( A 2   a n d   B 2 ) .
B- PSP with MMSE£ 28 compared to healthy controls (1) and to PSP 
patients with MMSE <28 (2) -p<0.001  uncorrected
2
ArPSP with MMSE<28 compared to healthy controls (1) and to PSP patients 
with MMSE £ 28 (2) -p<0.001  uncorrected
292Figure 11.15 Patterns of regional tissue expansion in PSP.
Statistical parametric maps (SPM) are shown indicating regions undergoing significantly increased rates of expansion in PSP with MMSE <28 vs.
healthy controls (A) and PSP with MMSE £ 28 vs.  healthy controls (B).
B PSP (MMSE £ 28) vs. healthy controls p<0.05 FDR corrected A PSP (MMSE <28) vs. healthy controls p<0.05 FDR corrected
29311.4.  Conclusions
The technique used  in this  chapter combines assessment of regional atrophy on an 
individual basis with robust statistical between group analysis and provides a means 
of assessing areas that undergo  significantly increased rates of atrophy in PSP and 
MSA-P.  The  results  indicate  areas  of  loss  that  are  consistent  with  the  known 
distribution of histopathology  in these  diseases (Litvan,  1997;  Ozawa et al.,  2004; 
Papp and Lantos,  1994).  Importantly, this data is in keeping with the results of the 
region of interest analysis described in chapters 6 and 9, and the cross sectional VBM 
analysis described in chapter 7.
PSP compared to healthy controls
Significantly increased rates of tissue contraction in PSP compared to healthy controls 
were  present  in  the  midbrain  and  cerebral  peduncles.  The  substantia  nigra, 
subthalamic  nucleus,  red  nuclei  and dentato-rubro-thalamic tract  are  present  in the 
regions  of  significantly  increased  atrophy  in  PSP.  All  of  these  regions  are 
significantly  affected  by  tau  positive  neurofibrilliary  tangle  formation,  tufted 
astrocytes, neuropil threads and neuronal cell loss. The implication is then that these 
histological changes are associated with increased rates of atrophy. Pathology in these 
regions is implicated in the expression of the typical clinical phenotype of PSP with 
early falls and an akinetic rigid syndrome. The typical gaze palsy associated with PSP 
also  probably  arises  as  a  consequence  of pathological  involvement  of the  upper 
brainstem.
No significant increase in frontal atrophy rates was detected in the PSP patients, when 
the whole PSP group was compared to the controls. This may be because the whole
294group  includes  some  subjects  with  increased  rates  of loss  and  a  number  without 
increased rates of frontal atrophy.
Cross sectional VBM analysis  demonstrated reduced grey matter voxel intensity in 
the  medial  frontal  gyrus  and  the  insular  cortex  in  the  PSP  patients  compared  to 
healthy controls.  It is possible that no  increase in atrophy rates was detected in the 
PSP group as a whole in this region because the rate of tissue contraction had already 
reached a plateau in the more advanced cases. A previous cross sectional VBM study 
helps to  support this theory  as  it  demonstrated a reduction in  frontal  volume  in a 
group of PSP patients with a mean disease duration of only 2.7 years, compared to 
that of 4.3 years in those recruited to this study. However the potential for ongoing 
frontal  atrophy  is  large  and  that  atrophy rates  simply  arrest  after  several  years  of 
disease seems unlikely.
It is more probable that the PSP group contains patients who have increased rates of 
frontal atrophy as well as those who do not, and overall, no significant difference is 
detected.
Increased rates of atrophy in the thalamus were detected in PSP compared to healthy 
controls  (figure  11.IB  and  11.2B)  supporting the  findings of the  DWI  analysis.  A 
recent  study  of thalamic  pathology  in  PSP  confirmed  that  the  medial  thalamus 
contains  large  numbers  of NFTs  (Henderson  et  al.,  2000).  Whereas,  the  limbic 
thalamus is less affected.  Atrophy in the centro-median nucleus of the thalamus  in 
PSP has been suggested as reflective of thalamic deafferentation due to degeneration 
of basal  ganglia  output  in PSP  (Hardman et  al.,  1997).  Whatever  the  mechanism 
behind atrophy of the median thalamus, it is likely that disruption to thalamic relays, 
either  as  a  consequence  of  direct  pathological  involvement  or  deafferentation
295secondary to extensive basal ganglia pathology contributes to the basal ganglia signs 
characteristic of PSP.
PSP compared to MSA-P
The  fluid-SPM  analysis  did  not  detect  any  significant  differences  in  atrophy rates 
between PSP  and  MSA-P  subjects.  This  is  in  contrast to  the  results  of the  serial 
volumetric ROI analysis reported in chapter 9. It is possible that no group differences 
survived the  strict statistical tests used in the fluid-SPM analysis; however the ROI 
analysis demonstrated that in addition to the midbrain atrophy rates being greater than 
controls in PSP as expected, they were also increased in MSA-P. This might explain 
why  no  significant  increase  in  atrophy  rates  in  this  region  was  observed  when 
comparing  PSP  and  MSA-P.  Atrophy  in  basal  ganglia  regions  and  even  cortical 
regions may be expected in MSA-P explaining why increased rates of atrophy in these 
regions when comparing the two diseases were not detected.
MSA-P compared to healthy controls
Regional  differences  in  atrophy  rates  between  MSA-P  and  healthy  controls  were 
present  in  the  pons  and  the  midbrain,  the  cerebellum  and  the  middle  cerebellar 
peduncle. The thalamus appeared relatively spared. There were, however, regions of 
increased rates of cortical atrophy in MSA-P including the superior frontal gyri, the 
temporal lobes and the anterior cingulate cortex and orbitofrontal gyri. That increased 
rates  of cortical  atrophy  occur  in  MSA-P  is  in  keeping  with post  mortem  studies 
demonstrating  some  frontal  atrophy  (Konagaya  et  al.,  1999b;  Wakabayashi  et al, 
1998).  Although,  these  case  reports  comment  on  post  mortem  pathological 
involvement  of  motor  cortical  areas  after  disease  durations  of  13  or  14  years. 
Conventionally,  frontal cortical atrophy detected on MRI during life would not have
296been  considered  indicative  of  MSA-P  and  might  even  have  been  considered 
supportive of a diagnosis of PSP or CBD (Schrag et al,  2000). The mean disease 
duration of MSA-P patients recruited for fluid-SPM analysis was 5.4 years and our 
results  suggest  that  frontal  atrophy  is  already  ongoing  at  this  stage  in the  disease 
process.  This together with the results of a previous cross sectional VBM study in 
MSA-P (Brenneis et al, 2003) and the results of our own cross sectional VBM study 
(chapter 7) confirm that atrophy affecting the insular cortex, the medial frontal gyrus, 
the anterior cingulate cortex and the dorsal pre-motor cortex occurs in MSA-P. These 
cortical regions are similar to those involved in MSA-C (Brenneis et al., 2005). The 
phenotypic differences in MSA subtypes are a matter of relative rather than absolute 
differences in the severity of the pathological involvement (Ozawa et al,  2004). As 
such, greater rates of cerebellar atrophy would be expected in MSA-C.
Cortical pathology in MSA has been demonstrated  in the  sensorimotor and higher 
cortical areas such as the supplementary motor area and the anterior cingulate cortex 
(Papp and Lantos,  1994).  Case reports of frontal cortical atrophy in MSA have also 
demonstrated loss of small and medium sized pyramidal cells in the pre-central gyrus, 
superior  and  middle  frontal  gyri,  with  glial  cytoplasmic  inclusions  in  the  deeper 
cortical areas resulting in extensive myelin and axonal loss in the frontal white matter. 
This supports the  notion that  in MSA,  the  increased MRI atrophy rates  occur as a 
consequence of direct pathological involvement rather than secondary deafferentation. 
An obvious clinical correlate of frontal cortical atrophy is pyramidal tract dysfunction 
in MSA-P. This was present in all, except one, MSA-P patient recruited to this study. 
The  MSA-P  patients  also  demonstrated  variable  neuropsychological  evidence  of 
frontal cognitive impairment.
297MSA-P compared to PSP
Regions of significantly increased rates of tissue atrophy in MSA-P compared to PSP 
are restricted to atrophy in the pons and in the cerebellum although the size of the 
regions  that  were  statistically  significantly  different  after  correction  for  multiple 
comparisons  is small.  Increased atrophy rates  in the region of the  insular cortex in 
MSA-P  was  also  identified  suggesting  that  some regional  cortical  atrophy may be 
occurring at a greater rate  in MSA-P than in PSP.  Alternatively,  it is possible that 
atrophy rates in these regions in PSP have fallen off as tissue contraction has already 
reached its maximum.
A number of conclusions can be drawn from the PSP subgroup analysis.
Frontal cortical atrophy seems to  occur early in the course of the disease.  In those 
with  less  severe  cognitive  impairment  on the  FAB,  rates  of frontal  atrophy  were 
greater  than  in  those  with  more  severe  cognitive  impairment.  One  potential 
explanation for this is that atrophy in frontal regions had already occurred in those 
with  more  severe  cognitive  impairment,  but  is  ongoing  in  those  with  less  severe 
cognitive  impairment.  The  lack  of more  severe  frontal  volume  reduction  in  PSP 
according to the cross sectional analysis (Chapter 7) may be due to varying rates of 
atrophy according to the disease phenotype. In the PSP patients with shorter reported 
disease duration,  atrophy rates were greater in the same  frontal regions implying it 
occurs early in PSP, and does not accelerate in the later stages of the disease.
Atrophy rates and the FAB
When divided according to the median FAB score in the PSP group, those with less 
frontal/subcortical  cognitive  impairment  according  to  the  bedside  rating  scale 
(FAB>12) had significantly greater rates of atrophy in the brainstem, the  superior and
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gyrus when compared to healthy controls.  Those with lower FAB  scores (<12) had 
increased rates of brainstem atrophy compared to controls but did not have increased 
rates of frontal cortical atrophy. Disease duration and age were no different between 
the two groups.
When  comparing  the  groups  directly,  increased  rates  of atrophy  persisted  in  the 
superior and medial frontal gyri in those with a higher FAB score. This suggests that 
atrophy  in these regions has  already occurred  in those  with more  severe  cognitive 
impairment  and  in  those  with  less  severe  cognitive  impairment  atrophy  in  frontal 
cortical  regions  is  still  ongoing.  That  these  frontal  regions  are  implicated  is  not 
surprising as the FAB test score is dependent on functions mediated by the pre-frontal 
cortex (Chapter 5.4)
The  regions  of significantly  increased  atrophy  correspond  with those  identified  in 
previous cross sectional imaging studies in PSP (Brenneis et al, 2004). These regions 
are targets of striatal projections and are engaged in regulation of motor initiation, 
response  selection,  motivation  and  goal  directed  behaviour.  Hence  that  increased 
atrophy rates  in the  superior and  medial  frontal cortex in PSP  is linked with FAB 
score is in keeping with the apathy, impaired executive function and action initiation 
as well as difficulty with set shifting consistently demonstrated on neuropsychological 
testing in PSP.
These  findings  support  the  conclusion  that  atrophy  as  a  consequence  of direct 
pathological  involvement  of  frontal  cortical  structures  as  well  as  secondary  to 
deafferentation contributes to the frontal/subcortical dementia syndrome of PSP.
299Atrophy rates and disease duration
When divided according to disease duration, increased rates of atrophy were detected 
in frontal cortical areas as well as brainstem regions in those with a shorter disease 
duration  compared  to  healthy  controls.  Frontal  cortical  atrophy  rates  were  not 
significantly increased when comparing those with longer disease duration to healthy 
controls. This suggests that cerebral atrophy in PSP occurs early in the course of the 
disease. When directly comparing PSP patients with a short and long disease duration, 
greater rates of atrophy were only identified in the brainstem regions in those with 
disease  duration of less than 4.5  years.  This  still  supports the theory that  rates of 
atrophy decline as the disease progresses. This has important implications if MRI is to 
be considered as a means of monitoring disease progression in drug trials and indeed 
when  considering  a  disease  modifying  therapy  in  the  later  stages  of the  disease. 
Firstly, in a drug trial, a real but small, drug effect may be missed if patients with 
longer disease duration are recruited as their atrophy rates are slower hence a greater 
number  will  be  needed  to  detect  a  treatment  effect  (see  chapter  14  for  further 
discussion).  Secondly if macroscopic  atrophy occurs as a consequence of neuronal 
cell loss and this has slowed in the later stages of the disease, it implies that a disease 
modifying  therapy  may  only  have  a  meaningful  effect  early  in  the  course  of the 
disease  when  atrophy  rates  are  greatest  and  there  is  more  neuronal  function  to 
preserve.
That  atrophy  rates  are  greater  early  in  the  course  of  the  illness  suggests  that 
application of MRI derived regional atrophy rates as a means of supporting a clinical 
diagnosis of a neurodegenerative disease is valid. This technique could also readily be 
applied to monitor disease progression early in the course of the illness.
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conclude that atrophy rates accelerate later in the disease course (Scahill et al, 2002). 
So  far, these conclusions assume that all PSP patients have similar rates of disease 
progression and the greater atrophy rates detected in those with a disease duration of 
<4.5  years reflect that  atrophy rates  slow as the  disease progresses.  An alternative 
explanation is that those with a longer disease duration have  survived longer (>4.5 
years) as they have a slower rate of cell death.
Atrophy rates and gaze palsy
Comparing PSP patients divided according to the severity of gaze palsy suggests that 
greater rates of cerebral and brainstem atrophy occur in those patients with a more 
severe  gaze palsy  when  compared  with healthy  controls.  When compared directly 
with each other, increased rates of atrophy were identified bilaterally in the superior 
parietal  lobe,  in  the  region  of the  supra  marginal  gyrus  suggesting  that  ongoing 
atrophy in this region occurs in those with a more severe gaze palsy. The parietal eye 
fields  project  to  the  superior  colliculus  and  from  there  to  the  brainstem  saccadic 
generators, and are important in the triggering of reflexive visually guided saccades. 
There is evidence to  suggest that the parietal eye fields accumulate sensory signals 
relevant to the selection of a target for an eye movement and in humans, the latency of 
visually  triggered  saccades  is  increased  when  lesions  occur  in  this  region. 
Transcortical magnetic stimulation of the posterior parietal cortex supports the view 
that it contributes to reflexive  saccades (Leigh and Kennard, 2004).  Clearly in PSP, 
the  pathological  involvement  of  brainstem  regions  responsible  in  part  for  the 
generation  of saccadic  eye  movements  means  that  more  than just  difficulty  with 
reflexive saccades occurs. Even in those with less severe gaze palsy, tissue atrophy is
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of the parietal eye fields has been demonstrated to be less severe in PSP cases with no 
documented  gaze  palsy  during  life,  confirming  a pathological  basis  for the  VBM 
findings demonstrated in this thesis.
Greater cerebral atrophy rates are detected when comparing  PSP  with  severe  gaze 
palsy than less severe gaze palsy to healthy controls. The increased atrophy rates are 
detected in parts of the posterior frontal cortex involved in the generation of saccadic 
eye  movements.  Damage  to  these  regions  results  in  difficulty  with  intentional 
saccades and the antisaccade task, resulting in hypometric saccades in all directions. 
Hence,  it  seems  that  greater  atrophy rates  as  a  result  of more  severe  pathological 
involvement  of  the  cortical  regions  involved  in  the  generation  of  saccadic  eye 
movements,  in combination with brainstem atrophy may result  in the  more  severe 
gaze palsy in some PSP patients.
As cortical atrophy rates were greater in those with more severe gaze palsy,  and in 
those with a higher FAB score, it is interesting to note that there was no significant 
difference in the mean FAB scores between the two groups.
Atrophy rates and the MMSE
Dividing the PSP patients according to the MMSE and comparing them with healthy 
controls  revealed  little  difference  in  atrophy  rates  between  the  two  groups  when 
compared with controls and each other. Both groups demonstrated similarly increased 
brainstem atrophy rates compared to healthy controls. This suggests that the MMSE 
does not identify phenotypic differences with the PSP group. This is not surprising 
given the particular weightings (verbal) of the MMSE. It also argues for a consistent 
(neither accelerating nor decelerating) global loss.
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The results of the fluid-SPM analysis demonstrate differing regional atrophy rates in 
PSP  and MSA-P  compared to healthy controls.  Differing regional rates  of atrophy 
were also clear when dividing the PSP group according to the FAB, disease duration 
and the severity of the gaze palsy. Interestingly, some of these regional atrophy rates 
were  not  identified  when  comparing  the  entire  PSP  cohort  with  healthy  control 
subjects. This suggests that the PSP phenotype is varied and that this variation may 
arise  as  a  consequence  of  differing  rates  of  cerebral  atrophy  secondary  to  the 
distribution of pathology.
The studies of pathologically proven cases of PSP outlined in Chapter 3 of this thesis 
suggest that a common presentation of PSP may occur with a less severe, or absent 
gaze palsy, later falls (after one year), prominent bradykinesia, a flexed posture and a 
longer disease duration. In the PSP patient groups with a more severe gaze palsy and 
shorter disease duration, there was an overlap, with 5 of 8 patients being common to 
both groups. Those patients with a more severe gaze palsy, also had higher scores on 
the Hoehn and Yahr (p=0.01)  and the UPDRS  II  (p=0.03), with a trend towards a 
higher score on the UPDRS III (p=0.07). There were no significant differences in the 
severity of motor deficit in the PSP patients separated on the basis of the FAB and the 
disease duration.
If we  consider  that  short  disease  duration  and  severe  gaze  palsy  are  key  to  the 
discrimination of Richardson’s syndrome from PSP-P then it is possible to conclude 
that  those  patients  with  these  symptoms  have  faster  rates  of cortical  atrophy  in 
addition to the brainstem atrophy that is common to both subtypes. This may help to 
explain the faster rates of clinical disease progression seen in classical Richardsons
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but  in  the  meantime  this  information  has  important  implications  if using  serially 
registered MRI and calculated atrophy rates to monitor disease progression.  Further 
clinico-radiological  correlates  on the  basis  of ROI  measurements  are  described  in 
Chapter 12.
30412. Correlating Clinical Features and Neuropsychology with Imaging.
12.1.  Introduction
Over time, motor handicap and functional disability increase, in both PSP and MSA-P 
and in PSP particularly, there is also a decline in cognitive function (chapter 3.4.2). 
Data from the fluid-SPM studies in Chapter  11  support the theory that pathological 
involvement of specific  brain regions results in the onset and evolution of specific 
clinical  signs.  An association between TIV  corrected  regional  brain  volumes with 
measures of disease severity would help to confirm this. Post mortem studies can infer 
this relationship  is present when,  for example a specific brain region is  seen to  be 
more  severely  affected  by  the  pathological  process  in  a  group  of patients  with  a 
specific clinical sign, but absent in a matched control group of patients. For example, 
in pathologically proven PSP without  a clear history of a  supranuclear gaze palsy 
(SNGP)  during  life,  less  severe  pathological  involvement  of the  nucleus  raphe 
interpositus (omnipause  neurons)  (Revesz et al.,  1996),  and the parietal eye  fields 
(Vemy  et al,  1996a)  has  been revealed.  Pathological  studies  are  often reliant  on 
retrospective clinical data however, and only limited conclusions can be made. The 
considerable heterogeneity in the timing of the onset of the clinical features and in the 
rate of their progression, suggests that there is likely to be variation in the regional 
atrophy rates in PSP and MSA-P.
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The objective of this section of the study was to determine whether regional atrophy, 
implied on the basis of cross sectional volumetric MRI analysis, was associated with 
the severity of the clinical features observed in PSP and MSA-P.
12.2.1.  Methods
Scores  on  the  UPDRS,  Hoehn  and  Yahr  rating  scale,  the  MMSE,  the  FAB,  the 
Schwab and England scale and the gaze palsy rating scale have been reported and 
compared in Chapter 4.
In this section, associations between ROI volume and motor deficit measured using 
the UPDRS and Hoehn and Yahr scores, as well as: falls; postural stability;  speech 
and swallowing UPDRS sub-scores; the MMSE and; the FAB scores were assessed. 
In the PSP group, the severity of the gaze palsy was assessed using a scaled scoring 
system (Chapter 4) and its relationship with ROI volume evaluated. Any relationship 
between ROI volume and disease duration was also noted. The associations between 
the neuropsychological test scores (see Chapter 5) and ROI volumes in the PSP and 
MSA-P groups were also studied. Associations between frontal volume, and bedside 
and formal tests of executive function as well as associations between brainstem and 
cerebellar volumes and motor deficit were specifically studied.
All statistical analysis was undertaken using STATA version 8 (Stata Corp. College 
Station TX.). Linear regression was used to investigate the relationship between ROI 
and age in the healthy control group alone and to establish the relationship between 
TIV corrected ROI volumes, and neuropsychological and clinical information in the 
PSP  and  MSA-P  groups.  Clinico-radiological  correlations  in the  PSP  and  MSA-P 
groups  were  studied  separately  using  multiple  regression  analysis  with  age  and 
disease duration as covariates.
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detected  in  order to  estimate  the  correlation that  would  occur  if age  and  disease 
duration were held constant.
12.2.2.  Results
Correlations  between  age  and  TIV  corrected  ROI  volumes  were  only  seen  in the 
healthy control group: midbrain (R2 = 0.47, p = 0.001); frontal volume (R2 = 0.41, p = 
0.004); and PI volume (R2 = 0.24, p = 0.04). The disease related losses are likely to 
obscure  the  effect  of age  in  the  small  disease  groups.  There  were  no  significant 
correlations between ROI volume and disease duration in PSP or MSA-P.
Associations between midbrain volume and clinical rating scales (UPDRS II and III, 
Hoehn and Yahr, gaze palsy and postural instability) were present in the PSP patients 
(table  12.1). The midbrain volume was most strongly associated with motor deficit 
and  postural  stability  as  well  as  swallowing  and  gaze  palsy.  There  were  fewer 
significant associations between ROI  volume and neuropsychological test scores in 
the  MSA-P  patients.  The  only  significant  associations  between  ROI  volume  and 
clinical  scores  in the  MSA-P  group were  between:  PI  volume  and FAB  (p=0.03); 
cerebellar  as  well  as  pontine  volume  and  FAB  (p=0.001);  and  the  third  ventricle 
volume and swallowing (p=0.04) (table 12.2).
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Brain region
whole
brain
volume
total
frontal
volume
PI
volume
cerebellar
volume
midbrain
volume
pons
volume
SCP
volume
LV
volume
third
ventricle
volume
Corr P Corr P Corr P Corr P Corr P Corr P Corr p Corr P Corr P
MMSE
FAB -0.5 0.05
UPDRS2 -0.6 0.02 -0.6 0.04 -0.6 0.02
UPDRS3 -0.6 0.04 -0.6 0.04 -0.6 0.03
HY -0.6 0.03 -0.6 0.04 -0.5 0.07 -0.8 .001 -0.6 0.03
Falls -0.5 0.08 -0.6 0.02 -0.5 0.08 -0.5 0.06 -0.7 0.01
Postural
Stability
-0.6 0.02 -0.6 0.05 -0.6 0.05 -0.6 0.02 -0.5 0.06
Speech -0.5 0.06 -0.5 0.08
Swallowing -0.5 0.07 -0.8 .001
Disease
duration
Gaze palsy 
score
-0.5 0.05 -0.6 0.03 -0.5 0.08
Significant positive or negative associations are shown in bold. Corr- pari 
at p=<0.05). PI- postero-inferior region, SCP-superior cerebellar peduncl 
age and disease duration as co-variables.
tial correlation coel 
e, LV- lateral ventr
Ticient, p- p value (significance 
cle. All regression calculations
evel
haveTable 12.2 ROI correlations with clinical scores in MSA-P
Brain region
whole
brain
volume
total
frontal
volume
PI
volume
cerebellar
volume
midbrain
volume
pons
volume
SCP
volume
LV
volume
third
ventricle
volume
Corr P Corr p Corr P Corr P Corr P Corr P Corr P Corr P Corr P
MMSE
FAB 0.7 0.07 0.8 0.03 0.96 .001 0.72 .007 0.94 .001
UPDRS2
UPDRS3
HY
Falls
Postural
Stability
Speech
Swallowing 0.78 0.04
Disease
duration
Significant positive or nega 
level at p=<0.05). PI- poste 
calculations have age and <
tive associations are shown in bold. Corr- partial correlation coefficient p- p value (significance 
ro-inferior region, SCP-superior cerebellar peduncle,  LV- lateral ventricle. All regression 
disease duration as co-variables.In the PSP group, more associations were demonstrated between frontal volume and 
neuropsychological tests of executive function (Reitan TMT, WCST, verbal fluency), 
than between whole brain volume and neuropsychological tests (table 14.3). Very few 
associations between neuropsychological test scores and regional volumes in MSA-P 
were detected.
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DRS ip  DRS c  voc  Simi  VIQ  RMF RTMTA/B WCST
c/n/p
VF
F/A/S/An/Alt
BV 0.55  0.05  0.61  0.03  -  0.62  0.03 - - -
Frontal 0.69  0.008  0.55  0.05  0.62  0.03  0.66  0.02  0.76  0.004  0.79  0.006 a-0.71  0.03 "-0.69  0.03 an0.67  0.01 
a,t0.64 0.02
BV-brain volume, Frontal-frontal volume. Upper number-partial correlation coefficient (assuming age and disease duration are constant), number in 
brackets-p value from regression equation with age and disease duration as co-variables.
DRS- Mattis dementia rating scale, ip-initiation, c-conceptualisation,  voc-vocabulary (WAIS-R), simi-similarities (WAIS-R), RMF- recognition memory 
test faces, RTMT-Reitan trail making test (A and/or B),  WCST-Wisconsin card sorting test, c-categories, n-errors,p-perseverative errors,  VF- verbal 
fluency, letters F,A,S, An-animals, Alt-altemating semantic.
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In  PSP,  the  correlation  between  midbrain  volume  and  clinical  scales  of disease 
severity and gaze palsy severity suggest a strong association between midbrain tissue 
loss  and  the  evolution  of the  characteristic  clinical  signs  and  symptoms.  All  the 
patients fulfilled the diagnostic criteria for PSP, but no relationships between disease 
duration and ROI volumes were apparent. Disease duration is either error prone or 
there are very different rates of loss in different PSP subgroups.  This is in keeping 
with the results of the  fluid-SPM studies.  Despite  support from logistic regression 
analysis, some caution in interpreting the relationship between disease duration and 
clinical features or regional volumes is needed, as reporting of disease onset may not 
always be precise.
PSP  may  have  different  individual rates  of progression,  which together  with ROI 
measurement error may contribute to the lack of a relationship between ROI volume 
and disease duration.
Increasing disease severity measured on UPDRS and Hoehn and Yahr scales, as well 
as falls and stability sub-scores, were significantly associated with a smaller midbrain 
volume,  in-keeping  with  the  results  of previous  studies  (Groschel  et  a l,  2004). 
However, one previous VBM study failed to demonstrate this association and instead 
found  a  correlation  between  motor  deficit  (UPDRS  III)  and  size  of the  caudate 
nucleus and motor cingulate cortex (Cordato  et al.,  2005).  Although these regions 
were  not  specifically  studied  here,  atrophy  of  the  motor  cingulate  cortex  may 
contribute to the association of increased motor deficit, with reduced frontal volume. 
Tissue loss in other regions may also contribute to the motor disability observed in 
PSP. For example, SCP volume was associated with Hoehn and Yahr score, with falls 
as  scored  on the  UPDRS  III,  and  there  was  a trend  towards  an  association  with
312postural stability (table 12.1). In addition to ascending pathways (Chapter 6.3), some 
fibres  run  inferiorly  to  the  brainstem  reticular  and  vestibular  nuclei  and  may  be 
involved in balance and posture, helping to explain this association.
In  the  PSP  group,  reduced  frontal  volume  was  associated  with  increased  motor 
disability  (as  already  discussed)  a  more  severe  gaze  palsy,  falls  and  postural 
instability.  Pathology  in  the  midbrain  and  pons,  particularly  the  nucleus  raphe 
interpositus, has been suggested as responsible for the gaze palsy in PSP (Revesz et 
al.,  1996). The association between a smaller frontal volume and a more severe gaze 
palsy score could be explained by the  contribution of pathology in the  frontal eye 
fields to abnormalities of gaze. These results from the ROI data reassuringly support 
the results from fluid-SPM analysis. Motor impulsivity and reduced risk awareness 
may be partially responsible for increased falls in PSP and could help to explain the 
association  between  falls  and  reduced  frontal  volume  However  any  association 
between frontal volume and gaze palsy could arise because frontal volume loss occurs 
in parallel with midbrain volume loss.
A lower frontal volume in PSP was also associated with poorer performance on tests 
of  executive  function  including  an  increased  number  of  errors  on  the  WCST, 
prolongation of the RTMT, reduced verbal fluency and poor performance on subsets 
of the Mattis DRS dependent on frontal function. These associations were not seen 
with  whole  brain  volume  but  remained  when  adding  whole  brain  volume  as  a 
covariate  into  the  regression model.  Surprisingly,  despite  significantly  lower  FAB 
scores in PSP, and correlation between FAB scores and other tests of frontal cognitive 
function, there was no association between FAB score and frontal volume. However, 
caution must be exercised in drawing too many conclusions from these associations
313because  the  template  method  for  measurement  of  frontal  volume  also  includes 
anterior temporal lobe structures and excludes some posterior frontal lobe structures.
In MSA-P, the only association between frontal volume and individual cognitive tests 
was with verbal fluency. There was no significant difference between frontal volumes 
in  MSA-P  and  PD  or  controls.  There  was  however  an  association  between pons 
volume and FAB suggesting that in MSA-P subcortical pathology contributes to the 
modest  executive  dysfunction.  There  was  also  an  association  between  cerebellar 
volume and the FAB as well as the RTMT, suggesting that cerebellar pathology may 
contribute to the pattern of cognitive dysfunction seen in MSA-P. An increased motor 
deficit seen in the MSA-P group was associated with smaller pontine volume.
The association of swallowing with third ventricle volume in MSA-P may reflect 
tissue loss in regions distant from this brain/CSF boundary, however functional 
imaging studies have concluded that structures surrounding the third ventricle are 
involved in swallowing (Harris et al., 2005), suggesting a basis for the association 
seen.
Falls occur less frequently in MSA-P than PSP and often a little later in the course of 
the  illness.  Mean  midbrain  volume  in  MSA-P  was  only  significantly  lower  than 
controls  (not  PD  or  PSP)  and  was  not  associated with  increased  motor  disability 
scores. There was no association between any region and falls or postural stability in 
MSA-P. It may be that more severe pathological involvement of midbrain structures 
in PSP explains the early and severe postural instability.
31412.3.  Serial Imaging data
12.3.1. Introduction
If the pathological involvement and degeneration of a particular brain region results in 
the evolution of particular features of a disease, then the regional atrophy rate should 
be associated with an increase in the measured severity of those clinical features. This 
is of course dependent on the methods used to measure atrophy rates and evaluation 
of the change in the clinical features of the disease being reliable and sensitive (i.e. 
not having floor and ceiling effects).
12.3.2. Methods
In all patients with serial imaging, the change in scores on the Unified Parkinson’s 
disease rating  scale  (UPDRS)  and the  Hoehn and Yahr  scale,  were  recorded.  The 
scores at time point one and time point two of: falls; postural instability; speech and; 
swallowing  difficulty  as recorded  in the  UPDRS  were  also  noted.  Changes  in the 
Folstein MMSE and the frontal assessment battery (FAB) scores were also recorded 
in PSP and MSA-P. In PSP, the change in the gaze palsy scale scores were recorded. 
Where possible, patients completed a full neuropsychological assessment (chapter 5).
Annualised brain and regional atrophy rates were calculated by taking the BBSI and 
the regional BSIs in each group, adjusting for scan interval and expressing this as a 
percentage change from the baseline volume (Chapter 9).
Data were analysed using STATA version 8 (Stata Corporation, College station, TX).
For  normally  distributed  data,  linear  regression  was  used  to  investigate  the 
relationship between brain or regional atrophy rates and the change  in  clinical and 
neuropsychological test scores over time. For this analysis, age, disease duration and 
the baseline clinical test score were used as covariates. Partial correlation coefficients
315(Corr.) were calculated to estimate the strength of the relationship if age and disease 
duration were constant.  For non-normally distributed data,  linear regression models 
with  95%  bootstrapped  confidence  intervals  (and  implied  p-values)  were  used  to 
investigate the relationship between atrophy rates and change in test scores, with age, 
disease duration and the baseline clinical test as covariates.
In order to investigate whether regions were independently associated with change in 
the clinical scores of motor deficit (UPDRS and Hoehn and Yahr) and bedside tests of 
cognition  (FAB  and  MMSE),  multiple  regression  models  were  performed  with 
regional atrophy rate  as the dependent variable  and change  in clinical  score as the 
independent variable.  Age, disease duration, baseline clinical rating scale score and 
the next most significant regional atrophy rate were included as covariates.
12.3.3.  Results
PSP
An increased rate of midbrain atrophy in PSP was associated with: a decline in the 
Mattis DRS-attention sub-test (Corr. =0.80, p=0.009); an increasing number of errors 
(but not perseverative errors) on the WCST (Corr. =0.72, p=0.04); a decrease in the 
PASAT  score  (Corr.  =0.89,  p=  0.04);  a  decrease  in  FAB  score  (Corr.  =0.70,  p= 
0.008); an increase in motor disability (UPDRS III) score (Corr. =0.58, p=0.04) and a 
decrease in the MMSE (Corr.  =0.56, p=0.04). Increased pontine atrophy rates were 
only associated with a decrease in FAB score (p<0.05). Increasing cerebellar atrophy 
rates were associated with decrease in the FAB score (Corr. =0.73, p=0.005) and in 
the MMSE score (Corr. =0.55, p=0.05).
Increased whole brain atrophy rates were associated with decline in performance on: 
the Mattis DRS  attention  sub-test  (Corr.  =0.77, p=0.009);  an increasing number of
316errors on the WCST (Corr. =0.83, p=0.006); an increase in the number of intrusions 
on the verbal  fluency test  (Corr.  =0.89, p=0.003); a decline  in performance on the 
PASAT  (Corr.  =0.82,  p=0.045);  and  a  reducing  score  on the  FAB  (Corr.  =0.65, 
p=0.02) and the MMSE (Corr. =0.68, p=0.01).
Increased rates of frontal and postero-inferior atrophy were similarly associated with a 
more severe deterioration in: the Mattis DRS attention sub-test (frontal, Corr. =0.70, 
p=0.02; postero-inferior,  Corr.  =0.65,  p=0.04); the  number of errors on the WCST 
(frontal, Corr. =0.85, p=0.004; postero-inferior, Corr. =0.72, p=0.03); a decline in the 
PASAT score (frontal, Corr. =0.94, p=0.005; postero-inferior, Corr. =0.83, p=0.04); 
the  FAB  (frontal,  Corr.  =0.62,  p=0.02;  postero-inferior,  Corr.  =0.67,  p=0.01);  the 
MMSE  (frontal,  Corr.  =0.56,  p=0.05;  postero-inferior,  Corr.  =0.75,  p=0.003).  An 
increasing rate of postero-inferior atrophy was also associated with increased motor 
disability measured on the UPDRS III (Corr. =0.56, p=0.05).
An increasing rate  of third ventricle  enlargement was associated with a decline  in 
performance  on:  the  DRS  attention  subtest  (Corr.  =0.73,  p=0.02,);  the  number  of 
errors on the WCST (Corr. =0.80, p=0.009); an increasing number of intrusions on the 
verbal fluency test (Corr. =0.81, p=0.014) and a decline on the PASAT (Corr. =0.93, 
p=0.008). An increasing rate of lateral ventricle enlargement was only associated with 
a decline in the FAB (p<0.05) and a decline in the MMSE (p<0.05).
Having  adjusted for age  and disease  duration,  decline  in the  FAB  score was most 
strongly associated with the rate of midbrain atrophy (p=0.008). The next strongest 
association was with atrophy rate in the  cerebellum (p=0.005), but neither of these 
had independent effects once the other was controlled for. Change in UPDRS III was 
most strongly associated with midbrain atrophy (p=0.04) and then posterior inferior
317atrophy. Again, neither of these had independent effects once the other was controlled 
for. Similar results were obtained for change in the MMSE.
MSA-P
In the  MSA-P  patients,  increased  rates  of pontine  atrophy were  associated with a 
decline in performance on: the DRS total score (Corr. =0.99, p=0.001); the digit span 
(Corr. =0.88, p=0.05) and semantic verbal fluency (Corr. =0.95, p=0.05) as well as an 
increase in the motor disability as scored on the UPDRS III (Corr. =0.8, p=0.05). 
Increasing cerebellar atrophy rates were also associated with declining performance 
on the  DRS  total  score  (Corr.  =0.96,  p=0.01);  the  DRS  conceptualisation  subtest 
(Corr. =0.89, p=0.04); semantic verbal fluency (Corr. =0.95, p=0.05) and UPDRS III 
(Corr. =0.86, p=0.03).
Increasing midbrain atrophy rates were associated with poorer performance on: the 
DRS  initiation  and  perseveration  subtest  (Corr.=0.97,  p=0.005);  the  recognition 
memory test for faces (Corr.=0.92, p=0.03); the digit span (Corr. =0.91, p=0.03) and 
intrusions on the verbal fluency test (Corr.=0.96, p=0.04).
Lower whole brain, frontal and postero-inferior atrophy rates were associated with a 
greater rate of decline in the PASAT score (p<0.05) and for frontal atrophy rates, the 
Beck anxiety inventory (p=0.04).
In the control subjects, an association, albeit weak, between age and increasing rates 
of lateral ventricle enlargement (p=0.04) and posterior-inferior atrophy (p=0.04) were 
noted. No associations between age or disease duration and atrophy rates were seen in 
PSP or MSA-P.
318As with the  associations noted  in PSP,  multiple regression analysis confirmed that 
change  in  motor  deficit  was  most  strongly  associated  with  cerebellar  and  pontine 
atrophy rates but that neither of these had independent effects.
12.3.4.  Conclusions
There are a number of associations between atrophy rates and the clinical features of 
these diseases. Crucially, rates of atrophy in PSP and MSA-P have clinical correlates 
reflecting progression in clinically meaningful end-points.  Worsening motor deficit 
was associated with increasing midbrain atrophy rates in PSP and increased ponto­
cerebellar  atrophy  in  MSA-P.  This  suggests  that  pathological  involvement  of the 
structures in these regions, represented by tissue loss (and presumably cell death), is 
strongly associated with progression in the critical clinical features of the diseases. 
Hence  regional  MRI  derived  atrophy  rates,  which correlate  with change  in  motor 
deficit  in  PSP  and  MSA-P,  may  be  useful  and  quantifiable  outcome  measures  in 
clinical trials. This is evaluated further in Chapter 14.
Associations between atrophy rates  and  change  in neuropsychological  and  clinical 
scores  were  largely  confined  to  subtests  of the  Mattis  DRS,  the  WCST  and  the 
PASAT.  Associations  between  increasing  rate  of frontal  atrophy  in  PSP  and  an 
increasing number of errors on the WCST, and declining PASAT and FAB scores, 
suggests that the  degree  of severity noted in the  dysexecutive  syndrome  in PSP  is 
related to  frontal atrophy.  This supports observations from cross  sectional imaging 
studies (Cordato et al,  2002; Cordato et al.,  2005) and also supports the findings of 
the fluid-SPM study, which showed that the greatest rates of frontal cortical atrophy 
occur in patients with the highest FAB scores. Damage to brainstem and sub-cortical 
structures also  contributes  to the  cognitive  dysfunction in PSP  and hence  it  is  not
319surprising that there is a strong association between a decline in the FAB score and 
increased rates of midbrain atrophy in PSP.
The association between a greater decline  in the FAB  score  in PSP  and  increasing 
lateral ventricle  atrophy rates  could  in part,  be explained  by changes at the  lateral 
ventricle/caudate  nucleus  boundary.  Atrophy  of the  caudate  nucleus  in PSP  could 
contribute to a worsening sub-cortical dementia. However, changes in lateral ventricle 
volume  (measured  using  the  BSI)  are  unlikely  to  reflect  tissue  loss  simply  from 
contiguous structures and are more likely to arise as a consequence of distant tissue 
loss and subsequent structural readjustments.
Correlations were also seen between some of the neuropsychological tests and whole 
brain rates of loss as well as posterior inferior atrophy rates in PSP. It is possible that 
the associations arise because the tests applied are those most sensitive to change over 
a relatively short period of time. Other tests may be less sensitive or may be at floor at 
the first assessment.
The  smaller  number  of patients  with  MSA-P  is  also  likely  to  have  limited  the 
associations detected in this group.
Additionally, the  results of multiple regression models,  using  age,  disease  duration 
and the next most significantly associated regional atrophy rate as covariates suggest 
that  some  of the  associations  seen  between  regional  atrophy  rates  and  change  in 
disease severity arise because atrophy in one region is likely to occur in parallel with 
another region. For example, the association between pontine atrophy and change in 
the FAB score in PSP may only arise because the real association is with midbrain
320atrophy,  and  pontine  atrophy  and  midbrain  atrophy  occur  in  parallel.  In  order  to 
clarify this, larger study numbers would be required.
The results outlined in chapters 9-12 confirm that volumetric imaging has a potential 
role as a marker of disease progression,  as  measured atrophy rates have  a clinical 
correlate, one of the criteria for a good surrogate marker. The results of cross sectional 
diffusion weighted  MRI  analysis  suggest  that  it  can  be  applied  to  detect  regional 
pathological differences and destruction of normal tissue architecture, between PSP, 
MSA-P PD and healthy controls. Whether it too has a potential role, as an imaging 
marker of disease progression over a short interval requires assessment.
32113. Serial diffusion weighted imaging
13.1.  Introduction
Diffusion  weighted  MRI  (DWI),  allows  detection  of damage  to  brain  tissue,  as 
reduced  “anisotropy”  results  in  an  increased  apparent  diffusion  coefficient  (ADC, 
Chapter 8). In neurodegenerative diseases, progression of symptoms over time occurs 
secondary to  increasingly  severe  pathology  in  specific  regions  of the brain.  These 
pathological changes can be tracked by measuring changes in brain volume (Chapter 
9). If the ADC value of a tissue is influenced by the degree of damage to the normal 
tissue  architecture,  then  it would be reasonable to  hypothesise that  changes  in the 
ADC value  of a region over time  may  be  used to track the progress of a disease. 
Whether measuring the difference in rADC over time (less than  1   year) is sensitive 
enough to measure this change is evaluated in this section.
13.2.  Methods
Follow  up  scans  were  conducted  using  the  same  DWI  protocol  as  used  for  the 
baseline  scans  (Chapter  8).  Image  analysis  was  undertaken  in the  same  way.  As 
before,  the  rater  was  blinded  to  the  identity  and  diagnosis  of the  subject  and  the 
images presented in a random sequence. ADC values were recorded for all 18 regions 
(Left and right middle cerebellar peduncle-MCP, caudal and rostral pons, midbrain, 
decussation of the superior cerebellar peduncle-SCP, left and right thalamus, left and 
right caudate nuclei, left and right putamen and globus pallidus, genu and splenium of 
the corpus callosum, the left and right frontal and parietal white matter and the white 
matter of the left and right centrum semi-ovale). The annualised difference between 
the baseline and follow up analysis was calculated by subtracting the baseline ADC 
value from the follow up ADC value and correcting the result for an annual interval.
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Whitney  U  tests  where  significant  group  differences  were  observed.  Normally 
distributed data were analysed using a one-way analysis of variance (ANOVA) with 
post hoc t-tests where significant group differences were identified.
In addition, the mean value from combined left and right regions was determined and 
the annualised difference between baseline and follow up values calculated.
13.3.  Results
In total,  16 PSP,  9 MSA-P,  9 PD patients and 6 healthy control subjects had serial 
DWI, and regional ADC measurements. The mean (SD) scan interval (days) was not 
significantly different between the groups (PSP- 288.8  (59.7), MSA-P-262.3  (65.5), 
PD-269.2 (48.7), Controls-217.8 (48.7), p=0.1).
The annualised changes in rADC values are detailed in the table below.
Table 13.1  Mean (SD) rADC difference (xiO^mm^s1) per annum.
—-------— ' PSP MSA-P PD HC P values
N 16 9 9 6 ------------- ------------
LMCP 0.038 (0.14) -0.036 (0.09) 0.008 (0.05) 0.016 (0.08) NS
RMCP 0.056 (0.22) -0.032(0.14) -0.006 (0.09) -0.058 (0.12) NS
Caudal Pons 0.050 (0.21) 0.073 (0.12) 0.060 (0.29) 0 (0.24) NS
Rostral Pons -0.001  (0.17) -0.023 (0.16) -0.001  (0.06) -0.118(0.23) NS
Midbrain 0.031  (0.12) -0.004 (0.12) 0.027 (0.10) -0.078 (0.12) NS
SCP 0.023 (0.19) -0.017(0.11) 0.011  (0.14) -0.051  (0.098) NS
L Thalamus 0.050 (0.14) 0.021  (0.05) 0.021  (0.08) 0.017(0.07) NS
R Thalamus 0.046 (0.16) -0.043 (0.07) -0.009 (0.08) -0.026 (0.08) NS
L putamen 0.031  (0.19) 0.018(0.06) 0.086 (0.15) -0.021  (0.04) NS
R putamen 0.016(0.15) -0.003 (0.07) 0.041  (0.12) -0.044 (0.06) NS
L Globus pallidus 0.057 (0.21) 0.019(0.08) 0.048 (0.13) -0.01  (0.07) NS
R Globus pallidus 0.038 (0.15) 0.012 (0.07) 0.043 (0.15) -0.003 (0.04) NS
Splenium CC 0.029 (0.26) 0.142 (0.22) 0.019(0.31) -0.337 (0.270) 0.01*
Genu CC 0.100 (0.28) -0.156(0.19) 0.090 (0.34) -0.035 (0.198) NS
L Caudate 0.074 (0.19) -0.018(0.14) 0.020 (0.086) -0.087 (0.097) NS
R Caudate 0.045 (0.21) -0.076 (0.19) 0.004 (0.074) -0.080 (0.131) NS
L Frontal WM 0.075 (0.21) -0.027 (0.06) 0.016 (0.026) 0.011  (0.059) NS
R Frontal WM 0.046 (0.15) -0.008 (0.04) 0.013(0.034) -0.019 (0.045) NS
L Parietal WM -0.018(0.11) -0.040 (0.06) 0.008 (0.048) -0.017 (0.050) NS
R Parietal WM 0.020 (0.09) -0.049 (0.07) -0.001  (0.07) -0.069 (0.026) 0.05#
L Centrum Semi Ovale 0.036(0.13) 0.007 (0.05) 0.028 (0.069) -0.026 (0.017) NS
R Centrum Semi Ovale 0.025 (0.14) 0.016 (0.06) 0.035 (0.079) -0.027 (0.049) NS
Post hoc tests: * PSP vs. HC,  p=0.006, MSA vs.  HC,  p=0.005; # PSP vs.  HC,  p=0.01
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~ ______________' PSP MSA-P PD HC P values
N 16 9 9 6 —— '
'   MCP 0.047 (0.18) -0.035 (0.11) 0.001  (0.06) -0.021  (0.09) 0.6
Thalamus 0.048 (0.14) -0.011  (0.05) 0.006 (0.07) -0.004 (0.07) 0.8
Putamen 0.024 (0.17) 0.007 (0.06) 0.063 (0.13) -0.032 (0.02) 0.09
Globus Pallidus 0.048 (0.17) 0.015(0.07) 0.045 (0.14) -0.006 (0.05) 0.9
Caudate 0.062 (0.19) -0.06(0.19) 0.012 (0.07) -0.084 (0.10) 0.1
Frontal WM 0.061  (0.18) -0.017 (0.05) 0.015(0.02) -0.004 (0.05) 0.4
Parietal WM 0.001  (0.09) -0.044 (0.06) 0.004 (0.06) -0.043 (0.02) 0.2
Centrum Semi Ovale 0.031  (0.13) 0.011  (0.03) 0.032 (0.07) -0.026 (0.03) 0.2
The right parietal white matter and the splenium of the corpus callosum were the only 
regions  in  which  significant  differences  in  the  change  in  ADC  value  over  time 
between the groups were found. When the left and right regions were combined and 
differences between these mean values from baseline to follow up were analysed, no 
significant differences were identified (table 13.2).
13.4.  Conclusions
The results suggest that diffusivity measured using the regional ADC is not sensitive 
to change over time  in PSP, MSA-P  or PD.  From this we can conclude that DWI 
seems unsuitable for measuring disease progression in these conditions, over a short 
interval. The significant differences identified in the change in rADC values for the 
splenium and the parietal white matter arose because of an apparently negative (i.e a 
decrease in the rADC) difference between baseline and follow up values in the control 
population, rather than because of an increase in the rADC value in any of the patient 
groups.  Measurement  error  is  likely  to  have  influenced  the  results  and  any  real 
difference in the baseline and follow up rADC values, is likely to be obscured by this. 
In addition,  while  in the MCP, the pons, midbrain,  thalamus,  and the white matter 
regions  the  repeatability  and  reliability  (within  subject  SD  and  the  ICC)  of the
324measurements were good, in the SCP, the caudate nucleus, the putamen and globus 
pallidus, repeatability and reliability of the measurements was poor.
The  only  previous  study  of  longitudinal  DWI  in  MSA-P  detected  a  significant 
difference between 8 MSA-P and 8 PD patients, in the putamen (Seppi et a l, 2004; 
Seppi et al, 2005) had a longer mean scan interval of 15 months. The ADC value in 
the putamen has been shown to discriminate MSA-P from PD and healthy controls in 
cross sectional studies (Schocke et al, 2002). In the cross sectional data in this study, 
the MCP and pons had significantly greater ADC values in MSA-P compared with 
PSP,  PD  and  healthy  controls  (Chapter  8).  Hence  it  is perhaps  surprising  that  no 
difference between the change in the pons rADC value in MSA and healthy controls 
was detected. Several factors could contribute to this failure. Firstly, DWI may not be 
sensitive enough to detect the mild changes occurring over the time interval in this 
study. Secondly, failure to measure exactly the same ROI on the follow up ADC map 
could create inaccurate results and contribute to the large variation in the mean rADC 
differences  seen  in  most  of the  regions  measured.  Unlike  the  volumetric  image 
analysis,  DWI  scans  were  not  registered  to  standard  space.  This  means  that  it  is 
unlikely the  exact  same  anatomical regional  ADC  was  taken  for the  baseline  and 
follow up scan. This is difficult to correct as registering the DWI images to standard 
space would result in a loss of anatomical resolution and subsequently new problems 
regarding the identification of regions of interest.
Measurement  error  secondary  to  partial  volume  artefact  was  minimised  as  pixels 
containing  predominantly  CSF  were  excluded  from  the  analysis  by  means  of 
thresholding (Chapter 8).
It seems that the methods of serial DWI cannot be applied as a measure of disease 
progression.  This  is  in  contrast  to  the  conclusions  of  serial  volumetric  imaging
325studies.  However,  in  order  to  confirm  that  volumetric  imaging  has  a  role  in 
monitoring disease progression, it needs to be demonstrated that a feasible number of 
patients enrolled in a drug trial will allow detection of that drug effect. This can be 
assessed using a power calculation.
32614. Power calculations using BBSI and regional BSI
14.1.  Sample size calculations
14.1.1.  Introduction
Advances  in the understanding of the pathological processes that underlie PSP and 
MSA means that potential disease-modifying drugs may soon become available. The 
disease modifying effect of these drugs will need to be quantified. Measurement of a 
true disease  modifying  effect  with clinical  scales  can be  difficult  and  it  would  be 
helpful  to  be  able  to  apply  imaging  as  a  truly  quantifiable  marker  of  disease 
progression.  Atrophy  rates  in  specific  regions  in  PSP  and  MSA-P  have  been 
demonstrated to have clinically meaningful correlates suggesting potential for serial 
volumetric  MRI  as  a  marker  of diseases  progression.  However,  determining  the 
feasibility  of atrophy  rates  as  a  marker  of disease  progression  depends  upon the 
sample size required to detect the slowed atrophy rate (the drug effect).
An essential part of planning any drug trial is an estimation of sample size required to 
show  the  desired  effect  of  a  drug.  Justifying  the  proposed  study  size  and 
demonstrating  that  the  study  is  capable  of answering  the  questions  posed  is  an 
important component of any research protocol.
If the  effect  of a  drug  is  to  be  measured  using  a  quantifiable  marker  of disease 
progression, then one has to decide what percentage difference in that marker between 
diseased patients treated with placebo and those treated with the drug, one would want 
to  be able to  detect (for example 20%  slowing)  (Fox et al.,  2000).  For a thorough 
power calculation, the significance  level (or P-value) required in order to reject the 
null hypothesis of no difference in rates of atrophy, between a treated and untreated 
group  needs  to  be  stated.  Finally  the  probability  that  we  would  like  to  have  of
327achieving this level of significance needs to be stated. This is required since because 
of sampling variation, the possibility that the size of the effect observed in the study 
will be smaller than the true effect cannot be ruled out.  Increasing the sample  size 
increases the power of the study and the probability of detecting a significant effect. 
The pathological process  that  underlies  PSP  and  MSA-P  is  greatest  in  subcortical 
regions in the  early stages of the disease.  Although cortical pathology is known to 
occur as both diseases progress (Bigio et al,  1999; Konagaya et al,  1999a; Verny et 
al,  1996a) and the fluid-SPM studies conducted as part of this thesis suggest cortical 
atrophy  may  occur  early  in  PSP,  using  whole  brain  atrophy rates  as  a  marker  of 
progression  in  PSP  and  MSA-P  may  not  be  practical.  Compared  to  Alzheimer’s 
disease,  the  number  of subjects  required  in  each  arm  of a  drug  trial  to  generate 
sufficient power to detect a disease modifying effect may be too large because rates of 
whole brain atrophy are only increased by a small amount in the early stages of the 
disease.  The  cortical  atrophy  that  occurs  in  PSP  is  relatively  focal.  In  PSP  the 
midbrain is known to be markedly affected by the disease process and in MSA the 
pons  and  cerebellum  are  involved  (Ozawa  et  al,  2004)  resulting  in  macroscopic 
atrophy  at  post  mortem.  Fewer  subjects  may  need  to  be  recruited  to  a  study  to 
generate statistical power if regions in which atrophy rates are greatest are used as a 
marker of disease progression in PSP and MSA-P.
The aim of this section of the study was to determine the feasibility of using whole 
brain and a number of hypothesis driven regional atrophy rates in PSP and MSA-P as 
measures of disease progression in clinical trials. The number of individuals needed to 
power a clinical trial of a proposed disease-modifying agent was used as a measure of 
feasibility.
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Whole brain BSI (BBSI) and regional BSIs (Pons, midbrain, frontal quadrants, lateral 
ventricle and third ventricle) measures of atrophy rates were assessed and sample size 
estimates  (power  calculations)  performed  for  potential  disease  modification trials. 
Separate power calculations were made for PSP and for MSA-P.
Data were analyzed using Stata version 8.0 (Stata Corporation, College Station, Tex, 
1997). Sample size requirements were estimated for whole brain and regional rates of 
atrophy expressed as a percentage of initial brain or region volume and annualised to 
give a yearly rate of atrophy. The following standard formula was applied to generate 
sample sizes (Kirkwood and Sterne, 2003) in the PSP and the MSA-P patients:
Sample size = (u + v)2 x (ai2 + O22) / (Hi - M 2 )2
Where:  u  =  1.28  (the  one  sided  percentage  point  of  the  normal  distribution 
corresponding  to  100%-  the  power)  to  provide  90%  power  and  v  =  1.96  (the 
percentage  point  of  the  normal  distribution  corresponding  to  the  two-sided 
significance level) to test at the 5% level; p and o are the mean and SDs of rates of 
atrophy (measured using the whole brain BSI and the regional BSIs);  oj- standard 
deviation in the placebo group (taken as the measured sd from the PSP, MSA or PD 
groups) ;  a2- standard deviation in the treatment group, presumed to equal that of the 
placebo group;  pj-mean BSI of the placebo group (taken as the measured mean BSI 
from the PSP or MSA-P groups);  P2- mean BSI in the treatment group (estimated as 
a 20%, 30%, 40% or 50% reduction in the rate of  atrophy).
The following modifications were included:
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MSA-P  and  healthy  age-matched  controls  was  taken  to  represent  the 
maximum possible  effect  a treatment  could  have  (ie,  100% impact).  If this 
assumption  is  not  made,  the  potential  for  a  therapeutic  effect  may  be 
overestimated. A reduction of 20% in progression was therefore considered to 
be equal to 20% of this difference rather than 20% of the total loss in patients 
with PSP or MSA-P.
2.  The  sample  size  thus  derived  was  increased by  10% to  allow  for losses to 
follow-up.
3.  The sample size was then further increased assuming that about 10% of scan 
pairs could not be used (e.g., too much movement on one of the scans).
Hence the adjustment factor for 20% loss = 100/ (100-20) = 1.25, which approximates 
to  the  number  of individuals  who  after  recruitment  to  the  study  did  not  have  a 
complete imaging dataset. All calculations were performed based on the requirement 
that a trial should have 90% power to detect the specified treatment effect when a 2- 
sided 5% level of significance is used (p<0.05).
14.1.3.  Results
The healthy control group and the PSP and MSA-P groups were closely matched for 
age  and  sex.  The  atrophy  rates  expressed  as  percentage  tissue  lost  per  annum 
(reported in Chapter 9) were used in the power calculations.
The results of the power calculations can be interpreted as follows: For a drug with an 
anticipated ability to reduce the rate of cerebral atrophy in PSP by 20%, over 1  year, to 
have 90% power to detect a drug effect (allowing for atrophy due to normal aging, a 
10% dropout rate, and assuming that 10% of scan pairs are unusable)  1122 patients
330will be needed in each treatment arm. If the drug reduces atrophy rates by 50%, only 
179 patients would be required per treatment arm (table  14.1). Table 14.2 shows the 
number needed to power studies of MSA-P patients for varying rates of atrophy.
Table 14.1  Necessary Sample Size per Treatment Ann Using Group Mean Rates of Atrophy
PSP
%  reduction 
in atrophy 
rate)
Number of individuals required in each arm of the trial
BBSI
Pons
BSI
Midbrain
BSI
Lateral
ventricle
BSI
Third
ventricle
BSI
SCP
BSI
Cereb
BSI
Frontal
BSI
Posterior
Inferior
BSI
"   20 1122 623 412 1559 1516 853 796 1691 1278
1   30 499 277 183 693 674 379 354 752 568
r   40 281 156 103 390 379 213 199 423 319
r  50 179 100 66 249 243 136 127 271 204
[BBSI-brain boundary shift integral, BSI-boundary shift integral, SCP- superior cerebellar peduncle, Cereb- 
!  Cerebellum______________________________________________________________________________________
[Table 14.2 Necessary Sample Size per Treatment Ami Using Group Mean Rates of Atrophy
MSA-P
%  reduction 
in atrophy 
rate)
Number of individuals required in each arm of the trial
BBSI
Pons
BSI
Midbrain
BSI
Lateral
ventricle
BSI
Third
ventricle
BSI
SCP
BSI
Cereb
BSI
Frontal
BSI
Posterior
Inferior
BSI
20 1786 369 1052 2596 2340 4852 290 3620 663
30 794 164 467 1154 1040 2156 129 1609 295
40 447 92 263 649 585 1213 72 905 166
50 281 59 168 415 374 776 46 579 106
BBSI-brain boundary shift integral,  BSI-boundary shift integral, SCP- superior cerebellar peduncle, Cereb- 
C e r e b e l l u m __________ __________________  __________________________________________
Calculations based on regional rather than whole brain rates of atrophy confirm that 
fewer subjects would be required to power a trial of a disease modifying drug.
14.2.  The effect of scan interval on variance
14.2.1.  Introduction
The  variance  in  the  calculated  atrophy  rates  arises  mainly  as  a  consequence  of 
measurement  error  and  true  inter-individual  variability  in  atrophy rates  in patients 
with the  same  disease.  This  variability  in  atrophy  rates  is  one  of the  factors that
331influences the  number  of patients required to power a trial of a disease-modifying 
drug.  If MRI  is  to  be  applied  as  a  method  of monitoring  disease progression and 
quantifying  the  effect  of disease  modifying  drugs,  then determining  how the  scan 
interval influences variability is important.
14.2.2. Methods
In order to investigate whether the calculated rate of atrophy and the variance in the 
measured  atrophy  rates  is  significantly  influenced  by  the  scan  interval,  the  PSP 
patients were divided into those with a scan interval below the median (50th centile) of 
300 days and those above. Mean annual percentage atrophy rates calculated using the 
BSI were compared, using a t-test for normally distributed data and a Kruskall Wallis 
test  for  non-parametric  data.  A  Pitman’s  test  was  used  to  determine  whether 
increasing  the  scan  interval  significantly  improved  (i.e.  reduced)  the  variance  in 
atrophy rates.
14.2.3. Results
Nine PSP patients had MRI  scans 300 days or more apart and 8 had scans 299  or 
fewer days  apart.  The mean age and disease duration in these two  groups was not 
significantly different and the mean annualised percentage volume loss in the whole 
brain, midbrain, pons, cerebellum, SCP, frontal and posterior inferior regions and the 
percentage expansion in the ventricles were no  different between the groups (table 
14.3).
However the results of Pitman’s test of the equality of variance  in the two  groups 
demonstrates that the variance in third ventricle  and lateral ventricle measurements 
was  significantly  greater  in the  patients with a  shorter  scan  interval.  There  was  a 
similar but non-significant trend towards a greater variance in measured midbrain and 
pontine atrophy rates in patients with a shorter scan interval (table 14.3).
332Table 14.3 Comparing mean (SD) % atrophy/year, in PSP with different scan intervals.
PSP <300d PSP 300d+ P value Pitman’s test
Brain 1.2(1.3) 11(0.8) 0.8 0.1
MB 2.5(19) 1.9(10) 0.4 0.06
Pons 1.8(16) 13(0.9) 0.8 0.07
Cerebellum 1.5(12) 1.3(11) 0.7 0.5
SCP 3.1(3.9) 3.8(4.2) 0.7 0.6
Frontal 1.5(15) 0.9(10) 0.3 0.2
PI 11(1.2) 0.9(0.8) 0.6 0.1
LV 11.5(13.7) 7.9(4.2) 0.6 0.002
3V 7.3(8.3) 5.1(2.9) 0.9 0.004
PSP <300d- PSP patients with scan interval less than 300 days,  PSP 300d+ - PSP 
patients with scan interval of 300 days or more.
These results suggest that while a shorter scan interval may mean less drop-out, the 
number of patients required to  power a trial  is  likely to  be  greater because  of the 
increased variance in measured atrophy rates.
14.3.  Overall Conclusions
The calculations presented above confirm that measuring regional rather than whole 
brain rates of atrophy allows for recruitment of fewer patients to clinical phase 2/3 
drug trials in PSP.  Recruiting several hundred subjects for each arm of a drug trial 
using whole brain atrophy rate as a surrogate marker would require a large,  multi- 
centre international trial. This would be more expensive to run and to evaluate than a 
study utilising regional rates of atrophy that might only need a half or even one third 
of the patient numbers in each arm to power the trial.
333Recruiting more subjects than necessary to power a study is not only more expensive, 
but exposes more patients to the risks and potential side effects (however m inim al) of 
a novel therapy.
In PSP and MSA-P, sample size calculations based on brainstem atrophy rates are of 
the order of three to five times smaller than those based on whole brain atrophy rates. 
In PSP, sample sizes were lowest when using midbrain atrophy rates (183 patients per 
study  arm to  detect  a  30%  treatment  effect).  In MSA-P,  Cerebellar  atrophy rates 
generated the smallest required sample sizes (129 patients per study arm to detect a 
30% treatment effect). This number takes into account patient drop out and problems 
with scan quality. Even fewer study numbers would be required if 100% attendance 
could  be  achieved  or  if the  drug  effect  were  greater.  This  confirms  that  regional 
atrophy  rates  rather  than  whole  brain  atrophy  rates  are  more  feasible  markers  of 
disease progression in PSP and MSA-P.
The calculations above take into account subject attrition and technical problems with 
scan acquisition, yet still indicate a potentially realistic sample size given the cost of 
including  serial  MRI  in  a  large  clinical  trial.  The  therapeutic effects  used  in  the 
examples given ranged  from 20% to  50%.  Less than a 20% disease-slowing effect 
would be difficult to show and might not be considered clinically relevant. A disease- 
slowing effect of more than 50% is unlikely to need a surrogate marker of progression 
because the clinical effects would be striking and obvious.
The factors that are important in determining sample size are: Firstly, the difference 
between  PSP/MSA-P  and  control  rates  of atrophy  for  the  structure measured;  the 
maximum treatment effect that could be expected is to reduce the rate of loss to that of 
age-matched controls (100% disease slowing); the second factor is the heterogeneity
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MSA group. This variability is the result of genuine differences between individuals, 
as  well  as  the  measurement  error  of the  technique.  The  more  homogeneous,  the 
measured rate  of atrophy, the  easier  it  is  to  detect  a  small treatment  change.  The 
results in Chapter 14.2.3 suggest that a short scan interval will increase the variability 
of measured atrophy rates and is likely to increase the number of subjects required to 
generate statistical power.
Techniques that measure brain substructures may be subject to greater measurement 
error because  of the  difficulty in manually  segmenting  (outlining)  these  structures. 
The use of manual methods of segmentation and volume measurement introduces the 
issue of inter-observer and intra-observer variability. Measurement errors are likely to 
be greater for smaller and less easily defined neuroanatomical structures, particularly 
if an arbitrary cut-off to the structure is used (as in the case of the SCP in this study). 
In these structures, while the difference in atrophy rates between diseased patients and 
controls is great, the variability in the measurement  is also  high, meaning  it is not 
practical to use such regions as markers of disease progression.
Brain substructures  may  have  variable  rates  of loss  as the  disease progresses.  For 
example, it may be that while the superior cerebellar peduncle atrophies early in the 
course of PSP, it may not lose tissue as rapidly in the later stages of the disease. This 
is also seen in AD where Jack et al (Jack, Jr. et al., 1997) found that in very mild AD, 
the mean hippocampal volume was already significantly smaller than that of controls. 
More  severely  affected  patients  had  a  mean  hippocampal  volume  that  was  only 
slightly smaller than that of the very mildly affected patients.
335PSP and MSA-P are heterogeneous neurodegenerative conditions, and rates of disease 
progression between subjects are variable.  Using  subjects as their own controls for 
rates of atrophy might allow for this variability. Subjects would need to have a 3- to 6- 
month placebo run-in with 2 MRI scans to establish their individual rate of atrophy. A 
further MRI  scan would  then be  performed after  9  to  12  months  on either  active 
treatment or placebo, with the outcome assessed by comparison with their baseline 
rate of atrophy. Unfortunately because of the increased number of scans required, the 
cost of running such a study would be greater and drop out rates might be higher than 
the predicted 10%.
Regional  atrophy rates  have  been  studied  in other  degenerative  diseases  but  most 
commonly  in  AD.  Ventricular  atrophy  rates  show  greater  separation  between 
cognitively normal  subjects and AD patients than whole brain measures of volume 
change (Gunter et al.,  2003) and effect size and power calculations have suggested 
that in AD, entorhinal cortex and hippocampal measurements may be more sensitive 
than ventricular or whole brain BSI for detecting progression and the potential effects 
of disease modifying agents (Ezekiel et a l, 2004).
In PSP and  MSA-P,  both less common diseases than AD, reducing the number of 
patients needed to power a drug trial is important as the calculated number required 
using whole brain atrophy rates is prohibitively high.
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Neurodegenerative  diseases  that  result  in  bradykinetic  rigid  syndromes  can  be 
difficult to distinguish on clinical grounds alone. A non-invasive test that supports the 
diagnosis of PSP would have considerable clinical value. The advent of symptomatic 
therapies for PSP and in time, disease modifying drugs means that accurate diagnosis 
in the early stages of the disease will become even more important.
•  Identifying an atrophic superior cerebellar peduncle (SCP) on cross sectional 
MRI supports a diagnosis of PSP over MSA-P or PD, and considering this as 
well  as  other  regions  together  rather  than  independently  increases  its 
diagnostic usefulness as it is the pattern of loss rather than the appearance of a 
single structure of interest that is important.
•  Serial  volumetric  MRI  analysis  is  a  feasible  method of monitoring  disease 
progression and would allow the effect of a putative drug that slowed atrophy 
rates by 20% to be detected.
The  conclusions  related  to  the  specific  aims  of the  study  detailed  in the  opening 
section are outlined below.
MRI as an aid to diagnosis in PSP
The clinical utility of region of interest volume measurements in discriminating PSP 
from degenerative diseases that may present with a similar phenotype is supportive of 
the  diagnosis  when  the  clinical  diagnostic  criteria  are  fulfilled  and  may  help  to 
discriminate cases that cannot clearly be categorised on the clinical diagnostic criteria 
alone. Because volumetric analysis is time consuming, the direct clinical application 
of this technique may be limited, however the results of this thesis include new data, 
which can be applied in this context.
337•  The superior cerebellar peduncle (SCP)  can be clearly visualised using MR 
imaging  and  atrophy  in  this  region  is  highly  specific  for  PSP  (chapter  6). 
Serial imaging studies also demonstrate that the region is clearly more affected 
by progressive atrophy in PSP than in MSA-P or PD. An important conclusion 
is that the clinician should look at the SCP when seeking imaging features to 
support the clinical diagnosis of PSP.
•  Midbrain volume  alone  is not a reliable discriminator of PSP  from MSA-P 
(specificity  of 33%)  and  statistical  analysis  of the  discriminating  ability  of 
various regions of atrophy confirms that discrimination of PSP from MSA-P is 
better  supported  by  considering  a  collection  of imaging  features  together 
rather than  independently.  In all  likelihood this  is,  subconsciously,  what  an 
experienced neuroradiologist does when interpreting an MRI scan. This study 
also  identifies  the  regions  that  when  assessed  together  may  best  allow 
identification of patients with PSP.
Diffusion weighted  imaging  provides  information regarding  tissue  integrity  as  the 
apparent  diffusion  coefficient  (ADC)  is  altered  by  any  pathological  process  that 
affects the normal tissue architecture.
•  Cross  sectional  diffusion  weighted  MRI  demonstrated  that  mean  regional 
apparent diffusion coefficients in the middle cerebellar peduncle were able to 
differentiate MSA-P  from PSP,  PD and healthy controls.  This  suggests that 
disruption  to  the  normal  tissue  architecture  as  a  consequence  of  the 
pathological process can be detected in life using MRI.  Similarly DWI was 
able  to  demonstrate  involvement  of the  frontal  white  matter  in  PSP.  The 
results of serial DWI analysis suggest that over the relatively short interval in
338this study (<1  year), disease progression cannot be monitored on the basis of 
change in regional ADC values.
DWI sequences are rapidly acquired and may still have utility in a cohort of patients 
who might not tolerate longer scan sequences. Changes to normal tissue architecture 
may be detected using DWI earlier than marked volume loss and allow discrimination 
of PSP from MSA-P earlier in the disease course. Further studies of DWI and ADC 
values in these diseases in their earliest stages would be interesting.
Novel image analysis techniques
The  region  of interest  studies  conducted,  as  part  of this  research,  required  that 
hypothesis driven a priori assumptions regarding the regions to  study needed to be 
made.
•  The  results  of unbiased  assessments  of  cross  sectional  volumetric  scans 
(VBM) confirm that these a priori assumptions were reasonable, with the most 
significant regions of volume difference being identified in the brainstem in 
PSP  and  MSA-P.  The  VBM  studies  also  identified  the  middle  cerebellar 
peduncle; a region not studied using manual segmentation, as discriminating 
MSA-P. This led to assessment of this region using diffusion weighted MRI.
•  Fluid-SPM  analysis,  a  way  of  assessing  atrophy  rates  with  no  a  priori 
assumptions regarding where that atrophy occurs,  demonstrates that atrophy 
rates  in  PSP  are  greatest  in  the  upper  brainstem.  Cortical  atrophy  occurs 
predominantly  in  anterior  structures  and  occurs  early  in  the  course  of the 
disease, contributing to the pattern of cognitive impairment typical in PSP.
•  Fluid-SPM analysis also  suggests that the frontal cortical atrophy may occur 
earlier in the disease course, however it may simply be that those patients with
339a  longer  disease  duration  have  slower  rates  of brain  atrophy  and  clinical 
progression.
•  Those PSP patients with more  severe gaze palsy, have differing patterns of 
ongoing atrophy suggesting more severe involvement of the cortical regions 
responsible  for the generation of saccadic eye movements in addition to the 
brainstem regions known to  be  affected.  This  has  important implications  if 
serial MRI is to be considered as a tool for monitoring progression in PSP, as 
the rate and region of atrophy may be heterogeneous within the disease.
MRI derived brain atrophy rates
•  The results presented in chapter 9 of this thesis confirm that applying the brain 
boundary shift integral (BBSI) to assess brain volume change over time in PSP 
is a valid method of determining whole brain atrophy rates, and shows that 
PSP and MSA-P have similar rates of whole brain atrophy (1.2% year'1   and 
1.0% year'1 ), approximately 2-3 times that seen in PD (0.6% year'l) or healthy 
age matched controls (0.4% year"1 ).
However, according to power calculations, an impractical number of patients would 
be required  in order to power trials of a disease  modifying drug with whole  brain 
atrophy rates as a marker of disease progression.
Regional brain atrophy rates as markers of progression
Manual  segmentation  techniques  outlined  in  this  study  demonstrate  that  PSP  and 
MSA-P have patterns of atrophy that distinguish them from PD, healthy controls and 
from each other.
•  Comparing manually segmented regional volumes at two time points confirms 
that regional atrophy rates are disproportionate to whole brain atrophy.
340•  Applying the boundary shift integral (BSI) to these local regions (chapter 9) 
reduces measurement error and provides a more accurate operator dependent 
and less time-consuming method of calculating regional atrophy rates.
•  Assessing  the  utility  and  feasibility  of these  measurements  as  markers  of 
disease progression with a power calculation confirms that regional rather than 
whole brain atrophy rates, measured using the BSI, are more practical markers 
of disease progression as they require fewer study numbers (recruited patients) 
to generate statistical power in a trial of a putative disease modifying drug that 
slows atrophy rates.
•  The shorter the scan interval, the greater the variance  in measurements and 
this  is  likely to  increase  the number of subjects  required to power a study. 
Increasing the interval to two years would reduce the variance considerably, 
possibly without a prohibitive increase in patient drop out.
Do regional brain volumes and atrophy rates have a clinical correlate?
The results outlined in Chapters 11 and 12 of this thesis identify associations between 
midbrain volume and clinical motor deficit, in keeping with the results of prior studies 
(Groschel et al). Additionally, SCP volume in the PSP patients was associated with 
motor deficit scored on the Hoehn and Yahr scale and with falls on the UPDRS II 
sub-section. Frontal volume was also related to neuropsychology test scores thought 
to be specific to that brain region, for example.
Far fewer associations were detected in the MSA-P patients but importantly; motor 
deficit was associated with pontine rather than midbrain volume.
•  Progression  in  motor  deficit  is  associated  with  a  greater  rate  of midbrain 
atrophy in PSP and ponto-cerebellar atrophy in MSA-P.
341•  There were also associations between greater rates of frontal atrophy in PSP 
and worsening performance on neuropsychological tests of frontal cognitive 
function, although change in the FAB score was more strongly associated with 
midbrain atrophy rates, suggesting that progression in the severity of cognitive 
impairment  occurs  as  a  consequence  of frontal  cortical  atrophy  as  well  as 
subcortical pathology.
The  associations  described  in  Chapters  11  and  12  are  likely  to  be  limited  by  the 
number of patients  studied,  particularly  in the  MSA-P  group.  A  larger prospective 
study of these  patients  rather than PSP patients would  help to  clarify the  clinico- 
radiological associations of MSA-P.
Other points
Several important conclusions can be drawn from the preliminary studies outlined in 
chapters 3 and 5 in this thesis.
•  PSP  appears  to  be  a  heterogeneous  disease.  The  analysis  of  clinical 
information collected from post mortem cases of PSP in a regional brain bank 
suggests  that  at  least  two  distinct  clinical  phenotypes  exist.  The  classical 
presentation  with  falls  and  a  supranuclear  gaze  palsy,  or  Richardson’s 
syndrome, and the more Parkinsonian variant, known as PSP-P.
It is important that these phenotypes have been identified: firstly as it means that cases 
of PSP previously labelled as atypical Parkinsonism (because they failed to fulfil the 
diagnostic criteria),  may  be  identified and the true prevalence of PSP revised;  and 
secondly  because  the  two  phenotypes  have  differing  rates  of  progression  and 
prognosis and may have differences in the underlying molecular pathological disease
342mechanisms influencing the rate of progression. These factors will have implications 
in the interpretation of trials of disease modifying drugs. If MRI is used as a marker of 
disease progression,  the  increased  variability  in the  measured  atrophy rates would 
increase the numbers required to power a clinical trial or even mean that a real disease 
modifying  effect  is  overlooked,  if PSP  patients  are  not  adequately  classified  with 
appropriate matching of treatment and placebo arms.
While the  results  of fluid-SPM  studies  in this thesis  suggest that in PSP there  are 
differences in atrophy patterns between PSP patients with a severe and a less severe 
gaze palsy and with differing disease durations,  further imaging research would be 
required to truly determine whether MRI derived rates of whole brain and regional 
atrophy differ between the two PSP phenotypes.
•  The results of analysis of the FAB score in PSP, MSA-P and PD suggest that 
in addition to  MRI  features that  support the  clinical diagnosis  of PSP,  the 
clinician can apply a simple and repeatable bedside test of cognitive function 
that  has  been  validated  and  quantified  in  PSP  as  well  as  other 
neurodegenerative diseases.
As such, the FAB correlates well with frontal tests of cognitive domains known to be 
affected  in PSP,  yet  can be  completed  in  a  few  minutes,  providing  a quantitative 
marker  of the  frontal  cognitive  impairment  in  an  individual with PSP,  helping  to 
discriminate the more severe cognitive deficit of PSP from that of MSA-P and PD.
Comparison of the results of semi-quantitative pathological analysis with the results 
of fluid registered serial MRI in a single case of PSP (chapter 3.5.2) suggests that the
343atrophy pattern detected during  life using this method of MRI analysis has a clear 
pathological basis.
•  Fluid  registered  MRI  demonstrates  a  greater  rate  of atrophy  in  the  motor 
cortex compared to the  anterior frontal cortex with subsequent  detection of 
more numerous tau positive structures, including glial inclusions and neuropil 
threads as well as neuronal loss. This preliminary study helps to confirm that 
regional  atrophy  detected  using  MRI  arises  as  a  consequence  of  direct 
pathological involvement of that region.
Finally, the results of the imaging studies suggest that PSP, MSA-P and PD patients 
with  moderate  to  severe  disease  can  tolerate  serial  MRI  scans.  The  entire  scan 
acquisition time for this study was under 20 minutes.
•  A  combination  of careful  explanation  of the  MRI  procedure,  along  with 
experienced and helpful staff ensuring patient comfort, meant that over 80% of 
patients  with  what  are  considerably  debilitating  neurological  disorders, 
profoundly affecting mobility, were able to complete the MRI protocol.
Factors which seemed to help maintain a high retention rate included: rapport with the 
patient and their carer, along with an explanation regarding the purpose of the study; 
an efficient means of transport to the scan appointment; performing all scans on the 
same  scanner  in  a  department  with  staff  who  have  experience  of patients  with 
neurodegenerative  disease  and;  using  a  scan protocol that  is  as  short  as  possible. 
These  simple  factors,  doubtless  help to  maintain  minimal  drop out  in any clinical 
study using MRI.
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•  Considering regional atrophy patterns together rather than independently on 
cross-sectional MRI may help to discriminate PSP more accurately during life.
•  Marked atrophy of both the midbrain and the superior cerebellar peduncle are 
characteristic MRI features of PSP.
•  The  superior  cerebellar peduncle  should  be  visualised  in  axial  and  coronal 
planes  and  the  midbrain  assessed  in  the  mid-sagittal  plane.  Considered 
together, these two regions may best identify PSP using MRI scans.
•  Serial imaging showing excess atrophy rates above that expected for age may
prove to be a useful means of detecting early neurodegeneration and patterns
of regional atrophy which may help to differentiate degenerative diseases that 
present in a similar fashion.
•  Regional atrophy rates derived from serial MRI scans rather than whole brain 
atrophy rates better discriminate PSP and MSA-P from PD, healthy controls 
and each other.
•  These regional atrophy rates allow disease progression,  as defined by tissue 
loss, to be accurately measured.
•  Regional  atrophy  rates  have  clinically  meaningful  correlates  and  as  such
provide  a  feasible  means  of monitoring  the  effects  of a  putative  disease-
modifying drug.
•  Definitive validation of MRI derived atrophy rates as a surrogate marker of 
progression  can  only  occur  when  a  confirmed  disease  modifying  agent 
becomes available.
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Patient information sheet
A prospective clinicoradiological study in Progressive Supranuclear Palsy 
(PSP) using serial MRI scanning with registration.
(MRI scanning of the brain, over time in PSP)
PATIENT INFORMATION SHEET.
You are being invited to take part in a research study. Before you decide it is important you 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully, before you decide whether to take part.
What is the purpose of the study?
1.  To help further understand the natural history of PSP.
2.  To help develop a non invasive and safe diagnostic aid in the form of MRI scanning.
3.  To help develop MRI as an aid to quantifying the results of therapeutic trials in PSP.
Why have I been chosen?
We have asked you to take part as you may have either PSP, multi system atrophy (MSA), 
Corticobasal degeneration (CBD) or Parkinson’s disease (PD).
PSP is often misdiagnosed in its early stages or if the onset of the disease pattern is atypical. 
For this reason we are including in the study patients with conditions that PSP is sometimes 
mistaken for.
We hope to include at least 25 patients with PSP and 25 patients with either MSA or PD.
Do I have to take part?
It is up to you whether you decide to or not. If you decide to take part, you will be asked to 
sign a consent form. You would be free to withdraw from the study at any point should you so 
choose. If you decide not to take part or to withdraw at a future date, the care you receive will 
not be affected in any way.
What happens if I agree to take part?
You will be involved in the study for one year.
You will have a clinical examination by a neurologist at the time of entry into the study.
At this time, an MRI scan of your brain will be arranged and undertaken.
Magnetic Resonance Imaging (MRI) is a painless and safe technique, which can obtain 
detailed pictures of the brain. As the name implies, it uses magnetic fields to generate the 
pictures and unlike X-ray techniques there is no ionising radiation used. As long as people 
with any magnetic metal implants are excluded (such as pacemakers) there are no known 
risks.
The clinical assessment will include a detailed neuropsychological examination as well as a 
physical examination. The visit will take up most of the day including breaks for lunch. 
Approximately one year later you will be seen in clinic again and a second MRI scan 
undertaken. We are happy to refund your travel expenses for these visits.
We will not be prescribing any medications as part of this trial.
You will be asked to fill out a questionnaire prior to scanning as cardiac pacemakers, 
containing magnetic metal, certain types of implants and artificial joints (not all types) will 
mean that MRI scanning cannot be undertaken.
We will inform you of the results of your scan should you so desire and if any unexpected 
abnormalities are found we would wish to notify you and your GP.
350Are there any risks?
We do not envisage any risks to you in taking part in this study.
In the unlikely event of an unexpected, significant abnormality being found on the MRI brain 
scan, we would desire permission to notify yourself and your GP.
Are there any benefits?
Being involved in the study will not specifically help you as an individual. The results will 
hopefully play a part in helping diagnose and treat patients with PSP in the future.
Any information collected in this study will be kept strictly confidential
The information collected will be analysed over a period of approximately a year, leading to
publication of the results. You will not be identified in any of the published results.
Who is funding the research?
The PSP association (Europe) is funding the costs of scanning and of the salary for one 
research assistant.
What if something goes wrong?
In the unlikely event of there being a problem with your participation and you wished to 
complain, the normal National Health Service (NHS) complaints mechanisms are available to 
you.
Other Points
The information obtained (clinical details regarding your illness, date of birth, name and 
address and the imaging data) will be stored on a computer and the study protocol has been 
reviewed by the National Hospital for Neurology and Neurosurgery and the Institute of 
Neurology Joint research Ethics Committee.
If you would like to take part then please sign and date the enclosed consent form and return 
it in the envelope provided. Alternatively contact Dr D. Paviour at the number or email 
address below.
Once entered into the study, a date for assessment and scanning will we allocated. If you 
desire, we will reimburse your travel costs.
Contact information  Mon-Fri 9am-5pm
Dr Dominic Paviour 
Other contacts
PSP Association (Europe)  The Old Rectory Wappenham
www.pspeur.org Tel   Fax 
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Version 1.3  - 12* May 2004  INFORMATION ON BRAIN DONATION
We appreciate your interest in becoming a brain donor. Although becoming a 
donor will not benefit you directly, it will contribute to the advancement of 
medical knowledge of brain disorders.
Please take time to read the following information carefully and discuss it with 
your family, friends or general practitioner if you wish.
An introduction to the Queen Square Brain Bank for Neurological 
Disorders
The Institute of Neurology and the National Hospital for Neurology and 
Neurosurgery have an international reputation as a centre of excellence for 
research into and treatment of neurological disorders.  The Queen Square 
Brain Bank for Neurological Disorders (QSBB) has established a unique brain 
collection, which is used to study the effects of disease and to support 
research into disorders such as Parkinson’s disease (PD), progressive 
supranuclear palsy (PSP), multiple system atrophy (MSA), dementia and 
dystonia. It has made a significant contribution to our understanding of the 
causes of neurological disease and in developing new treatments.
A brain donation is a gift.  Because it is a very complicated organ, the whole 
brain is needed for diagnosis and research.  In special cases we also examine 
the spinal cord, if it is thought to contribute to the disease process.  Some 
tissue samples are preserved in fixative for diagnosis. Other tissue is frozen 
and kept at a low temperature so that it can be used for research over long 
periods of time.  The research usually begins by examining the tissue under a 
microscope to identify any disease processes that have affected the brain.
We then use specialist techniques to investigate possible abnormalities in 
brain and nerve cell proteins and in blood vessels in the brain.  We may also 
analyse the DNA (genetic material) to look for abnormalities that may be 
specific to some diseases.
Brains are stored in a locked facility where only certain staff have access. To 
ensure all information remains confidential, the tissue is given a unique code 
number and records are held securely.  To ensure anonymity the same 
unique code numbers are also used on photographs that may be taken of 
tissue specimens and microscopic slides.
Nervous system tissue is supplied to researchers in other universities both in 
the UK and world-wide.  We also carry out some research with the support of 
industry.  This is in line with the Institute of Neurology’s policy of encouraging 
research that will lead to new therapies.  In these instances intellectual 
property agreements are set up which means neither the scientists nor the 
donor’s families gain a financial advantage.
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The importance of correct diagnosis
Further information about many neurological disorders can only be gained by 
a detailed post-mortem and microscopic examination of the brain.  For 
research to be precise a diagnosis made in life must be confirmed by 
neuropathological evaluation.
Results of research, which rely on collections of data from a large number of 
cases, are published in scientific journals and are not available on an 
individual basis.  The anonymity of individual cases will be preserved in the 
research procedure and subsequent publications.
We would be happy to provide further information on the diagnosis and any 
other information available after the post-mortem, and this would be provided 
through the consultant physician in charge or the GP upon request by the next 
of kin. Relatives of the donor often gain comfort in knowing the nature of their 
loved one’s illness. With development of scientific knowledge and 
improvements in neuropathological diagnosis further significant information 
relating to individual cases may become available in the future. At the request 
of the next of kin such information will be provided either by trained QSBB 
staff or appropriate medical or nursing personnel.
Brain donation by people with no neurological disease is of equal importance, 
providing essential ‘control’ tissue for comparison.  Without this important gift 
research cannot go ahead.
How to become a brain donor
You should be over 18 years of age and a resident in the UK.  You should 
discuss with your family your wish to donate your brain and if you wish, your 
spinal cord, to the QSBB following your death.  Please complete and sign the 
enclosed  “Declaration of Intent to Donate” form witnessed by your next of kin 
and send it to the Queen Square Brain Bank, Institute of Neurology, 
.  If you are unable to complete this form 
yourself it is acceptable for a relative or appointed representative to do this for 
you.
Once your declaration form has been received by the QSBB you will be 
registered as a donor.  We will send you a letter of welcome and a donor card, 
which you should carry at all times. You will also receive a self-assessment 
form, requesting information on your health and lifestyle.  Potential donors 
with a neurological condition will be asked to complete this form on a yearly 
basis.  This information will be stored on our computerised database so that 
essential clinical information is available to the pathologist.
The identity and the data collected about all registered donors remain strictly 
confidential.
353At the time of your death your next of kin or appointed representative will be 
required to sign a consent form giving permission for the brain donation to 
take place.
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Actions to be taken following the death of a donor
Following the death of a donor the QSBB must be contacted as soon as 
possible.  Once informed of a donor’s death by the next of kin, the QSBB will 
arrange for the donor’s body to be transported to the nearest hospital where 
the removal of the brain and, if agreed, the spinal cord, can be performed. 
Before a post-mortem examination can be performed a QSBB consent form 
must be signed. The hospital at which the post-mortem examination is 
performed may require an additional local post-mortem consent form to be 
signed. Only the brain and the spinal cord are transferred to the QSBB.  The 
donor’s body can then be returned to the family’s chosen funeral director and 
the usual funeral arrangements can then proceed.  As brain donation does not 
require removal of the eyes or lead to disfigurement of the face, it does not 
prevent open casket or other traditional funeral arrangements.  Removal of 
the spinal cord results in a long scar on either the front or back of the body, 
but this is not visible once the body has been prepared for the funeral. 
However, in view of this some donors may decide not to donate the spinal 
cord. All costs directly related to the removal of the brain will be met by the 
QSBB. Funeral costs must be met by the family.
For legal reasons some deaths require a post-mortem examination to be 
performed on behalf of HM Coroner.  In these circumstances it is often still 
possible to arrange for the transfer and examination of the brain at the QSBB. 
This would require discussion between HM Coroner, QSBB medical staff and 
the next of kin at the time of death.
A letter to the next of kin will acknowledge receipt of the donor’s brain. 
Important notes
Even if registration was not completed during life, next-of-kin or appointed 
representative can still arrange for brain donation following death (in the 
knowledge that the donor was or would had been in agreement).
If any of your details change, for example your address, your general 
practitioner, diagnosis, etc. please notify the QSBB so that our records can be 
amended.
As time passes it may be necessary for you to alert new people to the 
bequest or remind others who may have forgotten.
Signing the declaration of intent form does not commit you to joining the 
scheme.  If you change your mind in the future, you can withdraw your 
permission at any time.
354DECLARATION OF INTENT TO DONATE MY BRAIN TO THE
QUEEN SQUARE BRAIN BANK FOR NEUROLOGICAL 
DISORDERS
Version 1.2-1* September 2003
Please initial appropriate
boxes
YES  NO
1)  I have read the Information Sheet, dated,  12th  May 2004-------------------   ------
and have been given a copy to keep.  I have had the
opportunity to ask questions about brain donation and 
understand why the research is being undertaken.
2)  I agree to donate my whole brain for confirmation of clinical  yes  no 
diagnosis and for research.  I understand how the brain will
be donated and the tissue retained.  I understand that giving  ____  ___
my brain for this research is voluntary and that I am free to 
withdraw my consent at any time without giving a reason.
YES  NO
3)  I agree to donate my spinal cord, if it is necessary, to aid
confirmation of clinical diagnosis and for research purposes.  ____  ___
4)  I agree that the brain will be retained and used for:
YES
NO
a)  medical research at the Institute of Neurology
YES  NO
b)  medical and scientific education
YES
NO
c) the development of diagnostic tests and drugs
with commercial organisations  -------  ------
YES  NO
d) research with collaborators at other academic
departments in the UK and worldwide.  -------  ------
YES  NO
e) genetic (DNA) research purposes
DECLARA TION OF INTENT TO DONA TE BRAIN TO THE QUEEN SQUARE BRAIN BANK FOR NEUROLOGICAL 
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3555)  I agree that members of the research team may look 
at my medical notes (All information will remain 
confidential)
6)  I agree that my details can be stored on a database 
in accordance with the Data Protection Act 1998.
7)  I understand that the results of genetic and other 
research will not be available on an individual basis.
If and  when such results are published they will be 
anonymised.
8)  I agree that all decisions regarding the future use of my 
donated tissue will be made by members of staff of the 
Institute of Neurology, who will organise the lawful and 
respectful disposal of any remaining tissue after research 
studies are completed, in accordance with the guidelines 
of the Royal College of Pathologists.
YES NO
YES NO
YES NO
Your Name (CAPITALS) Your Signature Date
Witness’s Name Witness’s Signature Date
If you are unable to complete this form yourself, it is acceptable for a relative or appointed 
representative to do this for you.
Please complete this form and return in the enclosed 
envelope
356Mini mental state examination
ORIENTATION
Maximum Score 
Score
5  (  )  What is the (year)(season)(date)(day)(month)?
5  (  )  Where are we: (state)(county)(town)(hospital)(floor)?
REGISTRATION
3  (  )  Name 3 objects: 1  second to say each. Then ask the patient  all 3
after you have said them. Give 1 point for each correct answer. Then repeat them 
until he learns all 3. Count trials and record.
Trials_____
ATTENTION AND CALCULATION
5  (  )  Serial 7’s, 1point for each correct. Stop after 5 answers.
Alternatively, spell OworldO backwards.
RECALL
3  (  )  Ask for the 3 objects repeated above. One point for each correct
answer
LANGUAGE
9  (  )  Identify and name a pencil and a watch (2 points)
Repeat the following “No ifs, ands, or buts” (1 point)
Follow a 3-stage command.
“Take a paper in your right hand, fold it in half, and put it on the 
floor” (3 points)
Read and obey the following:
Close your eyes (1 point)
Write a sentence (1 point)
Copy design (angles must intersect properly as shown)(l point)
Total Score
INSTRUCTIONS FOR ADMINISTRATION 
ORIENTATION
(1)  Ask for the date. Then ask specifically for parts omitted, e.g., “can you tell 
me what season it is?” One point for each correct.
357(2)  Ask in turn “Can you tell me the name of this hospital?” (town, county, etc.) 
One point for each correct.
REGISTRATION
Ask the patient if you may test his memory. Then say the names of 3 unrelated 
objects, clearly and slowly, about 1  second for each. After you have said all 3, 
ask him to repeat them. This first repetition determines his score (0-3) but keep 
saying them until he can repeat all 3, up to 6 trials. If he does not eventually 
learn all 3, recall cannot be meaningfully tested.
ATTENTION AND CALCULATION
Ask the patient to begin with 100 and count backwards by 7. Stop after 5 
subtractions (93, 86, 79, 72, 65). Score the total number of correct answers.
If the patient cannot or will not perform this task, ask him to spell the word 
“world’  backwards. The score is the number of letters in correct order. E.g., 
dirow = 5, dlorw = 3
RECALL
Ask the patient if he can recall the 3 words you previously asked him to 
remember. Score 0-3.
LANGUAGE
Naming: Show the patient a wrist watch and ask him what it is. Repeat for 
pencil. Score 0-2.
Repetition: Ask the patient to repeat the sentence after you. Allow only one trial. 
Score 0 or 1.
Three-stage command: Give the patient a piece of plain blank paper and repeat 
the command. Score 1  point for each part correctly executed.
Reading: On a blank piece of paper, print the sentence “close your eyes” in 
letters large enough for the patient to see clearly. Ask him to read it and do what 
it says. Score 1  point only if he actually closes his eyes.
Writing: Give the patient a blank piece of paper and ask him to write a sentence 
for you. Do not dictate a sentence; it is to be written spontaneously. It must 
contain a subject and verb and be sensible. Correct grammar and punctuation are 
not necessary.
Copying: On a clean piece of paper, draw intersecting pentagons, each side about 
1 inch and ask him to copy it exactly as it is. All 10 angles must be present and 2 
must intersect to score 1  point. Tremor and rotation are ignored.
Estimate the patient’s level of sensorium along a continuum, from alert on the 
left to coma on the right.
CLOSE YOUR EYES
(Folstein et al.,  1975)
358Unified Parkinson’s Disease Rating Scale (UPDRS)
I.  Mentation, Behavior and Mood
1.  Intellectual Impairment:
0—None.
1—Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.
2—Moderate memory loss, with disorientation and moderate difficulty handling complex 
problems. Mild but definite impairment of function at home with need of occasional 
prompting.
3—Severe memory loss with disorientation for time and often to place. Severe impairment in 
handling problems.
4—Severe memory loss with orientation preserved to person only. Unable to make judgments or 
solve problems. Requires much help with personal care. Cannot be left alone at all.
2.  Thought Disorder: (Due to dementia or drug intoxication)
0—None.
1—Vivid dreaming.
2—“Benign” hallucinations with insight retained.
3—Occasional to frequent hallucinations or delusions; without insight; could interfere with daily 
activities.
4—Persistent hallucinations, delusions, or florid psychosis. Not able to care for self.
3.  Depression:
0—Not present.
1—Periods of sadness or guilt greater than normal, never sustained for day or weeks.
2—Sustained depression (1 week or more).
3—Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of 
interest).
4—Sustained depression with vegetative symptoms and suicidal thoughts or intent
4.  Motivation/Initiative:
0—Normal.
1—Less assertive than usual; more passive.
2—Loss of initiative or disinterest in elective (non-routine) activities.
3—Loss of initiative or disinterest in day to day (routine) activities.
4—Withdrawn, complete loss of motivation.
II.  Activities of Daily Living (Determine for “on/off”)
5.  Speech:
0—Normal.
1—Mildly affected. No difficulty being understood.
2—Moderately affected. Sometimes asked to repeat statements.
3—Severely affected. Frequently asked to repeat statements.
4—Unintelligible most of the time.
6.  Salivation:
0—Normal.
1—Slight but definite excess of saliva in mouth; may have nighttime drooling.
2—Moderately excessive saliva; may have minimal drooling.
3—Marked excess of saliva with some drooling.
4—Marked drooling, requires constant tissue or handkerchief.
7.  Swallowing:
0—Normal.
1—Rare choking.
3592—Occasional choking.
3—Requires soft food.
4—Requires NG tube or gastrotomy feeding.
8.  Handwriting:
0—Normal.
1—Slightly slow or small.
2—Moderately slow or small; all words are legible.
3—Severely affected; not all words are legible.
4—The majority of words are not legible.
9.  Cutting Food and Handling Utensils:
0—Normal.
1—Somewhat slow and clumsy, but no help needed.
2—Can cut most foods, although clumsy and slow; some help needed.
3—Food must be cut by someone, but can still feed slowly.
4—Needs to be fed.
10.  Dressing:
0—Normal.
1—Somewhat slow, but no help needed.
2—Occasional assistance with buttoning, getting arms in sleeves.
3—Considerable help required, but can do some things alone.
4—Helpless.
11.  Hygiene:
0—Normal.
1—Somewhat slow, but no help needed.
2—Needs help to shower or bathe, or very slow in hygienic care.
3—Requires assistance for washing, brushing teeth, combing hair, going to bathroom.
4—Foley catheter or other mechanical aids.
12.  Turning in Bed and Adjusting Bed Clothes:
0—Normal.
1—Somewhat slow and clumsy, but no help needed.
2—Can turn alone or adjust sheets, but with great difficulty.
3—Can initiate, but not turn or adjust sheets alone.
4—Helpless.
13.  Falling (unrelated to freezing):
0—None.
1—Rare falling.
2—Occasionally falls, less than once per day.
3—Falls an average of once daily.
4—Falls more than once daily.14.  Freezing When Walking:
0—None.
1—Rare freezing when walking; may have start-hesitation.
2—Occasional freezing when walking.
3—Frequent freezing. Occasionally falls from freezing.
4—Frequent falls from freezing.
15.  Walking:
0—Normal.
1—Mild difficulty. May not swing arms or may tend to drag leg.
2—Moderate difficulty, but requires little or no assistance.
3—Severe disturbance of walking, requiring assistance.
4—Cannot walk at all, even with assistance.
16.  Tremor:
0—Absent.
1—Slight and infrequently present
2—Moderate; bothersome to patient
3—Severe; interferes with many activities.
4—Marked; interferes with most activities.
17.  Sensory Complaints Related to Parkinsonism:
0—None
1—Occasionally has numbness, tingling, or mild aching.
2—Frequently has numbness, tingling, or aching; not distressing.
3—Frequent painful sensations.
4—Excruciating pain.
IIL Motor Examinations:
18.  Speech:
0—Normal.
1—Slight loss of expression, diction, and/or volume.
2—Monotone, slurred but understandable; moderately impaired
3—Marked impairment, difficult to understand
4—Unintelligible.
19.  Facial Expression:
0—Normal.
1—Minimal hypomimia, could be normal “poker face.”
2—Slight but definitely abnormal diminution of facial expression.
3—Moderate hypomimia; lips parted some of the time.
4—Masked or fixed facies with severe of complete loss of facial expression; lips parted 1/4 inch <  
more.
20.  Tremor at Rest: Head L+R upper and lower limbs
0—Absent.
1—Slight and infrequently present
2—Mild in amplitude and persistent Or moderate in amplitude, but only intermittently present.
3—Moderate in amplitude and present most of the time.
4—Marked in amplitude and present most of the time.21.  Action or Postural Tremor of Hands: Left and Right
0—Absent.
1—Slight; present with action.
2—Moderate in amplitude, present with action.
3—Moderate in amplitude with posture holding as well as action.
4—Marked in amplitude; interferes with feeding.
22.  Rigidity: (Judged on passive movement of major joints with patient relaxed in sitting position. 
Cogwheeling to be ignored.) Neck, Left and Right upper and lower limbs
0—Absent.
1—Slight or detectable only when activated by mirror or other movements.
2—Mild to moderate.
3—Marked, but full range of motion easily achieved.
4—Severe, range of motion achieved with difficulty.
23.  Finger Taps: (Patient taps thumb with index finger in rapid succession with widest amplitude 
possible, each hand separately.) Left and Right
0—Normal.
1—Mild slowing and/or reduction in amplitude.
2—Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.
3—Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement.
4—Can barely perform the task.
24.  Hand Movements: (Patient opens and closes hand in rapid succession with widest 
amplitude possible, each hand separately.) Left and Right
0—Normal.
1—Mild slowing and/or reduction in amplitude.
2—Moderately impaired Definite and early fatiguing. May have occasional arrests in movement.
3—Severely impaired Frequent hesitation in initiating movements or arrests in ongoing 
movement.
4—Can barely perform the task.
25.  Rapid Alternating Movements of Hands: (Pronation-supination movements of hands, vertically or 
horizontally, with as large an amplitude as possible, both hands simultaneously.)
0—Normal.
1—Mild slowing and/or reduction in amplitude.
2—Moderately impaired Definite and early fatiguing. May have occasional arrests in movement.
3—Severely impaired Frequent hesitation in initiating movements or arrests in ongoing 
movement.
4—Can barely perform the task.
26.  Foot Agility: (Patient taps heel on ground in rapid succession, picking up entire foot. Amplitude 
should be about 3 indies) Left and Right.
0—Normal.
1—Mild slowing and/or reduction in amplitude.
2—Moderately impaired Definite and early fatiguing. May have occasional arrests in movement.
3—Severely impaired Frequent hesitation in initiating movements or arrests in ongoing 
movement.
4—Can barely perform the task.
36227.  Arising from Chair: (Patient attempts to arise from a straight-back wood or metal chair with arms 
folded across chest.)
0—Normal.
1—Slow; or may need more than one attempt
2—Pushes self up from arms of seat.
3—Tends to fall back and may have to try more than one time, but can get up without help.
4—Unable to arise without help.
28.  Posture:
0—Normal erect
1—Not quite erect slightly stooped posture; could be normal for older person.
2—Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.
3—Severely stooped posture with kyphosis; can be moderately leaning to one side.
4—Marked flexion with extreme abnormality of posture.
29.  Gait:
0—Normal
1—Walks slowly, may shuffle with short steps, but no festinalion or propulsion.
2—Walks with difficulty, but requires little or no assistance; may have some festination, short 
steps, or propulsion.
3—Severe disturbance of gait, requiring assistance.
4—Cannot walk at all, even with assistance.
30.  Postural Stability: (Response to sudden posterior displacement produced by pull on shoulders 
while patient erect with eyes open and feet slightly apart. Patient is prepared.)
0—Normal.
1—Retropulsion, but recovers unaided.
2—Absence of postural response; would fall if not caught by examiner.
3—Very unstable, tends to lose balance spontaneously.
4—Unable to stand without assistance.
31.  Body Bradykinesia and Hypokinesia: (Combining slowness, hesitancy, decreased arm swing, small 
amplitude, and poverty of movement in general.)
0—None.
1—Minimal slowness, giving movement a deliberate character; could be normal for some persons. 
Possibly reduced amplitude.
2—Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, 
some reduced amplitude.
3—Moderate slowness, poverty or small amplitude of movement.
4—Marked slowness, poverty or small amplitude of movement.
IV.  Complications of Therapy (in the past week)
A.  Dyskinesias
32.  Duration: What proportion of the waking day are dyskinesias present?  (Historical 
information)
0 - None
1-1-25% of day
2-26-50% of day
3-51-75% of day
4-76-100% of day
33.  Disability: How disabling are the dyskinesias? (Historical information; may be modified by office 
examination.)
0—Not disabling
1—Mildly disabling
2—Moderately disabling
3—Severely disabling
3634—Completely disabling
34.  Painful Dyskinesias: How painful are the dyskinesias?
0—No painful dyskinesias
1—Slight
2—Moderate
3—Severe
4—Marked
35.  Presence of Early Morning Dystonia: (Historical information)
0—No
1—Yes
B.  Clinical Fluctuations
36.  Are any “off’ periods predictable as to timing after a dose of medication?
0—No
1—Yes
37.  Are any “off’ periods unpredictable as to timing after a dose of medication?
0—No
1—Yes
38.  Do any of the “off’ periods come on suddenly, e.g., over a few seconds?
0—No
1—Yes
39.  What proportion of the waking day is patient “off’ on average?
0—None
1—1-25% of day
2—26-50% of day
3—51-75% of day
4—76-100% of day
C.  Other Complications
40.  Does the patient have anorexia, nausea, or vomiting?
0—No
1—Yes
41.  Does the patient have any sleep disturbances, e.g., insomnia or hypersomnolence?
0—No
1—Yes
42.  Does the patient have symptomatic orthostasis?
0—No
1—Yes
(Faihnetal., 1987)Hoehn and Yahr
Modified Hoehn and Yahr Staging
Stage 0—No signs of disease.
Stage 1—Unilateral disease.
Stage 1.5—Unilateral plus axial involvement.
Stage 2—Bilateral disease, without impairment of balance.
Stage 2.5—Mild bilateral disease with recovery on pull test.
Stage 3—Mild to moderate bilateral disease; some postural instability; physically independent. 
Stage 4— Severe disability; still able to walk or stand unassisted.
Stage 5—Wheelchair bound or bedridden unless aided.
(Hoehn and Yahr, 1967)Schwab and England ADL score
Modified Schwab and England Activities of Daily Living Scale
100%—Completely independent Able to do all chores without slowness, difficulty, or impairment 
Essentially normal. Unaware of any difficulty.
90%—Completely independent Able to do all chores with some degree of slowness, difficulty, and 
impairment Might take twice as long. Beginning to be aware of difficulty.
80%—Completely independent in most chores. Takes twice as long. Conscious of difficulty and 
slowness.
70%—Not completely independent. More difficulty with some chores. Three to four times as long in 
some. Must spend a large part of the day with chores.
60%—Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; 
some impossible.
50%—More dependent. Help with half, slower, etc. Difficulty with everything.
40%—Very dependent Can assist with all chores, but few alone.
30%—With effort, now and then does a few chores alone or begins alone. Much help needed.
20%—Nothing alone. Can be a slight help with some chores. Severe invalid.
10%—Total dependent helpless. Complete invalid.
0%—Vegetative functions such as swallowing, bladder and bowel functions are not functioning. 
Bedridden.
366Frontal assessment battery
1.Similarities (conceptualisation)
3 correct responses □ 3
2 correct responses □ 2
1  correct response □ 1
no correct response □ 0
2. Lexical fluency (mental flexibility)
more than 9 words □ 3
6-9 words □ 2
3-5 words □ 1
less than 3 words □ 0
3. motor series (programming)
patient performs alone 6 correct consecutive series □ 3
patient performs alone at least 3 consecutive series □ 2
patient fails alone, but performs 3 correct consecutive
series with the examiner □ 1
patient cannot perform 3 correct consecutive series
even with the examiner □ 0
4. Conflicting instructions (sensitivity to interference)
no errors □ 3
1  or 2 errors □ 2
more than 2 errors □ 1
the patient taps as the examiner at least 4 consecutive times □ 0
5. Go-No go
no errors □ 3
1  or 2 errors □ 2
more than 2 errors □ 1
the patient taps as the examiner at least 4 consecutive times □ 0
6. Prehension behaviour (environmental autonomy)
the patient does not take the examiners hands □ 3
the patient hesitates and asks what he/she has to do □ 2
the patient takes the hands without hesitation □ 1
the patient takes the examiners hands even after he
or she has been told no to □ 0
total score /18
3671  .Similarities
In what way are they alike:
A banana and an orange 
A table and a chair 
A tulip a rose and a daisy
Only categorical responses (fruits, furniture, flowers are considered correct)
2.Lexical fluency
“say as many words as you can beginning with the letter “S”, no surnames or 
proper nouns”
Prompt the patient if no response in the first 5 seconds, e.g snake 
If there are pauses then ask the question again 
No repetitions, or variations allowed 
Test duration is 60 seconds
3. Motor series
“look carefully at what I am doing” examiner performs “fist-edge-palm series” 
“now you will do with your right hand, the same series, first with me then 
alone” examiner performs three times the series with the patient then tells the 
patient to continue alone.
4. Conflicting instructions
“tap twice when I tap once” to be sure that the patient has understood the 
instruction, a series of three trials is run 1-1-1.
“tap once when I tap twice” to be sure that the patient has understood the 
instruction, a series of three trials is run 2-2-2.
Then perform the following series: 1-1-2-1-2-2-2-1-1-2.
5. Go-no-go
“tap once when I tap once” to be sure that the patient has understood the 
instruction, a series of three trials is run 1-1-1.
“do not tap when I tap twice” to be sure that the patient has understood the 
instruction, a series of three trials is run 2-2-2.
Then perform the following series: 1  -1 -2-1 -2-2-2-1-1-2.
6. Prehension behaviour
The examiner is seated in front of the patient. Place the patient’s hands palms 
up on his/her knees. Without saying or looking at the patient, the examiner 
brings his/her hands close to the patient’s hands and touches the patient’s 
palms of both hands, to see if he/she will spontaneously take them. If the 
patient takes the hands, the examiner will try again after asking him/her: “now 
do not take my hands”.
(Dubois et al., 2000)
368Gaze palsy score
Speed of voluntary upward saccades
Normal  0
Mild slowness  1
Definite slowness  2
Severe slowness  3
Amplitude of voluntary upward saccades
Not hypometric  0
Mild limitation  1
Moderate limitation  2
Severe limitation  3
Speed of voluntary downward saccades
Normal speed  0
Mild slowness  1
Definite slowness  2
Severe slowness  3
Amplitude of voluntary downward saccades
Not hypometric  0
Mild limitation  1
Moderate limitation  2
Severe limitation  3
Speed of voluntary left and right saccades
Normal speed  0
Mild slowness  1
Definite slowness  2
Severe slowness  3
Amplitude of voluntary left and right saccades
Not hypometric  0
Mild limitation  1
Moderate limitation  2
Severe limitation  3
Eyelid dysfunction
None  0
Mild inhibition of opening or closing or mild blepharospasm: no visual disability  1  
Moderate lid-opening inhibition or blepharospasm causing partial visual disability  2 
Functional blindness or near blindness because of involuntary eyelid closure  3
TOTAL =  /21
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